
<html lang="en"     class="pb-page"  data-request-id="0581bb12-4143-47b4-a699-d6dbb5cc7dc1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-19;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01050;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators" /></meta><meta name="dc.Creator" content="Nicoletta  Brindani" /></meta><meta name="dc.Creator" content="Ambra  Gianotti" /></meta><meta name="dc.Creator" content="Simone  Giovani" /></meta><meta name="dc.Creator" content="Francesca  Giacomina" /></meta><meta name="dc.Creator" content="Paolo  Di Fruscia" /></meta><meta name="dc.Creator" content="Federico  Sorana" /></meta><meta name="dc.Creator" content="Sine Mandrup  Bertozzi" /></meta><meta name="dc.Creator" content="Giuliana  Ottonello" /></meta><meta name="dc.Creator" content="Luca  Goldoni" /></meta><meta name="dc.Creator" content="Ilaria  Penna" /></meta><meta name="dc.Creator" content="Debora  Russo" /></meta><meta name="dc.Creator" content="Maria  Summa" /></meta><meta name="dc.Creator" content="Rosalia  Bertorelli" /></meta><meta name="dc.Creator" content="Loretta  Ferrera" /></meta><meta name="dc.Creator" content="Emanuela  Pesce" /></meta><meta name="dc.Creator" content="Elvira  Sondo" /></meta><meta name="dc.Creator" content="Luis J. V.  Galietta" /></meta><meta name="dc.Creator" content="Tiziano  Bandiera" /></meta><meta name="dc.Creator" content="Nicoletta  Pedemonte" /></meta><meta name="dc.Creator" content="Fabio  Bertozzi" /></meta><meta name="dc.Description" content="Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported..." /></meta><meta name="Description" content="Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 18, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01050" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01050" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01050" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01050" /></link>
        
    
    

<title>Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01050" /></meta><meta property="og:title" content="Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0019.jpeg" /></meta><meta property="og:description" content="Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported to address the basic defects associated with CF-causing mutations, partially restoring the CFTR function in terms of protein processing and/or channel gating. Small-molecule compounds, called potentiators, are known to ameliorate the gating defect. In this study, we describe the identification of the 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole core as a novel chemotype of potentiators. In-depth structure–activity relationship studies led to the discovery of enantiomerically pure 39 endowed with a good efficacy in rescuing the gating defect of F508del- and G551D-CFTR and a promising in vitro druglike profile. The in vivo characterization of γ-carboline 39 showed considerable exposure levels and good oral bioavailability, with detectable distribution to the lungs after oral administration to rats. Overall, these findings may represent an encouraging starting point to further expand this chemical class, adding a new chemotype to the existing classes of CFTR potentiators." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01050"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01050">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01050&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01050&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01050&amp;href=/doi/10.1021/acs.jmedchem.0c01050" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 11169-11194</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01116" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01128" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indoles as a Novel Class of CFTR Potentiators</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Nicoletta Brindani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicoletta Brindani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicoletta++Brindani">Nicoletta Brindani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ambra Gianotti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ambra Gianotti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ambra++Gianotti">Ambra Gianotti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simone Giovani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simone Giovani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simone++Giovani">Simone Giovani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francesca Giacomina</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Giacomina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Giacomina">Francesca Giacomina</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paolo Di Fruscia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paolo Di Fruscia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Di+Fruscia">Paolo Di Fruscia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Federico Sorana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Federico Sorana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Federico++Sorana">Federico Sorana</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sine Mandrup Bertozzi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sine Mandrup Bertozzi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sine+Mandrup++Bertozzi">Sine Mandrup Bertozzi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giuliana Ottonello</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giuliana Ottonello</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giuliana++Ottonello">Giuliana Ottonello</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luca Goldoni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luca Goldoni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luca++Goldoni">Luca Goldoni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ilaria Penna</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ilaria Penna</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ilaria++Penna">Ilaria Penna</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Debora Russo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debora Russo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debora++Russo">Debora Russo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Summa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Summa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Summa">Maria Summa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rosalia Bertorelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rosalia Bertorelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rosalia++Bertorelli">Rosalia Bertorelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Loretta Ferrera</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Loretta Ferrera</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Loretta++Ferrera">Loretta Ferrera</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emanuela Pesce</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emanuela Pesce</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emanuela++Pesce">Emanuela Pesce</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elvira Sondo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elvira Sondo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elvira++Sondo">Elvira Sondo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luis J. V. Galietta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luis J. V. Galietta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy</div><div class="loa-info-affiliations-info">Department of Translational Medical Sciences (DISMET), University of Naples Federico II, 80138 Naples, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luis+J.+V.++Galietta">Luis J. V. Galietta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tiziano Bandiera</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tiziano Bandiera</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tiziano++Bandiera">Tiziano Bandiera</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicoletta Pedemonte</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicoletta Pedemonte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#77191e14181b1203031659071213121a181903123702191e1012591e03"><span class="__cf_email__" data-cfemail="abc5c2c8c4c7cedfdfca85dbcecfcec6c4c5dfceebdec5c2ccce85c2df">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicoletta++Pedemonte">Nicoletta Pedemonte</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5161-1720" title="Orcid link">http://orcid.org/0000-0002-5161-1720</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Fabio Bertozzi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabio Bertozzi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3e585f5c5751105c5b4c4a514444577e57574a10574a"><span class="__cf_email__" data-cfemail="badcdbd8d3d594d8dfc8ced5c0c0d3fad3d3ce94d3ce">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabio++Bertozzi">Fabio Bertozzi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7434-3688" title="Orcid link">http://orcid.org/0000-0001-7434-3688</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01050&amp;href=/doi/10.1021%2Facs.jmedchem.0c01050" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 11169–11194</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 18, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 June 2020</li><li><span class="item_label"><b>Published</b> online</span>18 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01050" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01050</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01050"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1152</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01050" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Nicoletta&quot;,&quot;last_name&quot;:&quot;Brindani&quot;},{&quot;first_name&quot;:&quot;Ambra&quot;,&quot;last_name&quot;:&quot;Gianotti&quot;},{&quot;first_name&quot;:&quot;Simone&quot;,&quot;last_name&quot;:&quot;Giovani&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Giacomina&quot;},{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Di Fruscia&quot;},{&quot;first_name&quot;:&quot;Federico&quot;,&quot;last_name&quot;:&quot;Sorana&quot;},{&quot;first_name&quot;:&quot;Sine&quot;,&quot;last_name&quot;:&quot;Mandrup Bertozzi&quot;},{&quot;first_name&quot;:&quot;Giuliana&quot;,&quot;last_name&quot;:&quot;Ottonello&quot;},{&quot;first_name&quot;:&quot;Luca&quot;,&quot;last_name&quot;:&quot;Goldoni&quot;},{&quot;first_name&quot;:&quot;Ilaria&quot;,&quot;last_name&quot;:&quot;Penna&quot;},{&quot;first_name&quot;:&quot;Debora&quot;,&quot;last_name&quot;:&quot;Russo&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Summa&quot;},{&quot;first_name&quot;:&quot;Rosalia&quot;,&quot;last_name&quot;:&quot;Bertorelli&quot;},{&quot;first_name&quot;:&quot;Loretta&quot;,&quot;last_name&quot;:&quot;Ferrera&quot;},{&quot;first_name&quot;:&quot;Emanuela&quot;,&quot;last_name&quot;:&quot;Pesce&quot;},{&quot;first_name&quot;:&quot;Elvira&quot;,&quot;last_name&quot;:&quot;Sondo&quot;},{&quot;first_name&quot;:&quot;Luis&quot;,&quot;last_name&quot;:&quot;J. V. Galietta&quot;},{&quot;first_name&quot;:&quot;Tiziano&quot;,&quot;last_name&quot;:&quot;Bandiera&quot;},{&quot;first_name&quot;:&quot;Nicoletta&quot;,&quot;last_name&quot;:&quot;Pedemonte&quot;},{&quot;first_name&quot;:&quot;Fabio&quot;,&quot;last_name&quot;:&quot;Bertozzi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;11169-11194&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01050&quot;},&quot;abstract&quot;:&quot;Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported to address the basic defects associated with CF-causing mutations, partially restoring the CFTR function in terms of protein processing and/or channel gating. Small-molecule compounds, called potentiators, are known to ameliorate the gating defect. In this study, we describe the identification of the 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole core as a novel chemotype of potentiators. In-depth structure–activity relationship studies led to the discovery of enantiomerically pure 39 endowed with a good efficacy in rescuing the gating defect of F508del- and G551D-CFTR and a promising in vitro druglike profile. The in vivo characterization of γ-carboline 39 showed considerable exposure levels and good oral bioavailability, with detectable distribution to the lungs after oral administration to rats. Overall, these findin&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01050&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01050" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01050&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01050" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01050&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01050" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01050&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01050&amp;href=/doi/10.1021/acs.jmedchem.0c01050" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01050" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01050" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01050%26sid%3Dliteratum%253Aachs%26pmid%3D32946228%26genre%3Darticle%26aulast%3DBrindani%26date%3D2020%26atitle%3DIdentification%252C%2BStructure%25E2%2580%2593Activity%2BRelationship%252C%2Band%2BBiological%2BCharacterization%2Bof%2B2%252C3%252C4%252C5-Tetrahydro-1H-pyrido%255B4%252C3-b%255Dindoles%2Bas%2Ba%2BNovel%2BClass%2Bof%2BCFTR%2BPotentiators%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D19%26spage%3D11169%26epage%3D11194%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291356" title="Defects">Defects</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/jmcmar.2020.63.issue-19/20201008/jmcmar.2020.63.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported to address the basic defects associated with CF-causing mutations, partially restoring the CFTR function in terms of protein processing and/or channel gating. Small-molecule compounds, called potentiators, are known to ameliorate the gating defect. In this study, we describe the identification of the 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole core as a novel chemotype of potentiators. In-depth structure–activity relationship studies led to the discovery of enantiomerically pure <b>39</b> endowed with a good efficacy in rescuing the gating defect of F508del- and G551D-CFTR and a promising <i>in vitro</i> druglike profile. The <i>in vivo</i> characterization of γ-carboline <b>39</b> showed considerable exposure levels and good oral bioavailability, with detectable distribution to the lungs after oral administration to rats. Overall, these findings may represent an encouraging starting point to further expand this chemical class, adding a new chemotype to the existing classes of CFTR potentiators.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec fnGroup"><div class="fnGroupItem" id="fn5"><span><h4></h4></span><span><p class="last">Pure regioisomer <b>52</b> was obtained as a racemate, starting from enantiopure (<i>R</i>)-<b>50</b>, because of the epimerization process during Fischer indole synthesis.</p></span></div><div class="fnGroupItem" id="fn6"><span><h4></h4></span><span><p class="last">Pure regioisomer <b>52</b> was obtained as a racemate starting from enantiopure (<i>S</i>)-<b>51</b> because of the epimerization process during Fischer indole synthesis.</p></span></div></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cystic fibrosis (CF) is the most frequent life-threatening autosomal recessive disease in Caucasians, caused by loss-of-function mutations in the CF transmembrane conductance regulator (<i>cftr</i>) gene, encoding for CFTR protein.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> CFTR is a cAMP-regulated chloride channel expressed at the apical membrane of epithelial cells, where it provides a route for electrogenic anion flux, thus regulating the composition and volume of epithelial secretions.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> CF is a multiorgan disease, affecting the lungs, pancreas, liver, and other organs.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> More than 2000 mutations have been described in the <i>cftr</i> gene; however, the pathogenicity has been demonstrated only for approximately 300 mutations.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> CF mutations cause the loss of function of CFTR protein by affecting its synthesis, trafficking, or its function as an anion channel.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> According to the mechanism causing CFTR dysfunction, CF mutations have been grouped into seven different classes: mutations introducing a premature stop codon (class I), mutations causing protein misfolding (class II), mutations causing defective channel gating (class III), mutations causing defective channel conductance (class IV), mutations leading to aberrant mRNA splicing (class V), mutations causing reduced stability at the plasma membrane (class VI), and mutations resulting in no mRNA expression (class VII).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Despite this clear classification, the majority of CF mutations cause CFTR dysfunction by multiple mechanisms,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> as in the case of the deletion of phenylalanine 508 (F508del), the most frequent mutation among CF patients.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Indeed, F508del causes a folding defect, leading to premature protein degradation.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> In addition, when F508del-CFTR is forced to traffic to the plasma membrane, for example, by rescue maneuvers, the mutant protein shows reduced stability because of the peripheral protein quality control mechanisms<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and defective channel gating.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Other mutations, however, are associated with a single mechanism of CFTR dysfunction, as in the case of the class III mutation G551D, which causes a severe CFTR channel gating defect.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Druglike small molecules, known as “CFTR modulators”, can target these specific defects caused by CFTR mutations restoring, at least partially, the CFTR function.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The maturation defect can be rescued by small molecules called correctors, such as VX-809<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> or VX-661,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> while the gating defect can be corrected by small molecules called potentiators, such as VX-770 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of known CFTR potentiators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Together with VX-770, other small-molecule potentiators have been reported ameliorating gating defects of mutant CFTR.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(20−23)</a> However, only a few have progressed to the stage of evaluation in clinical trials. Among them, the corresponding nona-deuterated (VX-561)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and bis-(trimethylsilyl) (PTI-808)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> analogues of VX-770 or AbbVie-Galapagos GLPG-1837<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> and GLPG-2451<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> compounds have successfully entered clinical trials in CF patients with different gating mutations (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><div class="NLM_p">Presently, VX-770 is the only potentiator drug that has been approved for monotherapy of different mutants displaying a gating defect.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Aiming to add new small-molecule compounds to the existing classes of CFTR potentiators, expanding the portfolio of modulators available to CF patients, we embarked on a drug discovery effort to the identification of novel chemotypes endowed with a promising pharmacological profile. After a high-throughput screening (HTS) campaign, few structurally diverse small-molecule hits were identified; among them, the most promising ones shared the 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (or 1,2,3,4-tetrahydro-γ-carboline) core structure.</div><div class="NLM_p last">In this work, we disclose the identification and an extended structure–activity relationship (SAR) study of tetrahydro-γ-carboline derivatives, which led to the discovery of novel CFTR potentiators, characterized by a nanomolar activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80837" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80837" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A screening collection of 11,334 maximally diverse small-molecule compounds was assembled starting from a set of ca. 300,000 commercially available molecules belonging to the diversity subsets of major vendors. A series of more and more stringent filters were applied in order to discard compounds with suboptimal druglike properties, and those containing chemically reactive moieties, unstable and known cytotoxic groups, and frequent hitters (e.g., PAINS).<a onclick="showRef(event, 'ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32">(29−32)</a> A subsequent stepwise clustering protocol based on an unweighted pair group method with arithmetic mean (UPGMA) hierarchical agglomerative algorithm<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> allowed for the selection of the final set of molecules suited for HTS.</div><div class="NLM_p">The chemical library was screened in duplicate on a Fischer rat thyroid (FRT) cell line, stably coexpressing F508del-CFTR and the halide-sensitive yellow fluorescent protein, HS-YFP.<a onclick="showRef(event, 'ref23 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref23 ref34 ref35">(23,34,35)</a> To overcome the F508del trafficking defect, cells were initially incubated for 24 h at 32 °C and then acutely treated (15–30 min) with a single compound (5 μM) in combination with forskolin (10 μM). After stimulation, the F508del-CFTR activity in the plasma membrane was calculated by measuring the rate of fluorescence quenching arising from iodide influx.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This activity was compared to that of wells containing forskolin alone (negative control) or forskolin plus VX-770 (1 μM, as a positive control) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Analysis of screening performance with the <i>Z</i>′ method gave a score of 0.6, which can be considered optimal for this type of assay. The activity scores for each compound were then plotted as an ordered distribution (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). All compounds whose average activity calculated from the two rounds of screening was greater than 185% with respect to the negative control (i.e., forskolin alone) were considered as primary hits. The screening detected 104 putative potentiators, with some compounds showing a promising initial activity comparable to VX-770 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Discovery of mutant CFTR potentiators by HTS. (A) Summary of results obtained by screening the entire chemical library on FRT cells expressing F508del-CFTR and HS-YFP, followed by 24 h of incubation at 32 °C to rescue the trafficking defect. The graphs report the normalized HS-YFP quenching rate (QR), reflecting CFTR-dependent iodide influx, for cells treated with forskolin (10 μM) plus test compounds (5 μM; gray dots), VX-770 (1 μM; red dots), or vehicle [dimethyl sulfoxide (DMSO), black dots]. (B) Ordered distribution of the QR scores measured, for each test compound, in the screening and displayed in (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The primary hits were confirmed by testing them at different concentrations, in order to extrapolate the dose–response relationship. First, we focused on the F508del mutant. The compounds were tested in the low micromolar range, in the presence of forskolin (10 μM), on F508del-CFTR FRT cells following rescue of the trafficking defect by low-temperature incubation, as done for the primary screening. The data for selected test compounds are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A. The most interesting hits were subsequently tested for their ability to overcome the more severe gating defect of pure class III mutant using FRT cells stably expressing G551D-CFTR (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Interestingly, some compounds were effective on both types of mutants with a strong increase in CFTR activity that in some cases approached the effect of VX-770 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Identification of novel potentiators of mutant CFTR. Dose–response relationships for selected compounds on (A) F508del-CFTR FRT cells rescued at 32 °C for 24 h and (B) on G551D-CFTR FRT cells, compared to VX-770 (1 μM for F508del and 5 μM for G551D). (C) Structures of potentiators <i>Hit-7</i> (<b>1</b>), <i>Hit-8</i> (<b>2</b>), and <i>Hit-9</i> (<b>3</b>), selected for further SAR evolution. The data are expressed as mean ± standard deviation (SD) (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric analysis of variance (ANOVA), followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance vs control (DMSO-treated): ***<i>p</i> < 0.001, **<i>p</i> < 0.01, and *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Notably, three compounds (<i>Hit-7</i> (<b>1</b>), <i>Hit-8</i> (<b>2</b>), and <i>Hit-9</i> (<b>3</b>), <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C) sharing the same chemical scaffold (i.e., 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole) were confirmed as hits on both cell types, when retested with the HS-YFP assay to extrapolate the dose–response relationship.</div><div class="NLM_p">This finding, besides being a promising preliminary data in this screening campaign, confirmed that this specific chemotype could be considered a reliable starting point to further evolve a newly identified chemical class. In particular, derivatives <b>1</b> and <b>3</b> showed a good efficacy and an interesting sub-micromolar potency (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><div class="NLM_p">The preliminary activity of these three hits was further evaluated in secondary screening assays. Although featuring the same common scaffold, in order to possibly discriminate the most interesting hit for further structural investigations, the compounds belonging to the family of tetrahydro-γ-carbolines were tested on more relevant cell models. First, the hits were tested on an immortalized bronchial epithelial cell line (CFBE41o-) stably expressing F508del-CFTR and HS-YFP. Acute stimulation with the compounds, in the presence of forskolin to increase the intracellular cAMP content, resulted in a dose-dependent activation of mutant CFTR (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), with compounds <b>1</b> and <b>3</b> being the most effective.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CFTR activation by tetrahydro-γ-carbolines on bronchial epithelial cells. (A) Dose–response relationships for selected compounds, compared to VX-770 (1 μM), on F508del-CFTR CFBE41o-cells rescued at 32 °C for 24 h. The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance vs control (DMSO-treated): ***<i>p</i> < 0.001 and **<i>p</i> < 0.01. (B) Representative traces show the response of CFTR to stimulation with the indicated concentrations of CPT-cAMP and compound <b>3</b>. The currents stimulated by compound <b>3</b> and CPT-cAMP were blocked by the selective CFTR inhibitor-172. Each experimental condition was tested in three independent experiments, each one performed with three biological replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Subsequently, the ability of compounds to elicit CFTR-mediated chloride secretion was verified on primary human bronchial epithelial (HBE) cells, from non-CF individuals, in short-circuit current experiments. In this respect, it should be noticed that potentiators are also able to stimulate wild-type CFTR, provided that a submaximal cAMP-dependent stimulation is applied.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> Accordingly, cells were stimulated with a submaximal concentration of the cAMP analogue, CPT-cAMP, followed by increasing concentrations of the potentiator hit.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> In such experimental conditions, compound <b>3</b> was able to stimulate CFTR-mediated chloride current of similar amplitude as that elicited by maximal cAMP stimulation, as confirmed by using the specific CFTR inhibitor-172 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><div class="NLM_p">Based on these initial, promising findings achieved in HBE experiments, compound <b>3</b> was selected as the reference molecule to explore the SAR around this chemotype, aiming to improve potency and efficacy of this novel class of CFTR potentiators. The SAR study focused on the investigation of the role of the heteroaromatic carboxylic acid (<b>A</b>) acylating the position <i>N</i><sup>2</sup> of the tetrahydro-γ-carboline, the substitution pattern of the phenyl ring (<b>B</b>), and the modification of the tetrahydropyridine portion (<b>C</b>) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Sites of chemical modifications on the structure of <b>3</b> to explore the SAR of the tetrahydro-γ-carboline class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The role of the heteroaryl group (<b>A</b>) acylating the position 2 of the tetrahydro-γ-carboline was initially explored by modifying the substituent on the pyrazolyl residue and replacing the pyrazole with other rings, while keeping the 8-methoxy carboline moiety unmodified. The activity of each compound is described in terms of normalized maximal efficacy (<i>E</i><sub>max</sub>), the maximum fold increase in the rescue of F508del-CFTR activity with respect to hit <b>3</b>, and potency (EC<sub>50</sub>), the concentration producing half-maximal efficacy. The chemical structures and the data of the first set of compounds are reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Chemical Structure, Efficacy (<i>E</i><sub>max</sub>), and Potency (EC<sub>50</sub>) Data of Tetrahydro-γ-carbolines <b>1–12</b> in F508del-CFTR FRT Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>E</i><sub>max</sub> values (normalized for the activity of analogue <b>3</b>).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">EC<sub>50</sub> values, calculated from experiments performed as in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A. Data are expressed as mean ± SD (<i>n</i> = 3–6).</p></div></div><div></div></div><div class="NLM_p">The removal (<b>4</b>, <i>E</i><sub>max</sub>: 0.17; EC<sub>50</sub>: 10.6 μM) or the replacement of the trifluoromethyl moiety in position 5′ of the pyrazolyl residue with a methyl (<b>5</b>, <i>E</i><sub>max</sub>: 0.59; EC<sub>50</sub>: 60 μM), isopropyl (<b>6</b>, <i>E</i><sub>max</sub>: 0.95; EC<sub>50</sub>: 5.7 μM), and phenyl (<b>7</b>, <i>E</i><sub>max</sub>: 0.84; EC<sub>50</sub>: 0.82 μM) group led to a marked loss of activity with respect to compound <b>3</b>. Replacing the 5′-trifluoromethyl-pyrazol-3′-yl residue with other heteroaromatic groups, such as a 2′-trifluoromethyl imidazolyl (<b>8</b>) or a 5-bromo furanyl (<b>9</b>) derivative, resulted in no improvements in activity, showing essentially a marked drop in potency (EC<sub>50</sub>: 2.8 and 3.7 μM, respectively). Not surprisingly, the insertion of a substituted indolyl moiety as in compound <b>10</b> allowed to retain a good effect on CFTR function (<i>E</i><sub>max</sub>: 0.91; EC<sub>50</sub>: 0.15 μM), as seen for hit compound <b>1</b>. Finally, the alkylation of either <i>N</i><sup>1′</sup> (<b>11</b>) or <i>N</i><sup>5</sup> (<b>12</b>) position with a methyl residue resulted in a marked reduction of activity (<b>11</b>, <i>E</i><sub>max</sub>: 1.2; EC<sub>50</sub>: 7.1 μM; <b>12</b>, <i>E</i><sub>max</sub>: 0.85; EC<sub>50</sub>: 2.1 μM), suggesting that these hydrogen atoms may be involved in key H-bond interactions with the biological target or insufficient space exists for accommodating the methyl group.</div><div class="NLM_p">Having demonstrated the importance of the 5′-trifluoromethyl-pyrazol-3′-yl residue as an ideal acylating group of the 8-methoxy-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole derivative in targeting the gating defects caused by CF mutations, the importance of the substitution pattern on the phenyl ring (<b>B</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was investigated by the synthesis of a number of phenyl-substituted analogues (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Chemical Structure, Efficacy (<i>E</i><sub>max</sub>), and Potency (EC<sub>50</sub>) Data of Tetrahydro-γ-carbolines <b>13–31</b> in F508del-CFTR FRT Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0015.gif" alt="" id="GRAPHIC-d7e948-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0016.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>E</i><sub>max</sub> values (normalized for the activity of analogue <b>3</b>).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">EC<sub>50</sub> values, calculated from experiments performed as in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A. Data are expressed as mean ± SD (<i>n</i> = 3–6).</p></div></div><div></div></div><div class="NLM_p">Initially, the importance of the substituent at position 8 of compound <b>3</b> was evaluated by preparing analogues where the methoxy residue was replaced by a hydrogen atom (<b>13</b>) or a methyl group (<b>14</b>). These changes led to an overall retention in the efficacy (<i>E</i><sub>max</sub> normalized to <b>3</b>), while potency was conserved for compound <b>14</b> (EC<sub>50</sub>: 0.27 μM) and slightly increased for analogue <b>13</b> (EC<sub>50</sub>: 0.23 μM). Based on these preliminary data achieved for 8-methyl-substituted tetrahydro-γ-carboline <b>14</b>, the effect of the position of the methyl substitution on the phenyl ring was investigated. While the efficacy changed progressively from an equal (6-methyl, <b>17</b>) to a lower (7-methyl, <b>16</b>) via a moderate value (9-methyl, <b>15</b>), an opposite trend was observed for potency with EC<sub>50</sub> values progressively decreasing from 7-methyl (<b>16</b>, EC<sub>50</sub>: 0.2 μM) to 8-methyl (<b>14</b>, EC<sub>50</sub>: 0.36 μM) to 9-methyl (<b>15</b>, EC<sub>50</sub>: 0.48 μM) to 6-methyl (<b>17</b>, EC<sub>50</sub>: 1.14 μM) substituted compound (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">Having demonstrated that position 8 of the γ-carboline moiety could affect positively both efficacy and potency, a number of new analogues of compounds <b>3</b> (8-OMe) and <b>14</b> (8-Me) were synthesized in order to gain additional information on the SAR of this class. The investigation of the importance of the substituent at position 8 was broadened by preparing derivatives where the methoxy residue was replaced by an isopropyl (<b>18</b>), a fluoro (<b>19</b>), a trifluoromethyl (<b>21</b>), a trifluoromethoxy (<b>22</b>), a cyano (<b>23</b>), and a methylsulfonyl (<b>24</b>) moiety. While compounds <b>19</b> and <b>21</b> showed potency and efficacy comparable to <b>3</b>, a relevant drop in the overall activity was observed with derivatives featuring a sterically demanding isopropyl (<b>18</b>) and methylsulfonyl (<b>24</b>) groups or the polar linear cyano residue (<b>23</b>). On the contrary, the 8-trifluoromethoxy (<b>22</b>) derivative showed improved potency (EC<sub>50</sub>: 0.16 μM) and a comparable normalized efficacy (<i>E</i><sub>max</sub> = 0.89) with respect to <b>3</b>. Interestingly, compound <b>20</b>, bearing a fluorine atom at position 6, turned out to be the most potent analogue within this small set of mono-substituted γ-tetrahydro-carbolines, displaying a double-digit nanomolar potency (EC<sub>50</sub> = 0.096 μM), while retaining a similar efficacy (<i>E</i><sub>max</sub> = 0.96) to analogue <b>3</b>.</div><div class="NLM_p">As a further step in the exploration of SAR within this chemotype, disubstituted phenyl derivatives were also explored. Based on the promising effect shown by <b>20</b> in dose–response data in F508del-CFTR FRT cells, a small set of disubstituted compounds bearing a fluorine atom at position 6 was prepared and tested. The introduction of a second substituent on the phenyl ring proved in general to be beneficial, leading to some compounds with efficacy comparable or superior to <b>3</b> and potency in the double-digit nanomolar range.</div><div class="NLM_p">Trying to possibly gain an additive effect by introducing previously identified substituents, the influence on the activity of 6-fluoro (as in <b>20</b>) was combined with a 8-methoxy, a 8-methyl, and a 8-fluoro group, as in disubstituted analogues <b>25</b>, <b>26</b>, and <b>27</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Unfortunately, these modifications turned out to be not so beneficial in terms of overall activity, showing in all cases a significant drop in potency when compared to mono-substituted analogue <b>20</b>. A similar effect was displayed by the insertion of a trifluoromethyl group at position 8, as in <b>28</b>, which caused a marked 6-fold drop in potency (EC<sub>50</sub>: 0.57 μM) with respect to <b>20</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">While retaining a fluorine atom at position 6, as in <b>20</b>, the SAR study around this scaffold was further expanded by modification of the substitution pattern on the phenyl ring of the tetrahydro-γ-carboline core. Accordingly, whereas the insertion of another fluorine in position 9 (<b>29</b>) negatively influenced the potency (EC<sub>50</sub> = 0.15 μM), the replacement of a hydrogen with a methyl group in the same position resulted in a double-digit nanomolar active disubstituted derivative <b>30</b> (EC<sub>50</sub> = 0.06 μM), with more than 6-fold increase in potency and comparable efficacy to hit <b>3</b>. To firmly prove that the 6-fluoro-9-methyl disubstitution pattern, as in <b>30</b>, was convenient to maintain the activity, we swapped the position of fluorine and methyl group, leading to compound <b>31</b>. This modification resulted to be detrimental for efficacy and led to more than 15-fold decrease in potency (EC<sub>50</sub> = 0.94 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">As the next step in the exploration of SAR of the class, modifications in the tetrahydropyridine ring (<b>C</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) were investigated, retaining the optimal 6-fluoro-9-methyl substitution on the phenyl ring. Remarkably, the introduction of a methyl group at position 1 or 3 of the tetrahydropyridine ring, as in racemic <b>32</b> and <b>33</b>, resulted in a considerable boost in activity, as shown by the good efficacy and low double-digit nanomolar potency (EC<sub>50</sub> = 0.03 and 0.022 μM, respectively) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). On the contrary, the insertion of a <i>gem</i>-dimethyl moiety at 3-position of the tetrahydropyridine ring, as for compound <b>34</b>, negatively affected both potency (EC<sub>50</sub> = 1.91 μM) and efficacy (<i>E</i><sub>max</sub> = 0.79) with respect to derivative <b>30</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Chemical Structure, Efficacy (<i>E</i><sub>max</sub>), and Potency (EC<sub>50</sub>) Data of Tetrahydro-γ-carbolines <b>32–42</b> in F508del-CFTR FRT Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0017.gif" alt="" id="GRAPHIC-d7e1267-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0018.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last"><i>E</i><sub>max</sub> values (normalized for the activity of analogue <b>3</b>).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">EC<sub>50</sub> values, calculated from experiments performed as in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A. Data are expressed as mean ± SD (<i>n</i> = 3–6).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Racemic compound.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Absolute configuration not determined and arbitrary drawn.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Absolute configuration known.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">n.a.: not active (up to 20 μM).</p></div></div><div></div></div><div class="NLM_p">A more sterically demanding modification of the γ-carboline nucleus was explored by incorporating an ethylene bridge in the tetrahydropyridine ring, as for racemic compound <b>35</b>. This modification leads to a more rigid skeleton, possibly resulting in increased affinity at the target binding site.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Unfortunately, this structural change was detrimental for both efficacy and potency with respect to <b>30</b>. The separation of the racemate into the two pure enantiomers did not result in any improvement because only one of them (<b>37</b>) retained some activity, whereas the opposite isomer <b>36</b> was completely inactive (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">Trying to evaluate the effect on the activity of the size of the heterocyclic ring, the corresponding tetrahydro-azepino-indole derivative <b>38</b> was synthesized and tested; the compound showed a marked 38-fold drop in potency with respect to the tetrahydropyridine analogue <b>30</b>.</div><div class="NLM_p">Based on the promising data in improving the gating of mutant F508del-CFTR in FRT cells shown by racemic tetrahydro-γ-carbolines <b>32</b> and <b>33</b>, the corresponding pure enantiomers were synthesized and tested. Notably, a strong difference (>100-fold) in the biological activity was displayed by these chiral analogues. While (<i>S</i>)-enantiomer <b>40</b> (distomer) resulted in a marked loss in potency but similar efficacy (<i>E</i><sub>max</sub>: 1.31, EC<sub>50</sub>: 1.1 μM) to racemic <b>33</b>, the corresponding (<i>R</i>)-enantiomer <b>39</b> (eutomer) showed a comparable activity with respect to racemate, retaining a low double-digit nanomolar potency (EC<sub>50</sub>: 0.017 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">A slightly different pattern of activity was observed with the 1-methyl-substituted enantiomers <b>41</b> and <b>42</b>, which showed no major differences in terms of efficacy and potency, also when compared to racemic <b>32</b>.</div><div class="NLM_p">Within this small set of alkyl-substituted analogues, the results observed with compounds <b>41</b> and <b>42</b>, along with the likelihood of 1-alkyl substituted γ-carboline analogues possibly undergoing epimerization in acidic aqueous media,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> convinced us to convey our attention primarily on compound <b>39</b>.</div><div class="NLM_p">A small set of selected potentiators with good efficacy and potency on F508del-CFTR FRT cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) was also tested at three concentrations on G551D-CFTR FRT cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). With the only exception of compound <b>3</b>, the potentiators displayed efficacy comparable to VX-770 at the highest concentration (20 μM), with analogue <b>39</b> being the most potent one, although the affinity was lower than that of VX-770.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Activity of selected tetrahydro-γ-carboline potentiators (<b>3</b>, <b>20</b>, <b>25</b>, <b>30</b>, and <b>39</b>) and, for comparison, VX-770 on (A) F508del-CFTR FRT and (B) on G551D-CFTR FRT cells. The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance vs control (DMSO-treated): ***<i>p</i> < 0.001, **<i>p</i> < 0.01, and *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In F508del-CFTR FRT cells, the selected potentiators displayed efficacy comparable to VX-770. Interestingly, enantiomer <b>39</b> resulted to be the most potent analogue within this set of novel tetrahydro-γ-carbolines, although showing a slightly lower activity than VX-770 when tested at 10 and 1 nM (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). For these selected compounds, a very similar trend was also observed in G551D-CFTR FRT cells, where <b>39</b> showed a comparable pattern of activity at the highest concentrations (20–3.3 μM) and a decrease in activity at 0.56 μM when compared to VX-770 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).</div><div class="NLM_p">Recent studies have shown that most potentiators have an undesired activity on F508del-CFTR protein processing/trafficking.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> According to these studies, chronic incubation with potentiators results in decreased activity of VX-809 as a corrector. To test the effect of our potentiators, we incubated F508del-CFTR CFBE41o-cells for 24 h with tetrahydro-γ-carboline <b>39</b> (5 μM) together with VX-809 (1 μM) and <b>ARN23765</b> (10 nM), the picomolar affinity corrector recently reported by our research team.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Interestingly, cotreatment with potentiator <b>39</b> did not affect the rescue efficacy of VX-809 or <b>ARN23765</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Potentiator <b>39</b> does not influence mutant F508del rescue by correctors VX-809 and <b>ARN23765</b>. The graphs report the (A) values of normalized QR measured in the YFP-based functional assay on CFBE41o-expressing F508del-CFTR treated for 24 h with VX-809 (1 μM) or <b>ARN23765</b> (10 nM) in the absence or presence of compound <b>39</b> (5 μM) and (B) equivalent short-circuit current (calculated from TEER/PD measurements) in F508del/F508del bronchial epithelial cells treated for 24 h with VX-809 (1 μM) or <b>ARN23765</b> (10 nM) in the absence or presence of compound <b>39</b> (0.5 μM). The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Tukey test (for multiple comparisons). Symbols indicate statistical significance: ***<i>p</i> < 0.001, n.s. (not significant) indicates <i>p</i> > 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A similar combination study was conducted on primary HBE cells from an F508del/F508del CF patient. The effect of the compound was assessed with the transepithelial electrical resistance and potential difference (TEER/PD) technique.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Epithelia were treated for 24 h with a vehicle, a corrector <b>ARN23765</b> alone (10 nM), or <b>ARN23765</b> (10 nM) plus the potentiator <b>39</b> (0.5 μM). TEER and PD values were taken at resting, after the addition of apical amiloride, after maximal stimulation of F508del-CFTR activity (with forskolin plus genistein), and after blocking with PPQ-102. For each epithelium, we measured the difference in the short-circuit current, <i>I</i><sub>eq</sub> (calculated from the TEER and PD values), before and after blocking with PPQ-102 (Δ<i>I</i><sub>eq</sub>). The results obtained on primary epithelia confirmed that the rescue of CFTR activity by the corrector <b>ARN23765</b> was not affected by coincubation with the novel potentiator <b>39</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B).</div><div class="NLM_p">Finally, potentiator <b>39</b> and VX-770 were further evaluated in primary HBE cells from non-CF individuals, using short-circuit current measurements, to assess the ability of compounds to maximally activate CFTR function in the presence of a submaximal cAMP stimulation. After the addition of amiloride to inhibit sodium absorption through the ENaC channel, the potentiators were added at the maximal effective concentration (1 μM) after which epithelia were stimulated with a submaximal concentration of CPT-cAMP (5 μM), followed by a maximal concentration of the cAMP analogue (100 μM) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). We then measured the extent of CFTR-mediated chloride current elicited by submaximal cAMP stimulation in the presence of a potentiator and compared it to total CFTR-mediated chloride current, determined as the current inhibited by CFTR inhibitor-172. In parallel, other epithelia were stimulated only with the two concentrations of the cAMP analogue, in the absence of a potentiator. Interestingly, the fraction of CFTR-mediated chloride current activated by submaximal cAMP stimulation was significantly increased by more than 2-fold when epithelia were prestimulated with a potentiator (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In this respect, VX-770 and compound <b>39</b> were similarly effective (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Efficacy of potentiator <b>39</b> on primary bronchial epithelial cells from non-CF individuals. (A) Representative traces of short-circuit current measurements showing the response of CFTR to stimulation with the indicated concentrations of CPT-cAMP in the absence or presence of potentiators <b>39</b> or VX-770 (1 μM for both compounds). (B) Bar graph showing the currents stimulated by submaximal concentration of CPT-cAMP measured in experiments performed as in (A). The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance: **<i>p</i> < 0.01 and *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The most interesting potentiators (<b>3</b>, <b>20</b>, <b>25</b>, <b>29</b>, <b>30</b>, and <b>39</b>), selected on the basis of their efficacy and potency in the HS-YFP assay on F508del-CFTR FRT cells, were profiled <i>in vitro</i> for their druglike properties. Kinetic solubility and metabolic stability in rat, dog, and human liver microsomes, in the presence of NADPH and UDPGA (only for human) as cofactors, were assessed along with an indication of potential for hepatotoxicity in HepG2 cells (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinetic Solubility, Liver Microsomal Stability, and Cytotoxicity of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="left" /></col><col align="center" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">kinetic solubility (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">rat LM_NADPH <i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">dog LM_NADPH <i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">human LM_NADPH <i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">human LM_UDPGA <i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HepG2 (% survival)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">237 ± 11</td><td class="colsep0 rowsep0" align="center">30 ± 1</td><td class="colsep0 rowsep0" align="left">>60 (68)</td><td class="colsep0 rowsep0" align="center">42 ± 11</td><td class="colsep0 rowsep0" align="left">n.a.<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">9 ± 4</td><td class="colsep0 rowsep0" align="center">>60 (64)</td><td class="colsep0 rowsep0" align="left">>60 (85)</td><td class="colsep0 rowsep0" align="center">>60 (78)</td><td class="colsep0 rowsep0" align="left">n.a.<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="center">2 ± 1</td><td class="colsep0 rowsep0" align="center">20 ± 1</td><td class="colsep0 rowsep0" align="left">>60 (90)</td><td class="colsep0 rowsep0" align="center">33 ± 1</td><td class="colsep0 rowsep0" align="left">n.a.<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="center">36 ± 5</td><td class="colsep0 rowsep0" align="center">50 ± 9</td><td class="colsep0 rowsep0" align="left">>60 (93)</td><td class="colsep0 rowsep0" align="center">>60 (60)</td><td class="colsep0 rowsep0" align="left">n.a.<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">32 ± 1</td><td class="colsep0 rowsep0" align="left">>60 (92)</td><td class="colsep0 rowsep0" align="center">53 ± 2</td><td class="colsep0 rowsep0" align="left">>60 (75)</td><td class="colsep0 rowsep0" align="left">>80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">>60 (70)</td><td class="colsep0 rowsep0" align="left">>60 (92)</td><td class="colsep0 rowsep0" align="center">>60 (71)</td><td class="colsep0 rowsep0" align="left">>60 (79)</td><td class="colsep0 rowsep0" align="left">>80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Kinetic solubility (PBS, pH 7.4; <i>n</i> = 3).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">4.6 μM in liver microsomes (LM) with NADPH or UDPGA as cofactors, 0.1% DMSO.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Data collected as <i>n</i> ≥ 3.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Percentage of survival of HepG2 cells at 20 μM determined by CTG and MTT assays. Viability of HepG2 cells is expressed as percent survival of the vehicle-treated controls (given as 100%). Values are from one experiment, performed in three technical replicates.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">n.a.: not available.</p></div></div></div><div class="NLM_p">In general, the selected compounds showed a low kinetic solubility (<40 μM), with the exception of the hit <b>3</b>, which exhibited high solubility (237 μM). The metabolic stability (phase I metabolism) in the presence of liver microsomes was generally quite good in both dog (<i>t</i><sub>1/2</sub> > 60 min) and human (<i>t</i><sub>1/2</sub> > 55 min), with the exception of compounds <b>3</b> and <b>25</b>, featuring both a methoxy group on the phenyl ring. Indeed, although quite promising in terms of overall activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), derivative <b>25</b>, along with hit <b>3</b>, turned out to be the least stable compounds among the selected novel potentiators. However, their metabolic stability to oxidative metabolism was generally higher in the presence of human liver microsomes compared to rat (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Tetrahydro-γ-carbolines <b>30</b> and <b>39</b> turned out to be quite stable to phase II conjugation reactions, showing half-life values (<i>t</i><sub>1/2</sub> > 60 min) in human liver microsomes, with UDPGA as a cofactor. In addition, a considerable amount (>75%) of parent compound remained at the last time point (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_p">In order to assess a possible liver toxicity liability, the selected analogues were also tested in HepG2 cells at two concentrations (2.0 and 20 μM) for 24 h, along with a reference compound (rotenone). A reduction of cell viability to less than 80% was set as the threshold for estimation of cytotoxicity.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> None of the compounds induced a decrease in cell viability at the highest dose tested (20 μM), resulting in a cell survival >80% (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_p">Based on both its biological profile, showing a good efficacy in primary and secondary assays, and preliminary <i>in vitro</i> ADME properties, potentiator <b>39</b> was further evaluated in <i>in vivo</i> studies. The compound was dosed in Sprague–Dawley rats by intravenous (i.v.) administration, at a dose of 3 mg/kg, and by oral gavage (p.o.), at a dose of 10 mg/kg, to determine its pharmacokinetic profile (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of <b>39</b> Following i.v and p.o. Administration to Male Sprague–Dawley Rats (<i>n</i> = 3 per Dose)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">i.v.</th><th class="colsep0 rowsep0" align="center">p.o.</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> [ng/mL (μM)]</td><td class="colsep0 rowsep0" align="left">2792 (7.3)</td><td class="colsep0 rowsep0" align="left">769 (2.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (min)</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC [ng·min/mL (μM·h)]</td><td class="colsep0 rowsep0" align="left">138,913 (6.1)</td><td class="colsep0 rowsep0" align="left">139,538 (6.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2.39</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">half-life (min)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(elimination phase)</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="left">212</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">30</td></tr></tbody></table></div></div><div class="NLM_p">After i.v. administration, the maximal plasma concentration was ca. 7.3 μM, with a volume of distribution (<i>V</i><sub>d</sub>) of 2.39 L/kg, indicating an overall good distribution to the tissues. The low clearance (19 mL/min/kg) was in accordance with the good stability of <b>39</b> as shown in the rat liver microsomal stability assays. After oral administration, the compound reached the maximal plasma concentration at 2 h, and considerable levels of compound (>450 ng/mL, corresponding to a ca. 1.2 μM) were still present at 6 h postadministration, showing a relatively slow elimination phase (see Figure S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf" class="ext-link">Supporting Information</a>). The exposure (area under the curve, AUC) over the time interval 0–4 h was 6.1 μM·h, resulting in a ca. 30% oral bioavailability, calculated over the same time interval.</div><div class="NLM_p">Taking into account both the encouraging results in rescuing the gating defect in mutant CFTR in both primary and secondary biological assays, and the promising <i>in vivo</i> PK profile, we quantified the amount of compound <b>39</b> in rat lung tissue, the main target organ for CF treatment. The lung tissue distribution of potentiator <b>39</b> was investigated following administration of a single oral dose of 10 mg/kg to Sprague–Dawley rats. Supported by the data obtained in the pharmacokinetic study after oral administration, two time points (2 and 4 h) were selected for collecting plasma and lung tissue samples. The mean concentration vs. time profiles of compound <b>39</b> in plasma and lung tissue are reported in Figure S2 (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf" class="ext-link">Supporting Information</a>). In this study, while the plasma levels at 2 and 4 h (1026 and 675 ng/mL, respectively) turned out to be in accordance with those observed in the PK experiment, the concentration of <b>39</b> in the lungs was quantified to be 4.5 and 2.2 ng/mg tissue at the two selected time points. Overall, this study demonstrated that tetrahydro-γ-carboline <b>39</b> distributed to the lung following oral administration, although with a low concentration.</div><div class="NLM_p last">Finally, based on both its biological and pharmacological profile, potentiator <b>39</b> could be fairly considered as a lead compound and a valuable starting point for further optimization of 1,2,3,4-tetrahydro-γ-carbolines as novel F508del-CFTR potentiators.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63728" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63728" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The chemistry for the preparation of acylated 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indoles, as final compounds (<b>1–42</b>), is outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Treatment of substituted γ-carbolines <b>45a–s</b> with heteroaryl carboxylic acids (<b>A–K</b>) following different coupling conditions afforded amides (<b>1–11</b>, <b>13–31</b>) in moderate to high yields (22–95%) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Substituted tetrahydro-γ-carbolines used to synthesize final compounds were either commercially available (<b>45p–s</b>) or synthesized (<b>45a–o</b>) in a straightforward manner from the corresponding aryl-hydrazines (<b>44a–o</b>) and a suitable Boc-protected 4-piperidone via a Fischer-indole synthesis approach.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> The synthesis of tetrahydro-carbolines proceeds through an acid-catalyzed rearrangement of the enehydrazine form of an arylhydrazone, via a [3,3]-sigmatropic rearrangement, followed by cyclization and elimination of ammonia. Although simple heating of the two reacting partners in either ethanol/HCl or EtOH/2,4,6-trichloro-1,3,5-triazine gave in general the desired γ-carboline in moderate to high yields (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), more forcing conditions (e.g., trifluoroboron etherate complex) were used with electron-poor hydrazines (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a></div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tetrahydro-γ-carboline Amide Analogues <b>1–11</b> and <b>13–31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) HCl (36%), 0 °C, then NaNO<sub>2</sub>, H<sub>2</sub>O, SnCl<sub>2</sub> in HCl (6 M), 0 °C to r.t., 24 h; (ii) protocol A: <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate, HCl (36%), EtOH, 80 °C, and 16 h; protocol B: <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate, EtOH, r.t., then 2,4,6-trichloro-1,3,5-triazine, 90 °C, 8 h; protocol C: <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate, EtOH, 30 min, r.t., then removal of the solvent and addition of BF<sub>3</sub>·Et<sub>2</sub>O, AcOH, 90 °C, 16 h; (iii) protocol A: carboxylic acid, HATU, DIPEA, DMF, 0 °C, 10–30 min, then <b>45a,h,j,p–r</b> r.t., 16 h, 22–95%; protocol B: carboxylic acid, <b>45a–h,k-m,o–s</b>, Et<sub>3</sub>N, EDC·HCl, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 16 h, 6–77%.</p></p></figure><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i><sup>5</sup>-Methyl-tetrahydro-γ-carboline Analogue <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) (BOC)<sub>2</sub>O, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to r.t., 1 h; (ii) NaH (60% dispersion in mineral oil), CH<sub>3</sub>I, DMF, 0 °C to r.t., 16 h; (iii) HCl (4.0 M) in dioxane, DCM, r.t., and 20 h; and (iv) 5-trifluoromethyl-1<i>H</i>-pyrazole-3-carboxylic acid, HATU, DIPEA, DMF, 10 min, then <b>48</b>, r.t., 16 h, and 24%.</p></p></figure><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 6-Fluoro-9-methyl-Substituted γ-Carbolines <b>32–37</b> and <b>39–42</b> with Modified Tetrahydro-pyridine Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) Protocol A: <i>tert</i>-butyl 2-methyl-4-oxo-piperidine-1-carboxylate [<i>rac</i>-<b>49</b>, (<i>R</i>)-<b>50</b>, and (<i>S</i>)-<b>51</b>] or <i>tert</i>-butyl 2,2-dimethyl-4-oxo-piperidine-1-carboxylate (<b>56</b>), toluene, 50 °C, then TsOH, 120 °C, and 24 h; protocol B: <i>tert</i>-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (<b>58</b>), HCl (36%), EtOH, 80 °C, and 16 h; (ii) 5-methyl-1<i>H</i>-pyrazole-3-carboxylic acid, HATU, DIPEA, DMF, 0 °C, 10–30 min, then <b>52–55</b>, <b>57</b>, <b>59</b>, r.t., 16 h, and 5–47%; (iii) semipreparative chiral separation: ChiralPak AD, <i>n</i>-heptane–EtOH (75:25) [for <b>36</b>, <b>37</b>, <b>41</b>, and <b>42</b>: absolute configuration not determined and arbitrary drawn].</p></p></figure><div class="NLM_p">Two specific hydrazines (<b>44a,b</b>) were easily prepared via an <i>in situ</i> one-pot diazotation/reduction step from suited aniline (<b>43a,b</b>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">The synthesis of <i>N</i><sup>5</sup>-methyl amide <b>12</b> was accomplished in 16% overall yield after a four-step protocol by means of an <i>N</i>-alkylation of γ-carboline <b>45q</b>, as a key synthetic modification (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><div class="NLM_p">Fischer-indole synthesis starting from phenyl hydrazine <b>44a</b> in the presence of racemic <i>N</i>-<i>tert</i>-butoxycarbonyl protected 2-methyl-piperidin-4-one (<b>49</b>), 2,2-dimethyl piperidin-4-one (<b>56</b>), or 8-azabicyclo[3.2.1]octan-3-one (<b>58</b>) led to the corresponding tetrahydro- (<b>52</b>, <b>53</b>, <b>57</b>) and bridged- (<b>59</b>)<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> γ-carbolines. Not surprisingly, whereas mono-methyl intermediates <b>52</b> (1-methyl) and <b>53</b> (3-methyl) were obtained as a 2:8 regioisomeric mixture, 3,3-<i>gem</i>-dimethyl analogue <b>57</b> was afforded as the only regioisomer. γ-Carbolines <b>52</b>, <b>53</b>, <b>57</b>, and <b>59</b> were then converted to final compounds <b>32–35</b>, as racemates, by HATU-mediated coupling with 5-methyl-1<i>H</i>-pyrazole-3-carboxylic acid (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_p">Enantiomerically pure analogues <b>36</b> and <b>37</b> were obtained by semipreparative chiral separation starting from racemic <b>35</b>. The reaction with (<i>R</i>)- and (<i>S</i>)-2-methyl-piperidin-4-ones <b>50</b> and <b>51</b> afforded the corresponding methyl-substituted tetrahydro-pyridoindoles, as mixtures of 1-methyl and 3-methyl regioisomers. Chromatographic purification allowed to obtain pure regioisomers, which upon amide coupling with pyrazolyl carboxylic acid led to the desired substituted compounds. Whereas 3-methyl analogues (<i>R</i>)-<b>39</b> and (<i>S</i>)-<b>40</b> were afforded enantiomerically pure from the corresponding chiral intermediates <b>54</b> and <b>55</b>, a careful investigation revealed for 1-methyl substituted γ-carbolines a complete racemization of the stereogenic center, probably because of the relatively acidic character of allylic proton in C1-position, allowing a enamine–imine equilibrium during Fischer indole synthesis.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Therefore, the corresponding 1-methyl-substituted compounds (<i>S</i>)-<b>41</b> and (<i>R</i>)-<b>42</b> were isolated as enantioenriched compounds after semipreparative chiral separation starting from racemic <b>32</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_p">Compound <b>38</b>, featuring a substituted tetrahydroazepino-indole scaffold, was synthesized starting from Boc-protected azepan-4-one <b>60</b> with an analogous approach,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> as seen for the previously described tetrahydropyridine-indole analogues, though slightly forcing the reaction conditions (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Probably because of conformational constraints, Fischer indole synthesis of hydrazine <b>44a</b> with ketone <b>60</b> led only to hexahydroazepino-indole <b>61</b> with complete regioselectivity. The intermediate <b>61</b> underwent classical amide coupling with 5-trifluoromethyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) to obtain final compound <b>38</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 7-Fluoro-10-methyl-2,4,5,6-tetrahydro-1<i>H</i>-azepino[4,5-<i>b</i>]indol-3-yl Amide <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) <i>tert</i>-butyl 4-oxo-azepane-1-carboxylate (<b>60</b>), HCl (36%), EtOH, 80 °C, and 16 h; (ii) 5-methyl-1<i>H</i>-pyrazole-3-carboxylic acid, HATU, DIPEA, dry DMF, 0 °C to r.t., 16 h, and 7%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CF, the most frequent autosomal recessive disease, is a multiorgan disease, primarily affecting the lungs. CF mutations cause CFTR protein dysfunction by multiple mechanisms, affecting its expression, stability, or its function as an anion channel. CFTR modulators have been reported to address the basic defects caused by CF mutations restoring, at least partially, the CFTR function. In particular, small-molecule compounds, called potentiators, are known to ameliorate the gating defect.</div><div class="NLM_p">In the present work, we describe the identification of a novel chemotype of CFTR potentiators. The screening of a library of compounds provided a few hits featuring a common 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole core, which were able to rescue the activity of F508del- and G551D-CFTR in an effective manner.</div><div class="NLM_p">1,2,3,4-Tetrahydro-γ-carbolines represent a chemical class of well-studied heterocycles, extensively characterized for their chemical and biological properties; therefore, as reported by Ivashchenko,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> such tricyclic compounds could be regarded as typical “privileged structures”.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The sustained interest in this scaffold is due to the fact that tetrahydro-γ-carbolines and their derivatives have shown a broad spectrum of biological activities,<a onclick="showRef(event, 'ref49 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref49 ref51 ref52 ref53">(49,51−53)</a> primarily for the treatment of central nervous system diseases.<a onclick="showRef(event, 'ref36 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref36 ref54 ref55 ref56">(36,54−56)</a> Although in the last few years substituted derivatives of tetrahydro-γ-carbolines have been reported to be active toward different biological targets,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> to the best of our knowledge, this type of heterocyclic small molecules has never been described as pharmacologically active compounds for the treatment of CF or related conditions.</div><div class="NLM_p">The initial hits were validated and further explored in SAR studies, leading to the discovery of novel potentiators active in the mid-to-low nanomolar range. Among them, the enantiomerically pure compound <b>39</b> turned out to be quite promising being able to rescue the gating defect of both F508del-CFTR (in FRT and CFBE41o-cells) and G551D-CFTR (in FRT cells) with good potency and efficacy, similarly to VX-770. Notably, the tetrahydro-γ-carboline <b>39</b> did not affect the rescue efficacy of correctors VX-809 or <b>ARN23765</b> in immortalized bronchial CFBE41o-cells and in primary HBE cells from an F508del/F508del CF patient and increased by more than 2-fold the fraction of CFTR-mediated chloride current activated by submaximal cAMP stimulation in HBE cells from non-CF individuals.</div><div class="NLM_p">Furthermore, potentiator <b>39</b> showed good <i>in vitro</i> druglike properties and was therefore evaluated <i>in vivo</i> for its pharmacokinetic profile in rats. Following oral administration, significant exposure levels were obtained, leading to good oral bioavailability. A subsequent study showed that potentiator <b>39</b> distributed to the lung after oral administration to rats, with compound levels also detectable at 4 h postdosing.</div><div class="NLM_p last">To conclude, this study allowed the identification of <i>N</i><sup>2</sup>-acyl-substituted 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indoles as novel CFTR potentiators endowed with a good efficacy in rescuing the gating defect of F508del- and G551D-CFTR and a preliminary promising druglike profile. These findings represent a promising starting point to further improve and develop this chemical class, adding a new chemotype to the existing classes of CFTR potentiators, possibly expanding the current portfolio of therapeutic solutions for the treatment of CF.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Synthetic Materials and Methods</h4><div class="NLM_p last">Solvents and reagents were obtained from commercial suppliers and were used without further purification. Automated column chromatography purifications were performed on a Teledyne ISCO apparatus (CombiFlash Rf) with prepacked silica gel columns of different sizes (RediSep). NMR experiments were run at 300 K on a Bruker AVANCE III 400 system (400.13 MHz for <sup>1</sup>H and 100.62 MHz for <sup>13</sup>C), equipped with a BBI probe and <i>Z</i>-gradients, and Bruker FT NMR AVANCE III 600 MHz spectrometer equipped with a 5 mm CryoProbe QCI <sup>1</sup>H/<sup>19</sup>F–<sup>13</sup>C/<sup>15</sup>N–D quadruple resonance, a shielded <i>Z</i>-gradient coil and the automatic sample changer SampleJet NMR system (600 MHz for <sup>1</sup>H, 151 MHz for <sup>13</sup>C, and 565 MHz for <sup>19</sup>F). Chemical shifts for <sup>1</sup>H and <sup>13</sup>C spectra were reported in parts per million (ppm), calibrating the residual nondeuterated solvent peak for <sup>1</sup>H and <sup>13</sup>C, respectively, to 7.26 and 77.16 ppm for CDCl<sub>3</sub> and 2.50 and 39.52 ppm for DMSO-<i>d</i><sub>6</sub>, whereas spectra in D<sub>2</sub>O were referred to trimethylsilylpropanoic acid peak set at 0.00 ppm. Ultra performance liquid chromatography–mass spectrometry (UPLC/MS) analyses were performed on a Waters ACQUITY UPLC/MS system consisting of a single quadrupole detector (SQD) mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. Electrospray ionization in positive and negative mode was applied in the mass scan range 100–500 Da. The PDA range was 210–400 nm. The mobile phase was 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in CH<sub>3</sub>CN–H<sub>2</sub>O (95:5) at pH 5 (B) with 0.5 mL/min as the flow rate. For intermediates, the analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> column (100 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm). A linear gradient was applied: 0–0.2 min: 5% B; 0.2–2.2 min: 5–95% B; 2.2–2.3 min: 95–100% B; and 2.3–3.0 min: 100% B. For final compounds, a 10 mM DMSO stock solution of test compound was prepared in DMSO-<i>d</i><sub>6</sub> and further diluted 20-fold in CH<sub>3</sub>CN–H<sub>2</sub>O (1:1) for analysis. The analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> column (100 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm). A linear gradient was applied: 0–0.2 min: 10% B; 0.2–6.2 min: 10–90% B; 6.2–6.3 min: 90–100% B; and 6.3–7.0 min: 100% B. The purifications by high-performance liquid chromatography–mass spectrometry (HPLC/MS) were performed on a Waters AutoPurification system consisting of a 3100 Single Quadrupole mass spectrometer equipped with an electrospray ionization interface and a 2998 Photodiode Array Detector. The HPLC system included a 2747 Sample Manager, a 2545 Binary Gradient Module, a system fluidic organizer, and a 515 HPLC pump. Electrospray ionization in positive and negative modes was performed in the mass scan range of 100–500 Da. The PDA range was 210–400 nm. The purifications were run on a XBridge Prep C<sub>18</sub> OBD column (100 × 19 mm ID, particle size 5 μm) with a XBridge Prep C<sub>18</sub> (10 × 19 mm ID, particle size 5 μm) Guard cartridge with a flow rate of 20 mL/min. The analytical chiral separations were performed on a Waters Alliance HPLC instrument consisting of an e2695 Separation Module and a 2998 Photodiode Array Detector. The PDA range was 210–400 nm. The analyses were run in isocratic mode on Daicel ChiralPak AD column (250 × 4.6 mm ID, particle size 10 μm) with a flow rate of 1.0 mL/min. The semipreparative chiral separations were performed on a Waters Alliance HPLC instrument consisting of a 1525 Binary HPLC Pump, a Waters Fraction Collector III, and a 2998 Photodiode Array Detector. The separations were run in the isocratic mode on a Daicel ChiralPak AD column (250 × 10 mm ID, particle size 10 μm) with a ChiralPak AD Semi-Prep. Guard precolumn (50 × 10 mm ID, particle size 10 μm) at room temperature (r.t.), with a flow rate of 5.0 mL/min. High-resolution mass spectrometry (HRMS) measurements were performed on a Waters SYNAPT G2 Q-ToF mass spectrometer equipped with an electrospray ionization interface and coupled to a Waters ACQUITY UPLC. Leucine enkephalin (2 ng/mL) was used as the lock mass reference compound for spectral recalibration. The analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> column (100 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm). The mobile phase was H<sub>2</sub>O + 0.1% HCOOH (A) and CH<sub>3</sub>CN + 0.1% HCOOH (B) with 0.5 mL/min as the flow rate. A linear gradient was applied: 0–0.2 min: 10% B; 0.2–6.2 min: 10–90% B; 6.2–6.3 min: 90–100% B; and 6.3–7.0 min: 100% B. The synthesis and characterization of all final compounds <b>1–42</b> is reported below. Purity of the initial hits (Hit 1–Hit 6) and final compounds was determined by UPLC/MS and quantitative <sup>1</sup>H NMR (qNMR, see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf" class="ext-link">Supporting Information</a>) and was equal to or greater than 95% for all of the compounds, except for Hit-6 (80% purity) and analogue <b>15</b> (93% purity).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of Phenylhydrazine Hydrochlorides <b>44a,b</b></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (2-Fluoro-5-methyl-phenyl)hydrazine Hydrochloride (<b>44a</b>)</h4><div class="NLM_p last">2-Fluoro-5-methyl-aniline (<b>43a</b>) (1.0 g, 8.0 mmol, 1.0 equiv) was added at 0 °C to a vigorously stirred aqueous solution of HCl 36% (3.0 mL). To the thus-obtained suspension, a solution of sodium nitrite (1.0 g, 15.2 mmol, 1.9 equiv) and a solution of tin chloride (4.3 g, 19.2 mmol, 2.4 equiv) in HCl 6 M (7.7 mL) were added. The reaction mixture was stirred at r.t. for 24 h and basified with NaOH 12 M. The aqueous phase was extracted with Et<sub>2</sub>O (3 × 20 mL), and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and filtered. To obtain the hydrazine hydrochloride, a saturated solution of HCl in Et<sub>2</sub>O was added. The salt was filtered and washed with Et<sub>2</sub>O, obtaining the title compound as a white solid (0.6 g, 45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (s, 3H), 8.22 (s, 1H), 7.11 (dd, <i>J</i> = 11.7, 8.2 Hz, 1H), 7.04 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 6.77 (dddd, <i>J</i> = 8.3, 4.6, 2.1, 0.8 Hz, 1H), 2.25 (s, 3H).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (2-Fluoro-4-methoxy-phenyl)hydrazine Hydrochloride (<b>44b</b>)</h4><div class="NLM_p">The title compound was afforded following the protocol reported for the synthesis of <b>44a</b>, starting from 2-fluoro-3-methoxy-aniline (<b>43b</b>) (1.0 g, 7.1 mmol, 1.0 equiv), aq HCl 36% (2.6 mL), sodium nitrite (0.93 g, 13.5 mmol, 1.9 equiv), and tin chloride (3.84 g, 17.0 mmol, 2.4 equiv) in HCl 6 M (6.8 mL). Treatment with HCl in Et<sub>2</sub>O afforded the title compound as a white solid (0.7 g, 51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.02 (br s, 3H), 7.79 (s, 1H), 7.22 (dd, <i>J</i> = 9.8, 8.9 Hz, 1H), 6.88 (dd, <i>J</i> = 13.1, 2.7 Hz, 1H), 6.77 (ddd, <i>J</i> = 8.9, 2.8, 1.2 Hz, 1H); UPLC-MS: <i>t</i><sub>R</sub> = 1.42 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>7</sub>H<sub>10</sub>FN<sub>2</sub>O (M + H)<sup>+</sup>, 157.1; found, 157.3.</div><div class="NLM_p last">Substituted phenylhydrazine hydrochlorides (<b>44c–o</b>) were commercially available and used as such without further purification.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of Tetrahydro-γ-carbolines <b>45a–o</b>, <b>48</b>, <b>52–55</b>, <b>57</b>, and <b>59</b></h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedures <b>1a</b> (Gp1a)</h4><div class="NLM_p last">HCl 36% (11 equiv) was added to a solution 0.3 M of suitable hydrazine of type <b>I</b> (1.0 equiv) and ketone of type <b>II</b> (1.0 equiv) in EtOH. The reaction mixture was heated at 80 °C and stirred for 16 h. The suspension was filtered and washed with Et<sub>2</sub>O to furnish the title compound of type <b>III</b>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure <b>1b</b> (Gp1b)</h4><div class="NLM_p last">A solution of hydrazine of type <b>I</b> (1.0 equiv) and ketone of type <b>II</b> (1.0 equiv) in EtOH (0.5 M) was stirred at r.t., until the formation of hydrazone intermediate. 2,4,6-Trichloro-1,3,5-triazine (0.4 equiv) was added and the reaction mixture was heated to 90 °C for 8 h. The reaction mixture was cooled to r.t. and the obtained precipitate was filtered and washed with cold EtOH. The crude product of type <b>III</b> was used as such in the next step without further purification.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure <b>1c</b> (Gp1c)</h4><div class="NLM_p last">Hydrazine of type <b>I</b> (1.0 equiv) and ketone of type <b>II</b> (1.0 equiv) were dissolved in EtOH (0.2 M) and the reaction mixture was stirred at r.t. for 30 min, until the complete formation of hydrazone. The solvent was removed under reduced pressure and the crude mixture was dissolved in AcOH (0.1 M), followed by addition of trifluoroborate diethyletherate (2.0 equiv). The reaction was stirred at 90 °C for 16 h. The solvent was removed and the crude mixture was poured into an aq 2.0 M NaOH solution and extracted with dichloromethane (DCM), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product of type <b>III</b>, which was used in the next step without any further purification.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure <b>1d</b> (Gp1d)</h4><div class="NLM_p last">A suspension of hydrazine of type <b>I</b> (1.0 equiv) and ketone of type <b>II</b> (1.0 equiv) in toluene (0.2 M) was stirred at 50 °C until the formation of hydrazone intermediate. <i>p</i>-Toluenesulfonic acid (1.5 equiv) was added and the reaction mixture was heated to 120 °C for 24 h. The reaction mixture was cooled to r.t. and sat. aq Na<sub>2</sub>CO<sub>3</sub> solution was added until pH 8. The crude was extracted with DCM, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>under vacuo</i>. The compound of type <b>III</b> was isolated by chromatography on alumina using DCM/MeOH·NH<sub>3</sub> (1.0 N) as an eluent.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 6-Fluoro-9-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45a</b>)</h4><div class="NLM_p last">Following Gp1b, the title compound was obtained from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) (0.86 g, 4.90 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.98 g, 4.90 mmol) as a light orange solid (0.65 g, 95%). UPLC-MS: <i>t</i><sub>R</sub> = 1.31 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>14</sub>FN<sub>2</sub> (M + H)<sup>+</sup>, 205.1; found, 205.8.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 6-Fluoro-8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45b</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2-fluoro-4-methoxy-phenyl)hydrazine hydrochloride (<b>44b</b>) (0.48 g, 2.50 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.49 g, 2.50 mmol) in a mixture with trace amounts of 6-chloro-8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole, as a by-product. The crude product was used as such in the next step without further purification. UPLC-MS: <i>t</i><sub>R1</sub> = 1.39 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>13</sub>ClN<sub>2</sub>O (M + H)<sup>+</sup>, 237.1; found, 237.4; <i>t</i><sub>R2</sub> = 1.52 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>14</sub>FN<sub>2</sub>O (M + H)<sup>+</sup>, 221.1; found, 221.8.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 6-Methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45c</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from <i>o</i>-tolylhydrazine (<b>44c</b>) (0.14 g, 0.86 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.17 g, 0.86 mmol) as a white solid (0.07 g, 42%). UPLC-MS: <i>t</i><sub>R</sub> = 1.31 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 187.1; found, 187.2.</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 7-Methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45d′</b>) and 9-Methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45d″</b>)</h4><div class="NLM_p last">Following Gp1a, a mixture of the title compounds was obtained from (3-methyl)phenylhydrazine hydrochloride (<b>44d</b>) (1.5 g, 9.46 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (1.88 g, 9.46 mmol) as a white solid (1.04 g, 50% combined). UPLC-MS: <i>t</i><sub>R1</sub> = 1.27 min, <i>t</i><sub>R2</sub> = 1.31 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 187.1; found, 187.1.</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 8-Isopropyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45e</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (4-isopropylphenyl)hydrazine (<b>44e</b>) (0.21 g, 1.1 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.22 g, 1.1 mmol) as a white solid (0.10 g, 42%). UPLC-MS: <i>t</i><sub>R</sub> = 1.67 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>19</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 215.1; found, 215.2.</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-Fluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45f</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2-fluorophenyl)hydrazine hydrochloride (<b>44f</b>) (0.68 g, 4.2 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.84 g, 4.2 mmol), after purification by trituration with chilled ethanol, as the solvent. The solid was partitioned between EtOAc (50 mL) and sat. aq NaHCO<sub>3</sub> sol. (50 mL). The organic phase was separated, washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered and the solvent evaporated under reduced pressure. The crude residue was purified by silica gel flash column chromatography, with DCM/MeOH/Et<sub>3</sub>N (9:1:0.1) as the eluent, to afford the title compound as an off-white solid (0.04 g, 5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.25 (s, 1H), 7.16 (d, <i>J</i> = 7.7 Hz, 1H), 6.96–6.77 (m, 1H), 3.94 (s, 2H), 3.11 (t, <i>J</i> = 5.8 Hz, 2H), 2.75 (t, <i>J</i> = 5.8 Hz, 2H); UPLC-MS: <i>t</i><sub>R</sub> = 1.25 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>12</sub>FN<sub>2</sub> (M + H)<sup>+</sup>, 191.1; found, 191.1.</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 8-(Trifluoromethyl)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45g</b>)</h4><div class="NLM_p last">Following GP1c, the title compound was obtained from (4-trifluoromethylphenyl)hydrazine (<b>44g</b>) (0.5 g, 2.35 mmol) and 4-oxopiperidine-1-carboxylate (0.24 g, 2.35 mmol) as a white solid (0.11 g, 20%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.68 (s, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 1H), 7.27 (d, <i>J</i> = 8.6 Hz, 1H), 3.88 (d, <i>J</i> = 4.9 Hz, 2H), 3.02 (q, <i>J</i> = 5.5 Hz, 2H), 2.70 (t, <i>J</i> = 5.7 Hz, 2H). UPLC-MS: <i>t</i><sub>R</sub> = 1.59 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 241.1; found, 242.1.</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 8-(Trifluoromethoxy)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45h</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (4-trifluoromethoxy)hydrazine hydrochloride (<b>44h</b>) (0.67 g, 2.92 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.58 g, 2.92 mmol), after purification by trituration with chilled ethanol, as the solvent. The solid was partitioned between EtOAc (50 mL) and sat. aq NaHCO<sub>3</sub> sol. (50 mL). The organic phase was separated, washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the solvent was evaporated under reduced pressure. The crude residue was purified by silica gel flash column chromatography, with DCM/MeOH (9:1) as the eluent, to afford the title compound as a yellow solid (0.6 g, 8%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.11 (s, 1H), 7.41–7.23 (m, 2H), 6.97 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 3.94 (s, 2H), 3.12 (t, <i>J</i> = 5.8 Hz, 2H), 2.76 (t, <i>J</i> = 5.8 Hz, 2H); UPLC-MS: <i>t</i><sub>R</sub> = 1.64 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O (M + H)<sup>+</sup>, 257.1; found, 257.2.</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2,3,4,5-Tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole-8-carbonitrile (<b>45j</b>)</h4><div class="NLM_p last">Following GP1c, the title compound was obtained from 4-hydrazinobenzonitrile hydrochloride (<b>44j</b>) (0.07 g, 0.31 mmol) and piperidin-4-one hydrochloride (0.042 g, 0.31 mmol), after purification by trituration with chilled ethanol as the solvent, as a yellow solid (0.045 g, 73%). UPLC-MS: <i>t</i><sub>R</sub> = 1.10 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>12</sub>N<sub>3</sub> (M + H)<sup>+</sup>, 198.1; found, 198.1.</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 8-Methylsulfonyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45k</b>)</h4><div class="NLM_p last">Following Gp1c, the title compound was obtained from (4-methylsulfonylphenyl)hydrazine hydrochloride (<b>44k</b>) (0.90, 0.4 mmol) and piperidin-4-one hydrochloride (0.055 g, 0.4 mmol), after purification by trituration with DCM, as the solvent, as a yellow solid (0.1 g, quant.). UPLC-MS: <i>t</i><sub>R</sub> = 1.08 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub>S (M + H)<sup>+</sup>, 251.1; found, 251.1.</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 6-Fluoro-8-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole Hydrochloride (<b>45i</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2-fluoro-4-methyl-phenyl)hydrazine hydrochloride (<b>44i</b>) (0.23 g, 1.32 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.26 g, 1.32 mmol) as a brown solid (0.17 g, 63%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.46 (s, 1H), 7.08 (s, 1H), 6.79 (d, <i>J</i> = 12.4 Hz, 1H), 4.27 (s, 2H), 3.47 (t, <i>J</i> = 6.1 Hz, 2H), 3.00 (t, <i>J</i> = 6.0 Hz, 2H), 2.37 (s, 3H). UPLC-MS: <i>t</i><sub>R</sub> = 1.44 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>14</sub>FN<sub>2</sub> (M + H)<sup>+</sup>, 205.1; found, 205.2.</div></div><div id="sec5_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 6,8-Difluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45l</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2,4-difluoro-phenyl)hydrazine hydrochloride (<b>44l</b>) (0.26 g, 1.41 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.28 g, 1.41 mmol) as a brown solid (0.15 g, 51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.76 (s, 1H), 9.28 (s, 2H), 7.19 (dd, <i>J</i> = 9.4, 2.2 Hz, 1H), 6.98 (ddd, <i>J</i> = 11.7, 9.8, 2.3 Hz, 1H), 4.26 (s, 2H), 3.46 (t, <i>J</i> = 6.1 Hz, 2H), 3.03 (t, <i>J</i> = 6.1 Hz, 2H). UPLC-MS: <i>t</i><sub>R</sub> = 1.35 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>11</sub>F<sub>2</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 209.1; found, 209.3.</div></div><div id="sec5_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-Fluoro-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45m</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2-fluoro-4-trifluoromethylphenyl)hydrazine (<b>44m</b>) (0.56 g, 2.42 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.48 g, 2.42 mmol) as a brown solid (0.2 g, 32%). UPLC-MS: <i>t</i><sub>R</sub> = 1.41 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>11</sub>F<sub>4</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 259.1; found, 259.1.</div></div><div id="sec5_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6,9-Difluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole Hydrochloride (<b>45n</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2,5-difluorophenyl)hydrazine hydrochloride (<b>44n</b>) (0.55 g, 3.06 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.61 g, 3.06 mmol) as a brown solid (0.14 g, 22%). UPLC-MS: <i>t</i><sub>R</sub> = 1.69 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>11</sub>F<sub>2</sub>N<sub>2</sub> (M + H)<sup>+</sup>, 209.1; found, 209.5.</div></div><div id="sec5_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 9-Fluoro-6-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole Hydrochloride (<b>45o</b>)</h4><div class="NLM_p">Following Gp1a, the title compound was obtained from (5-fluoro-2-methyl-phenyl)hydrazine (<b>44o</b>) (0.48 g, 2.64 mmol) and <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (0.52 g, 2.64 mmol) as a brown solid (0.14 g, 26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 6.87–6.80 (m, 1H), 6.68 (dd, <i>J</i> = 10.8, 7.9 Hz, 1H), 4.38 (s, 2H), 3.46 (t, <i>J</i> = 6.1 Hz, 2H), 3.03 (t, <i>J</i> = 6.2 Hz, 2H), 2.40 (s, 3H). UPLC-MS: <i>t</i><sub>R</sub> = 1.44 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>14</sub>FN<sub>2</sub> (M + H)<sup>+</sup>, 205.1; found, 205.3.</div><div class="NLM_p last">2,3,4,5-Tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45p</b>), 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>), 8-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45r</b>), and 8-fluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45s</b>) were commercially available and used as such without further purification.</div></div><div id="sec5_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>rac</i>)-6-Fluoro-1,9-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>52</b>)</h4><div class="NLM_p last">Following Gp1d, starting from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) (1.35 g, 7.64 mmol) and racemic <i>tert</i>-butyl 2-methyl-4-oxo-piperidine-1-carboxylate (<b>49</b>) (1.5 g, 7.64 mmol), a crude mixture of regioisomers <b>52</b>/<b>53</b> in a 20:80 ratio (by <sup>1</sup>H NMR) was afforded. Purification by neutral alumina column chromatography with DCM/MeOH/NH<sub>3</sub> (95:5:0.1) afforded the title compound as a pure regioisomer as a brown resin (0.1 g, 6%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.06 (br s), 6.66 (dd, <i>J</i> = 11.1, 7.6 Hz, 1H), 6.58–6.61 (m, 1H), 4.39 (q, <i>J</i> = 6.5 Hz, 1H), 3.10 (ddd, <i>J</i> = 13.1, 10.2, 4.9 Hz, 1H), 2.97 (ddd, <i>J</i> = 12.8, 6.1, 2.2 Hz, 1H), 2.66 (m, 1H), 2.56 (ddd, <i>J</i> = 16.0, 4.8, 2.0 Hz, 1H), 2.50 (s, 3H), 1.37 (d, <i>J</i> = 6.5 Hz, 3H). UPLC-MS: <i>t</i><sub>R</sub> = 1.46 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>2</sub>O (M + H)<sup>+</sup>, 218.27; found, 219.4.</div></div><div id="sec5_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>rac</i>)-6-Fluoro-3,9-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>53</b>)</h4><div class="NLM_p last">Following Gp1d, starting from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) (1.35 g, 7.64 mmol) and racemic <i>tert</i>-butyl 2-methyl-4-oxo-piperidine-1-carboxylate (<b>49</b>) (1.5 g, 7.64 mmol), a crude mixture of regioisomers <b>52</b>/<b>53</b> in a 20:80 ratio (by <sup>1</sup>H NMR) was afforded. Purification by neutral alumina column chromatography with DCM/MeOH/NH<sub>3</sub> (95:5:0.1) afforded the title compound as a pure regioisomer as a brown resin (0.48 g, 29%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.03 (br s), 6.64 (dd, <i>J</i> = 11.3, 7.6 Hz, 1H), 6.57 (ddd, <i>J</i> = 7.9, 4.8, 0.7 Hz, 1H), 4.17 (dd, <i>J</i> = 14.8, 1.1 Hz, 1H), 4.08 (<i>app</i>-dt, <i>J</i> = 14.8, 1.8, 1.8 Hz, 1H), 2.89 (m, 1H), 2.67 (ddd, <i>J</i> = 17.5, 3.5, 1.5 Hz, 1H), 2.34 (m, 1H), 2.44 (s, 3H), 1.18 (d, <i>J</i> = 6.3 Hz, 3H). UPLC-MS: <i>t</i><sub>R</sub> = 1.46 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>2</sub>O (M + H)<sup>+</sup>, 218.27; found, 219.4.</div></div><div id="sec5_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>R</i>)-6-Fluoro-3,9-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>54</b>)</h4><div class="NLM_p last">Following Gp1d, starting from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) and enantiomerically pure (<i>R</i>)-<i>tert</i>-butyl 2-methyl-4-oxo-piperidine-1-carboxylate (<b>50</b>), a crude mixture of regioisomers <b>52</b><a class="ref internalNav" href="#fn5" aria-label="a">a</a>/<b>54</b> in a ca. 20:80 ratio (by <sup>1</sup>H NMR) was afforded. Purification by neutral alumina column chromatography with DCM/MeOH/NH<sub>3</sub> (95:5:0.1) afforded the title compound as a pure regioisomer as a brown resin (0.8 g, 30%).</div></div><div id="sec5_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>S</i>)-6-Fluoro-3,9-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>55</b>)</h4><div class="NLM_p last">Following Gp1d, starting from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) and enantiomerically pure (<i>S</i>)-<i>tert</i>-butyl 2-methyl-4-oxo-piperidine-1-carboxylate (<b>51</b>), a crude mixture of regioisomers <b>52</b><a class="ref internalNav" href="#fn6" aria-label="b">b</a>/<b>55</b> in a ca. 20:80 ratio (by <sup>1</sup>H NMR) was afforded. Purification by neutral alumina column chromatography with DCM/MeOH/NH<sub>3</sub> (95:5:0.1) afforded the title compound as a pure regioisomer as a brown resin (0.8 g, 30%).</div></div><div id="sec5_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-Fluoro-3,3,9-trimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>57</b>)</h4><div class="NLM_p last">Following GP1d, starting from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) (0.3 g, 1.72 mmol) and <i>tert</i>-butyl 2,2-dimethyl-4-oxo-piperidine-1-carboxylate (<b>56</b>) (0.34 g, 1.72 mmol), the title compound was obtained as a pure regioisomer, after purification by neutral alumina chromatography with DCM/MeOH/NH<sub>3</sub> (95:5:0.1), as a brown solid (0.06 g, 15%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.28 (br s, 1H), 6.62–6.72 (m, 2H), 4.28 (s, 2H), 2.52 (s, 2H), 2.35 (s, 3H), 1.42 (s, 6H). UPLC-MS: <i>t</i><sub>R</sub> = 1.46 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>17</sub>FN<sub>2</sub> (M + H)<sup>+</sup>, 233.3; found, 233.5.</div></div><div id="sec5_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-Fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indole Hydrochloride (<b>59</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) (0.43 g, 2.47 mmol) and <i>tert</i>-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (<b>58</b>) (0.53 g, 2.47) as a white solid (0.21 g, 37%). UPLC-MS: <i>t</i><sub>R</sub> = 1.56 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>16</sub>FN<sub>2</sub> (M + H)<sup>+</sup>, 231.1; found, 231.3.</div></div><div id="sec5_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 8-Methoxy-5-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>48</b>)</h4><div id="sec5_3_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Step 1: <i>tert</i>-Butyl 8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indole-2-carboxylate (<b>46</b>)</h5><div class="NLM_p last">To a cooled suspension of 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.25 g, 1.24 mmol) in dry DCM (7.0 ml) at 0 °C were added <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) (0.04 ml) and di-<i>tert</i>-butyl dicarbonate (0.28 g, 1.30 mmol). The resulting white mixture was stirred at r.t. for 1 h under the nitrogen atmosphere. Sat. aq NH<sub>4</sub>Cl solution (3 mL) was added, and the resulting aqueous phase was extracted twice with DCM (2 × 3 mL). The collected organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to afford the title compound (0.33 g, 88%), which was used in the next step without any further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.69 (1H, NH), 7.17 (d, <i>J</i> = 8.7 Hz, 1H), 6.88 (br s, 1H), 6.66 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 4.49 (br s, 2H), 3.74 (s, 3H), 3.69 (t, <i>J</i> = 5.6 Hz, 2H), 2.74 (t, <i>J</i> = 5.6 Hz, 2H), 1.44 (s, 9H). UPLC-MS: <i>t</i><sub>R</sub> = 2.28 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> (M – H)<sup>−</sup><i>m</i>/<i>z</i>: 301.3; found, 301.1 (M – H)<sup>−</sup>.</div></div><div id="sec5_3_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Step 2: <i>tert</i>-Butyl 8-Methoxy-5-methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indole-2-carboxylate (<b>47</b>)</h5><div class="NLM_p last">In a flame-dried Schlenk reactor, under the nitrogen atmosphere, sodium hydride (60% dispersion in mineral oil) (0.025 g, 0.621 mmol) was suspended in dry dimethylformamide (DMF) (3.0 mL). The mixture was cooled to 0 °C and intermediate <b>46</b> (0.15 g, 0.50 mmol) was added followed, after 30 min, by dropwise addition of iodomethane (0.038 mL, 0.61 mmol). The mixture turned yellow and was stirred at r.t. for 16 h, and then cooled water (5 mL) was added dropwise to the crude mixture. A white precipitate was formed, filtered, washed with water, and dried under high vacuum to afford the pure title compound (0.144 g, 91%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.29 (d, <i>J</i> = 8.7 Hz, 1H), 6.93 (br s, 1H), 6.74 (d, <i>J</i> = 8.7 Hz, 1H), 4.50 (br s, 2H), 3.75 (s, 3H), 3.71 (t, <i>J</i> = 5.8 Hz, 2H), 3.58 (s, 3H), 2.77 (t, <i>J</i> = 5.8 Hz, 2H), 1.44 (s, 9H). UPLC-MS: <i>t</i><sub>R</sub> = 2.49 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 317.4; found, 317.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_26_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> Step 3: 8-Methoxy-5-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>48</b>)</h5><div class="NLM_p last">To a solution of <b>47</b> (0.12 g, 0.39 mmol) in dry DCM (3.0 mL), HCl (4.0 M) in dioxane (1.16 mL, 4.66 mmol) was added dropwise at r.t. During addition, the mixture turned dark. After being stirred at r.t. for 20 h, the solvents were removed under vacuum and the residue was treated with water (2 mL) and NaOH until pH 12 and extracted with DCM (3 × 3 mL). The organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated <i>in vacuo</i>, affording the title compound (0.083 g, 81%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.24 (d, <i>J</i> = 8.7 Hz, 1H), 6.83 (d, <i>J</i> = 2.4 Hz, 1H), 6.69 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 3.80 (br s, 2H), 3.73 (s, 3H), 3.56 (s, 3H), 3.51 (s, 1H, NH), 3.28 (br s, 2H), 3.02 (t, <i>J</i> = 5.6 Hz, 2H). UPLC-MS: <i>t</i><sub>R</sub> = 1.28 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>O (M + H)<sup>+</sup>, <i>m</i>/<i>z</i>: 217.3; found, 217.0 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 7-Fluoro-10-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-<i>b</i>]indole Hydrochloride (<b>61</b>)</h4><div class="NLM_p last">Following Gp1a, the title compound was obtained from (2-fluoro-5-methyl-phenyl)hydrazine hydrochloride (<b>44a</b>) (0.58 g, 3.29 mmol) and <i>tert</i>-butyl 4-oxo-azepane-1-carboxylate (<b>60</b>) (0.7 g, 3.29 mmol) as a brown solid (0.2 g, 28%). UPLC-MS: <i>t</i><sub>R</sub> = 1.69 min; MS calcd for C<sub>13</sub>H<sub>15</sub>FN<sub>2</sub><i>m</i>/<i>z</i>: 217.32; found, 218.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Preparation of Tetrahydro-γ-carboline <b>1–42</b> (<a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch4" aria-label="4">4</a>)</h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> General Procedure 1 (GP1)</h4><div class="NLM_p last">The properly substituted 2,3,4,5-tetrahydropyrido[4,3-<i>b</i>]indole or hexahydroazepino[4,5-<i>b</i>]indole (1.0 equiv) and the desired, commercially available carboxylic acid (1.1 equiv), placed in a moisture-free round-bottom flask, were dissolved in anhydrous DMF (from 0.5 to 2.0 mL) under the argon atmosphere and cooled to 0 °C in an ice bath. The chosen coupling agent and a base, usually HATU (1.2 equiv) and DIPEA (2.0 equiv), were added to the reaction mixture, and the suspension was stirred at 0 °C for 30 min, then warmed to 25 °C, and stirred for 16 h. Work-up was then started: EtOAc was added to the reaction mixture, and the organic phase was washed with HCl 1.0 M (3 × 2 mL), followed by NaHCO<sub>3</sub> SS (3 × 2 mL) and brine (3 × 2 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Crude product was purified by flash chromatography (eluting mixture composed by EtOAc in cyclohexane or DCM in MeOH) and eventually triturated with 10–20% DCM in <i>n</i>-pentane or 100% cyclohexane. The purified product was dried in Hi-Vac or lyophilized when necessary.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> General Procedure 2 (GP2)</h4><div class="NLM_p last">Commercially available carboxylic acid (1.0 equiv), substituted 2,3,4,5-tetrahydropyrido[4,3-<i>b</i>]indole (1.0 equiv), Et<sub>3</sub>N (2.0 equiv), and EDC·HCl (1.1 equiv) were dissolved in DCM (0.15–0.2 M solution) and stirred at r.t. for 16 h. The reaction was quenched with aq. HCl 2.0 M solution (10 mL), and the aqueous phase was extracted with EtOAc (2 × 5 mL). The combined extracts were washed with water (2 mL), brine (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product. The crude product was purified by flash chromatography (eluting mixture composed by EtOAc in cyclohexane or DCM in MeOH) and eventually triturated with 10–20% DCM in <i>n</i>-pentane or 100% cyclohexane. The purified product was dried in Hi-Vac or lyophilized when necessary.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (6-(Dimethylamino)-1<i>H</i>-indol-2-yl)-(1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)methanone (<b>1</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45p</b>) (0.05 g, 0.13 mmol) and 6-(dimethylamino)-1<i>H</i>-indole-2-carboxylic acid (<b>A</b>) (0.03 g, 0.13 mmol) after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O (A) and CH<sub>3</sub>CN (B); linear gradient: 0–0.5 min 10% B; and 0.5–7.0 min 100% B] as a white solid (0.014 g, 34%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.11 (s, 1H, NH), 10.97 (s, 1H, NH), 7.46 (d, <i>J</i> = 8.6 Hz, 1H), 7.44 (d, <i>J</i> = 8.4 Hz, 1H), 7.31 (d, <i>J</i> = 8.0 Hz, 1H), 7.04 (t, <i>J</i> = 7.6 Hz, 1H), 6.96 (t, <i>J</i> = 7.5, Hz, 1H), 6.85 (s, 1H), 6.74 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.63 (d, <i>J</i> = 2.2 Hz, 1H), 4.93 (s, 2H), 4.10 (s, 2H), 2.97 (s, 2H), 2.92 (s, 6H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.8 (Cq), 148.4 (Cq), 137.9 (Cq), 135.9 (Cq), 132.7 (Cq), 127.8 (Cq), 125.1 (Cq), 121.8 (CH), 120.7 (CH), 119.1 (Cq), 118.6 (CH), 117.2 (CH), 111.0 (CH), 110.0 (CH), 105.7 (Cq), 104.4 (CH). 93.8 (CH), 44.0 (CH<sub>2</sub>), 41.0 (CH<sub>3</sub>, 2C), 40.0 (CH<sub>2</sub>), 23.5 (CH<sub>2</sub>). UPLC-MS: <i>t</i><sub>R</sub> = 2.27 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 359.2; found, 359.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 359.1872; found, 359.1862.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (1-Phenyl-1<i>H</i>-pyrazol-4-yl)-(1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)methanone (<b>2</b>)</h4><div class="NLM_p last">Following GP1, the title compound <b>2</b> was obtained from commercially available 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45p</b>) (0.06 g, 0.32 mmol) and 1-phenylpyrazole-4-carboxylic acid (<b>B</b>) (0.03 g, 0.32 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (8:2) as the eluent, as a white solid (0.03 g, 26%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 56/44 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.97 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 8.90 (s, 1H, C<i>a</i> + <i>Cb</i>), 8.08 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.94 (m, 2H, C<i>a</i> + <i>Cb</i>), 7.55–7.52 (m, 2H, C<i>a</i> + <i>Cb</i>), 7.46 (d, <i>J</i> = 7.8 Hz, 1H, C<i>a</i> + <i>Cb</i>), 7.37 (tt, <i>J</i> = 7.4, 1.1 Hz, 1H, C<i>a</i> + <i>Cb</i>), 7.31 (d, <i>J</i> = 8.3 Hz, 1H, C<i>a</i> + <i>Cb</i>), 7.04 (br s, 1H, C<i>a</i> + <i>Cb</i>), 6.96 (s, 1H, C<i>a</i> + <i>Cb</i>), 4.94 (m, 2H <i>Cb</i>), 4.77 (m, 2H, C<i>a</i>), 3.98 (m, 2H, C<i>a</i> + <i>Cb</i>), 3.00 (s, 2H, C<i>a</i>), 2.88 (s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.0 (Cq, C<i>a</i> + <i>Cb</i>), 141.4 (CH, <i>Cb</i>), 140.9 (CH, C<i>a</i>), 139.2 (Cq, C<i>a</i> + <i>Cb</i>), 135.9 (Cq, C<i>a</i> + <i>Cb</i>), 132.7 (Cq, C<i>a</i> + <i>Cb</i>), 129.6 (CH, 2C, C<i>a</i> + <i>Cb</i>), 129.2 (Cq, <i>Cb</i>), 128.7 (Cq, C<i>a</i>), 126.9 (CH, C<i>a</i> + <i>Cb</i>), 125.2 (Cq, C<i>a</i>), 125.0 (Cq, <i>Cb</i>), 120.7 (CH, C<i>a</i> + <i>Cb</i>), 119.1 (CH, C<i>a</i> + <i>Cb</i>), 118.9 (CH, 2C, C<i>a</i> + <i>Cb</i>), 118.5 (CH, C<i>a</i> + <i>Cb</i>), 117.3 (CH, C<i>a</i> + <i>Cb</i>), 110.9 (CH, C<i>a</i> + <i>Cb</i>), 105.5 (Cq, C<i>a</i> + <i>Cb</i>), 44.8 (CH<sub>2</sub>, C<i>a</i>), 44.7 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 24.0 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, C<i>b</i>). UPLC-MS: <i>t</i><sub>R</sub> = 2.12 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 343.1; found, 343.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 343.1559; found, 343.1552.</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (8-Methoxy-1,3,4,5-tetrahydropyrido[4,3-<i>b</i>]indol-2-yl)-[5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl]methanone (<b>3</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.04 g, 0.20 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.036 g, 0.20 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (8:2) as the eluent, as a white solid (0.055 g, 76%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 64/36 ratio. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.38 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 10.79 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.26 (br s, 1H, <i>Cb</i>), 7.19 (m, 2H, C<i>a</i>, 1H, <i>Cb</i>), 7.00 (br s, 1H, C<i>a</i>), 6.95 (br s, 1H, <i>Cb</i>), 6.68 (d, <i>J</i> = 8.3 Hz, 1H, C<i>a</i> + <i>Cb</i>), 4.84 (m, 2H, C<i>a</i>), 4.78 (s, 2H, <i>Cb</i>), 4.00 (s, 2H, <i>Cb</i>), 3.92 (s, 2H, C<i>a</i>), 3.76 (s, 3H, C<i>a</i>), 3.72 (s, 3H, <i>Cb</i>), 2.96 (s, 2H, C<i>a</i>), 2.87 (s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.4 (Cq, C<i>a</i>), 159.1 (Cq, <i>Cb</i>), 153.2 (Cq, C<i>a</i> + <i>Cb</i>), 140.9 (Cq, <sup>2</sup><i>J</i><sub>CF</sub> = 39.2 Hz, C<i>a</i> + <i>Cb</i>), 137.7 (Cq, C<i>a</i> + <i>Cb</i>), 133.2 (Cq, <i>Cb</i>), 132.8 (Cq, C<i>a</i>), 130.9 (Cq, C<i>a</i> + <i>Cb</i>), 125.5 (Cq, C<i>a</i>), 125.2 (Cq, <i>Cb</i>), 121.0 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.0 Hz, Cq, CF3, C<i>a</i> + <i>Cb</i>), 111.6 (CH, C<i>a</i> + <i>Cb</i>), 110.5 (CH, C<i>a</i> + <i>Cb</i>), 104.9 (Cq, C<i>a</i> + <i>Cb</i>), 104.7 (CH, <i>Cb</i>), 104.0 (CH, C<i>a</i>) 99.9 (CH, <i>Cb</i>), 99.6 (CH, C<i>a</i>), 55.4 (CH<sub>3</sub>, <i>Cb</i>), 55.3 (CH<sub>3</sub>, C<i>a</i>), 44.6 (CH<sub>2</sub>, <i>Cb</i>), 44.4 (CH<sub>2</sub>, C<i>a</i>), 40.0 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.7 (s) UPLC-MS: <i>t</i><sub>R</sub> = 2.00 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 365.1; found, 365.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 365.1225; found, 365.1217.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (8-Methoxy-1,3,4,5-tetrahydropyrido[4,3-<i>b</i>]indol-2-yl)-(1<i>H</i>-pyrazol-3-yl)methanone (<b>4</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.07 g, 0.35 mmol) and 1<i>H</i>-pyrazole-3-carboxylic acid (<b>D</b>) (0.039 g, 0.35 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (55:45) as the eluent, as a white solid (0.03 g, 30%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 64/36 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.26 (br s, NH, 1H, C<i>a</i> + <i>Cb</i>), 10.71 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.79 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.19 (d, <i>J</i> = 8.6 Hz, 1H, C<i>a</i> + <i>Cb</i>), 6.99 (br s, 1H C<i>a</i>), 6.77 (br s, <i>Cb</i>), 6.68 (m, 1H, C<i>a</i> + <i>Cb</i>), 6.62 (s, 1H, C<i>a</i> + <i>Cb</i>), 5.02 (br s, 2H, <i>Cb</i>), 4.77 (br s, C<i>a</i>), 4.14 (br s, 2H, C<i>a</i>), 3.99 (br s, 2H, <i>Cb</i>), 3.77 (br s, 2H, C<i>a</i>), 3.72 (2H, <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.5 (Cq, C<i>a</i> + <i>Cb</i>), 153.6 (Cq, C<i>a</i> + <i>Cb</i>), 133.9 (Cq, C<i>a</i>), 133.6 (Cq, <i>Cb</i>), 131.4 (Cq, C<i>a</i> + <i>Cb</i>), 129.7 (Cq, C<i>a</i> + <i>Cb</i>), 129.9 (CH, C<i>a</i> + <i>Cb</i>, extrapolated from HSQC), 126.1 (Cq, C<i>a</i>), 125.7 (Cq, <i>Cb</i>), 112.0 (CH, C<i>a</i> + <i>Cb</i>), 110.8 (CH, C<i>a</i> + <i>Cb</i>), 107.3 (CH, C<i>a</i> + <i>Cb</i>), 106.4 (Cq, <i>Cb</i>), 106.0 (Cq, C<i>a</i>), 100.1 (CH, C<i>a</i>), 99.8 (CH, <i>Cb</i>), 44.7 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.5 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 24.7 (CH<sub>2</sub>, C<i>a</i>), 23.4 (CH<sub>2</sub>, <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 1.52 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 297.1; found, 297.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 297.1352; found, 297.1336.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-methyl-1<i>H</i>-pyrazol-3-yl)methanone (<b>5</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.04 g, 0.20 mmol) and 5-methyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>E</b>) (0.25 g, 0.20 mmol), after purification by silica gel flash column chromatography with DCM/MeOH (95:5) as the eluent, as an off-white solid (0.058 g, 95%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 71/29 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.85 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.70 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 7.18 (m, 1H, C<i>a</i> + <i>Cb</i>), 6.98 (s, 1H, C<i>a</i>), 6.76 (s, 1H, <i>Cb</i>), 6.68 (m, 1H, C<i>a</i> + <i>Cb</i>), 6.30 (m, 1H, C<i>a</i> + <i>Cb</i>), 5.06 (s, 2H, <i>Cb</i>), 4.75 (s, 2H, C<i>a</i>), 4.18–3.98 (m, 2H, C<i>a</i> + <i>Cb</i>), 3.77 (s, 3H, C<i>a</i>), 3.73 (s, 3H, <i>Cb</i>), 2.89–2.97 (m, 2H, C<i>a</i> + <i>Cb</i>), 2.28 (m, 3H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.3 (Cq, C<i>a</i> + <i>Cb</i>), 153.1 (Cq, C<i>a</i> + <i>Cb</i>), 147.2 (Cq, C<i>a</i> + <i>Cb</i>), 138.7 (Cq, C<i>a</i> + <i>Cb</i>), 133.4 (Cq, <i>Cb</i>), 133.1 (Cq, C<i>a</i>), 130.9 (Cq, C<i>a</i> + <i>Cb</i>), 125.6 (Cq, C<i>a</i>), 125.2 (Cq, <i>Cb</i>), 111.5 (CH, C<i>a</i> + <i>Cb</i>), 110.2 (CH, C<i>a</i> + <i>Cb</i>), 106.0 (Cq, C<i>a</i> + <i>Cb</i>), 105.9 (CH, C<i>a</i>), 105.5 (CH, <i>Cb</i>), 99.6 (CH, C<i>a</i>), 99.2 (CH, <i>Cb</i>), 55.3 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 44.0 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 24.2 (CH<sub>2</sub>, C<i>a</i>), 22.96 (CH<sub>2</sub>, <i>Cb</i>), 10.16 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 1.61 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 311.1; found, 311.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 311.1508; found 311.1502.</div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido-(5-isopropyl-1<i>H</i>-pyrazol-3-yl)-[4,3-<i>b</i>]indol-2-yl)methanone (<b>6</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.04 g, 0.20 mmol) and 5-isopropyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>F</b>) (0.031 g, 0.20 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (7:3) as the eluent, as a pink solid (0.052 g, 78%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 69/31 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.95 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.73 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 7.19–7.16 (m, 1H, C<i>a</i> + <i>Cb</i>), 6.98 (s, 1H, C<i>a</i>), 6.75 (s, 1H, <i>Cb</i>), 6.69–6.66 (m, 1H, C<i>a</i> + <i>Cb b</i>), 6.36 (m, 1H, C<i>a</i> + <i>Cb</i>), 5.11 (s, 2H, <i>Cb b</i>), 4.74 (2H, C<i>a</i>), 4.20 (dd, <i>J</i> = 5.5, 5.5 Hz, 2H, C<i>a</i>), 3.97 (dd, <i>J</i> = 5.5, 5.5 Hz 2H, <i>Cb</i>), 3.76 (s, 3H, C<i>a</i>), 3.72 (s, 3H, <i>Cb</i>), 2.99 (quint, <i>J</i> = 6.9 Hz, 1H, C<i>a</i> + <i>Cb</i>), 2.88 (dd, <i>J</i> = 5.3, 5.3 Hz, 2H, C<i>a</i>), 2.82 (dd, <i>J</i> = 5.0, 5.0 Hz, 2H, C<i>a</i>), 1.25 (s, 6H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.3 (Cq, C<i>a</i> + <i>Cb</i>), 153.1 (Cq, C<i>a</i> + <i>Cb</i>), 149.8 (Cq, C<i>a</i>), 149.7 (Cq, <i>Cb</i>), 146.9 (Cq, C<i>a</i> + <i>Cb b</i>), 133.5 (Cq, <i>Cb</i>), 133.2 (Cq, C<i>a</i>), 130.9 (Cq, <i>Cb</i>), 125.7 (Cq, <i>Cb</i>), 125.2 (Cq, C<i>a</i>), 111.6 (CH, <i>Cb</i>), 111.5 (CH, C<i>a</i>), 110.3 (CH, C<i>a</i> + <i>Cb</i>), 106.1 (Cq, <i>Cb</i>), 105.6 (Cq, C<i>a</i>), 103.8 (CH, <i>Cb</i>), 103.5 (CH, C<i>a</i>), 99.6 (CH, C<i>a</i>), 99.2 (CH, <i>Cb</i>), 55.3 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 44.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 25.0 (CH, C<i>a</i>), 24.3 (CH, <i>Cb</i>), 23.0 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>), 22.2 (CH<sub>3</sub>, 2C, C<i>a</i> + <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 1.85 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 339.1; found, 339.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 339.1821; found, 339.1813.</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-phenyl-1<i>H</i>-pyrazol-3-yl)methanone (<b>7</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.03 g, 0.15 mmol) and 5-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>G</b>) (0.028 g, 0.15 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (50:50) as the eluent, as a white solid (0.016 g, 29%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 64/36 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.70 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.78 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 7.84 (m, 2H, C<i>a</i> + <i>Cb</i>), 7.46 (m, 2H, C<i>a</i>), 7.36 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.20–7.17 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.09 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.00 (s, 1H, C<i>a</i>), 6.80 (s, 1H, <i>Cb</i>), 6.69–6.65 (m, 1H, C<i>a</i> + <i>Cb</i>), 5.06 (s, 2H, <i>Cb</i>), 4.78 (2H, C<i>a</i>), 4.16–4.02 (m, 2H, C<i>a</i> + <i>Cb</i>), 3.77 (s, 3H, C<i>a</i>), 3.71 (s, 3H, <i>Cb</i>), 2.94–2.96 (m, 2H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.9 (Cq, C<i>a</i> + <i>Cb</i>), 153.2 (Cq, C<i>a</i> + <i>Cb</i>), 142.5 (Cq, C<i>a</i> + <i>Cb</i>), 133.4 (Cq, <i>Cb</i>), 133.1 (Cq, C<i>a</i>), 130.9 (Cq, C<i>a</i> + <i>Cb</i>), 129.0 (CH, 3C, C<i>a</i>), 128.2 (CH, 3C, <i>Cb</i>), 125.6 (CH, 2C, <i>Cb</i>), 125.3 (CH, 2C, C<i>a</i>), 111.5 (CH, C<i>a</i> + <i>Cb</i>), 110.3 (CH, C<i>a</i> + <i>Cb b</i>), 105.4 (Cq, C<i>a</i> + <i>Cb</i>), 104.3 (CH, C<i>a</i> + <i>Cb</i>), 99.6 (CH, C<i>a</i>), 99.3 (CH, <i>Cb</i>), 55.3 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 44.4 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 24.2 (CH<sub>2</sub>, C<i>a</i>), 23.0 (CH<sub>2</sub>, <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 2.00 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 373.2; found, 373.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 373.1665; found 373.1651.</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(2-(trifluoromethyl)-1<i>H</i>-imidazol-4-yl)methanone (<b>8</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.03 g, 0.15 mmol) and 2-(trifluoromethyl)-1<i>H</i>-imidazole-4-carboxylic acid (<b>H</b>) (0.027 g, 0.15 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (60:40) as the eluent, as a white solid (0.022 g, 40%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 69/31 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.75 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 7.90 (br s, 1H, C<i>a</i> + <i>Cb</i>), 7.18 (d, <i>J</i> = 8.7 Hz, 1H, C<i>a</i> + <i>Cb</i>), 6.98 (br s, 1H, C<i>a</i>), 6.80 (br s, 1H, <i>Cb</i>), 6.67 (dd, <i>J</i> = 8.7, 2.4 Hz, 1.45H, C<i>a</i> + <i>Cb</i>), 5.09 (s, 2H, <i>Cb</i>), 4.74 (s, 2H, C<i>a</i>), 4.25 (s, 2H, C<i>a</i>), 3.97 (br s, 2H, <i>Cb</i>), 3.75 (br s, 3H, C<i>a</i> + <i>Cb</i>), 2.91–2.84 (m, 2H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 161.9 (Cq, C<i>a</i> + <i>Cb</i>), 153.1 (Cq, C<i>a</i> + <i>Cb</i>), 137.1 (Cq, C<i>a</i> + <i>Cb</i>), 134.3 (Cq, C<i>a</i> + <i>Cb</i>), 133.4 (Cq, <i>Cb</i>), 133.1 (Cq, C<i>a</i>), 130.9 (Cq, C<i>a</i> + <i>Cb</i>), 125.6 (Cq, C<i>a</i> + <i>Cb</i>), 125.2 (CH, C<i>a</i> + <i>Cb</i>), 118.7 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.9 Hz, C<i>a</i> + <i>Cb</i>), 111.6 (CH, C<i>a</i> + <i>Cb</i>), 110.3 (CH, C<i>a</i> + <i>Cb</i>), 105.9 (Cq, <i>Cb</i>), 105.4 (Cq, C<i>a</i>), 99.5 (CH, C<i>a</i> + <i>Cb</i>), 55.3 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 44.0 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 24.2 (CH<sub>2</sub>, C<i>a</i>), 23.0 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.8 (s). UPLC-MS: <i>t</i><sub>R</sub> = 1.69 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 365.1; found, 365.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 365.1225; found, 365.1219.</div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-bromofuran-2-yl)methanone (<b>9</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.063 g, 0.26 mmol) and 5-bromofuran-2-carboxylic acid (<b>J</b>) (0.05 g, 0.26 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (8:2) as the eluent, as an off-white solid (0.076 g, 77%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.09 (s, NH), 7.19 (d, <i>J</i> = 8.7 Hz, 1H), 7.00 (d, <i>J</i> = 3.4 Hz, 1H), 6.9 (br s, 1H), 6.81 (d, <i>J</i> = 8.9 Hz, 1H), 6.44 (d, <i>J</i> = 3.5 Hz, 1H), 4.92 (br s, 2H), 4.08 (t, <i>J</i> = 5.9 Hz, 2H), 3.85 (s, 3H), 2.95 (br s, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 159.0 (Cq), 154.3 (Cq), 149.9 (Cq), 131.2 (Cq, 2C), 126.0 (Cq), 124.5 (Cq), 118.7 (CH), 113.5 (CH), 111.7 (CH, 2C), 106.8 (Cq), 100.2 (CH), 56.09 (CH<sub>3</sub>), 44.6 (CH<sub>2</sub>), 41.2 (CH<sub>2</sub>), 24.3 (CH<sub>2</sub>). UPLC-MS: <i>t</i><sub>R</sub> = 2.07 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>BrN<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup>, 375.0; found, 375.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>BrN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 375.0344; found, 375.0335.</div></div><div id="sec5_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(6-(dimethylamino)-1<i>H</i>-indol-2-yl)methanone (<b>10</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.025 g, 0.12 mmol) and 6-(dimethylamino)-1<i>H</i>-indole-2-carboxylic acid (<b>A</b>) (0.025 g, 0.12 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (50:50) as the eluent, as a white solid (0.023 g, 50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.09 (s, NH, 1H), 10.76 (s, NH, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.18 (d, <i>J</i> = 8.6 Hz, 1H), 6.97 (s, 1H), 6.86 (s, 1H), 6.74 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.68 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 6.63 (s, 1H), 4.89 (br s, 2H), 4.05 (s, 2H), 3.74 (s, 3H), 2.93 (br s, 2H), 2.90 (s, 6H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.9 (Cq), 153.2 (Cq), 148.5 (Cq), 137.9 (Cq), 133.3 (Cq), 130.93 (Cq), 127.8 (Cq), 125.5 (Cq), 121.8 (CH), 119.1 (Cq), 111.6 (CH), 110.4 (CH), 110.0 (CH), 105.6 (Cq), 104.4 (CH), 99.5 (CH), 93.8 (CH), 59.8 (CH<sub>2</sub>), 55.3 (CH<sub>3</sub>), 41.0 (2C, CH<sub>3</sub>), 40.1 (CH<sub>2</sub>), 23.7 (CH<sub>2</sub>). UPLC-MS: <i>t</i><sub>R</sub> = 2.17 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 389.2; found, 389.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 389.1978; found, 389.1973.</div></div><div id="sec5_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (8-Methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(1-methyl-5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>11</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45q</b>) (0.052 g, 0.26 mmol) and 2-(trifluoromethyl)-1<i>H</i>-imidazole-4-carboxylic acid (<b>K</b>) (0.05 g, 0.26 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (80:20) as the eluent, as a white solid (0.022 g, 22%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 67/33 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.77 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.22 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.19 (d, <i>J</i> = 8.6 Hz, 1H, C<i>a</i> + <i>Cb</i>), 7.17 (br s, 1H, <i>Cb</i>), 6.99 (d, <i>J</i> = 2.4 Hz, 1H, C<i>a</i>), 6.84 (d, <i>J</i> = 2.3 Hz, 1H, <i>Cb</i>), 6.69 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H, C<i>a</i>), 6.67 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H, C<i>b</i>), 4.95 (s, 2H, <i>Cb</i>), 4.78 (s, 2H, C<i>a</i>), 4.07 (t, <i>J</i> = 5.6 Hz, 2H, C<i>a</i>), 4.05 (s, 3H, C<i>a</i> + <i>Cb</i>), 3.99 (t, <i>J</i> = 5.6 Hz, 2H, <i>Cb</i>), 3.76 (s, 3H, C<i>a</i>), 3.76 (s, 3H, <i>Cb</i>), 2.90 (t, <i>J</i> = 5.8 Hz, 2H, C<i>a</i>), 2.90 (t, <i>J</i> = 5.8 Hz, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 161.4 (Cq, C<i>a</i> + <i>Cb</i>), 153.2 (Cq, C<i>a</i> + <i>Cb</i>), 145.8 (Cq, C<i>a</i> + <i>Cb</i>), 133.3 (Cq, <i>Cb</i>), 132.9 (Cq, C<i>a</i>), 131.3 (q, <sup>2</sup><i>J</i><sub>CF</sub> = 38.8 Hz, C<i>a</i> + <i>Cb</i>), 130.9 (Cq, C<i>a</i> + <i>Cb</i>), 125.6 (Cq, C<i>a</i>), 125.2 (Cq, <i>Cb</i>), 119.7 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.4 Hz, C<i>a</i> + <i>Cb</i>), 111.6 (CH, C<i>a</i> + <i>Cb</i>), 110.4 (CH, C<i>a</i>), 110.3 (CH, <i>Cb</i>), 109.8 (CH, <i>Cb</i>), 109.7 (CH, C<i>a</i>), 105.6 (Cq, <i>Cb</i>), 105.1 (Cq, C<i>a</i>), 99.7 (CH, <i>Cb</i>), 99.6 (CH, C<i>a</i>), 55.3 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 44.3 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 38.6 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 24.1 (CH<sub>2</sub>, C<i>a</i>), 22.9 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.2 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.07 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M – H)<sup>−</sup>, 377.4; found, 377.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 379.1382; found, 379.1370.</div></div><div id="sec5_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (8-Methoxy-5-methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>12</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 8-methoxy-5-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole hydrochloride (<b>48</b>) (0.068 g, 0.31 mmol) and 2-(trifluoromethyl)-1<i>H</i>-imidazole-4-carboxylic acid (<b>C</b>) (0.057 g, 0.31 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (80:20) as the eluent, as a white solid (0.28 g, 24%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 62/38 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.31–7.26 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.18 (s, 1H, C<i>a</i>), 7.04 (br s, 1H, C<i>a</i>), 6.98 (br s, 1H, <i>Cb</i>), 6.76–6.74 (m, 1H, C<i>a</i> + <i>Cb</i>), 4.86 (s, 2H, <i>Cb</i>), 4.79 (s, 2H, C<i>a</i>), 4.03 (t, <i>J</i> = 5.3 Hz, 2H, <i>Cb b</i>), 3.95 (t, <i>J</i> = 6.0 Hz, 2H, C<i>a</i>), 3.77 (s, 3H, C<i>a</i>), 3.73 (s, 3H, <i>Cb</i>), 3.60 (s, 3H, C<i>a</i> + <i>Cb</i>), 2.99 (t, <i>J</i> = 5.8 Hz, 2H, C<i>a</i>), 2.90 (s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.4 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 158.5 (Cq, C<i>a</i> + <i>Cb</i>), 140.6 (Cq, C<i>a</i> + <i>Cb</i>), 138.3 (Cq, C<i>a</i>), 135.8 (Cq, <i>Cb</i>), 135.0 (Cq, <i>Cb</i>), 134.3 (Cq, C<i>a</i>), 131.9 (Cq, C<i>a</i> + <i>Cb</i>), 125.0 (Cq, C<i>a</i>), 124.6 (Cq <i>Cb</i>), 121.5 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.0 Hz, C<i>a</i>), 121.3 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.0 Hz, <i>Cb</i>), 110.5 (CH, <i>Cb</i>), 110.1 (CH, C<i>a</i>), 107.4 (CH, C<i>a</i> + <i>Cb</i>), 105.1 (CH, <i>Cb</i>), 104.7 (Cq, <i>Cb</i>), 104.5 (Cq, C<i>a</i>), 104.2 (CH, C<i>aa</i>), 100.0 (CH, <i>Cb</i>), 99.6 (CH, C<i>a</i>), 55.5 (CH<sub>3</sub>, C<i>a</i>), 55.4 (CH<sub>3</sub>, <i>Cb</i>), 44.5 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 40.2 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 29.6 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 22.8 (CH<sub>2</sub>, C<i>a</i>), 21.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.2 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.13 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M – H)<sup>−</sup>, 377.4; found, 377.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 379.1382; found, 379.1371.</div></div><div id="sec5_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (1,3,4,5-Tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>13</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45p</b>) (0.02 g, 0.12 mmol) and 2-(trifluoromethyl)-1<i>H</i>-imidazole-4-carboxylic acid (<b>C</b>) (0.02 g, 0.12 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (80:20) as the eluent, as a white solid (0.02 g, 45%) <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 59/41 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.39 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.99 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.48–7.42 (1H, C<i>a</i> + <i>Cb</i>), 7.32–7.27 (1H, C<i>a</i> + <i>Cb</i>), 7.19 (s, 1H, C<i>a</i>), 7.07–7.03 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.00–6.94 (1H, C<i>a</i> + <i>Cb</i>), 4.90 (s, 2H, <i>Cb</i>), 4.80 (s, 2H, C<i>a</i>), 4.03 (br s, 2H, <i>Cb</i>), 3.94 (br s, 2H, C<i>a</i>), 2.98 (br s, 2H, <i>Cb</i>), 2.89 (br s, 2H, C<i>a</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq, C<i>a</i>), 159.2 (Cq, <i>Cb</i>), 140.9 (Cq, C<i>a</i> + <i>Cb</i>), 137.9 (Cq, C<i>a</i> + <i>Cb</i>), 135.9 (Cq, C<i>a</i> + <i>Cb</i>), 132.5 (Cq, <i>Cb</i>), 132.3 (Cq, C<i>a</i>), 125.2 (Cq, C<i>a</i>), 124.8 (Cq, <i>Cb</i>), 121.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.4 Hz, C<i>a</i> + <i>Cb</i>), 120.8 (CH, C<i>a</i> + <i>Cb</i>), 118.6 (CH, C<i>a</i>), 118.5 (CH, C<i>b</i>), 117.4 (CH, <i>Cb</i>), 117.3 (CH, C<i>a</i>), 111.0 (CH, C<i>a</i> + <i>Cb</i>), 105.1 (Cq, C<i>a</i> + <i>Cb</i>), 104.8 (CH, <i>Cb</i>), 104.2 (CH, C<i>a</i>), 44.5 (CH<sub>2</sub>, C<i>a</i>), 44.3 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.27 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 335.1; found, 335.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 335.1120; found, 335.1100.</div></div><div id="sec5_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (8-Methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>14</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from commercially available 8-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45r</b>) (0.037 g, 0.20 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.036 g, 0.20 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (8:2) as the eluent, as a white solid (0.03 g, 40%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 59/41 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.37 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.84 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 7.27 (s, 1H, <i>Cb</i>), 7.24 (1H, C<i>a</i>), 7.20–7.16 (2H, C<i>a</i> + <i>Cb</i>), 6.88–6.84 (1H, C<i>a</i> + <i>Cb</i>), 4.86 (s, 2H, <i>Cb</i>), 4.77 (s, 2H, C<i>a</i>), 4.02 (br s, 2H, <i>Cb</i>), 3.92 (br s, 2H, C<i>a</i>), 2.96 (br s, 2H, C<i>a</i>), 2.87 (br s, 2H, <i>Cb</i>), 2.37 (s, 3H, C<i>a</i>), 2.33 (s, 3H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq, C<i>a</i>), 159.2 (Cq, <i>Cb</i>), 140.9 (Cq, C<i>a</i> + <i>Cb</i>), 137.9 (Cq, C<i>a</i> + <i>Cb</i>), 134.3 (Cq, C<i>a</i> + <i>Cb</i>), 132.5 (Cq, <i>Cb</i>), 132.3 (Cq, C<i>a</i>), 127.1 (Cq, C<i>a</i> + <i>Cb</i>), 125.4 (Cq, C<i>a</i>), 125.1 (Cq, <i>Cb</i>), 122.3 (CH, C<i>a</i> + <i>Cb</i>), 121.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 262.2 Hz, C<i>a</i> + <i>Cb</i>), 117.0 (CH, C<i>a</i> + <i>Cb</i>), 110.7 (CH, <i>Cb</i>), 105.0 (CH, C<i>a</i> + <i>Cb</i>), 104.6 (Cq, <i>Cb</i>), 104.3 (Cq, C<i>a</i>), 104.1 (CH, C<i>a</i>), 44.5 (CH<sub>2</sub>, C<i>a</i>), 44.4 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>), 21.2 (CH<sub>3</sub>, C<i>a</i>), 21.1 (CH<sub>3</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.21 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 349.1; found, 349.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 349.1276; found, 349.1262.</div></div><div id="sec5_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (9-Methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>15</b>)</h4><div class="NLM_p last">Following GP2, a mixture of regioisomers <b>15</b> and <b>16</b> was obtained from a mixture of 7-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45d′</b>) and 9-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45d″</b>) (0.2 g, 1.07 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.212 g, 1.18 mmol). The title compound was obtained, as a pure regioisomer, after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O + 0.1% NH<sub>3</sub> (A) and CH<sub>3</sub>CN + 0.1% NH<sub>3</sub> (B); linear gradient: 0–0.5 min 30% B; 0.5–7.0 min 70% B], as a white solid (0.006 g, 7%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 62/38 ratio. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.36 (s, 1H, C<i>a</i> + <i>Cb</i>), 10.92 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.15 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.11 (s, 1H, <i>Cb</i>), 7.09 (s, 1H, C<i>a</i>), 6.90 (t, <i>J</i> = 7.5 Hz, 1H, C<i>a</i> + <i>Cb</i>), 6.72–6.67 (m, 1H, C<i>a</i> + <i>Cb</i>), 5.18 (s, 2H, <i>Cb</i>), 5.04 (s, 2H, C<i>a</i>), 3.94 (br s, 2H, C<i>a</i> + <i>Cb</i>), 2.96 (br s, 2H, C<i>a</i>), 2.87 (br s, 2H, <i>Cb</i>), 2.58 (s, 3H, C<i>a</i>), 2.46 (s, 3H, <i>Cb</i>). NOESY-2D: strong dipolar coupling between multiplet at 5.24–4.96 ppm and singlet at 5.58 ppm. <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.8 (Cq, C<i>a</i>), 159.5 (Cq, <i>Cb</i>), 135.9 (Cq, C<i>a</i> + <i>Cb</i>), 131.6 (Cq, C<i>a</i> + <i>Cb</i>), 128.3 (Cq, C<i>a</i>), 128.2 (Cq, <i>Cb</i>), 124.7 (Cq, C<i>a</i> + <i>Cb</i>), 124.3 (Cq, C<i>a</i> + <i>Cb</i>, extrapolated from HMBC), 123.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 285.6 Hz, C<i>a</i> + <i>Cb</i>), 120.8 (CH, C<i>a</i> + <i>Cb</i>), 119.6 (CH, C<i>a</i> + <i>Cb</i>), 108.8 (CH, C<i>a</i> + <i>Cb</i>), 105.3 (Cq, C<i>a</i> + <i>Cb</i>), 104.2 (CH, C<i>a</i> + <i>Cb</i>), 45.7 (CH<sub>2</sub>, <i>Cb</i>), 44.1 (CH<sub>2</sub>, C<i>a</i>), 40.4 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>), 19.6.2 (CH<sub>3</sub>, C<i>a</i>), 19.3 (CH<sub>3</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.0 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.13 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 349.1; found, 349.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 349.1276; found, 349.1263.</div></div><div id="sec5_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (7-Methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>16</b>)</h4><div class="NLM_p last">Following GP2, a mixture of regioisomer <b>15</b> and <b>16</b> was obtained from a mixture of 7-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45d′</b>) and 9-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45d″</b>) (0.20 g, 1.07 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.212 g, 1.18 mmol). The title compound was obtained, as a pure regioisomer, after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O + 0.1% NH<sub>3</sub> (A) and CH<sub>3</sub>CN + 0.1% NH<sub>3</sub> (B); linear gradient: 0–0.5 min 30% B; 0.5–7.0 min 70% B], as a white solid (0.006 g, 7%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 62/38 ratio. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.35 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.83 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.33 (d, <i>J</i> = 8.3 Hz, 1H, C<i>a</i>), 7.29 (d, <i>J</i> = 8.4 Hz, 0.6 Hz, 1H, <i>Cb</i>), 7.25 (s, 1H, <i>Cb</i>), 7.17 (s, 1H, C<i>a</i>), 7.10 (s, 1H, C<i>a</i>), 7.08 (s, 1H, <i>Cb</i>), 6.82 (d, <i>J</i> = 8.1 Hz, 1H, C<i>a</i>), 6.78 (d, <i>J</i> = 8.1 Hz, 1H, <i>Cb</i>), 4.87 (s, 2H, <i>Cb</i>), 4.77 (s, 2H, C<i>a</i>), 4.01 (br s, 2H, <i>Cb</i>), 3.93 (br s, 2H, C<i>a</i>), 2.95 (br s, 2H, C<i>a</i>), 2.86 (br s, 2H, <i>Cb</i>), 2.38 (s, 3H, C<i>a</i>), 2.36 (s, 3H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) for major C<i>a</i>: δ 159.6 (Cq), 136.4 (Cq), 131.7 (Cq), 131.5 (Cq), 129.7 (Cq), 123.1 (Cq), 121.6 (Cq, CF<sub>3</sub>, extrapolated from HMBC), 120.3 (CH), 117.0 (CH), 110.9 (CH), 105.0 (Cq), 104.2 (CH), 44.2 (CH<sub>2</sub>), 40.1 (CH<sub>2</sub>), 23.8 (CH<sub>2</sub>), 21.4 (CH<sub>3</sub>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.0 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.17 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 349.1; found, 349.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 349.1276; found, 349.1263.</div></div><div id="sec5_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (6-Methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>17</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 6-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole hydrochloride (<b>45c</b>) (0.06 g, 0.27 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.053 g, 0.30 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (85:15) as the eluent, as a white solid (0.04 g, 42%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 61/39 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.39 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 10.91 (s, 1H, NH, C<i>a</i> + <i>Cb</i>), 7.29–7.26 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.25–2.23 (m, 1H, <i>Cb</i>), 7.20 (s, 1H, C<i>a</i>), 6.9 (t, <i>J</i> = 7.3 Hz, 1H, C<i>a</i>), 6.86–6.84 (m, 1H, C<i>a</i>, 2H, <i>Cb</i>), 4.88 (s, 2H, <i>Cb</i>), 4.79 (s, 2H, C<i>a</i>), 4.03 (t, <i>J</i> = 5.0 Hz, 2H, <i>Cb</i>), 3.93 (t, <i>J</i> = 5.2 Hz, 2H, C<i>a</i>), 3.00 (br s, 2H, C<i>a</i>), 2.90 (br s, 2H, <i>Cb</i>), 2.43 (s, 3H, C<i>a</i>), 2.42 (s, 1.95H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq, C<i>a</i>), 159.0 (Cq, <i>Cb</i>), 140.6 (Cq, <i>Cb</i>), 137.8 (Cq, C<i>a</i>), 135.4 (Cq, C<i>a</i> + <i>Cb</i>), 132.3 (Cq, <i>Cb</i>), 132.1 (Cq, C<i>a</i>), 124.8 (Cq, C<i>a</i>), 124.5 (Cq, <i>Cb</i>), 121.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 267.8 Hz, C<i>a</i> + <i>Cb</i>), 121.4 (CH, C<i>a</i> + <i>Cb</i>), 120.5 (Cq, C<i>a</i> + <i>Cb</i>), 118.9 (CH, C<i>a</i>), 108.8 (CH, <i>Cb</i>), 115.0 (CH, <i>Cb</i>), 114.9 (CH, C<i>a</i>), 105.5 (Cq, <i>Cb</i>), 105.2 (Cq, C<i>a</i>), 105.0 (CH, <i>Cb</i>), 105.1 (CH, C<i>a</i>), 44.6 (CH<sub>2</sub>, C<i>a</i>), 44.2 (CH<sub>2</sub>, <i>Cb</i>), 40.2 (CH<sub>2</sub>, <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>), 16.8 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.19 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 349.2; found, 349.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 349.1276; found, 349.1257.</div></div><div id="sec5_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (8-Isopropyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>18</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 8-isopropyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole hydrochloride (<b>45e</b>) (0.06 g, 0.24 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.047 g, 0.26 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (80:20) as the eluent, as a white solid (0.056 g, 62%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 59/41 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.38 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 10.79 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.30–7.17 (m, 3H, C<i>a</i> + <i>Cb</i>), 6.95 (d, <i>J</i> = 8.1 Hz, 1H, C<i>a</i> + <i>Cb</i>), 4.86 (s, 2H, <i>Cb</i>), 4.80 (s, 2H, C<i>a</i>), 4.01 (br s, 2H, <i>Cb</i>), 3.93 (br s, 2H, C<i>a</i>), 2.96 (m, 3H, C<i>a</i>), 2.88 (m, 3H, <i>Cb</i>), 1.24 (m, 6H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 140.5 (Cq, C<i>a</i> + <i>Cb</i>), 138.7 (Cq, C<i>a</i> + <i>Cb</i>), 138.2 (Cq, C<i>a</i> + <i>Cb</i>), 134.5 (Cq, C<i>a</i> + <i>Cb</i>), 132.5 (Cq, <i>Cb</i>), 132.2 (Cq, C<i>a</i>), 125.3 (Cq, C<i>a</i>), 124.9 (Cq, <i>Cb</i>), 121.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.1 Hz, C<i>a</i> + <i>Cb</i>), 119.8 (CH, C<i>a</i>), 119.6 (CH, <i>Cb</i>), 114.3 (CH, <i>Cb</i>), 114.1 (CH, C<i>a</i>), 110.7 (CH, C<i>a</i> + <i>Cb</i>), 104.8 (Cq, C<i>a</i> + <i>Cb</i>), 104.6 (CH, C<i>a</i>), 104.1 (CH, <i>Cb</i>), 44.5 (CH<sub>2</sub>, C<i>a</i>), 44.4 (CH<sub>2</sub>, <i>Cb</i>), 40.2 (CH<sub>2</sub>, <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 33.6 (CH, C<i>a</i> + <i>Cb</i>), 24.6 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.0 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.43 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 377.2; found, 377.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 377.1589; found, 377.1574.</div></div><div id="sec5_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (8-Fluoro-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>19</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from commercially available 8-fluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45s</b>) (0.05 g, 0.26 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.047 g, 0.26 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (80:20) as the eluent, as a white solid (0.012 g, 13%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 61/39 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.38 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.10 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.30–7.26 (m, 2H, C<i>a</i> + <i>Cb</i>), 7.19 (s, 1H, C<i>a</i>), 6.89–6.84 (m, 1H, C<i>a</i> + <i>Cb</i>), 4.86 (s, 2H, <i>Cb</i>), 4.77 (s, 2H, C<i>a</i>), 4.02 (br s, 2H, <i>Cb</i>), 3.91 (br s, 2H, C<i>a</i>), 2.99 (br s, 2H, C<i>a</i>), 2.89 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.4 (Cq, C<i>a</i>), 159.0 (Cq, <i>Cb</i>), 156.8 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 230.9 Hz, C<i>a</i> + <i>Cb</i>), 141.0 (Cq, q, <sup>2</sup><i>J</i><sub>CF</sub> = 36.6 Hz, C<i>a</i> + <i>Cb</i>), 137.7 (Cq, C<i>a</i>), 137.6 (Cq, <i>Cb</i>), 134.8 (Cq, <i>Cb</i>), 134.5 (Cq, C<i>a</i>), 132.6 (Cq, C<i>a</i> + <i>Cb</i>), 125.4 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 7.9 Hz, C<i>a</i> + <i>Cb</i>), 121.5 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.1 Hz, C<i>a</i> + <i>Cb</i>), 111.8 (CH, d, <sup>3</sup><i>J</i><sub>CF</sub> = 9.5 Hz, C<i>a</i> + <i>Cb</i>), 108.6 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 25.9 Hz, C<i>a</i> + <i>Cb</i>), 105.4 (Cq, C<i>a</i> + <i>Cb</i>), 105.2 (CH, <sup>2</sup><i>J</i><sub>CF</sub> = 23.7 Hz, C<i>a</i> + <i>Cb</i>), 104.0 (CH, C<i>a</i>), 102.6 (CH, C<i>a</i>), 44.5 (CH<sub>2</sub>, C<i>a</i>), 44.2 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.1 (s, C<i>a</i> + <i>Cb</i>), −123.0 (s, C<i>a</i>), −123.3 (s, <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 2.08 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 353.2; found, 353.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 353.1025; found, 353.1011.</div></div><div id="sec5_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (6-Fluoro-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>20</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 6-fluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45f</b>) (0.038 g, 0.20 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.036 g, 0.20 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (8:2) as the eluent, as a white solid (0.052 g, 92%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 62/38 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.37 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.44 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.31–7.25 (m, 2H, C<i>a</i> + <i>Cb</i>), 7.19 (s, 1H, C<i>a</i>), 6.95–6.87 (m, 1H, C<i>a</i> + <i>Cb</i>), 4.90 (s, 2H, <i>Cb</i>), 4.82 (s, 2H, C<i>a</i>), 4.04 (br s, 2H, <i>Cb</i>), 3.95 (br s, 2H, C<i>a</i>), 3.00 (br s, 2H, C<i>a</i>), 2.92 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 148.8 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 242.1 Hz, C<i>a</i> + <i>Cb</i>), 140.6 (Cq, C<i>a</i> + <i>Cb</i>), 138.2 (Cq, C<i>a</i> + <i>Cb</i>), 133.9 (Cq, <i>Cb</i>), 133.7 (Cq, C<i>a</i>), 129.1 (Cq, C<i>a</i>), 128.8 (Cq, <i>Cb</i>), 123.5 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 12.8 Hz, C<i>a</i> + <i>Cb</i>), 121.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 267.8 Hz, C<i>a</i> + <i>Cb</i>), 119.0 (CH, C<i>a</i> + <i>Cb</i>), 113.6 (CH, C<i>a</i> + <i>Cb</i>), 106.2 (Cq, <i>Cb</i>), 106.0 (Cq, C<i>a</i>), 105.8 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 16.8 Hz, C<i>a</i> + <i>Cb</i>), 105.0 (CH, <i>Cb</i>), 104.2 (CH, C<i>a</i>), 44.4 (CH<sub>2</sub>, C<i>a</i>), 44.2 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.1 (s), −133.7 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.12 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 353.1; found, 353.1. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 353.1025; found, 353.1007.</div></div><div id="sec5_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (8-(Trifluoromethyl)-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>21</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 8-(trifluoromethyl)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole (<b>45g</b>) (0.1 g, 0.42 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.075 g, 0.42 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (80:20) as the eluent, as a white solid (0.038 g, 22%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 56/44 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.31 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.51 (s, NH, 1.0H, C<i>a</i>), 11.48 (s, NH, 1H, <i>Cb</i>), 7.93 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.51–7.46 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.33–7.36 (s, 1H, C<i>a</i>; 2H, <i>Cb</i>), 7.21 (s, 1H, C<i>a</i>), 4.97 (s, 2H, <i>Cb</i>), 4.87 (s, 2H, C<i>a</i>), 4.04 (br s, 2H, <i>Cb</i>), 3.95 (br s, 2H, C<i>a</i>), 3.03 (br s, 2H, C<i>a</i>), 2.93 (br s, 1.6H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.2 (Cq, <i>Cb</i>), 140.8 (Cq, C<i>a</i>), 137.9 (Cq, <i>Cb</i>), 137.5 (Cq, C<i>a</i> + <i>Cb</i>), 135.2 (Cq, <i>Cb</i>), 134.9 (Cq, C<i>a</i>) 125.7 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 271.6 Hz, C<i>a</i> + <i>Cb</i>), 124.6 (Cq, C<i>a</i>), 124.3 (Cq, <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.2 Hz, C<i>a</i> + <i>Cb</i>), 119.5 (Cq, q, <sup>2</sup><i>J</i><sub>CF</sub> = 31.2 Hz, C<i>a</i>), 119.4 (Cq, q, <sup>2</sup><i>J</i><sub>CF</sub> = 31.7 Hz, <i>Cb</i>), 117.2 (CH, q, <sup>3</sup><i>J</i><sub>CF</sub> = 3.3 Hz, C<i>a</i> + <i>Cb</i>), 115.5 (CH, <i>Cb</i>), 115.2 (CH, C<i>a</i>), 111.6 (CH, C<i>a</i> + <i>Cb</i>), 106.4 (Cq, <i>Cb</i>), 106.2 (Cq, C<i>a</i>), 105.3 (CH, C<i>a</i>), 104.3 (CH, <i>Cb</i>), 44.4 (CH<sub>2</sub>, C<i>a</i>), 44.1 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −57.1 (s, <i>Cb</i>), −57.3 (s, C<i>a</i>) −59.0 (s, C<i>a</i>), −59.1 (s, <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 2.26 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 403.1; found, 403.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 403.0994; found, 403.0986.</div></div><div id="sec5_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (8-(Trifluoromethoxy)-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>22</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 8-(trifluoromethoxy)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45h</b>) (0.051 g, 0.20 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.036 g, 0.20 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (7:3) as the eluent, as a white solid (0.072 g, 88%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 59/41 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.41 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.31 (s, NH, 1.0H, C<i>a</i>), 11.29 (s, NH, 1H, <i>Cb</i>), 7.52 (s, 1H, C<i>a</i> + <i>Cb</i>), 7.40–7.36 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.30 (s, 1H, <i>Cb</i>), 7.20 (s, 1H, C<i>a</i>), 7.03–6.99 (m, 1H, C<i>a</i> + <i>Cb</i>), 4.91 (s, 2H, <i>Cb</i>), 4.81 (s, 2H, C<i>a</i>), 4.03 (br s, 2H, <i>Cb</i>), 3.94 (br s, 2H, C<i>a</i>), 3.01 (br s, 2H, C<i>a</i>), 2.91 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq, C<i>a</i>), 159.2 (Cq, <i>Cb</i>), 141.6 (Cq, C<i>a</i> + <i>Cb</i>), 140.8 (Cq, C<i>a</i> + <i>Cb</i>), 137.7 (Cq, C<i>a</i> + <i>Cb</i>), 135.2 (Cq, <i>Cb</i>), 135.0 (Cq, C<i>a</i>), 134.4 (Cq, C<i>a</i> + <i>Cb</i>), 125.3 (Cq, C<i>a</i>), 125.0 (Cq, <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.5 Hz, C<i>a</i> + <i>Cb</i>), 120.5 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 254.2 Hz, C<i>a</i> + <i>Cb</i>), 114.2 (CH, C<i>a</i> + <i>Cb</i>), 111.8 (CH, C<i>a</i> + <i>Cb</i>), 110.3 (CH, <i>Cb</i>), 110.0 (CH, C<i>a</i>), 105.9 (Cq, C<i>a</i>), 105.7 (Cq, C<i>a</i>), 105.2 (CH, C<i>a</i>), 104.2 (CH, <i>Cb</i>), 44.4 (CH<sub>2</sub>, C<i>a</i>), 44.1 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −55.9 (s), −59.1 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.33 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 419.1; found, 419.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>F<sub>6</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 419.0943; found, 419.0932.</div></div><div id="sec5_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 2-(5-(Trifluoromethyl)-1<i>H</i>-pyrazole-3-carbonyl)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole-8-carbonitrile (<b>23</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole-8-carbonitrile (<b>45j</b>) (0.039 g, 0.20 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.036 g, 0.20 mmol), after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O (A) and CH<sub>3</sub>CN (B); linear gradient: 0–0.5 min 10%B; 0.5–7.0 min 100%B], as a white solid (0.012 g, 20%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 56/44 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.40 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.65 (s, NH, 1.0H, C<i>a</i>), 11.62 (s, NH, 1H, <i>Cb</i>), 8.09 (br s, 1H, C<i>a</i> + <i>Cb</i>), 7.49–7.45 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.42–7.38 (m, 1H, C<i>a</i> + <i>Cb</i>), 7.29 (s, 1H, <i>Cb</i>), 7.20 (s, 1H, C<i>a</i>), 4.94 (s, 2H, <i>Cb</i>), 4.84 (s, 2H, C<i>a</i>), 4.03 (br s, 2H, <i>Cb</i>), 3.95 (br s, 2H, C<i>a</i>), 3.02 (br s, 2H, C<i>a</i>), 2.92 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 140.8 (Cq, C<i>a</i> + <i>Cb</i>), 137.8 (Cq, C<i>a</i> + <i>Cb</i>), 135.6 (Cq, <i>Cb</i>), 135.4 (Cq, C<i>a</i>), 125.1 (Cq, C<i>a</i>), 124.8 (Cq, <i>Cb</i>), 123.8 (CH, C<i>a</i> + <i>Cb</i>), 123.4 (Cq, C<i>a</i> + <i>Cb</i>), 123.2 (CH, C<i>a</i> + <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.7 Hz, C<i>a</i> + <i>Cb</i>), 120.9 (Cq, C<i>a</i> + <i>Cb</i>), 112.2 (CH, C<i>a</i> + <i>Cb</i>), 106.4 (Cq, <i>Cb</i>), 106.2 (Cq, C<i>a</i>), 105.3 (CH, <i>Cb</i>), 104.3 (CH, C<i>a</i>), 100.7 (Cq, C<i>a</i>), 100.5 (Cq, <i>Cb</i>), 44.3 (CH<sub>2</sub>, C<i>a</i>), 43.9 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.7 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1 (s). UPLC-MS: <i>t</i><sub>R</sub> = 1.92 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>F<sub>3</sub>N<sub>5</sub>O (M + H)<sup>+</sup>, 360.1; found, 360.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>F<sub>3</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 360.1072; found, 360.1063.</div></div><div id="sec5_4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (8-(Methylsulfonyl)-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>24</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 8-methylsulfonyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>45k</b>) (0.068 g, 0.24 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.043 g, 0.24 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (50:50) as the eluent, as a white solid in (0.031 g, 31%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 56/44 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.41 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.64 (s, NH, 1.0H, C<i>a</i>), 11.62 (s, 1H, <i>Cb</i>), 8.13 (br s, 1H, C<i>a</i> + <i>Cb</i>), 7.58 (t, <i>J</i> = 8.8 Hz, 1H, C<i>a</i> + <i>Cb</i>), 7.52 (t, <i>J</i> = 9.3 Hz, 1H, C<i>a</i> + <i>Cb</i>), 7.37 (s, 1H, <i>Cb</i>), 7.21 (s, 1H, C<i>a</i>), 4.99 (s, 2H, <i>Cb</i>), 4.88 (s, 2H, C<i>a</i>), 4.04 (br s, 2H, <i>Cb</i>), 3.97 (br s, 2H, C<i>a</i>), 3.17 (s, 3H, C<i>a</i>), 3.12 (2.4, 3H, <i>Cb</i>), 3.04 (br s, 2H, C<i>a</i>), 2.94 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.2 (Cq, <i>Cb</i>), 140.8 (Cq, C<i>a</i> + <i>Cb</i>), 138.1 (Cq, C<i>a</i> + <i>Cb</i>), 137.6 (Cq, C<i>a</i> + <i>Cb</i>), 135.7 (Cq, <i>Cb</i>), 135.6 (Cq, C<i>a</i>), 131.1 (Cq, C<i>a</i>), 131.0 (Cq, <i>Cb</i>), 124.6 (Cq, C<i>a</i>), 124.3 (Cq, <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 267.7 Hz, C<i>a</i> + <i>Cb</i>), 119.2 (CH, <i>Cb</i>), 119.1 (CH, C<i>a</i>), 118.0 (CH, <i>Cb</i>), 117.8 (CH, C<i>a</i>), 111.45 (CH, C<i>a</i> + <i>Cb</i>), 106.9 (Cq, <i>Cb</i>), 106.7 (Cq, C<i>a</i>), 105.3 (CH, <i>Cb</i>), 104.3 (CH, C<i>a</i>), 44.6 (CH<sub>3</sub>, <i>Cb</i>), 44.5 (CH<sub>3</sub>, C<i>a</i>), 44.3 (CH<sub>2</sub>, C<i>a</i>), 44.1 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.8 (CH<sub>2</sub>, C<i>a</i>), 22.7 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.0 (s). UPLC-MS: <i>t</i><sub>R</sub> = 1.71 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S (M + H)<sup>+</sup>, 413.1; found, 413.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 413.0895; found, 413.0896.</div></div><div id="sec5_4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (6-Fluoro-8-methoxy-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>25</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 6-fluoro-8-methoxy-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole hydrochloride (<b>45b</b>) (0.15 g, 0.58 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.115 g, 0.64 mmol), after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O (A) and CH<sub>3</sub>CN (B); linear gradient: 0–0.5 min 10% B; 0.5–7.0 min 100% B], as a white solid (0.056 g, 25%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 62/38 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.40 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.27 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.27 (br s, 1H, <i>Cb</i>), 7.20 (br s, 1H, C<i>a</i>), 6.88 (br s, 1H, C<i>a</i>), 6.82 (br s, 1H, <i>Cb</i>), 6.58 (d, <i>J</i> = 12.3, 1H, C<i>a</i> + <i>Cb</i>), 4.85 (s, 2H, <i>Cb</i>), 4.77 (s, 2H, C<i>a</i>), 4.01 (br s, 2H, <i>Cb</i>), 3.92 (t, <i>J</i> = 5.6 Hz, 2H, C<i>a</i>), 3.77 (s, 3H, C<i>a</i>), 3.74 (1.8, 3H, <i>Cb</i>), 2.97 (t, <i>J</i> = 5.5 Hz, 2H, C<i>a</i>), 2.87 (t, <i>J</i> = 5.5 Hz, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 153.3 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 9.0 Hz, C<i>a</i> + <i>Cb</i>), 149.2 (Cq, d, <i>J</i> = 242.0 Hz, C<i>a</i> + <i>Cb</i>), 140.7 (Cq, C<i>a</i> + <i>Cb</i>), 137.9 (Cq, C<i>a</i> + <i>Cb</i>), 134.6 (Cq, <i>Cb</i>), 134.2 (Cq, C<i>a</i>), 128.5 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 7.7 Hz, C<i>a</i>), 128.1 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 7.2 Hz, <i>Cb</i>), 121.3 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.0 Hz, C<i>a</i> + <i>Cb</i>), 118.5 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 13.2 Hz, C<i>a</i> + <i>Cb</i>), 106.1 (Cq, <i>Cb</i>), 105.9 (Cq, C<i>a</i>), 105.1 (CH, <i>Cb</i>), 104.3 (CH, C<i>a</i>), 96.6 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 19.6 Hz, C<i>a</i> + <i>Cb</i>), 96.1 (CH, <i>Cb</i>), 95.8 (CH, C<i>a</i>), 55.8 (CH<sub>3</sub>, <i>Cb</i>), 55.7 (CH<sub>3</sub>, C<i>a</i>), 44.4 (CH<sub>2</sub>, C<i>a</i>), 44.3 (CH<sub>2</sub>, <i>Cb</i>), 40.2 (CH<sub>2</sub>, <i>Cb</i>), (40.1, CH<sub>2</sub>, <i>Ca</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.1 (s), −132.0 (s). UPLC-MS: <i>t</i><sub>R</sub> = 1.86 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup>, 383.1; found, 383.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 383.1131; found, 383.1129.</div></div><div id="sec5_4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (6-Fluoro-8-methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>26</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 6-fluoro-8-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole hydrochloride (<b>45i</b>) (0.147 g, 0.61 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.11 g, 0.61 mmol), after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O (A) and CH<sub>3</sub>CN (B); linear gradient: 0–0.5 min 50% B; 0.5–7.0 min 100% B], as a white solid (0.015 g, 6%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 56/44 ratio. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.39 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.29 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.27 (br s, 1H, <i>Cb</i>), 7.19 (br s, 1H, C<i>a</i>), 7.07 (m, 1H, C<i>a</i> + <i>Cb</i>), 6.74 (d, <i>J</i> = 12.3 Hz, 1H, C<i>a</i> + <i>Cb</i>), 4.85 (s, 2H, <i>Cb</i>), 4.77 (br s, 2H, C<i>a</i>), 4.02 (br s, 2H, <i>Cb</i>), 3.92 (br s, 2H, C<i>a</i>), 2.96 (br s, 2H, C<i>a</i>), 2.88 (br s, 2H, <i>Cb</i>), 2.35 (s, 3H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) for major C<i>a</i>: δ 159.4 (Cq), 148.4 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 242.7 Hz), 140.9 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 37.8 Hz), 137.6 (Cq), 133.7 (Cq), 129.1 (Cq), 128.4 (Cq), 121.6 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 12.1 Hz), 121.5 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.4 Hz, C<i>a</i> + <i>Cb</i>), 113.2 (CH), 107.2 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 16.2 Hz), 105.4 (Cq), 104.1 (CH), 44.4 (CH<sub>2</sub>), 40.4 (CH<sub>2</sub>), 23.8 (CH<sub>2</sub>), 21.0 (CH<sub>3</sub>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.1 (s), −134.2 (s). UPLC-MS: <i>t</i><sub>R</sub> = 2.24 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 367.1; found, 367.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 367.1182; found, 367.1170.</div></div><div id="sec5_4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (6,8-Difluoro-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>27</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 6,8-difluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole hydrochloride (<b>45l</b>) (0.1 g, 0.41 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.074 g, 0.41 mmol), after purification by preparative HPLC-MS [mobile phase: H<sub>2</sub>O (A) and CH<sub>3</sub>CN (B); linear gradient: 0–0.5 min 10% B; 0.5–7.0 min 100% B], as a white solid (0.049 g, 32%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 57/43 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.27 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.59 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.27–7.20 (m, 1H, C<i>a</i>; 2H, <i>Cb</i>), 7.19 (br s, 1H, C<i>a</i>), 6.93–6.87 (m, 1H, C<i>a</i> + <i>Cb</i>), 4.87 (s, 2H, <i>Cb</i>), 4.77 (br s, 2H, C<i>a</i>), 4.02 (br s, 2H, <i>Cb</i>), 3.94 (br s, 2H, C<i>a</i>), 3.00 (br s, 2H, C<i>a</i>), 2.88 (br s, 1.5H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.2 (Cq, <i>Cb</i>), 155.7 (Cq, dd, <sup>1,2</sup><i>J</i><sub>CF</sub> = 233.7, 9.8 Hz, C<i>a</i> + <i>Cb</i>), 147.7 (Cq, d, <sup>1,2</sup><i>J</i><sub>CF</sub> = 245.1, 9.6 Hz, C<i>a</i> + <i>Cb</i>), 140.5 (Cq, C<i>a</i> + <i>Cb</i>), 138.0 (Cq, C<i>a</i> + <i>Cb</i>), 135.9 (Cq, <i>Cb</i>), 135.7 (Cq, C<i>a</i>), 127.8 (Cq, C<i>a</i>), 127.5 (Cq, <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.8 Hz, C<i>a</i> + <i>Cb</i>), 120.2 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 12.8 Hz, C<i>a</i> + <i>Cb</i>), 106.8 (Cq, <i>Cb</i>), 106.5 (Cq, C<i>a</i>), 105.2 (CH, <i>Cb</i>), 104.3 (CH, C<i>a</i>), 99.1 (CH, t, <sup>2</sup><i>J</i><sub>CF</sub> = 26.3 Hz, C<i>a</i> + <i>Cb</i>), 95.9 (CH, dd, <sup>2</sup><i>J</i><sub>CF</sub> = 21.0 Hz, <i>Cb</i>), 95.9 (CH, dd, <sup>2</sup><i>J</i><sub>CF</sub> = 21.0 Hz, C<i>a</i>), 44.3 (CH<sub>2</sub>, C<i>a</i>), 44.0 (CH<sub>2</sub>, <i>Cb</i>), 40.0 (CH<sub>2</sub>, C<i>a</i> + <i>Cb</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.0 (s, C<i>a</i> + <i>Cb</i>), −121.4 (s, C<i>a</i>), −121.7 (s, <i>Cb</i>) −129.3 (s, C<i>a</i> + <i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 2.23 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>5</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 371.1; found, 371.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>5</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 371.0931; found, 371.0931.</div></div><div id="sec5_4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (6-Fluoro-8-trifluoromethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>28</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 6-fluoro-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole hydrochloride (<b>45m</b>) (0.15 g, 0.51 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.101 g, 0.56 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 50%) as the eluent, as a white solid (0.012 g, 6%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 57/43 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.27 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 12.03 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.85 (br s, 1H, C<i>a</i> + <i>Cb</i>), 7.27–7.22 (m, 2H, C<i>a</i> + <i>Cb</i>), 4.96 (s, 2H, <i>Cb</i>), 4.87 (br s, 2H, C<i>a</i>), 4.03 (br s, 2H, <i>Cb</i>), 3.94 (br s, 2H, C<i>a</i>), 3.04 (br s, 2H, C<i>a</i>), 2.93 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) for the major C<i>a</i>: δ 159.5 (Cq), 148.2 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 244.0 Hz), 141.0 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 37.1 Hz), 137.5 (Cq), 136.3 (Cq), 128.4 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 7.5 Hz), 124.8 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 271.6 Hz), 125.0 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 12.6), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.0 Hz), 112.2 (CH), 107.5 (Cq), 105.2 (Cq), 104.0 (CH), 102.8 (d, <sup>2</sup><i>J</i><sub>CF</sub> = 20.2 Hz), 44.3 (CH<sub>2</sub>), 40.1 (CH<sub>2</sub>), 23.8 (CH<sub>2</sub>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −56.4, −58.0, −129.9. UPLC-MS: <i>t</i><sub>R</sub> = 2.06 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>12</sub>F<sub>7</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 421.1; found, 421.5. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>12</sub>F<sub>7</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 421.0899; found, 421.0901.</div></div><div id="sec5_4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (6,9-Difluoro-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>29</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 6,9-difluoro-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole hydrochloride (<b>45n</b>) (0.1 g, 0.41 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.081 g, 0.45 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 30%) as the eluent, as a white solid (0.02 g, 13%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 67/33 ratio. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.42 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.80 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.21 (br s, 1H, C<i>a</i> + <i>Cb</i>), 6.87–6.82 (br s, 1H, C<i>a</i> + <i>Cb</i>), 6.72–6.67 (m, 1H, C<i>a</i> + <i>Cb</i>), 4.96 (s, 2H, <i>Cb</i>), 4.88 (br s, 2H, C<i>a</i>), 4.02 (br s, 2H, <i>Cb</i>), 3.94 (br s, 2H, C<i>a</i>), 3.00 (br s, 2H, C<i>a</i>), 2.90 (br s, 2H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) for the major C<i>a</i>: δ 159.5 (Cq), 151.3 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 236.7 Hz), 145.3 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 238.2 Hz), 140.8 (Cq), 137.8 (Cq), 134.1 (Cq), 125.5 (Cq), 120.6 (Cq), 116.7 (Cq), 105.6 (CH, dd, <sup>2,3</sup><i>J</i><sub>CF</sub> = 19.8, 8.8 Hz), 104.6 (Cq), 104.0 (CH), 103.3 (CH, dd, <sup>2,3</sup><i>J</i><sub>CF</sub> = 21.7, 7.3 Hz), 44.1 (CH<sub>2</sub>), 40.1 (CH<sub>2</sub>), 23.7 (CH<sub>2</sub>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ – 68.7, −128.6, −136.5. UPLC-MS: <i>t</i><sub>R</sub> = 2.32 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>5</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 371.1; found, 371.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>F<sub>5</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 371.0931; found, 371.0921.</div></div><div id="sec5_4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (6-Fluoro-9-methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>30</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 6-fluoro-9-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole hydrochloride (<b>45a</b>) (0.1 g, 0.42 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.076 g, 0.42 mmol), after purification by silica gel flash column chromatography with DCM/EtOAc (80:20) as the eluent, as a white solid (0.031 g, 20%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 62/38 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.43 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.40 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.20 (br s, 1H, C<i>a</i> + <i>Cb</i>), 6.75–6.61 (m, 2H, C<i>a</i> + <i>Cb</i>), 5.12 (s, 2H, <i>Cb</i>), 5.04 (br s, 2H, C<i>a</i>), 4.00 (br s, 2H, <i>Cb</i>), 3.90 (br s, 2H, C<i>a</i>), 2.97 (br s, 2H, C<i>a</i>), 2.88 (br s, 2H, <i>Cb</i>), 2.54 (s, 3H, C<i>a</i>), 2.40 (s, 3H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 147.6 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.8 Hz, C<i>a</i> + <i>Cb</i>), 140.8 (Cq, C<i>a</i> + <i>Cb</i>), 137.8 (Cq, C<i>a</i> + <i>Cb</i>), 133.2 (Cq, <i>Cb</i>), 133.1 (Cq, C<i>a</i>), 128.1 (Cq, C<i>a</i>), 127.8 (Cq, <i>Cb</i>), 124.5 (Cq, C<i>a</i>), 124.3 (Cq, <i>Cb</i>), 123.4 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 13.8 Hz, C<i>a</i> + <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.4 Hz, C<i>a</i> + <i>Cb</i>), 119.4 (CH, d, <sup>3</sup><i>J</i><sub>CF</sub> = 6.3 Hz, C<i>a</i> + <i>Cb</i>), 106.8 (Cq, <i>Cb</i>), 106.4 (Cq, C<i>a</i>), 105.4 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 16.4 Hz, C<i>a</i> + <i>Cb</i>), 104.8 (CH, <i>Cb</i>), 104.3 (CH, C<i>a</i>), 45.4 (CH<sub>2</sub>, <i>Cb</i>), 44.0 (CH<sub>2</sub>, C<i>a</i>), 41.2 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i>), 23.9 (CH<sub>2</sub>, C<i>a</i>), 22.8 (CH<sub>2</sub>, <i>Cb</i>), 18.9 (CH<sub>3</sub>, C<i>a</i>), 18.6 (CH<sub>3</sub>, <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1, −136.9. UPLC-MS: <i>t</i><sub>R</sub> = 2.22 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 367.2; found, 367.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 367.1182; found, 367.1168.</div></div><div id="sec5_4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (9-Fluoro-6-methyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>31</b>)</h4><div class="NLM_p last">Following GP2, the title compound was obtained from 9-fluoro-6-methyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido [4,3-<i>b</i>]indole hydrochloride (<b>45o</b>) (0.09 g, 0.37 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.067 g, 0.37 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 80%) as the eluent, as a white solid (0.041 g, 13%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 64/36 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.42 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.21 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 7.21 (br s, 1H, C<i>a</i> + <i>Cb</i>), 7.17 (br s, 1H, <i>Cb</i>), 6.80–6.76 (m, 1H, C<i>a</i> + <i>Cb</i>), 6.65 (t, <i>J</i> = 8.5 Hz, 1H, C<i>a</i>), 6.60 (t, <i>J</i> = 8.8 Hz, 1H, <i>Cb</i>), 4.96 (s, 2H, <i>Cb</i>), 4.89 (br s, 2H, C<i>a</i>), 4.02 (br s, 2H, <i>Cb</i>), 3.93 (br s, 2H, C<i>a</i>), 3.00 (br s, 2H, C<i>a</i>), 2.91 (br s, 2H, <i>Cb</i>), 2.39 (s, 3H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.6 (Cq, C<i>a</i> + <i>Cb</i>), 154.0 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.1 Hz, C<i>a</i>), 153.8 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.8 Hz, <i>Cb</i>), 140.8 (Cq, <i>Cb</i>), 137.8 (Cq, <i>Cb</i>), 137.7 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 11.3 Hz, C<i>a</i> + <i>Cb</i>), 132.7 (Cq, <i>Cb</i>), 132.5 (Cq, C<i>a</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.2 Hz, C<i>a</i> + <i>Cb</i>), 121.3 (CH, d, <sup>3</sup><i>J</i><sub>CF</sub> = 7.3 Hz, C<i>a</i> + <i>Cb</i>), 116.6 (Cq, d, <sup>4</sup><i>J</i><sub>CF</sub> = 2.9 Hz, C<i>a</i> + <i>Cb</i>), 113.2 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 21.4 Hz, C<i>a</i>), 112.9 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 21.3 Hz, <i>Cb</i>), 104.6 (CH, <i>Cb</i>), 104.2 (CH, C<i>a</i>), 103.5 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 18.2 Hz, C<i>a</i> + <i>Cb</i>), 103.2 (Cq, C<i>a</i> + <i>Cb</i>), 44.9 (CH<sub>2</sub>, <i>Cb</i>), 44.2 (CH<sub>2</sub>, C<i>a</i>), 40.7 (CH<sub>2</sub>, <i>Cb</i>), 40.1 (CH<sub>2</sub>, C<i>a</i>), 23.7 (CH<sub>2</sub>, C<i>a</i>), 22.6 (CH<sub>2</sub>, <i>Cb</i>), 16.2 (CH<sub>3</sub>, C<i>a</i> + <i>Cb</i>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.1, −129.5. UPLC-MS: <i>t</i><sub>R</sub> = 2.21 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 367.1; found, 367.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 367.1182; found, 367.1171.</div></div><div id="sec5_4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (±)-(6-Fluoro-1,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>32</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from racemic 6-fluoro-1,9-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>52</b>) (0.09 g, 0.35 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.062 g, 035 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 50%) as the eluent, as a white solid (0.06 g, 45%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 77/33 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.33 (br s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.42 (br s, 1H, C<i>a</i>), 11.40 (br s, NH, 1H, <i>Cb</i>), 7.18 (br s, 1H, C<i>a</i>), 7.07 (br s, 1H, <i>Cb</i>), 6.76 (dd, <i>J</i> = 11.1, 7.9 Hz, 1H, C<i>a</i>), 6.73 (dd, <i>J</i> = 11.1, 8.2 Hz, 1H, <i>Cb</i>), 6.69 (dd, <i>J</i> = 8.0, 4.8 Hz, 1H, C<i>a</i>), 6.63 (dd, <i>J</i> = 7.6, 4.7 Hz, 1H, <i>Cb</i>), 5.99 (q, <i>J</i> = 6.6 Hz, 1H, C<i>a</i>), 5.57 (br s, 1H, <i>Cb</i>), 4.69 (dd, <i>J</i> = 13.2, 5.6 Hz, 1H, <i>Cb</i>), 4.15 (dd, <i>J</i> = 13.7, 5.4 Hz, 1H, C<i>a</i>), 3.71 (ddd, <i>J</i> = 14.1, 11.9, 4.4 Hz, 1H, C<i>a</i>), 3.47 (td, <i>J</i> = 12.4, 5.3 Hz, 1H, <i>Cb</i>), 3.12 (ddd, <i>J</i> = 17.1, 11.9, 6.0 Hz, 1H, C<i>a</i>), 2.84–2.93 (m, 1H, <i>Cb</i>), 2.82 (dd, <i>J</i> = 16.5, 4.2 Hz, 1H, C<i>a</i>), 2.57 (s, 3H, C<i>a</i>), 2.35 (s, 3H, <i>Cb</i>), 1.65 (d, <i>J</i> = 6.5 Hz, 3H, <i>Cb</i>), 1.56 (d, <i>J</i> = 6.5 Hz, 3H, C<i>a</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.3 (Cq, <i>Cb</i>), 158.8 (Cq, C<i>a</i>), 147.6 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.4 Hz, C<i>a</i> + <i>Cb</i>), 140.8 (Cq, <i>Cb</i>), 138.0 (Cq, <i>Cb</i>), 132.7 (Cq, <i>Cb</i>), 132.5 (Cq, C<i>a</i>), 127.4 (d, <sup>4</sup><i>J</i><sub>CF</sub> = 5.5 Hz, C<i>a</i>), 126.9 (d, <sup>4</sup><i>J</i><sub>CF</sub> = 5.2 Hz, <i>Cb</i>), 124.0 (Cq, C<i>a</i> + <i>Cb</i>), 123.8 (Cq, d, <sup>4</sup><i>J</i><sub>CF</sub> = 2.3 Hz, C<i>a</i> + <i>Cb</i>), 123.5 (Cq, q, <sup>2</sup><i>J</i><sub>CF</sub> = 14.4 Hz, C<i>a</i> + <i>Cb</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 267.7 Hz, C<i>a</i> + <i>Cb</i>), 120.0 (CH, d, <sup>3</sup><i>J</i><sub>CF</sub> = 7.4 Hz, <i>Cb</i>), 119.9 (CH, d, <sup>3</sup><i>J</i><sub>CF</sub> = 6.1 Hz, C<i>a</i>), 112.2 (Cq, <i>Cb</i>), 111.8 (Cq, C<i>a</i>), 105.4 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 6.1 Hz, C<i>a</i> + <i>Cb</i>), 104.1 (CH, C<i>a</i>), 103.4 (CH, <i>Cb</i>), 50.0 (CH, <i>Cb</i>), 45.3 (CH, C<i>a</i>), 40.1 (CH<sub>2</sub>, C<i>a</i>), 34.1 (CH<sub>2</sub>, <i>Cb</i>), 23.6 (CH<sub>2</sub>, C<i>a</i>), 23.1 (CH<sub>3</sub>, <i>Cb</i>), 22.5 (CH<sub>2</sub>, <i>Cb</i>), 21.6 (CH<sub>3</sub>, C<i>a</i>), 19.3 (CH<sub>3</sub>, C<i>a</i>), 18.80 (CH<sub>3</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.0, −137.0. UPLC-MS: <i>t</i><sub>R</sub> = 2.58 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub> (M + H)<sup>+</sup>, 381.1; found, 381.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub> [M + H]<sup>+</sup>, 381.1338; found, 381.1333.</div></div><div id="sec5_4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (±)-(6-Fluoro-3,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>33</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from racemic 6-fluoro-3,9-dimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>53</b>) (0.07 g, 0.27 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.048 g, 0.27 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 50%) as the eluent, as a white solid (0.049 g, 47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.37 (br s, NH), 11.36 (br s, NH), 7.18 (br s, 1H), 6.73 (dd, <i>J</i> = 11.2, 8.0 Hz, 1H), 6.66 (m, 1H), 4.48–5.57 (m, 3H), 3.13 (m, 1H), 2.65 (m, 1H), 2.56 (s, 3H), 2.34 (m, 1H), 1.26 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq), 147.5 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.2 Hz), 140.5 (Cq), 138.6 (Cq), 127.8 (Cq), 124.4 (Cq), 123.5 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 13.7 Hz), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 268.4 Hz), 119.3 (CH, d, <i>J</i> = 6.1 Hz), 118.7 (Cq), 105.2 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 15.9 Hz), 104.8 (Cq), 103.8 (CH), 48.1 (CH), 37.2 (CH<sub>2</sub>), 28.9 (CH<sub>2</sub>), 18.7 (CH<sub>3</sub>), 18.1 (CH<sub>3</sub>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −60.0, −138.0. UPLC-MS: <i>t</i><sub>R</sub> = 2.58 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 381.1; found, 381.3. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 381.1338; found 381.1333.</div></div><div id="sec5_4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (6-Fluoro-3,3,9-trimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>34</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from 6-fluoro-3,3,9-trimethyl-2,3,4,5-tetrahydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indole (<b>57</b>) (0.045 g, 0.19 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.08 g, 0.44 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 50%) as the eluent, as a white solid (0.016 g, 20%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.29 (br s, 1H), 11.38 (br s, 1H), 7.14 (s, 1H), 6.70 (dd, <i>J</i> = 11.3, 7.8 Hz, 1H), 6.59 (ddd, <i>J</i> = 7.8, 4.7, 0.6 Hz, 1H), 5.0 (s, 2H), 2.96 (s, 2H), 2.30 (s, 3H), 1.59 (s, 6H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.0 (Cq), 147.6 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.9 Hz), 140.1 (Cq), 133.6 (Cq), 127.5 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 5.5 Hz), 124.1 (Cq, <sup>4</sup><i>J</i><sub>CF</sub> = 2.8 Hz), 123.1 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 13.7 Hz), 120.5 (Cq), 119.4 (CH, d, <sup>3</sup><i>J</i><sub>CF</sub> = 6.3 Hz), 106.6 (Cq), 105.2 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 15.4 Hz), 104.6 (CH), 55.8 (Cq), 45.0 (CH<sub>2</sub>), 35.3 (CH<sub>2</sub>), 26.9 (CH<sub>3</sub>), 18.6 (CH<sub>3</sub>). <sup>19</sup>F NMR (565 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.3, −135.8. UPLC-MS: <i>t</i><sub>R</sub> = 2.45 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>19</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 394.4; found, 394.5. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>19</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 395.1495; found, 395.1481.</div></div><div id="sec5_4_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (±)-(4-Fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indol-11-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>35</b>)</h4><div class="NLM_p last">Following GP1, the title compound was obtained from racemic 4-fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indole hydrochloride (<b>59</b>) (0.2 g, 0.75 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.135 g, 0.75 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 80%) as the eluent, as a white solid (0.056 g, 5%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 56/44 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.39 (s, 1.6H, C<i>a</i> + <i>Cb</i>), 11.43 (br s, NH, C<i>a</i>), 11.40 (s, 1H, <i>Cb</i>), 7.30 (s, 1H, <i>Cb</i>), 7.04 (s, 1H, C<i>a</i>), 6.73–6.64 (m, 2H, C<i>a</i> + <i>Cb</i>), 5.92 (d, <i>J</i> = 5.5 Hz, 1H, C<i>a</i>), 5.76 (br s, 1H, <i>Cb</i>), 4.99 (dd, <i>J</i> = 7.5, 5.5 Hz, 1H, C<i>a</i>), 4.95 (s, 1H, <i>Cb</i>), 3.42 (dd, <i>J</i> = 16.3, 4.4 Hz, 1H, C<i>a</i>), 3.30 (m, 1H, <i>Cb</i>), 2.74 (d, <i>J</i> = 16.5 Hz, 1H, <i>Cb</i>), 2.70 (d, <i>J</i> = 16.4 Hz, 1H, C<i>a</i>), 2.56 (br s, 3H, <i>Cb</i>), 2.43 (br s, 3H, C<i>a</i>), 2.39–2.36 (m, 1H, C<i>a</i>), 2.32–2.27 (m, 1H, <i>Cb</i>), 2.06–2.08 (m, 1H, C<i>a</i> + <i>Cb</i>), 1.78–1.72 (m, 1H, C<i>a</i> + <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 156.4 (Cq, C<i>a</i>), 155.8 (Cq, <i>Cb</i>), 147.7 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.7 Hz, C<i>a</i> + <i>Cb</i>), 141.1 (Cq, <i>Cb</i>), 138.2 (Cq, C<i>a</i>), 132.3 (Cq, <i>Cb</i>), 131.8 (Cq, C<i>a</i>), 126.8 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 5.5 Hz, C<i>a</i>), 126.2 (Cq, d, <sup>3</sup><i>J</i><sub>CF</sub> = 5.4 Hz, <i>Cb</i>), 123.9 (Cq, C<i>a</i>), 123.5 (Cq, C<i>a</i> + <i>Cb</i>), 123.0 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 10.9 Hz, C<i>a</i>), 122.9 (Cq, d, <sup>2</sup><i>J</i><sub>CF</sub> = 10.9 Hz, C<i>a</i>), 121.4 (Cq, q, <sup>1</sup><i>J</i><sub>CF</sub> = 269.5 Hz, C<i>a</i> + <i>Cb</i>), 119.7 (Cq, d, <sup>4</sup><i>J</i><sub>CF</sub> = 5.7 Hz, C<i>a</i>), 119.5 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 28.5 Hz, C<i>a</i> + <i>Cb</i>), 115.5 (Cq, <i>Cb</i>), 115.1 (Cq, C<i>a</i>), 105.00 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 15.7 Hz, C<i>a</i>), 104.9 (CH, d, <sup>2</sup><i>J</i><sub>CF</sub> = 15.6 Hz, <i>Cb</i>), 104.4 (CH, <i>Cb</i>), 104.1 (CH, C<i>a</i>), 55.3 (CH, <i>Cb</i>), 53.5 (CH, <i>Cb</i>), 51.5 (CH, C<i>a</i>), 51.1 (CH, C<i>a</i>), 36.6 (CH<sub>2</sub>, C<i>a</i>), 34.8 (CH<sub>2</sub>, <i>Cb</i>), 33.7 (CH<sub>2</sub>, <i>Cb</i>), 31.6 (CH<sub>2</sub>, C<i>a</i>), 29.6 (CH<sub>2</sub>, C<i>a</i>), 27.3 (CH<sub>2</sub>, <i>Cb</i>), 19.3 (CH<sub>3</sub>, <i>Cb</i>), 18.9 (CH<sub>3</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1, −136.7. UPLC-MS: <i>t</i><sub>R</sub> = 2.29 min; MS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O (M + H)<sup>+</sup>, 393.1; found, 393.2. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 393.1338; found, 393.1340.</div></div><div id="sec5_4_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (<i>R</i>)- or (<i>S</i>)-(4-Fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indol-11-yl)(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>36</b>)</h4><div class="NLM_p last">The title compound was obtained after semipreparative chiral separation of racemic (4-fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indol-11-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>35</b>) on a Daicel ChiralPak AD column (250 × 10 mm ID, particle size 10 μm) using heptane–EtOH (75:25) as the mobile phase, as a white solid (0.023 g, 28%). NMR spectra, UPLC-MS data, and HRMS data are consistent with the corresponding racemate <b>35</b>. Enantiomeric excess was determined to be >99% after chiral HPLC analysis. [α]<sub class="stack">589</sub><sup class="stack">25</sup> +78.2 (<i>c</i> 0.5, CH<sub>3</sub>OH).</div></div><div id="sec5_4_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (<i>S</i>)- or (<i>R</i>)-(4-Fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indol-11-yl)(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>37</b>)</h4><div class="NLM_p last">The title compound was obtained after semipreparative chiral separation of racemic (4-fluoro-1-methyl-5,6,7,8,9,10-hexahydro-7,10-epiminocyclohepta[<i>b</i>]indol-11-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>35</b>) on a Daicel ChiralPak AD column (250 × 10 mm ID, particle size 10 μm) using heptane–EtOH (75:25) as the mobile phase, as a white solid (0.024 g, 28%). NMR spectra, UPLC-MS and HRMS data are consistent with the corresponding racemate <b>35</b>. Enantiomeric excess was determined to be >99% after chiral HPLC analysis. [α]<sub class="stack">589</sub><sup class="stack">25</sup> −75.0 (<i>c</i> 0.25, CH<sub>3</sub>OH).</div></div><div id="sec5_4_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (7-Fluoro-10-methyl-1,4,5,6-tetrahydroazepino[4,5-<i>b</i>]indol-3(2<i>H</i>)-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>38</b>)</h4><div class="NLM_p last">Following the GP1, the title compound was obtained from 7-fluoro-10-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-<i>b</i>]indole hydrochloride (<b>61</b>) (0.2 g, 0.75 mmol) and 5-(trifluoromethyl)-1<i>H</i>-pyrazole-3-carboxylic acid (<b>C</b>) (0.135 g, 0.75 mmol), after purification by silica gel flash column chromatography with cyclohexane/EtOAc (0 to 50%) as the eluent, as a white solid (0.019 g, 7%). <sup>1</sup>H NMR showed the presence of two conformers C<i>a</i>/<i>Cb</i> in a 50/50 ratio. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.34 (s, NH, 1H, C<i>a</i> + <i>Cb</i>), 11.24 (br s, NH, 1H, C<i>a</i>), 11.19 (br s, 1H, <i>Cb</i>), 7.16 (s, 1H, C<i>a</i>), 7.14 (s, 1H, <i>Cb</i>), 6.67 (ddd, <i>J</i> = 11.0, 7.8, 1.2 Hz, 2H, C<i>a</i> + <i>Cb</i>), 6.60–6.57 (m, 2H, C<i>a</i> + <i>Cb</i>), 3.96 (m, 1H, C<i>a</i> + <i>Cb</i>), 3.93–3.90 (m, 3H, C<i>a</i> + <i>Cb</i>), 3.29–3.25 (m, 2H, C<i>a</i> + <i>Cb</i>), 3.14–3.10 (m, 2H, C<i>a</i> + <i>Cb</i>), 2.56 (s, 3H, C<i>a</i>), 2.54 (s, 3H, <i>Cb</i>). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.5 (Cq, C<i>a</i>), 159.3 (Cq, <i>Cb</i>), 147.6 (Cq, d, <sup>1</sup><i>J</i><sub>CF</sub> = 239.3 Hz, C<i>a</i> + <i>Cb</i>), 137.8 (Cq, C<i>a</i> + <i>Cb</i>), 136.1 (Cq, C<i>a</i> + <i>Cb</i>), 135.2 (Cq, C<i>a</i> + <i>Cb</i>), 130.0 (Cq, <i>J</i> = 22.2 Hz, C<i>a</i>), 129.9 (Cq, <i>Cb</i>), 124.9 (Cq, d, <i>J</i> = 7.8 Hz, C<i>a</i> + <i>Cb</i>), 122.43 (Cq, d, <i>J</i> = 13.8) 122–42 (Cq, d, <i>J</i> = 13.8), 121.4 (Cq, <sup>1</sup><i>J</i><sub>CF</sub> = 268.0 Hz, C<i>a</i> + <i>Cb</i>), 119.9 (CH, d, <i>J</i> = 6.0 Hz, C<i>a</i>), 119.7 (CH, <i>J</i> = 6.0 Hz, <i>Cb</i>), 111.2 (Cq, C<i>a</i>), 111.2 (Cq, <i>Cb</i>), 107.4 (Cq, d, C<i>a</i> + <i>Cb</i>), 104.7 (CH, d, <i>J</i> = 15.3 Hz, <i>Cb</i>), 104.6 (CH, d, <i>J</i> = 15.3 Hz, C<i>a</i>), 104.2 (CH, C<i>a</i> + <i>Cb</i>), 49.2 (CH<sub>2</sub>, C<i>a</i>), 48.2 (CH<sub>2</sub>, <i>Cb</i>), 45.3 (CH<sub>2</sub>, C<i>a</i>), 44.8 (CH<sub>2</sub>, <i>Cb</i>), 27.8 (CH<sub>2</sub>, C<i>a</i>), 27.0 (CH<sub>2</sub>, <i>Cb</i>), 26.7 (CH<sub>2</sub>, C<i>a</i>), 25.7 (CH<sub>2</sub>, <i>Cb</i>), 20.1 (CH<sub>3</sub>, C<i>a</i>), 19.9 (CH<sub>3</sub>, <i>Cb</i>). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.1 (C<i>a</i> + <i>Cb</i>), −137.1 (C<i>a</i>), −137.2 (<i>Cb</i>). UPLC-MS: <i>t</i><sub>R</sub> = 2.00 min; MS calcd for C<sub>18</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O <i>m</i>/<i>z</i>: 380.33; found, 381.5 [M + H]<sup>+</sup>. HRMS (AP-ESI) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>16</sub>F<sub>4</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 381.1338; found, 381.1333.</div></div><div id="sec5_4_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (<i>R</i>)-(6-Fluoro-3,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>39</b>)</h4><div class="NLM_p last">In a similar fashion to racemic (6-fluoro-3,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>33</b>), the title compound was obtained from commercially available, enantiomerically pure (<i>R</i>)-<i>tert</i>-butyl 2-methyl-4-oxopiperidine-1-carboxylate (<b>54</b>) as a white solid (0.065 g, 51%). NMR spectra, UPLC-MS data, and HRMS data are consistent with the corresponding racemate <b>33</b>. Enantiomeric excess was determined to be 97% after chiral HPLC analysis. [α]<sub class="stack">589</sub><sup class="stack">25</sup> +68.8 (<i>c</i> 1.0, CH<sub>3</sub>OH).</div></div><div id="sec5_4_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (<i>S</i>)-(6-Fluoro-3,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>40</b>)</h4><div class="NLM_p last">In a similar fashion to racemic (6-fluoro-3,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>33</b>), the title compound was obtained from commercially available, enantiomerically pure (<i>S</i>)-<i>tert</i>-butyl 2-methyl-4-oxopiperidine-1-carboxylate (<b>55</b>) as a white solid (0.060 g, 50%). NMR spectra, UPLC-MS data, and HRMS data are consistent with the corresponding racemate <b>33</b>. Enantiomeric excess was determined to be 78% (least value due to peak-tailing) after chiral HPLC analysis. [α]<sub class="stack">589</sub><sup class="stack">25</sup> −56.8 (<i>c</i> 1.0, CH<sub>3</sub>OH).</div></div><div id="sec5_4_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (<i>R</i>)- or (<i>S</i>)-(6-Fluoro-1,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-b]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>41</b>)</h4><div class="NLM_p last">The title compound was obtained after semipreparative chiral separation of racemic (6-fluoro-1,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>32</b>) on a Daicel ChiralPak AD column (250 × 10 mm ID, particle size 10 μm) using heptane/2-propanol (95:5) as the mobile phase, as a white solid (0.005 g, 19%). NMR spectra, UPLC-MS data, and HRMS data are consistent with the corresponding racemate <b>32</b>. Enantiomeric excess was determined to be 97% after chiral HPLC analysis. [α]<sub class="stack">589</sub><sup class="stack">25</sup> +57.7 (<i>c</i> 1.0, CH<sub>3</sub>OH).</div></div><div id="sec5_4_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (<i>S</i>)- or (<i>R</i>)-(6-Fluoro-1,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>42</b>)</h4><div class="NLM_p last">The title compound was obtained after semipreparative chiral separation of racemic (6-fluoro-1,9-dimethyl-1,3,4,5-tetrahydro-2<i>H</i>-pyrido[4,3-<i>b</i>]indol-2-yl)-(5-(trifluoromethyl)-1<i>H</i>-pyrazol-3-yl)methanone (<b>32</b>) on a Daicel ChiralPak AD column (250 × 10 mm ID, particle size 10 μm) using heptane/2-propanol (95:5) as the mobile phase, as a white solid (0.003 g, 11%). NMR spectra, UPLC-MS data, and HRMS data are consistent with the corresponding racemate. Enantiomeric excess was determined to be 63% (least value due to peak-tailing) after chiral HPLC analysis.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Biology</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Cell Models and Cell Culture procedures</h4><div class="NLM_p">FRT cells stably expressing mutant F508del-CFTR or G551D-CFTR and the halide-sensitive yellow fluorescent protein (HS-YFP) YFP-H148Q/I152L and CFBE41o-cells stably expressing F508del-CFTR and HS-YFP were generated as previously described.<a onclick="showRef(event, 'ref21 ref57'); return false;" href="javascript:void(0);" class="ref ref21 ref57">(21,57)</a> FRT cells were cultured using the Coon’s modification of Ham’s F12 medium, while CFBE41o-cells were cultured in the modified Eagle’s medium. Media were supplemented with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 100 U/mL of penicillin, and 100 mg/mL of streptomycin. For functional assays of CFTR activity based on the HS-YFP assays, CFBE41o- or FRT cells were plated (50,000 cells/well) on clear-bottom 96-well black microplates (Corning Life Sciences, Acton, MA). The following day, cells were assayed. In the case of FRT cells expressing F508del-CFTR, plates were kept at 32 °C (or treated with correctors at 37 °C where indicated) for an additional 24 h to rescue the mutant trafficking defect, before assays.</div><div class="NLM_p last">Primary bronchial epithelial cells were cultured as previously described.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In brief, epithelial cells were cultured in a serum-free medium (LHC9 mixed with RPMI 1640, 1:1) supplemented with hormones and supplements to support cell number amplification. Then, the cells were seeded at high density on porous membranes (500,000 cells for 1 cm<sup>2</sup> Snapwell inserts, for Ussing chamber studies; 200,000 cells for 0.33 cm<sup>2</sup> Mini-Transwell inserts, for TEER/PD measurements). After 24 h, the serum-free medium was replaced with Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F12 containing 2% fetal bovine serum (FBS) plus hormones and supplements. Differentiation of cells to form a tight epithelium was monitored by measuring transepithelial electrical resistance and potential difference with an epithelial voltohmmeter (EVOM1, World Precision Instruments). After 8–10 days, the apical medium was removed, and the cells received nutrients only from the basolateral side (air–liquid interface, ALI) to promote further differentiation of the epithelium. Cells were maintained under ALI for 2–3 weeks before experiments.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> HS-YFP-Based Assay for CFTR Activity</h4><div class="NLM_p">Prior assay, cells were washed with phosphate-buffered saline (PBS) containing (in mM) 137 NaCl, 2.7 KCl, 8.1 Na<sub>2</sub>HPO<sub>4</sub>, 1.5 KH<sub>2</sub>PO<sub>4</sub>, 1 CaCl<sub>2</sub>, and 0.5 MgCl<sub>2</sub>. Cells were then incubated for 25 min with 60 μL of PBS plus forskolin (20 μM) and test compounds (at the desired concentration) to stimulate mutant CFTR. Cells were then transferred to microplate readers (FluoStar Optima; BMG Labtech, Offenburg, Germany) for CFTR activity determination. The plate readers were equipped with high-quality excitation (HQ500/20X: 500 ± 10 nm) and emission (HQ535/30M: 535 ± 15 nm) filters for YFP (Chroma Technology). The assay consisted of a continuous 14 s fluorescence reading, 2 s before and 12 s after injection of 165 μL of an iodide-containing solution (PBS with Cl<sup>–</sup> replaced by I<sup>–</sup>; final I<sup>–</sup> concentration 100 mM). Data were normalized to the initial background-subtracted fluorescence. To determine the I<sup>–</sup> influx rate, the final 10 s of the data for each well was fitted with a linear function to extrapolate the initial slope (d<i>F</i>/d<i>t</i>).</div><div class="NLM_p last">Each experimental condition was tested in three independent experiments, each one performed with three biological replicates (<i>n</i> = 9).</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> TEER/PD Measurements</h4><div class="NLM_p">Differentiated bronchial epithelia were treated with compounds included in the appropriate culture medium at the indicated concentrations for 24 h at 37 °C and 5% CO<sub>2</sub>, before measuring the TEER and/or PD by means of an epithelial voltohmmeter (EVOM1, World Precision Instruments).</div><div class="NLM_p">The electrical measurements were done in Coon’s modified Ham’s F-12 medium, where NaHCO<sub>3</sub> was replaced with 20 mM Na–HEPES (pH 7.3). TEER and PD were measured in each well under basal conditions, after ENaC inhibition with apical amiloride (10 μM), after CFTR stimulation with forskolin (10 μM) plus test compounds (at the desired concentration) on both sides, and after CFTR inhibition with apical PPQ102 (30 μM). After each treatment, we waited 10 min before recording the electrical parameters. The TEER and PD values for each well were converted into short-circuit current equivalent by Ohm’s law.</div><div class="NLM_p last">Each experimental condition was tested in three independent experiments, each one performed with three biological replicates (<i>n</i> = 9).</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Short-Circuit Current Recordings</h4><div class="NLM_p">Differentiated bronchial epithelia on Snapwell inserts were mounted in a Ussing chamber with internal fluid circulation. Apical and basolateral hemichambers were filled with 5 mL of a solution containing (in mM) 126 NaCl, 0.38 KH<sub>2</sub>PO<sub>4</sub>, 2.13 K<sub>2</sub>HPO<sub>4</sub>, 1 MgSO<sub>4</sub>, 1 CaCl<sub>2</sub>, 24 NaHCO<sub>3</sub>, and 10 glucose, and both sides were continuously bubbled with a 5% CO<sub>2</sub>–95% air mixture, with the temperature of the solution maintained at 37 °C. The transepithelial voltage was short-circuited with a voltage clamp (DVC-1000, World Precision Instruments) connected to the apical and basolateral chambers via Ag/AgCl electrodes and agar bridges (1 M KCl in 1% agar). The offset between voltage electrodes and the fluid electrical resistance were set to zero before each set of experiments. The short-circuit current was recorded with a PowerLab 4/25 (ADInstruments) analog-to-digital converter connected to a personal computer.</div><div class="NLM_p last">Each experimental condition was tested in three independent experiments, each one performed with three biological replicates (<i>n</i> = 9).</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Statistical Analysis</h4><div class="NLM_p last">Each experimental condition was tested in three independent experiments, each one performed with three biological replicates (<i>n</i> = 9). The Kolmogorov–Smirnov test was used to evaluate the assumption of normality. The statistical significance of the effect of single treatments on CFTR activity or expression was tested by parametric one-way ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group) as a post-hoc test. In the case of a combination of treatments, statistical significance was verified by ANOVA, followed by the Tukey test (for multiple comparisons) as the post-hoc test. Normally distributed data are expressed as mean ± SD, and significances are two-sided. Differences were considered statistically significant when <i>P</i> was less than 0.05.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> <i>In Vitro</i> ADMET</h3><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Aqueous Kinetic Solubility Assay</h4><div class="NLM_p last">The aqueous kinetic solubility was determined from a 10 mM DMSO stock solution of test compound in PBS at pH 7.4. The study was performed by incubation of an aliquot of 10 mM DMSO stock solution in PBS (pH 7.4) at a target concentration of 250 μM (2.5% DMSO). The incubation was carried out under shaking at 25 °C for 24 h, followed by centrifugation at 21,100<i>g</i> for 30 min. The supernatant was further diluted (4:1) with CH<sub>3</sub>CN and the dissolved test compound was quantified by UV at 215 nm on a Waters ACQUITY UPLC/MS system consisting of an SQD mass spectrometer equipped with an electrospray ionization interface and a photodiode array detector. Electrospray ionization in the positive mode was used in the mass scan range of 100–500 Da. The PDA range was 210–400 nm. The analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> column (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm) using 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O at pH 5 adjusted with AcOH (A) and 10 mM NH<sub>4</sub>OAc in CH<sub>3</sub>CN–H<sub>2</sub>O (95:5) at pH 5 (B) as the mobile phase. The aqueous kinetic solubility (in μM) was calculated by dividing the peak areas of the dissolved test compound and the test compound in the reference (250 μM of test compound in CH<sub>3</sub>CN) and multiply by the target concentration and dilution factor.</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Liver Microsomal Stability Assay</h4><div class="NLM_p">Phase I: 10 mM DMSO stock solution of the test compound was preincubated at 37 °C for 15 min with rat, dog, or human liver microsomes in 0.1 M Tris–HCl buffer (pH 7.5) with 10% DMSO. The final concentration was 4.6 μM. After preincubation, the cofactors (NADPH, G6P, G6PDH, and MgCl<sub>2</sub> predissolved in 0.1 M Tris–HCl) were added to the incubation mixture and the incubation was continued at 37 °C for 1 h.</div><div class="NLM_p">Phase II: 10 mM DMSO stock solution of the test compound was preincubated at 37 °C for 15 min with human liver microsomes added alamethicin in 0.1 M Tris–HCl buffer (pH 7.5) with 10% DMSO. The final concentration was 4.6 μM. After preincubation, the cofactors (UDPGA, <span class="smallcaps smallerCapital">d</span>-saccharic acid lactone, and MgCl<sub>2</sub> predissolved in 0.1 M Tris–HCl) were added to the incubation mixture and the incubation was continued at 37 °C for 1 h.</div><div class="NLM_p last">For both phase I and II studies: At each time point (0, 5, 15, 30, and 60 min), 30 μL of the incubation mixture was diluted with 200 μL of cold CH<sub>3</sub>CN spiked with 200 nM of an appropriate internal standard, followed by centrifugation at 3270<i>g</i> for 15 min. The supernatant was further diluted with H<sub>2</sub>O (1:1) for analysis. A reference incubation mixture (microsomes without cofactors) was prepared for each test compound and analyzed at <i>t</i> = 0 and 60 min in order to verify the compound’s stability in the matrix. The two time points were diluted as for the time points of the incubation mixture above. The supernatants were analyzed by LC/MS–MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD (triple quadrupole detector) mass spectrometer equipped with an electrospray ionization interface and a photodiode array eλ detector. Electrospray ionization was applied in positive mode. Compound-dependent parameters as MRM transitions and collision energy were developed for each compound. The analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C, using H<sub>2</sub>O + 0.1% HCOOH (A) and CH<sub>3</sub>CN + 0.1% HCOOH (B) as the mobile phase. The percentage of test compound remaining at each time point relative to <i>t</i> = 0 was calculated by the response factor on the basis of the internal standard peak area. The percentage of test compound versus time was plotted and fitted by GraphPad Prism (GraphPad Software, Version 5 for Windows, CA, USA, <a href="http://www.graphpad.com" class="extLink">www.graphpad.com</a>) to estimate the compound’s half-life (<i>t</i><sub>1/2</sub>), which was reported as mean value along with the standard deviation (<i>n</i> = 3).</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> HepG2 Cell toxicity Assay</h4><div id="sec5_6_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> Cell Culture Conditions</h5><div class="NLM_p last">To increase the detection of drug-induced mitochondrial effects in a preclinical cell-based assay, HepG2 hepatocellular carcinoma cells (ATCC HB-8065) were forced to rely on mitochondrial oxidative phosphorylation rather than glycolysis by substituting galactose (10 mM) for glucose (25 mM) in the growth media (DMEM, Life Technologies).</div></div><div id="sec5_6_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> Media Composition</h5><div class="NLM_p last">High-glucose media: high-glucose DMEM (Invitrogen 11995-065) containing 25 mM glucose, 1.0 mM sodium pyruvate, supplemented with 5 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-(2-ethanesulfonic acid) (HEPES), and 10% FBS. Galactose media: DMEM deprived of glucose (Invitrogen 11966-025), supplemented with 10 mM galactose, 2.0 mM glutamine (6 mM final), 5.0 mM HEPES, 10% FBS, and 1.0 mM sodium pyruvate.</div></div><div id="sec5_6_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> Cell Viability Assessment</h5><div class="NLM_p last">For the cytotoxicity assay, cells were plated at 20,000 cells/well in 100 μL of cell culture media in 96-well plates and allowed to grow overnight. The cells were treated for 24 h with 2.0 or 20 μM of each compound. All compounds were dissolved in DMSO with a stock concentration of 4 mM. The first dilution step of compounds was prepared in DMSO (200× stock solutions), while the second dilution step was carried out in a complete cell culture medium (5% DMSO). Of this dilution, 10 μL were added to the wells of the 96-well plate, with a final DMSO concentration of 0.5%. Rotenone, a well-known mitochondrial inhibitor, was used as a reference compound. After treatment, cellular viability was assessed by using two different assays, run on independent plates: the CellTiter-Glo (CTG) Luminescent Cell Viability Assay (Promega), which determines the number of viable cells based on the quantitation of the ATP present, and the thiazolyl blue tetrazolium blue (MTT) dye (Aldrich), which is converted to water-insoluble MTT formazan crystals by mitochondrial dehydrogenases of living cells. Each experimental condition (i.e., control, reference, and compounds’ doses) has been tested in three technical replicates.</div></div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> <i>In Vivo</i> Pharmacology</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Animals</h4><div class="NLM_p last">Male Sprague–Dawley rats, 2 month old and weighing 175–200 g (Charles River, Calco, Italy), were used. Animals were group-housed in ventilated cages and had free access to food and water. They were maintained under a 12 h light/dark cycle (lights on at 8:00 am) at a controlled temperature (21 ± 1 °C) and relative humidity (55 ± 10%). All experiments were carried out in accordance with the guidelines established by the European Communities Council Directive (Directive 2010/63/EU of September 22, 2010) and approved by the National Council on Animal Care of the Italian Ministry of Health. All efforts were made to minimize animal suffering and to use the minimal number of animals required to produce reliable results.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Pharmacokinetic Methods</h4><div class="NLM_p last">Compound <b>39</b> was administered intravenously (i.v.) and orally (p.o.) to cannulated Sprague–Dawley rats at doses of 3 and 10 mg/kg, respectively. PEG400/Tween 80/saline solution was used as a vehicle at 10/10/80% in volume, respectively. Three animals per dose were treated. Blood samples at 0, 15, 30, 60, 90, 120, 240, and 360 min after administration were collected for p.o. arm. Blood samples at 0, 5, 15, 30, 60, 90, 120, and 240 min after administration were collected for i.v. arm. Plasma was separated from blood by centrifugation for 15 min at 3500 rpm at 4 °C, collected in an Eppendorf tube, and frozen (−80 °C). Control animals treated with vehicle only were also included in the experimental protocol.</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Sample Preparation for Lung Exposure Analysis</h4><div class="NLM_p last">Three animals per dose and timing were treated. Compound <b>39</b> was dissolved in PEG400/Tween80/saline solution at 10/10/80% in volume and administered orally at a dose of 10 mg/kg. After 120 and 240 min, rats were sacrificed and lungs were immediately dissected, frozen on dry ice, and stored at −80 °C until analysis. Lung samples were homogenized in RIPA buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, and pH 8.0) and then split into two aliquots kept at −80 °C until analysis. An aliquot was used for compound lung-level evaluations. The second aliquot was kept for protein content evaluation using the bicinchoninic acid assay (Thermo Scientific, Rockford, IL, USA).</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Bioanalytical Analyses</h4><div class="NLM_p last">Plasma samples were centrifuged at 21,100<i>g</i> for 15 min at 4 °C, while homogenized lung samples were vigorously whirled. An aliquot of each sample was extracted (1:3) with cold CH<sub>3</sub>CN containing 200 nM of an appropriate internal standard being a close analogue of the parent compound. A calibration curve was prepared in both blank mouse plasma and naïve lung homogenate over a 1 nM to 10 μM range. Three quality controls were prepared by spiking the parent compound in both blank mouse plasma and naïve lung homogenate to 20, 200, and 2000 nM as final concentrations. The calibrators and quality controls were extracted (1:3) with the same extraction solution as the plasma and lung samples. The plasma and lung samples, the calibrators, and quality controls were centrifuged at 3270<i>g</i> for 15 min at 4 °C. The supernatants were further diluted (1:1) with H<sub>2</sub>O and analyzed by LC/MS–MS on a Waters ACQUITY UPLC/MS TQD system consisting of a TQD mass spectrometer equipped with an electrospray ionization interface and a photodiode array eλ detector. Electrospray ionization was applied in the positive mode. Compound-dependent parameters such as MRM transitions and collision energy were developed for the parent compound and the internal standard. The mobile phase was H<sub>2</sub>O + 0.1% HCOOH (A) and CH<sub>3</sub>CN + 0.1% HCOOH (B) at a flow rate of 0.5 mL/min. For plasma samples, the analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> (50 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. A linear gradient was applied starting at 30% B with an initial hold for 0.2 min and then 30–100% B in 2 min. For lung samples, the analyses were run on an ACQUITY UPLC BEH C<sub>18</sub> (100 × 2.1 mm ID, particle size 1.7 μm) with a VanGuard BEH C<sub>18</sub> precolumn (5 × 2.1 mm ID, particle size 1.7 μm) at 40 °C. A linear gradient was applied starting at 30% B with an initial hold for 0.2 min and then 30–100% B in 6 min. All samples (plasma and lung samples, calibrators, and quality controls) were quantified by MRM peak area response factor in order to determine the levels of the parent compound in plasma and lung. The concentrations versus time data were plotted and the profiles were fitted using PK Solutions Excel Application (Summit Research Service, USA) in order to determine the pharmacokinetic parameters.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i115"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01050" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01050?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01050</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">UPLC/MS traces and <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectral data for final compounds; chiral HPLC data for enantioenriched final compounds; UPLC/MS traces of primary hits from screening; and experimental procedures and results from additional <i>in vivo</i> assays (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf">jm0c01050_si_001.pdf (12.43 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_002.csv">jm0c01050_si_002.csv (3.47 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01050" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicoletta Pedemonte</span> - <span class="hlFld-Affiliation affiliation">UOC
Genetica Medica, IRCCS Istituto Giannina
Gaslini, 16147 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5161-1720" title="Orcid link">http://orcid.org/0000-0002-5161-1720</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6b05020804070e1f1f0a451b0e0f0e0604051f0e2b1e05020c0e45021f"><span class="__cf_email__" data-cfemail="56383f35393a3322223778263332333b393822331623383f3133783f22">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabio Bertozzi</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7434-3688" title="Orcid link">http://orcid.org/0000-0001-7434-3688</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3f595e5d5650115d5a4d4b504545567f56564b11564b"><span class="__cf_email__" data-cfemail="d7b1b6b5beb8f9b5b2a5a3b8adadbe97bebea3f9bea3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicoletta Brindani</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span>; 
    <span>Present Address:
                        Laboratory of Molecular Modeling and Drug Design (IIT)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ambra Gianotti</span> - <span class="hlFld-Affiliation affiliation">UOC
Genetica Medica, IRCCS Istituto Giannina
Gaslini, 16147 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simone Giovani</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span>; 
    <span>Present Address:
                        Pharma Integration s.r.l., 53100 Siena, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Giacomina</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span>; 
    <span>Present Address:
                        Supply Chain, Siegfried Evionnaz SA, 1902 Evionnaz (VS), Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Di Fruscia</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span>; 
    <span>Present Address:
                        Structure, Biophysics & Fragments, Discovery Sciences, R&D-AstraZeneca, CB4 0WG, Cambridge, UK</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federico Sorana</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span>; 
    <span>Present Address:
                        Aptuit, An Evotec Company, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sine Mandrup Bertozzi</span> - <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuliana Ottonello</span> - <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luca Goldoni</span> - <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ilaria Penna</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debora Russo</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Summa</span> - <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosalia Bertorelli</span> - <span class="hlFld-Affiliation affiliation">Analytical
Chemistry and Translational Pharmacology, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loretta Ferrera</span> - <span class="hlFld-Affiliation affiliation">UOC
Genetica Medica, IRCCS Istituto Giannina
Gaslini, 16147 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emanuela Pesce</span> - <span class="hlFld-Affiliation affiliation">UOC
Genetica Medica, IRCCS Istituto Giannina
Gaslini, 16147 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elvira Sondo</span> - <span class="hlFld-Affiliation affiliation">UOC
Genetica Medica, IRCCS Istituto Giannina
Gaslini, 16147 Genova, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luis J. V. Galietta</span> - <span class="hlFld-Affiliation affiliation">Telethon
Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Translational Medical Sciences (DISMET), University of Naples Federico II, 80138 Naples, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tiziano Bandiera</span> - <span class="hlFld-Affiliation affiliation">D3-PharmaChemistry, Istituto Italiano di Tecnologia (IIT), 16163 Genova, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>N.B. and A.G. contributed equally to this work. N.B., A.G., S.G., F.G., P.D.F., F.S., S.M.B., G.O., L.G., I.P., D.R., M.S., R.B., L.F., E.P., and E.S. did the experimental work. L.J.V.G., T.B., N.P., and F.B. designed the study and analyzed the data. N.B., N.P., and F.B. wrote the manuscript. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by Fondazione Italiana per la Ricerca sulla Fibrosi Cistica through a strategic project named “Task Force for Cystic Fibrosis”.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): T.B., F.B., F.G., S.G., F.S., E.C., L.F., N.P., and L.J.V.G. are inventors in a patent application protecting the class of compounds disclosed in this paper, and filed by Fondazione Istituto Italiano di Tecnologia, Istituto Giannina Gaslini, and Fondazione per la Ricerca sulla Fibrosi Cistica-Onlus (PCT international publication no. WO 2020/012427 A1; international publication date, 16 January 2020). The authors declare no other competing interests.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. G. Bottegoni for the computational work for the selection of the compounds of the library, S. Venzano for the preparation of plates with the compounds’ solution for screening, and M. Veronesi for NMR technical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">CF</td><td class="NLM_def"><p class="first last">cystic fibrosis</p></td></tr><tr><td class="NLM_term">CFTR</td><td class="NLM_def"><p class="first last">cystic fibrosis transmembrane conductance regulator</p></td></tr><tr><td class="NLM_term">F508del</td><td class="NLM_def"><p class="first last">deletion of phenylalanine 508</p></td></tr><tr><td class="NLM_term">FRT</td><td class="NLM_def"><p class="first last">Fischer rat thyroid</p></td></tr><tr><td class="NLM_term">HS-YFP</td><td class="NLM_def"><p class="first last">halide-sensitive yellow fluorescent protein</p></td></tr><tr><td class="NLM_term">HBE</td><td class="NLM_def"><p class="first last">primary human bronchial epithelial cells</p></td></tr><tr><td class="NLM_term">TEER/PD</td><td class="NLM_def"><p class="first last">transepithelial electrical resistance/potential difference</p></td></tr><tr><td class="NLM_term">CPT-cAMP</td><td class="NLM_def"><p class="first last">8-(4-chlorophenylthio)adenosine 3′,5′-cyclic monophosphate</p></td></tr><tr><td class="NLM_term">PPQ-102</td><td class="NLM_def"><p class="first last">7,9-dimethyl-11-phenyl-6-(5-methylfuran-2-yl)-5,6-dihydro-pyrimido-[4′,5′-3,4]pyrrolo[1,2-<i>a</i>]quinoxaline-8,10-(7<i>H</i>,9<i>H</i>)-dione</p></td></tr><tr><td class="NLM_term">ENaC</td><td class="NLM_def"><p class="first last">epithelial sodium channel (or amiloride-sensitive sodium channel)</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate (reduced)</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine-diphosphate-glucuronic acid trisodium salt</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDC·HCl</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr></table><span class="title" id="d674461383e14211">Additional Notes</span><div class="NLM_fn" id="fn5"><sup>a</sup> <p class="last">Pure regioisomer <b>52</b> was obtained as a racemate, starting from enantiopure (<i>R</i>)-<b>50</b>, because of the epimerization process during Fischer indole synthesis.</p></div><div class="NLM_fn" id="fn6"><sup>b</sup> <p class="last">Pure regioisomer <b>52</b> was obtained as a racemate starting from enantiopure (<i>S</i>)-<b>51</b> because of the epimerization process during Fischer indole synthesis.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28036" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28036" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerholz, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, M. J.</span></span> <span> </span><span class="NLM_article-title">Origins of Cystic Fibrosis Lung Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1056/nejmra1300109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1056%2FNEJMra1300109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25607428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=351-362&author=D.+A.+Stoltzauthor=D.+K.+Meyerholzauthor=M.+J.+Welsh&title=Origins+of+Cystic+Fibrosis+Lung+Disease&doi=10.1056%2Fnejmra1300109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Origins of cystic fibrosis lung disease</span></div><div class="casAuthors">Stoltz, David A.; Meyerholz, David K.; Welsh, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-362/1-351-362/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discussing about the new animal models that mirror to cystic fibrosis in humans for discovering the origins of the lung disease.  Loss of CFTR gene function will leads to reduced chloride secretion, sodium hyperabsorption and reduced pH of airway-surface liq. that impairs bacteria killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovF2zZPdvgxrVg90H21EOLACvtfcHk0lhavqOU5lAM2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGqtLs%253D&md5=2bca233cffb6701decfed5a340432b01</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1300109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1300109%26sid%3Dliteratum%253Aachs%26aulast%3DStoltz%26aufirst%3DD.%2BA.%26aulast%3DMeyerholz%26aufirst%3DD.%2BK.%26aulast%3DWelsh%26aufirst%3DM.%2BJ.%26atitle%3DOrigins%2520of%2520Cystic%2520Fibrosis%2520Lung%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D351%26epage%3D362%26doi%3D10.1056%2Fnejmra1300109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castellani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assael, B. M.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis: A Clinical View</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2393-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2Fs00018-016-2393-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27709245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1eiurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=129-140&author=C.+Castellaniauthor=B.+M.+Assael&title=Cystic+Fibrosis%3A+A+Clinical+View&doi=10.1007%2Fs00018-016-2393-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis: a clinical view</span></div><div class="casAuthors">Castellani, Carlo; Assael, Baroukh M.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-140</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF), a monogenic disease caused by mutations in the CFTR gene on chromosome 7, is complex and greatly variable in clin. expression.  Airways, pancreas, male genital system, intestine, liver, bone, and kidney are involved.  The lack of CFTR or its impaired function causes fat malabsorption and chronic pulmonary infections leading to bronchiectasis and progressive lung damage.  Previously considered lethal in infancy and childhood, CF has now attained median survivals of 50 years of age, mainly thanks to the early diagnosis through neonatal screening, recognition of mild forms, and an aggressive therapeutic attitude.  Classical treatment includes pancreatic enzyme replacement, respiratory physiotherapy, mucolitics, and aggressive antibiotic therapy.  A significant proportion of patients with severe symptoms still requires lung or, less frequently, liver transplantation.  The great no. of mutations and their diverse effects on the CFTR protein account only partially for CF clin. variability, and modifier genes have a role in modulating the clin. expression of the disease.  Despite the increasing understanding of CFTR functioning, several aspects of CF need still to be clarified, e.g., the worse outcome in females, the risk of malignancies, the pathophysiol., and best treatment of comorbidities, such as CF-related diabetes or CF-related bone disorder.  Research is focusing on new drugs restoring CFTR function, some already available and with good clin. impact, others showing promising preliminary results that need to be confirmed in phase III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpLpaQ4nR-M7Vg90H21EOLACvtfcHk0lhavqOU5lAM2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1eiurfO&md5=9743e56d25aefba23d45b672df278f35</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2393-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2393-9%26sid%3Dliteratum%253Aachs%26aulast%3DCastellani%26aufirst%3DC.%26aulast%3DAssael%26aufirst%3DB.%2BM.%26atitle%3DCystic%2520Fibrosis%253A%2520A%2520Clinical%2520View%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D129%26epage%3D140%26doi%3D10.1007%2Fs00018-016-2393-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, J. W.</span></span> <span> </span><span class="NLM_article-title">Physiology of Epithelial Chloride and Fluid Secretion</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">a009563</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a009563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1101%2Fcshperspect.a009563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=22675668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a009563&author=R.+A.+Frizzellauthor=J.+W.+Hanrahan&title=Physiology+of+Epithelial+Chloride+and+Fluid+Secretion&doi=10.1101%2Fcshperspect.a009563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Physiology of epithelial chloride and fluid secretion</span></div><div class="casAuthors">Frizzell, Raymond A.; Hanrahan, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a009563/1-a009563/19</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Epithelial salt and water secretion serves a variety of functions in different organ systems, such as the airways, intestines, pancreas, and salivary glands.  In cystic fibrosis (CF), the vol. and/or compn. of secreted luminal fluids are compromised owing to mutations in the gene encoding CFTR, the apical membrane anion channel that is responsible for salt secretion in response to cAMP/PKA stimulation.  This article examines CFTR and related cellular transport processes that underlie epithelial anion and fluid secretion, their regulation, and how these processes are altered in CF disease to account for organ-specific secretory phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvsW9XvchFd7Vg90H21EOLACvtfcHk0lg3EhZgladsFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemurw%253D&md5=812a3f3732ffa5e043a8cba77b364ee6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a009563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a009563%26sid%3Dliteratum%253Aachs%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DHanrahan%26aufirst%3DJ.%2BW.%26atitle%3DPhysiology%2520of%2520Epithelial%2520Chloride%2520and%2520Fluid%2520Secretion%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26spage%3Da009563%26doi%3D10.1101%2Fcshperspect.a009563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Criq, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of CFTR in Epithelial Physiology</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2391-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2Fs00018-016-2391-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27714410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ehsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=93-115&author=V.+Saint-Criqauthor=M.+A.+Gray&title=Role+of+CFTR+in+Epithelial+Physiology&doi=10.1007%2Fs00018-016-2391-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CFTR in epithelial physiology</span></div><div class="casAuthors">Saint-Criq, Vinciane; Gray, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-115</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Salt and fluid absorption and secretion are two processes that are fundamental to epithelial function and whole body fluid homeostasis, and as such are tightly regulated in epithelial tissues.  The CFTR anion channel plays a major role in regulating both secretion and absorption in a diverse range of epithelial tissues, including the airways, the GI and reproductive tracts, sweat and salivary glands.  It is not surprising then that defects in CFTR function are linked to disease, including life-threatening secretory diarrhoeas, such as cholera, as well as the inherited disease, cystic fibrosis (CF), one of the most common life-limiting genetic diseases in Caucasian populations.  More recently, CFTR dysfunction has also been implicated in the pathogenesis of acute pancreatitis, chronic obstructive pulmonary disease (COPD), and the hyper-responsiveness in asthma, underscoring its fundamental role in whole body health and disease.  CFTR regulates many mechanisms in epithelial physiol., such as maintaining epithelial surface hydration and regulating luminal pH.  Indeed, recent studies have identified luminal pH as an important arbiter of epithelial barrier function and innate defense, particularly in the airways and GI tract.  In this chapter, we will illustrate the different operational roles of CFTR in epithelial function by describing its characteristics in three different tissues: the airways, the pancreas, and the sweat gland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBfwGPqFkjnLVg90H21EOLACvtfcHk0lg3EhZgladsFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ehsrvM&md5=0d99eb0787bd06c3a87f4d2b469e16ff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2391-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2391-y%26sid%3Dliteratum%253Aachs%26aulast%3DSaint-Criq%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520CFTR%2520in%2520Epithelial%2520Physiology%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D93%26epage%3D115%26doi%3D10.1007%2Fs00018-016-2391-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><a href="https://cftr2.org/mutations_history" class="extLink">https://cftr2.org/mutations_history</a> (accessed Mar 18, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fcftr2.org%2Fmutations_history+%28accessed+Mar+18%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pranke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinzpeter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sermet-Gaudelus, I.</span></span> <span> </span><span class="NLM_article-title">Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">121</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2019.00121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30873022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlaktb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=121&author=I.+Prankeauthor=A.+Golecauthor=A.+Hinzpeterauthor=A.+Edelmanauthor=I.+Sermet-Gaudelus&title=Emerging+Therapeutic+Approaches+for+Cystic+Fibrosis.+From+Gene+Editing+to+Personalized+Medicine&doi=10.3389%2Ffphar.2019.00121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine</span></div><div class="casAuthors">Pranke, Iwona; Golec, Anita; Hinzpeter, Alexandre; Edelman, Aleksander; Sermet-Gaudelus, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">An improved understanding of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein structure and the consequences of CFTR gene mutations have allowed the development of novel therapies targeting specific defects underlying CF.  Some strategies are mutation specific and have already reached clin. development; some strategies include a read-through of the specific premature termination codons (read-through therapies, nonsense mediated decay pathway inhibitors for Class I mutations); correction of CFTR folding and trafficking to the apical plasma membrane (correctors for Class II mutations); and an increase in the function of CFTR channel (potentiators therapy for Class III mutations and any mutant with a residual function located at the membrane).  Other therapies that are in preclin. development are not mutation specific and include gene therapy to edit the genome and stem cell therapy to repair the airway tissue.  These strategies that are directed at the basic CF defects are now revolutionizing the treatment for patients and should pos. impact their survival rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowHTuM1yYFRrVg90H21EOLACvtfcHk0lg3EhZgladsFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlaktb7M&md5=aa52affc198bae86359ced65c9716ca4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00121%26sid%3Dliteratum%253Aachs%26aulast%3DPranke%26aufirst%3DI.%26aulast%3DGolec%26aufirst%3DA.%26aulast%3DHinzpeter%26aufirst%3DA.%26aulast%3DEdelman%26aufirst%3DA.%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26atitle%3DEmerging%2520Therapeutic%2520Approaches%2520for%2520Cystic%2520Fibrosis.%2520From%2520Gene%2520Editing%2520to%2520Personalized%2520Medicine%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D121%26doi%3D10.3389%2Ffphar.2019.00121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Boeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, M. D.</span></span> <span> </span><span class="NLM_article-title">Progress in Therapies for Cystic Fibrosis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/s2213-2600(16)00023-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2FS2213-2600%2816%2900023-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27053340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2ht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=662-674&author=K.+De%0ABoeckauthor=M.+D.+Amaral&title=Progress+in+Therapies+for+Cystic+Fibrosis&doi=10.1016%2Fs2213-2600%2816%2900023-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in therapies for cystic fibrosis</span></div><div class="casAuthors">De Boeck, Kris; Amaral, Margarida D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">662-674</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Std. follow-up and symptomatic treatment have allowed most patients with cystic fibrosis to live to young adulthood.  However, many patients still die prematurely from respiratory insufficiency.  Hence, further investigations to improve these therapies are important and might have relevance for other diseases-eg, exploring how to increase airway hydration, how to safely downscale the increased inflammatory response in the lung, and how to better combat lung infections assocd. with cystic fibrosis.  In parallel, development of modulators that target the underlying dysfunction in the cystic fibrosis transmembrane conductance regulator (CFTR) is fast moving forward.  Existing treatments are specific to certain mutations, or mutation class, in CFTR.  An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost.  Corrective treatments that are non-specific to mutation class and thus applicable to all patients-eg, gene therapy, cell-based therapies, and activation of alternative ion channels that bypass CFTR-are being explored, but they are still in early stages of development.  In view of the large no. of patients with very rare mutations, a plan to advance personalised biomarkers to predict treatment effect is also being investigated and validated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooQ4wbeuHKo7Vg90H21EOLACvtfcHk0lgWJVNpx7bDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2ht7w%253D&md5=e33405c2e6166a27b4df430706562670</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2900023-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252900023-0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBoeck%26aufirst%3DK.%26aulast%3DAmaral%26aufirst%3DM.%2BD.%26atitle%3DProgress%2520in%2520Therapies%2520for%2520Cystic%2520Fibrosis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D662%26epage%3D674%26doi%3D10.1016%2Fs2213-2600%2816%2900023-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramescu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houck, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guggino, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skach, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutting, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span> <span> </span><span class="NLM_article-title">From CFTR Biology toward Combinatorial Pharmacotherapy: Expanded Classification of Cystic Fibrosis Mutations</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1091/mbc.e14-04-0935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1091%2Fmbc.e14-04-0935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=26823392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=424-433&author=G.+Veitauthor=R.+G.+Avramescuauthor=A.+N.+Chiangauthor=S.+A.+Houckauthor=Z.+Caiauthor=K.+W.+Petersauthor=J.+S.+Hongauthor=H.+B.+Pollardauthor=W.+B.+Gugginoauthor=W.+E.+Balchauthor=W.+R.+Skachauthor=G.+R.+Cuttingauthor=R.+A.+Frizzellauthor=D.+N.+Sheppardauthor=D.+M.+Cyrauthor=E.+J.+Sorscherauthor=J.+L.+Brodskyauthor=G.+L.+Lukacs&title=From+CFTR+Biology+toward+Combinatorial+Pharmacotherapy%3A+Expanded+Classification+of+Cystic+Fibrosis+Mutations&doi=10.1091%2Fmbc.e14-04-0935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</span></div><div class="casAuthors">Veit, Gudio; Avramescu, Radu G.; Chiang, Annette N.; Houck, Scott A.; Cai, Zhiwei; Peters, Kathryn W.; Hong, Jeong S.; Pollard, Harvey B.; Guggino, William B.; Balch, William E.; Skach, William R.; Cutting, Garry R.; Frizzell, Raymond A.; Sheppard, David N.; Cyr, Douglas M.; Sorscher, Eric J.; Brodsky, Jeffrey L.; Lukacs, Gergely L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">424-433</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of mol. cell biol. and functional phenotypes.  Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity.  Based on the mol. phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biol.  This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clin. benefit over available low-efficacy monotherapies.  Indeed, recent phase 3 clin. trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del).  This drug combination was recently approved by the U.S.  Food and Drug Administration for patients homozygous for ΔF508.  Emerging studies of the structural, cell biol., and functional defects caused by rare mutations provide a new framework that reveals a mixt. of deficiencies in different CFTR alleles.  Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq66J1miev7J7Vg90H21EOLACvtfcHk0lgWJVNpx7bDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N&md5=d8e30db897e38fc9e7f15f883d0050d6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e14-04-0935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e14-04-0935%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DChiang%26aufirst%3DA.%2BN.%26aulast%3DHouck%26aufirst%3DS.%2BA.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DPeters%26aufirst%3DK.%2BW.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26aulast%3DPollard%26aufirst%3DH.%2BB.%26aulast%3DGuggino%26aufirst%3DW.%2BB.%26aulast%3DBalch%26aufirst%3DW.%2BE.%26aulast%3DSkach%26aufirst%3DW.%2BR.%26aulast%3DCutting%26aufirst%3DG.%2BR.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DSheppard%26aufirst%3DD.%2BN.%26aulast%3DCyr%26aufirst%3DD.%2BM.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBrodsky%26aufirst%3DJ.%2BL.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DFrom%2520CFTR%2520Biology%2520toward%2520Combinatorial%2520Pharmacotherapy%253A%2520Expanded%2520Classification%2520of%2520Cystic%2520Fibrosis%2520Mutations%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2016%26volume%3D27%26spage%3D424%26epage%3D433%26doi%3D10.1091%2Fmbc.e14-04-0935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bobadilla, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macek, M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, P. M.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis: A Worldwide Analysis of CFTR Mutations-Correlation with Incidence Data and Application to Screening</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1002/humu.10041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1002%2Fhumu.10041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12007216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=575-606&author=J.+L.+Bobadillaauthor=M.+Macekauthor=J.+P.+Fineauthor=P.+M.+Farrell&title=Cystic+Fibrosis%3A+A+Worldwide+Analysis+of+CFTR+Mutations-Correlation+with+Incidence+Data+and+Application+to+Screening&doi=10.1002%2Fhumu.10041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening</span></div><div class="casAuthors">Bobadilla, Joseph L.; Macek, Milan, Jr.; Fine, Jason P.; Farrell, Philip M.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-606</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review with refs.  Although there have been numerous reports from around the world of mutations in the gene of chromosome 7 known as CFTR (cystic fibrosis transmembrane conductance regulator), little attention has been given to integrating these mutant alleles into a global understanding of the population mol. genetics assocd. with cystic fibrosis (CF).  We detd. the distribution of CFTR mutations in as many regions throughout the world as possible in an effort designed to: (1) increase our understanding of ancestry-genotype relationships, (2) compare mutational arrays with disease incidence, and (3) gain insight for decisions regarding screening program enhancement through CFTR multi-mutational analyses.  Information on all mutations that have been published since the identification and cloning of the CFTR gene's most common allele, ΔF508 (or F508del), was reviewed and integrated into a centralized database.  The data were then sorted and regional CFTR arrays were detd. using mutations that appeared in a given region with a frequency of 0.5% or greater.  Final analyses were based on 72,431 CF chromosomes, using data compiled from over 100 original papers, and over 80 regions from around the world, including all nations where CF has been studied using anal. mol. genetics.  Initial results confirmed wide mutational heterogeneity throughout the world; however, characterization of the most common mutations across most populations was possible.  We also examd. CF incidence, ΔF508 frequency, and regional mutational heterogeneity in a subset of populations.  Data for these analyses were filtered for reliability and methodol. strength before being incorporated into the final anal.  Statistical assessment of these variables revealed that there is a significant pos. correlation between ΔF508 frequency and the CF incidence levels of regional populations.  Regional analyses were also performed to search for trends in the distribution of CFTR mutations across migrant and related populations; this led to clarification of ancestry-genotype patterns that can be used to design CFTR multi-mutation panels for CF screening programs.  From comprehensive assessment of these data, we offer recommendations that multiple CFTR alleles should eventually be included to increase the sensitivity of newborn screening programs employing two-tier testing with trypsinogen and DNA anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewtcZ-Xuh27Vg90H21EOLACvtfcHk0lgWJVNpx7bDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVGktr0%253D&md5=56613b894dce26c9bb1840146464d95c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fhumu.10041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.10041%26sid%3Dliteratum%253Aachs%26aulast%3DBobadilla%26aufirst%3DJ.%2BL.%26aulast%3DMacek%26aufirst%3DM.%26aulast%3DFine%26aufirst%3DJ.%2BP.%26aulast%3DFarrell%26aufirst%3DP.%2BM.%26atitle%3DCystic%2520Fibrosis%253A%2520A%2520Worldwide%2520Analysis%2520of%2520CFTR%2520Mutations-Correlation%2520with%2520Incidence%2520Data%2520and%2520Application%2520to%2520Screening%26jtitle%3DHum.%2520Mutat.%26date%3D2002%26volume%3D19%26spage%3D575%26epage%3D606%26doi%3D10.1002%2Fhumu.10041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. E.</span></span> <span> </span><span class="NLM_article-title">Defective Intracellular Transport and Processing of CFTR Is the Molecular Basis of Most Cystic Fibrosis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(90)90148-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2F0092-8674%2890%2990148-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1699669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3MXnvFKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1990&pages=827-834&author=S.+H.+Chengauthor=R.+J.+Gregoryauthor=J.+Marshallauthor=S.+Paulauthor=D.+W.+Souzaauthor=G.+A.+Whiteauthor=C.+R.+O%E2%80%99Riordanauthor=A.+E.+Smith&title=Defective+Intracellular+Transport+and+Processing+of+CFTR+Is+the+Molecular+Basis+of+Most+Cystic+Fibrosis&doi=10.1016%2F0092-8674%2890%2990148-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis</span></div><div class="casAuthors">Cheng, Seng H.; Gregory, Richard J.; Marshall, John; Paul, Sucharita; Souza, David W.; White, Gary A.; O'Riordan, Catherine R.; Smith, Alan E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-34</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The gene assocd. with cystic fibrosis (VF) encodes a membrane-assocd., N-linked glycoprotein called CFTR.  Mutations were introduced into CFTR at residues known to be altered in CF chromosomes and in residues believed to play a role in its function.  Examn. of the various mutant proteins in COS-7 cells indicated that mature, fully glycosylated CFTR was absent from cells contg. ΔF508, ΔI507, K464M, F508R, and S549I cDNA plasmids.  Instead, an incompletely glycosylated version of the protein was detected.  The authors propose that the mutant versions of CFTR are recognized as abnormal and remain incompletely processed in the endoplasmic reticulum where they are subsequently degraded.  Since mutations with this phenotype represent at least 70% of known CF chromosomes, the authors argue that the mol. basis of most cystic fibrosis is the absence of mature CFTR at the correct cellular location.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDj-TBTgjbB7Vg90H21EOLACvtfcHk0li4ooEbMvpsZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXnvFKguw%253D%253D&md5=cb0ccaa858a164a7897715df83e9f040</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990148-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990148-8%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DS.%2BH.%26aulast%3DGregory%26aufirst%3DR.%2BJ.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DSouza%26aufirst%3DD.%2BW.%26aulast%3DWhite%26aufirst%3DG.%2BA.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DC.%2BR.%26aulast%3DSmith%26aufirst%3DA.%2BE.%26atitle%3DDefective%2520Intracellular%2520Transport%2520and%2520Processing%2520of%2520CFTR%2520Is%2520the%2520Molecular%2520Basis%2520of%2520Most%2520Cystic%2520Fibrosis%26jtitle%3DCell%26date%3D1990%26volume%3D63%26spage%3D827%26epage%3D834%26doi%3D10.1016%2F0092-8674%2890%2990148-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denning, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, M. J.</span></span> <span> </span><span class="NLM_article-title">Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator Is Temperature-Sensitive</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1038/358761a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1038%2F358761a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1380673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK38Xls1yrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=1992&pages=761-764&author=G.+M.+Denningauthor=M.+P.+Andersonauthor=J.+F.+Amaraauthor=J.+Marshallauthor=A.+E.+Smithauthor=M.+J.+Welsh&title=Processing+of+Mutant+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Is+Temperature-Sensitive&doi=10.1038%2F358761a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive</span></div><div class="casAuthors">Denning, Gerene M.; Anderson, Matthew P.; Amara, Jane F.; Marshall, John; Smith, Alan E.; Welsh, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6389</span>),
    <span class="NLM_cas:pages">761-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Cystic fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cAMP-dependent phosphorylation and by intracellular ATP.  Mutations in CFTR cause cystic fibrosis partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia.  The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTRΔF508). Studies on the biosynthesis and localization of CFTRΔF508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane.  These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTRΔF508. Chloride channel activity was detected, however, when CFTRΔF508 was expressed in Xenopus oocytes, Vero cells and Sf9 insect cells.  Because oocytes and Sf9 cells are typically maintained at lower temps. than mammalian cells, and because processing of nascent proteins can be sensitive to temp., the authors tested the effect of temp. on the processing of CFTRΔF508.  Here the authors show that the processing of CFTRΔF508 reverts towards that of wild-type as the incubation temp. is reduced.  When the processing defect is cor., cAMP-regulated Cl- channels appear in the plasma membrane.  These results reconcile previous contradictory observations and suggest that the mutant most commonly assocd. with cystic fibrosis is temp.-sensitive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMX1YIn_dUwbVg90H21EOLACvtfcHk0li4ooEbMvpsZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1yrur8%253D&md5=de4f38aa61b6e10173aad5223db47156</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F358761a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F358761a0%26sid%3Dliteratum%253Aachs%26aulast%3DDenning%26aufirst%3DG.%2BM.%26aulast%3DAnderson%26aufirst%3DM.%2BP.%26aulast%3DAmara%26aufirst%3DJ.%2BF.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%2BE.%26aulast%3DWelsh%26aufirst%3DM.%2BJ.%26atitle%3DProcessing%2520of%2520Mutant%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Is%2520Temperature-Sensitive%26jtitle%3DNature%26date%3D1992%26volume%3D358%26spage%3D761%26epage%3D764%26doi%3D10.1038%2F358761a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okiyoneda, T.</span></span> <span> </span><span class="NLM_article-title">Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1100</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2018.01100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30319426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1100&author=R.+Fukudaauthor=T.+Okiyoneda&title=Peripheral+Protein+Quality+Control+as+a+Novel+Drug+Target+for+CFTR+Stabilizer&doi=10.3389%2Ffphar.2018.01100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral protein quality control as a novel drug target for CFTR stabilizer</span></div><div class="casAuthors">Fukuda, Ryosuke; Okiyoneda, Tsukasa</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1100</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Conformationally defective cystic fibrosis transmembrane conductance regulator (CFTR) including rescued ΔF508-CFTR is rapidly eliminated from the plasma membrane (PM) even in the presence of a CFTR corrector and potentiator, limiting the therapeutic effort of the combination therapy.  CFTR elimination from the PM is detd. by the conformation-dependent ubiquitination as a part of the peripheral quality control (PQC) mechanism.  Recently, the mol. machineries responsible for the CFTR PQC mechanism which includes mol. chaperones and ubiquitination enzymes have been revealed.  This review summarizes the mol. mechanism of the CFTR PQC and discusses the possibility that the peripheral ubiquitination mechanism becomes a novel drug target to develop the CFTR stabilizer as a novel class of CFTR modulator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7TVcV28xoO7Vg90H21EOLACvtfcHk0li4ooEbMvpsZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWjur4%253D&md5=f104f00a5e667ceafbda883a003b0069</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01100%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DR.%26aulast%3DOkiyoneda%26aufirst%3DT.%26atitle%3DPeripheral%2520Protein%2520Quality%2520Control%2520as%2520a%2520Novel%2520Drug%2520Target%2520for%2520CFTR%2520Stabilizer%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1100%26doi%3D10.3389%2Ffphar.2018.01100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riordan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinstein, S.</span></span> <span> </span><span class="NLM_article-title">The Delta F508 Mutation Decreases the Stability of Cystic Fibrosis Transmembrane Conductance Regulator in the Plasma Membrane. Determination of Functional Half-Lives on Transfected Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">21592</span>– <span class="NLM_lpage">21598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2FS0021-9258%2820%2980582-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=7691813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFOls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=21592-21598&author=G.+L.+Lukacsauthor=X.+B.+Changauthor=C.+Bearauthor=N.+Kartnerauthor=A.+Mohamedauthor=J.+R.+Riordanauthor=S.+Grinstein&title=The+Delta+F508+Mutation+Decreases+the+Stability+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+in+the+Plasma+Membrane.+Determination+of+Functional+Half-Lives+on+Transfected+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells</span></div><div class="casAuthors">Lukacs, Gergely L.; Chang, Xiu Bao; Bear, Christine; Kartner, Norbert; Mohamed, Abdalla; Riordan, John R.; Grinstein, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">21592-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Deletion of the phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR) is the most prevalent mutation in cystic fibrosis (CF).  This mutation (ΔF508CFTR) leads to a reduced cAMP-sensitive Cl- conductance in epithelial cells.  While the mutant protein can function as a Cl- channel, it seems to be misprocessed and unable to accumulate at normal levels in the plasma membrane.  Under conditions where the biosynthetic block of ΔF508CFTR is not complete, the residence time of ΔF508CFTR in the plasma membrane is a crit. determinant of the cAMP-sensitive Cl- conductance.  To assess the stability of the mutant and wild-type CFTR, the authors compared their functional half-lives at the plasma membrane of transfected Chinese hamster ovary cells.  The plasma membrane Cl- conductance was assessed by patch-clamp recordings and/or by fluorimetric detns. of the membrane potential.  Accumulation of ΔF508CFTR in the plasma membrane was promoted by growing the transfected cells at reduced temp. (24-28°), and was verified by immunoblotting and by detecting the appearance of a plasmalemmal cAMP-activated Cl- conductance.  Subsequently increasing the temp. to 37° inhibited further delivery of newly synthesized ΔF508CFTR to the surface membrane.  By studying the time dependence of the disappearance of the Cl- conductance, the functional half-life of the mutant protein at the plasma membrane was detd. to be <4 h, which is considerably shorter than the half-life of wild-type CFTR (>24 h).  The latter was estd. by terminating protein synthesis or secretion with cycloheximide or brefeldin A, resp.  Inhibition of protein synthesis did not alter the rate of disappearance of ΔF508CFTR at 37°, validating the difference in turnover between mutant and wild-type CFTR.  These results indicate that the structural abnormality of ΔF508CFTR affects not only the delivery of the protein to the plasma membrane, but also its stability therein.  Moreover, they suggest that overcoming the processing block at the endoplasmic reticulum may not suffice to restore normal Cl- conductance in CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6e6tsFZ_g7bVg90H21EOLACvtfcHk0lg04PZAhjPW6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFOls7o%253D&md5=4406d9ad4ecc91a49a684c2b484ff562</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2820%2980582-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252820%252980582-1%26sid%3Dliteratum%253Aachs%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26aulast%3DChang%26aufirst%3DX.%2BB.%26aulast%3DBear%26aufirst%3DC.%26aulast%3DKartner%26aufirst%3DN.%26aulast%3DMohamed%26aufirst%3DA.%26aulast%3DRiordan%26aufirst%3DJ.%2BR.%26aulast%3DGrinstein%26aufirst%3DS.%26atitle%3DThe%2520Delta%2520F508%2520Mutation%2520Decreases%2520the%2520Stability%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520in%2520the%2520Plasma%2520Membrane.%2520Determination%2520of%2520Functional%2520Half-Lives%2520on%2520Transfected%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D21592%26epage%3D21598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalemans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champigny, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavirani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecocq, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdunski, M.</span></span> <span> </span><span class="NLM_article-title">Altered Chloride Ion Channel Kinetics Associated with the Delta F508 Cystic Fibrosis Mutation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1038/354526a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1038%2F354526a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1722027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK38Xls1OnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=1991&pages=526-528&author=W.+Dalemansauthor=P.+Barbryauthor=G.+Champignyauthor=S.+Jallatauthor=S.+Jallatauthor=K.+Dottauthor=D.+Dreyerauthor=R.+G.+Crystalauthor=A.+Paviraniauthor=J.-P.+Lecocqauthor=M.+Lazdunski&title=Altered+Chloride+Ion+Channel+Kinetics+Associated+with+the+Delta+F508+Cystic+Fibrosis+Mutation&doi=10.1038%2F354526a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Altered chloride ion channel kinetics associated with ΔF508 cystic fibrosis mutation</span></div><div class="casAuthors">Dalemans, Wilfried; Barbry, Pascal; Champigny, Guy; Jallat, Sophie; Dott, Karin; Dreyer, Dominique; Crystal, Ronald G.; Pavirani, Andrea; Lecocq, Jean Pierre; Lazdunski, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6354</span>),
    <span class="NLM_cas:pages">526-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Cystic fibrosis is assocd. with a defect in epithelial chloride ion transport which is caused by mutations in a membrane protein called CFTR (cystic fibrosis transmembrane conductance regulator).  Heterologous expression of CFTR produces cAMP-sensitive Cl--channel activity.  Deletion of phenylalanine at amino acid position 508 in CFTR (ΔF508 CFTR) is the most common mutation in cystic fibrosis.  It has been proposed that this mutation prevents glycoprotein maturation and its transport to its normal cellular location.  The present study expressed both CFTR and ΔF508 CFTR in Vero cells using recombinant vaccinia virus.  Although far less ΔF508 CFTR reached the plasma membrane then normal CFTR, sufficient ΔF508 CFTR was expressed at the plasma membrane to permit functional anal.  ΔF508 CFTR expression induced a reduced activity of the cAMP-activated Cl- channel, with conductance, anion selectivity and open-time kinetics similar to those of CFTR, but with much greater closed times, resulting in a large decrease of open probability.  The ΔF508 mutation thus seems to have two major consequences, an abnormal translocation of the CFTR protein which limits membrane insertion, and an abnormal function in mediating Cl- transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyoig2cumxULVg90H21EOLACvtfcHk0lg04PZAhjPW6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1OnsQ%253D%253D&md5=620a06b7bf34b0e762064914dcca0b60</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F354526a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F354526a0%26sid%3Dliteratum%253Aachs%26aulast%3DDalemans%26aufirst%3DW.%26aulast%3DBarbry%26aufirst%3DP.%26aulast%3DChampigny%26aufirst%3DG.%26aulast%3DJallat%26aufirst%3DS.%26aulast%3DJallat%26aufirst%3DS.%26aulast%3DDott%26aufirst%3DK.%26aulast%3DDreyer%26aufirst%3DD.%26aulast%3DCrystal%26aufirst%3DR.%2BG.%26aulast%3DPavirani%26aufirst%3DA.%26aulast%3DLecocq%26aufirst%3DJ.-P.%26aulast%3DLazdunski%26aufirst%3DM.%26atitle%3DAltered%2520Chloride%2520Ion%2520Channel%2520Kinetics%2520Associated%2520with%2520the%2520Delta%2520F508%2520Cystic%2520Fibrosis%2520Mutation%26jtitle%3DNature%26date%3D1991%26volume%3D354%26spage%3D526%26epage%3D528%26doi%3D10.1038%2F354526a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bompadre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T.-C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of G551D-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Potentiation by a High Affinity ATP Analog</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">5364</span>– <span class="NLM_lpage">5369</span>, <span class="refDoi"> DOI: 10.1074/jbc.m709417200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1074%2Fjbc.M709417200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=18167357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1Omsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=5364-5369&author=S.+G.+Bompadreauthor=M.+Liauthor=T.-C.+Hwang&title=Mechanism+of+G551D-CFTR+%28Cystic+Fibrosis+Transmembrane+Conductance+Regulator%29+Potentiation+by+a+High+Affinity+ATP+Analog&doi=10.1074%2Fjbc.m709417200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of G551D-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Potentiation by a High Affinity ATP Analog</span></div><div class="casAuthors">Bompadre, Silvia G.; Li, Min; Hwang, Tzyh-Chang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5364-5369</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel gated by ATP binding and hydrolysis at its nucleotide binding domains (NBD).  The NBDs dimerize in a head-to-tail configuration, forming two ATP binding pockets (ABP) with the ATP mols. buried at the dimer interface.  Previous studies have indicated that ABP2, formed by the Walker A and B motifs of NBD2 and the signature sequence of NBD1, is the site crit. for the ATP-dependent opening of CFTR.  The G551D mutation in ABP2, the third most common cystic fibrosis-assocd. mutation, abolishes ATP-dependent gating, resulting in an open probability that is ∼100-fold lower than that of wild-type channels.  Interestingly, we found that the ATP analog N6-(2-phenylethyl)-ATP (P-ATP) increases G551D currents mainly by increasing the open time of the channel.  This effect is reduced when P-ATP is applied together with ATP, suggesting a competition between ATP and P-ATP for a common binding site.  Introducing mutations that lower the nucleotide binding affinity at ABP2 did not alter significantly the effects of P-ATP on G551D-CFTR, whereas an equiv. mutation at ABP1 (consisting of the Walker A and B motifs of NBD1 and the signature sequence of NBD2) dramatically decreased the potency of P-ATP, indicating that ABP1 is the site where P-ATP binds to increase the activity of G551D-CFTR.  These results substantiate the idea that nucleotide binding at ABP1 stabilizes the open channel conformation.  Our observation that P-ATP enhances the G551D activity by binding at ABP1 implicates that ABP1 can potentially be a target for drugs to bind and increase the channel activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlLz-J9RaKbLVg90H21EOLACvtfcHk0lg04PZAhjPW6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1Omsb0%253D&md5=51d93593ea61679db976c9040eb21748</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M709417200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M709417200%26sid%3Dliteratum%253Aachs%26aulast%3DBompadre%26aufirst%3DS.%2BG.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DT.-C.%26atitle%3DMechanism%2520of%2520G551D-CFTR%2520%2528Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2529%2520Potentiation%2520by%2520a%2520High%2520Affinity%2520ATP%2520Analog%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D5364%26epage%3D5369%26doi%3D10.1074%2Fjbc.m709417200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Approaches to CFTR Dysfunction: From Discovery to Drug Development</span>. <i>J. Cystic Fibrosis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">S14</span>– <span class="NLM_lpage">S21</span>, <span class="refDoi"> DOI: 10.1016/j.jcf.2017.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.jcf.2017.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=28916430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=S14-S21&author=H.+Liauthor=E.+Pesceauthor=D.+N.+Sheppardauthor=A.+K.+Singhauthor=N.+Pedemonte&title=Therapeutic+Approaches+to+CFTR+Dysfunction%3A+From+Discovery+to+Drug+Development&doi=10.1016%2Fj.jcf.2017.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic approaches to CFTR dysfunction: From discovery to drug development</span></div><div class="casAuthors">Li, Hongyu; Pesce, Emanuela; Sheppard, David N.; Singh, Ashvani K.; Pedemonte, Nicoletta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2_Suppl.</span>),
    <span class="NLM_cas:pages">S14-S21</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) mutations have complex effects on the cystic fibrosis transmembrane conductance regulator (CFTR) protein.  They disrupt its processing to and stability at the plasma membrane and function as an ATP-gated Cl- channel.  Here, we review therapeutic strategies to overcome defective CFTR processing and stability.  Because CF mutations have multiple impacts on the assembly of CFTR protein, combination therapy with several pharmacol. chaperones is likely to be required to rescue mutant CFTR expression at the plasma membrane.  Alternatively, proteostasis regulators, proteins which regulate the synthesis, intracellular transport and membrane stability of CFTR might be targeted to enhance the plasma membrane expression of mutant CFTR.  Finally, we consider an innovative approach to bypass CFTR dysfunction in CF, the delivery of artificial anion transporters to CF epithelia to shuttle Cl- across the apical membrane.  The identification of therapies or combinations of therapies, which rescue all CF mutations, is now a priority.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2SZYcOKiVZ7Vg90H21EOLACvtfcHk0lixZA-hI4hImw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsb3M&md5=af3c0c02bd7a0ee583544672a15fae6c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2017.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2017.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DPesce%26aufirst%3DE.%26aulast%3DSheppard%26aufirst%3DD.%2BN.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DPedemonte%26aufirst%3DN.%26atitle%3DTherapeutic%2520Approaches%2520to%2520CFTR%2520Dysfunction%253A%2520From%2520Discovery%2520to%2520Drug%2520Development%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2018%26volume%3D17%26spage%3DS14%26epage%3DS21%26doi%3D10.1016%2Fj.jcf.2017.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Goor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCartney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wine, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashlock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negulescu, P. A.</span></span> <span> </span><span class="NLM_article-title">Correction of the F508del-CFTR Protein Processing Defect in Vitro by the Investigational Drug VX-809</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">18843</span>– <span class="NLM_lpage">18848</span>, <span class="refDoi"> DOI: 10.1073/pnas.1105787108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1073%2Fpnas.1105787108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=21976485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1WnsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18843-18848&author=F.+Van%0AGoorauthor=S.+Hadidaauthor=P.+D.+J.+Grootenhuisauthor=B.+Burtonauthor=J.+H.+Stackauthor=K.+S.+Straleyauthor=C.+J.+Deckerauthor=M.+Millerauthor=J.+McCartneyauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+A.+Negulescu&title=Correction+of+the+F508del-CFTR+Protein+Processing+Defect+in+Vitro+by+the+Investigational+Drug+VX-809&doi=10.1073%2Fpnas.1105787108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809</span></div><div class="casAuthors">Van Goor, Fredrick; Hadida, Sabine; Grootenhuis, Peter D. J.; Burton, Bill; Stack, Jeffrey H.; Straley, Kimberly S.; Decker, Caroline J.; Miller, Mark; McCartney, Jason; Olson, Eric R.; Wine, Jeffrey J.; Frizzell, Ray A.; Ashlock, Melissa; Negulescu, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">18843-18848, S18843/1-S18843/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs.  Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amts. of CFTR at the cell surface.  One strategy to treat these patients is to correct the processing of F508del-CFTR with small mols.  Here we describe the in vitro pharmacol. of VX-809, a CFTR corrector that was advanced into clin. development for the treatment of CF.  In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approx. 14% of non-CF human bronchial epithelial cells (EC50, 81 ± 19 nM), a level assocd. with mild CF in patients with less disruptive CFTR mutations.  F508del-CFTR cor. by VX-809 exhibited biochem. and functional characteristics similar to normal CFTR, including biochem. susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability.  VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors.  VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeOa93zl2aYLVg90H21EOLACvtfcHk0lixZA-hI4hImw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1WnsL%252FO&md5=26ad0866327fd2f645bcc68e91c87354</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1105787108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1105787108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DStraley%26aufirst%3DK.%2BS.%26aulast%3DDecker%26aufirst%3DC.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%2BA.%26atitle%3DCorrection%2520of%2520the%2520F508del-CFTR%2520Protein%2520Processing%2520Defect%2520in%2520Vitro%2520by%2520the%2520Investigational%2520Drug%2520VX-809%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D18843%26epage%3D18848%26doi%3D10.1073%2Fpnas.1105787108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor for the Treatment of Cystic Fibrosis</span>. <i>Expert Rev. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1080/17476348.2018.1507741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1080%2F17476348.2018.1507741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30073878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=725-732&author=M.+A.+Salaauthor=M.+Jain&title=Tezacaftor+for+the+Treatment+of+Cystic+Fibrosis&doi=10.1080%2F17476348.2018.1507741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor for the treatment of cystic fibrosis</span></div><div class="casAuthors">Sala, Marc A.; Jain, Manu</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">725-732</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Cystic fibrosis (CF) is the most common, life-limiting autosomal recessive disease in Caucasians, and is caused by defects in prodn. of the CFTR ion channel.  Until recently, there were no available treatments targeting the disease-causing defects in CFTR but newly developed CFTR modulators are changing the course of disease in CF.  The newest modulator, tezacaftor, is a CFTR corrector that was recently approved by the FDA to be used in combination with the first approved CFTR potentiator, ivacaftor.  A detailed review of the clin. trials and published literature, focusing on safety and efficacy, leading to the approval of tezacaftor in CF.: Recent trials have demonstrated that the combination of tezacaftor-ivacaftor is a slightly superior combination to its predecessor, lumacaftor-ivacaftor, with respect to an increase in FEV1, adverse event profile, and drug-drug interactions.  It is also approved for a large no. of non-F508del, residual function mutations that are predicted to respond based on in vitro testing.  The horizon for continued improvements in CFTR-targeted treatments is promising, with three-drug combinations currently in Phase 3 clin. trials, and other drugs with novel mechanisms of action being studied.  Within the next 5 years, the vast majority of patients with CF are expected to have a modulator approved for their genotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotXmy8PebTLrVg90H21EOLACvtfcHk0lixZA-hI4hImw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isbvE&md5=d1f61fc51ab8fef966df314c78bf101f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F17476348.2018.1507741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17476348.2018.1507741%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DM.%2BA.%26aulast%3DJain%26aufirst%3DM.%26atitle%3DTezacaftor%2520for%2520the%2520Treatment%2520of%2520Cystic%2520Fibrosis%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2018%26volume%3D12%26spage%3D725%26epage%3D732%26doi%3D10.1080%2F17476348.2018.1507741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Goor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlewood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCartney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wine, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashlock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negulescu, P.</span></span> <span> </span><span class="NLM_article-title">Rescue of CF Airway Epithelial Cell Function in Vitro by a CFTR Potentiator, VX-770</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">18825</span>– <span class="NLM_lpage">18830</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904709106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1073%2Fpnas.0904709106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=19846789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18825-18830&author=F.+Van%0AGoorauthor=S.+Hadidaauthor=P.+D.+J.+Grootenhuisauthor=B.+Burtonauthor=D.+Caoauthor=T.+Neubergerauthor=A.+Turnbullauthor=A.+Singhauthor=J.+Joubranauthor=A.+Hazlewoodauthor=J.+Zhouauthor=J.+McCartneyauthor=V.+Arumugamauthor=C.+Deckerauthor=J.+Yangauthor=C.+Youngauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+Negulescu&title=Rescue+of+CF+Airway+Epithelial+Cell+Function+in+Vitro+by+a+CFTR+Potentiator%2C+VX-770&doi=10.1073%2Fpnas.0904709106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</span></div><div class="casAuthors">Van Goor, Fredrick; Hadida, Sabine; Grootenhuis, Peter D. J.; Burton, Bill; Cao, Dong; Neuberger, Tim; Turnbull, Amanda; Singh, Ashvani; Joubran, John; Hazlewood, Anna; Zhou, Jinglan; McCartney, Jason; Arumugam, Vijayalaksmi; Decker, Caroline; Yang, Jennifer; Young, Chris; Olson, Eric R.; Wine, Jeffrey J.; Frizzell, Raymond A.; Ashlock, Melissa; Negulescu, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">18825-18830, S18825/1-S18825/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung.  Most CF mutations either reduce the no. of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both.  There are currently no approved therapies that target CFTR.  Here we describe the in vitro pharmacol. of VX-770, an orally bioavailable CFTR potentiator in clin. development for the treatment of CF.  In recombinant cells VX-770 increased CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation.  VX-770 also increased Cl- secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈ 10-fold, to ≈ 50% of that obsd. in HBE isolated from individuals without CF.  Furthermore, VX-770 reduced excessive Na+ and fluid absorption to prevent dehydration of the apical surface and increased cilia, beating in these epithelial cultures.  These results support the hypothesis that pharmacol. agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo89BTNOARZ5bVg90H21EOLACvtfcHk0lj-O1t-c2YiFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI&md5=786c6c860d90115c29863a706f0e1248</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904709106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904709106%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DNeuberger%26aufirst%3DT.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DJoubran%26aufirst%3DJ.%26aulast%3DHazlewood%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DArumugam%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%26atitle%3DRescue%2520of%2520CF%2520Airway%2520Epithelial%2520Cell%2520Function%2520in%2520Vitro%2520by%2520a%2520CFTR%2520Potentiator%252C%2520VX-770%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D18825%26epage%3D18830%26doi%3D10.1073%2Fpnas.0904709106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrivel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">High-Affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughput Screening</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">37235</span>– <span class="NLM_lpage">37241</span>, <span class="refDoi"> DOI: 10.1074/jbc.m205932200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1074%2Fjbc.M205932200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12161441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVaquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=37235-37241&author=T.+Maauthor=L.+Vetrivelauthor=H.+Yangauthor=N.+Pedemonteauthor=O.+Zegarra-Moranauthor=L.+J.+V.+Galiettaauthor=A.+S.+Verkman&title=High-Affinity+Activators+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+%28CFTR%29+Chloride+Conductance+Identified+by+High-Throughput+Screening&doi=10.1074%2Fjbc.m205932200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughput Screening</span></div><div class="casAuthors">Ma, Tonghui; Vetrivel, L.; Yang, Hong; Pedemonte, Nicoletta; Zegarra-Moran, Olga; Galietta, Luis J. V.; Verkman, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">37235-37241</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein that reduce cAMP-stimulated Cl- conductance in airway and other epithelia.  The purpose of this investigation was to identify new classes of potent CFTR activators.  A collection of 60,000 diverse drug-like compds. was screened at 10 μm together with a low concn. of forskolin (0.5 μm) in Fisher rat thyroid epithelial cells co-expressing human CFTR and a green fluorescent protein-based Cl- sensor.  Primary screening yielded 57 strong activators (greater activity than ref. compd. apigenin), most of which were unrelated in chem. structure to known CFTR activators, and 284 weaker activators.  Secondary anal. of the strong activators included anal. of CFTR specificity, forskolin requirement, transepithelial short-circuit current, activation kinetics, dose response, toxicity, and activation mechanism.  Three compds., the most potent being a dihydroisoquinoline, activated CFTR by elevating cellular cAMP, probably by phosphodiesterase inhibition.  Fourteen compds. activated CFTR without cAMP elevation or phosphatase inhibition, suggesting direct CFTR interaction.  The most potent compds. had tetrahydrocarbazol, hydroxycoumarin, and thiazolidine core structures.  These compds. induced CFTR Cl- currents rapidly (<5 min) with Kd down to 200 nm and were CFTR-selective, reversible, and nontoxic.  Several compds., the most potent being a trifluoromethylphenylbenzamine, activated the CF-causing mutant G551D, but with much weaker affinity (Kd > 10 μm).  When added for 10 min, none of the compds. activated ΔPhe508-CFTR in transfected cells grown at 37° (with ΔPhe508-CFTR trapped in the endoplasmic reticulum).  However, after correction of trafficking by 48 h of growth at 27°, tetrahydrocarbazol and N-phenyltriazine derivs. strongly stimulated Cl- conductance with Kd < 1 μm.  The new activators identified here may be useful in defining mol. mechanisms of CFTR activation and as lead compds. in CF drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsfjCd611fW7Vg90H21EOLACvtfcHk0lj-O1t-c2YiFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVaquro%253D&md5=e792713776f4884685b8c974263efffd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M205932200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M205932200%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DT.%26aulast%3DVetrivel%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DHigh-Affinity%2520Activators%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520%2528CFTR%2529%2520Chloride%2520Conductance%2520Identified%2520by%2520High-Throughput%2520Screening%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D37235%26epage%3D37241%26doi%3D10.1074%2Fjbc.m205932200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopinath, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">35079</span>– <span class="NLM_lpage">35085</span>, <span class="refDoi"> DOI: 10.1074/jbc.m303098200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1074%2Fjbc.M303098200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12832418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntVWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=35079-35085&author=H.+Yangauthor=A.+A.+Shelatauthor=R.+K.+Guyauthor=V.+S.+Gopinathauthor=T.+Maauthor=K.+Duauthor=G.+L.+Lukacsauthor=A.+Taddeiauthor=C.+Folliauthor=N.+Pedemonteauthor=L.+J.+V.+Galiettaauthor=A.+S.+Verkman&title=Nanomolar+Affinity+Small+Molecule+Correctors+of+Defective+%CE%94F508-CFTR+Chloride+Channel+Gating&doi=10.1074%2Fjbc.m303098200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating</span></div><div class="casAuthors">Yang, Hong; Shelat, Anang A.; Guy, R. Kiplin; Gopinath, Vadiraj S.; Ma, Tonghui; Du, Kai; Lukacs, Gergely L.; Taddei, Alessandro; Folli, Chiara; Pedemonte, Nicoletta; Galietta, Luis J. V.; Verkman, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">35079-35085</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Deletion of Phe-508 (ΔF508) is the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) causing cystic fibrosis.  ΔF508-CFTR has defects in both channel gating and endoplasmic reticulum-to-plasma membrane processing.  We identified six novel classes of high affinity potentiators of defective ΔF508-CFTR Cl- channel gating by screening 100,000 diverse small mols.  Compds. were added 15 min prior to assay of iodide uptake in epithelial cells co-expressing ΔF508-CFTR and a high sensitivity halide indicator (YFP-H148Q/I152L) in which ΔF508-CFTR was targeted to the plasma membrane by culture at 27° for 24 h.  Thirty-two compds. with submicromolar activating potency were identified; most had tetrahydrobenzothiophene, benzofuran, pyramidinetrione, dihydropyridine, and anthraquinone core structures (360-480 Da).  Further screening of >1000 structural analogs revealed tetrahydrobenzothiophenes that activated ΔF508-CFTR Cl- conductance reversibly with Kd < 100 nM.  Single-cell voltage clamp anal. showed characteristic CFTR currents after ΔF508-CFTR activation.  Activation required low concns. of a cAMP agonist, thus mimicking the normal physiol. response.  A Bayesian computational model was developed using tetrahydrobenzothiophene structure-activity data, yielding insight into the phys. character and structural features of active and inactive potentiators and successfully predicting the activity of structural analogs.  Efficient potentiation of defective ΔF508-CFTR gating was also demonstrated in human bronchial epithelial cells from a ΔF508 cystic fibrosis subject after 27° temp. rescue.  In conjunction with correctors of defective ΔF508-CFTR processing, small mol. potentiators of defective ΔF508-CFTR gating may be useful for therapy of cystic fibrosis caused by the ΔF508 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKsIxV5mMoybVg90H21EOLACvtfcHk0lj-O1t-c2YiFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntVWqt7g%253D&md5=0ddaaaf14e4876baf40e6f1c41055966</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M303098200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M303098200%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26aulast%3DGopinath%26aufirst%3DV.%2BS.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DK.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26aulast%3DTaddei%26aufirst%3DA.%26aulast%3DFolli%26aufirst%3DC.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DNanomolar%2520Affinity%2520Small%2520Molecule%2520Correctors%2520of%2520Defective%2520%25CE%2594F508-CFTR%2520Chloride%2520Channel%2520Gating%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D35079%26epage%3D35085%26doi%3D10.1074%2Fjbc.m303098200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springsteel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sammelson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantz, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">CFTR Activation in Human Bronchial Epithelial Cells by Novel Benzoflavone and Benzimidazolone Compounds</span>. <i>Am. J. Physiol.: Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">L180</span>– <span class="NLM_lpage">L188</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00351.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1152%2Fajplung.00351.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12651632" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2003&pages=L180-L188&author=E.+Caciauthor=C.+Folliauthor=O.+Zegarra-Moranauthor=T.+Maauthor=M.+F.+Springsteelauthor=R.+E.+Sammelsonauthor=M.+H.+Nantzauthor=M.+J.+Kurthauthor=A.+S.+Verkmanauthor=L.+J.+V.+Galietta&title=CFTR+Activation+in+Human+Bronchial+Epithelial+Cells+by+Novel+Benzoflavone+and+Benzimidazolone+Compounds&doi=10.1152%2Fajplung.00351.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00351.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00351.2002%26sid%3Dliteratum%253Aachs%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DFolli%26aufirst%3DC.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DSpringsteel%26aufirst%3DM.%2BF.%26aulast%3DSammelson%26aufirst%3DR.%2BE.%26aulast%3DNantz%26aufirst%3DM.%2BH.%26aulast%3DKurth%26aufirst%3DM.%2BJ.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DCFTR%2520Activation%2520in%2520Human%2520Bronchial%2520Epithelial%2520Cells%2520by%2520Novel%2520Benzoflavone%2520and%2520Benzimidazolone%2520Compounds%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2003%26volume%3D285%26spage%3DL180%26epage%3DL188%26doi%3D10.1152%2Fajplung.00351.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diena, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieddu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravazzolo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Antihypertensive 1,4-Dihydropyridines as Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating Defect Caused by Cystic Fibrosis Mutations</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1124/mol.105.015149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1124%2Fmol.105.015149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=16150931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yksbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2005&pages=1736-1746&author=N.+Pedemonteauthor=T.+Dienaauthor=E.+Caciauthor=E.+Niedduauthor=M.+Mazzeiauthor=R.+Ravazzoloauthor=O.+Zegarra-Moranauthor=L.+J.+V.+Galietta&title=Antihypertensive+1%2C4-Dihydropyridines+as+Correctors+of+the+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Channel+Gating+Defect+Caused+by+Cystic+Fibrosis+Mutations&doi=10.1124%2Fmol.105.015149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations</span></div><div class="casAuthors">Pedemonte, Nicoletta; Diena, Tullia; Caci, Emanuela; Nieddu, Erika; Mazzei, Mauro; Ravazzolo, Roberto; Zegarra-Moran, Olga; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1736-1746</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel gene.  CF mutations like ΔF508 cause both a mistrafficking of the protein and a gating defect.  Other mutations, like G551D, cause only a gating defect.  Our aim was to find chem. compds. able to stimulate the activity of CFTR mutant proteins by screening a library contg. approved drugs.  Two thousand compds. were tested on Fischer rat thyroid cells coexpressing ΔF508-CFTR and a halide-sensitive yellow fluorescent protein (YFP) after correction of the trafficking defect by low-temp. incubation.  The YFP-based screening allowed the identification of the antihypertensive 1,4-dihydropyridines (DHPs) nifedipine, nicardipine, nimodipine, isradipine, nitrendipine, felodipine, and niguldipine as compds. able to activate ΔF508-CFTR.  This effect was not derived from the inhibition of voltage-dependent Ca2+ channels, the pharmacol. target of antihypertensive DHPs.  Indeed, methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-2(trifluoromethylphenyl)pyridine-5-carboxylate (BayK-8644), a DHP that is effective as an activator of such channels, also stimulated CFTR activity.  DHPs were also effective on the G551D-CFTR mutant by inducing a 16- to 45-fold increase of the CFTR Cl- currents.  DHP activity was confirmed in airway epithelial cells from patients with CF.  DHPs may represent a novel class of therapeutic agents able to correct the defect caused by a set of CF mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh_q5JcwdXJrVg90H21EOLACvtfcHk0lg2VcNR5WRPYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yksbfI&md5=b9a52dffd8f9d1108dbd4ae5c80d6d8a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.015149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.015149%26sid%3Dliteratum%253Aachs%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DDiena%26aufirst%3DT.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DNieddu%26aufirst%3DE.%26aulast%3DMazzei%26aufirst%3DM.%26aulast%3DRavazzolo%26aufirst%3DR.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DAntihypertensive%25201%252C4-Dihydropyridines%2520as%2520Correctors%2520of%2520the%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Channel%2520Gating%2520Defect%2520Caused%2520by%2520Cystic%2520Fibrosis%2520Mutations%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D68%26spage%3D1736%26epage%3D1746%26doi%3D10.1124%2Fmol.105.015149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbeson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilja, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttamsingh, V.</span></span> <span> </span><span class="NLM_article-title">Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.241497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1124%2Fjpet.117.241497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=28611092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=359-367&author=S.+L.+Harbesonauthor=A.+J.+Morganauthor=J.+F.+Liuauthor=A.+M.+Aslanianauthor=S.+Nguyenauthor=G.+W.+Bridsonauthor=C.+L.+Brummelauthor=L.+Wuauthor=R.+D.+Tungauthor=L.+Piljaauthor=V.+Bramanauthor=V.+Uttamsingh&title=Altering+Metabolic+Profiles+of+Drugs+by+Precision+Deuteration+2%3A+Discovery+of+a+Deuterated+Analog+of+Ivacaftor+with+Differentiated+Pharmacokinetics+for+Clinical+Development&doi=10.1124%2Fjpet.117.241497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development</span></div><div class="casAuthors">Harbeson, Scott L.; Morgan, Adam J.; Liu, Julie F.; Aslanian, Ara M.; Nguyen, Sophia; Bridson, Gary W.; Brummel, Christopher L.; Wu, Lijun; Tung, Roger D.; Pilja, Lana; Braman, Virginia; Uttamsingh, Vinita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">359-367</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ivacaftor is currently used for the treatment of cystic fibrosis as both monotherapy (Kalydeco; Vertex Pharmaceuticals, Boston, MA) and combination therapy with lumacaftor (Orkambi; Vertex Pharmaceuticals).  Each therapy targets specific patient populations: Kalydeco treats patients carrying one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, whereas Orkambi treats patients homozygous for the F508del CFTR mutation.  In this study, we explored the pharmacol. and metabolic effects of precision deuteration chem. on ivacaftor by synthesizing two novel deuterated ivacaftor analogs, CTP-656 (d9-ivacaftor) and d18-ivacaftor.  Ivacaftor is administered twice daily and is extensively converted in humans to major metabolites M1 and M6; therefore, the corresponding deuterated metabolites were also prepd.  Both CTP-656 and d18-ivacaftor showed in vitro pharmacol. potency similar to that in ivacaftor, and the deuterated M1 and M6 metabolites showed pharmacol. equiv. to that in the corresponding metabolites of ivacaftor, which is consistent with the findings of previous studies of deuterated compds.  However, CTP-656 exhibited markedly enhanced stability when tested in vitro.  The deuterium isotope effects for CTP-656 metab. (DV = 3.8, DV/K = 2.2) were notably large for a cytochrome P 450-mediated oxidn.  The pharmacokinetic (PK) profile of CTP-656 and d18-ivacaftor were assessed in six healthy volunteers in a single-dose crossover study, which provided the basis for advancing CTP-656 in development.  The overall PK profile, including the 15.9-h half-life for CTP-656, suggests that CTP-656 may be dosed once daily, thereby enhancing patient adherence.  Together, these data continue to validate deuterium substitution as a viable approach for creating novel therapeutic agents with properties potentially differentiated from existing drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopNUSS95AadbVg90H21EOLACvtfcHk0lg2VcNR5WRPYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbI&md5=bf7d11a94c047902d2c6e1a3cd3e8a62</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241497%26sid%3Dliteratum%253Aachs%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DMorgan%26aufirst%3DA.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DAslanian%26aufirst%3DA.%2BM.%26aulast%3DNguyen%26aufirst%3DS.%26aulast%3DBridson%26aufirst%3DG.%2BW.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DPilja%26aufirst%3DL.%26aulast%3DBraman%26aufirst%3DV.%26aulast%3DUttamsingh%26aufirst%3DV.%26atitle%3DAltering%2520Metabolic%2520Profiles%2520of%2520Drugs%2520by%2520Precision%2520Deuteration%25202%253A%2520Discovery%2520of%2520a%2520Deuterated%2520Analog%2520of%2520Ivacaftor%2520with%2520Differentiated%2520Pharmacokinetics%2520for%2520Clinical%2520Development%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D359%26epage%3D367%26doi%3D10.1124%2Fjpet.117.241497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span> </span><span class="NLM_article-title">Study Designed to Assess the Safety, Tolerability
and PK of PTI-808
in Healthy Volunteers and in Adults with Cystic Fibrosis</span>. <span class="NLM_publisher-name">Proteostasis Therapeutics, Inc.</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03251092" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03251092</a>. , clinical trial: NCT03251092 (accessed Apr 27, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+Designed+to+Assess+the+Safety%2C+Tolerability%0Aand+PK+of+PTI-808%0Ain+Healthy+Volunteers+and+in+Adults+with+Cystic+Fibrosis.+Proteostasis+Therapeutics%2C+Inc.%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03251092.+%2C+clinical+trial%3A+NCT03251092+%28accessed+Apr+27%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520Designed%2520to%2520Assess%2520the%2520Safety%252C%2520Tolerability%250Aand%2520PK%2520of%2520PTI-808%250Ain%2520Healthy%2520Volunteers%2520and%2520in%2520Adults%2520with%2520Cystic%2520Fibrosis%26pub%3DProteostasis%2520Therapeutics%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
der Plas, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelgtermans, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Munck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, S. L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dropsit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Blieck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joannesse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaskovic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgonovi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Schueren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-Pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01288</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1425-1435&author=S.+E.+Van%0Ader+Plasauthor=H.+Kelgtermansauthor=T.+De+Munckauthor=S.+L.+X.+Martinaauthor=S.+Dropsitauthor=E.+Quintonauthor=A.+De+Blieckauthor=C.+Joannesseauthor=L.+Tomaskovicauthor=M.+Jansauthor=T.+Christopheauthor=E.+van+der+Aarauthor=M.+Borgonoviauthor=L.+Nellesauthor=M.+Geesauthor=P.+Stoutenauthor=J.+Van+Der+Schuerenauthor=O.+Mammolitiauthor=K.+Conrathauthor=M.+Andrews&title=Discovery+of+N-%283-carbamoyl-5%2C5%2C7%2C7-tetramethyl-5%2C7-dihydro-4H-thieno%5B2%2C3-c%5Dpyran-2-yl%29-1H-Pyrazole-5-carboxamide+%28GLPG1837%29%2C+a+Novel+Potentiator+Which+Can+Open+Class+III+Mutant+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+%28CFTR%29+Channels+to+a+High+Extent&doi=10.1021%2Facs.jmedchem.7b01288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent</span></div><div class="casAuthors">Van der Plas, Steven E.; Kelgtermans, Hans; De Munck, Tom; Martina, Sebastien L. X.; Dropsit, Sebastien; Quinton, Evelyne; De Blieck, Ann; Joannesse, Caroline; Tomaskovic, Linda; Jans, Mia; Christophe, Thierry; van der Aar, Ellen; Borgonovi, Monica; Nelles, Luc; Gees, Maarten; Stouten, Pieter; Van Der Schueren, Jan; Mammoliti, Oscar; Conrath, Katja; Andrews, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1425-1435</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR).  With the discovery of Ivacaftor and Orkambi, it has been shown that CFTR function can be partially restored by administering one or more small mols.  These mols. aim at either enhancing the amt. of CFTR on the cell surface (correctors) or at improving the gating function of the CFTR channel (potentiators).  Here the authors describe the discovery of a novel potentiator GLPG1837 which shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor, the first marketed potentiator.  The optimization of potency, efficacy and pharmacokinetic profile will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRXdwDJ_CX7Vg90H21EOLACvtfcHk0lhYfriyF8sAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqur%252FI&md5=74d8fdc364fad1d31a39cf47a87dcb37</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01288%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DS.%2BE.%26aulast%3DKelgtermans%26aufirst%3DH.%26aulast%3DDe%2BMunck%26aufirst%3DT.%26aulast%3DMartina%26aufirst%3DS.%2BL.%2BX.%26aulast%3DDropsit%26aufirst%3DS.%26aulast%3DQuinton%26aufirst%3DE.%26aulast%3DDe%2BBlieck%26aufirst%3DA.%26aulast%3DJoannesse%26aufirst%3DC.%26aulast%3DTomaskovic%26aufirst%3DL.%26aulast%3DJans%26aufirst%3DM.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%26aulast%3DBorgonovi%26aufirst%3DM.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DGees%26aufirst%3DM.%26aulast%3DStouten%26aufirst%3DP.%26aulast%3DVan%2BDer%2BSchueren%26aufirst%3DJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DAndrews%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520N-%25283-carbamoyl-5%252C5%252C7%252C7-tetramethyl-5%252C7-dihydro-4H-thieno%255B2%252C3-c%255Dpyran-2-yl%2529-1H-Pyrazole-5-carboxamide%2520%2528GLPG1837%2529%252C%2520a%2520Novel%2520Potentiator%2520Which%2520Can%2520Open%2520Class%2520III%2520Mutant%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520%2528CFTR%2529%2520Channels%2520to%2520a%2520High%2520Extent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1425%26epage%3D1435%26doi%3D10.1021%2Facs.jmedchem.7b01288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Plas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesse, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandevelde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der
Schueren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of Novel CFTR Potentiators</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1221</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2018.01221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30416447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1221&author=M.+Geesauthor=S.+Muschauthor=S.+Van+der+Plasauthor=A.+S.+Wesseauthor=A.+Vandeveldeauthor=K.+Verdonckauthor=O.+Mammolitiauthor=T.+C.+Hwangauthor=K.+Sonckauthor=P.+Stoutenauthor=A.+M.+Swensenauthor=M.+Jansauthor=J.+Van+der%0ASchuerenauthor=L.+Nellesauthor=M.+Andrewsauthor=K.+Conrath&title=Identification+and+Characterization+of+Novel+CFTR+Potentiators&doi=10.3389%2Ffphar.2018.01221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of novel CFTR potentiators</span></div><div class="casAuthors">Gees, Maarten; Musch, Sara; Van Der Plas, Steven; Wesse, Anne-Sophie; Vandevelde, Ann; Verdonck, Katleen; Mammoliti, Oscar; Hwang, Tzyh-Chang; Sonck, Kathleen; Stouten, Pieter; Swensen, Andrew M.; Jans, Mia; Van Der Schueren, Jan; Nelles, Luc; Andrews, Martin; Conrath, Katja</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1221</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There is still a high unmet need for the treatment of most patients with cystic fibrosis (CF).  The identification and development of new Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators is necessary to achieve higher clin. benefit in patients.  In this report we describe the characterization of novel potentiators.  From a small screening campaign on F508del CFTR, hits were developed leading to the identification of preclin. candidates GLPG1837 and GLPG2451, each derived from a distinct chem. series.  Both drug candidates enhance WT CFTR activity as well as low temp. or corrector rescued F508del CFTR, and are able to improve channel activity on a series of Class III, IV CFTR mutants.  The obsd. activities in YFP halide assays translated well to primary cells derived from CF lungs when measured using Trans-epithelial clamp circuit (TECC).  Both potentiators improve F508del CFTR channel opening in a similar manner, increasing the open time and reducing the closed time of the channel.  When evaluating the potentiators in a chronic setting on cor. F508del CFTR, no redn. of channel activity in presence of potentiator was obsd.  The current work identifies and characterizes novel CFTR potentiators GLPG1837 and GLPG2451, which may offer new therapeutic options for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD98U-UNJ6gLVg90H21EOLACvtfcHk0lhYfriyF8sAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7P&md5=5a6ace814644342a62fb5e947651b055</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01221%26sid%3Dliteratum%253Aachs%26aulast%3DGees%26aufirst%3DM.%26aulast%3DMusch%26aufirst%3DS.%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DS.%26aulast%3DWesse%26aufirst%3DA.%2BS.%26aulast%3DVandevelde%26aufirst%3DA.%26aulast%3DVerdonck%26aufirst%3DK.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DHwang%26aufirst%3DT.%2BC.%26aulast%3DSonck%26aufirst%3DK.%26aulast%3DStouten%26aufirst%3DP.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DJans%26aufirst%3DM.%26aulast%3DVan%2Bder%2BSchueren%26aufirst%3DJ.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DConrath%26aufirst%3DK.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520Novel%2520CFTR%2520Potentiators%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1221%26doi%3D10.3389%2Ffphar.2018.01221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southern, K. W.</span></span> <span> </span><span class="NLM_article-title">Potentiators (Specific Therapies for Class III and IV Mutations) for Cystic Fibrosis</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">CD009841</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD009841.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1002%2F14651858.CD009841.pub3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30616300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2019&pages=CD009841&author=M.+Skiltonauthor=A.+Krishanauthor=S.+Patelauthor=I.+P.+Sinhaauthor=K.+W.+Southern&title=Potentiators+%28Specific+Therapies+for+Class+III+and+IV+Mutations%29+for+Cystic+Fibrosis&doi=10.1002%2F14651858.CD009841.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD009841.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD009841.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DSkilton%26aufirst%3DM.%26aulast%3DKrishan%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DI.%2BP.%26aulast%3DSouthern%26aufirst%3DK.%2BW.%26atitle%3DPotentiators%2520%2528Specific%2520Therapies%2520for%2520Class%2520III%2520and%2520IV%2520Mutations%2529%2520for%2520Cystic%2520Fibrosis%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2019%26volume%3D1%26spage%3DCD009841%26doi%3D10.1002%2F14651858.CD009841.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G.</span></span> <span> </span><span class="NLM_article-title">Failure and Success in Modern Drug Discovery: Guiding Principles in the Establishment of High Probability of Success Drug Discovery Organizations</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.2174/1573406054864106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.2174%2F1573406054864106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=16787336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXovFSjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=519-527&author=G.+Rishton&title=Failure+and+Success+in+Modern+Drug+Discovery%3A+Guiding+Principles+in+the+Establishment+of+High+Probability+of+Success+Drug+Discovery+Organizations&doi=10.2174%2F1573406054864106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Failure and success in modern drug discovery: Guiding principles in the establishment of high probability of success drug discovery organizations</span></div><div class="casAuthors">Rishton, Gilbert M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  The pharmaceutical industry currently suffers un-sustainably high program failure rates despite our best efforts to implement drug design methods and to develop high throughput biochem. screening technologies over the past 20 years.  While much of this failure is rationalized to be due to uncontrollable late stage drug development issues and clin. events, it has become increasingly clear that the choices we make in early drug discovery are vital to the ultimate failure or success outcomes of our drug discovery programs.  The judicious selection of high probability of success therapeutic modalities, the rigorous detn. of lead likeness and drug-likeness, and the all-important selection of high probability of success enzyme and receptor targets are the vital drivers of failure and success in small mol. drug discovery as it is performed in the age of biochem. screening.  Consideration of these guiding principles will improve our chances of success in drug discovery, and increase our ability to address unmet medical need in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQM24l-iJnLbVg90H21EOLACvtfcHk0lguFLjml15NbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXovFSjtbw%253D&md5=c1184c063af82e457ed3db26cb15a66b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1573406054864106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406054864106%26sid%3Dliteratum%253Aachs%26aulast%3DRishton%26aufirst%3DG.%26atitle%3DFailure%2520and%2520Success%2520in%2520Modern%2520Drug%2520Discovery%253A%2520Guiding%2520Principles%2520in%2520the%2520Establishment%2520of%2520High%2520Probability%2520of%2520Success%2520Drug%2520Discovery%2520Organizations%26jtitle%3DMed.%2520Chem.%26date%3D2005%26volume%3D1%26spage%3D519%26epage%3D527%26doi%3D10.2174%2F1573406054864106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T.</span></span> <span> </span><span class="NLM_article-title">Strategies for Compound Selection</span>. <i>Curr. Drug Discovery Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.2174/1570163043334965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.2174%2F1570163043334965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=16472248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsFCnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=211-220&author=M.+Olahauthor=C.+Bologaauthor=T.+Oprea&title=Strategies+for+Compound+Selection&doi=10.2174%2F1570163043334965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for compound selection</span></div><div class="casAuthors">Olah, Marius M.; Bologa, Cristian G.; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-220</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhouse pharmaceutical collections are no longer sufficient for sampling chem. spaces.  As novel bioactive chemotypes are successfully identified by virtual and high -throughput screening, the ability to rapidly shift through large nos. of chems. prior to acquisition or expt. is required.  Strategies for compd. selection include some of the following steps:(1.) database assembly ('in silico' inventory);(2a.) structural integrity verification (keep unique structures only); (2b.) limited exploration of alternative chem. representations for the uniques (stereoisomers, tautomers, ionization states); (3.) property and structural filtering (remove unwanted structures); (4.) 3D-structure generation (for virtual screening or 3D-based similarity); (5a.) clustering or statistical design for selection; (5b.) similarity-based selection (if bioactives are known); (c.) receptor-based selection (if target binding site is known); (6.) add a random subset to the final list.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8LqW9273lrbVg90H21EOLACvtfcHk0lguFLjml15NbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsFCnsr0%253D&md5=0df46725a91a4c4e9c04b83d33740f78</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F1570163043334965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570163043334965%26sid%3Dliteratum%253Aachs%26aulast%3DOlah%26aufirst%3DM.%26aulast%3DBologa%26aufirst%3DC.%26aulast%3DOprea%26aufirst%3DT.%26atitle%3DStrategies%2520for%2520Compound%2520Selection%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D211%26epage%3D220%26doi%3D10.2174%2F1570163043334965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuegge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alanine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleicher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutknecht, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neidhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjögren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotouhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodnow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Saal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Development of a Virtual Screening Method for Identification of “Frequent Hitters” in Compound Libraries</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1021/jm010934d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010934d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslais78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=137-142&author=O.+Rocheauthor=P.+Schneiderauthor=J.+Zueggeauthor=W.+Gubaauthor=M.+Kansyauthor=A.+Alanineauthor=K.+Bleicherauthor=F.+Danelauthor=E.-M.+Gutknechtauthor=M.+Rogers-Evansauthor=W.+Neidhartauthor=H.+Stalderauthor=M.+Dillonauthor=E.+Sj%C3%B6grenauthor=N.+Fotouhiauthor=P.+Gillespieauthor=R.+Goodnowauthor=W.+Harrisauthor=P.+Jonesauthor=M.+Taniguchiauthor=S.+Tsujiiauthor=W.+von+der+Saalauthor=G.+Zimmermannauthor=G.+Schneider&title=Development+of+a+Virtual+Screening+Method+for+Identification+of+%E2%80%9CFrequent+Hitters%E2%80%9D+in+Compound+Libraries&doi=10.1021%2Fjm010934d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries</span></div><div class="casAuthors">Roche, Olivier; Schneider, Petra; Zuegge, Jochen; Guba, Wolfgang; Kansy, Manfred; Alanine, Alexander; Bleicher, Konrad; Danel, Franck; Gutknecht, Eva-Maria; Rogers-Evans, Mark; Neidhart, Werner; Stalder, Henri; Dillon, Michael; Sjoegren, Eric; Fotouhi, Nader; Gillespie, Paul; Goodnow, Robert; Harris, William; Jones, Phil; Taniguchi, Mikio; Tsujii, Shinji; von Saal, Wolfgang; Zimmermann, Gerd; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A computer-based method was developed for rapid and automatic identification of potential "frequent hitters".  These compds. show up as hits in many different biol. assays covering a wide range of targets.  A scoring scheme was elaborated from substructure anal., multivariate linear and nonlinear statistical methods applied to several sets of one and two-dimensional mol. descriptors.  The final model is based on a three-layered neural network, yielding a predictive Matthews correlation coeff. of 0.81.  This system was able to correctly classify 90% of the test set mols. in a 10-times cross-validation study.  The method was applied to database filtering, yielding between 8% (compilation of trade drugs) and 35% (Available Chems. Directory) potential frequent hitters.  This filter will be a valuable tool for the prioritization of compds. from large databases, for compd. purchase and biol. testing, and for building new virtual libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXTt-wIDExe7Vg90H21EOLACvtfcHk0lguFLjml15NbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslais78%253D&md5=8cdde2cd09735cbf0f6236b3aeb4452d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm010934d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010934d%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DO.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DZuegge%26aufirst%3DJ.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DAlanine%26aufirst%3DA.%26aulast%3DBleicher%26aufirst%3DK.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DGutknecht%26aufirst%3DE.-M.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DStalder%26aufirst%3DH.%26aulast%3DDillon%26aufirst%3DM.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DE.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DGillespie%26aufirst%3DP.%26aulast%3DGoodnow%26aufirst%3DR.%26aulast%3DHarris%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DTaniguchi%26aufirst%3DM.%26aulast%3DTsujii%26aufirst%3DS.%26aulast%3Dvon%2Bder%2BSaal%26aufirst%3DW.%26aulast%3DZimmermann%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520a%2520Virtual%2520Screening%2520Method%2520for%2520Identification%2520of%2520%25E2%2580%259CFrequent%2520Hitters%25E2%2580%259D%2520in%2520Compound%2520Libraries%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D137%26epage%3D142%26doi%3D10.1021%2Fjm010934d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed During a Sulfhydryl-Scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+Assay%3A+Chemical+Mechanisms+of+Assay+Interference+and+Promiscuous+Enzymatic+Inhibition+Observed+During+a+Sulfhydryl-Scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lgRAODXpBks0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520Assay%253A%2520Chemical%2520Mechanisms%2520of%2520Assay%2520Interference%2520and%2520Promiscuous%2520Enzymatic%2520Inhibition%2520Observed%2520During%2520a%2520Sulfhydryl-Scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span> <i>An Introduction to Chemoinformatics</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2F978-1-4020-6291-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=A.+R.+Leach&title=An+Introduction+to+Chemoinformatics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-1-4020-6291-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4020-6291-9%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26btitle%3DAn%2520Introduction%2520to%2520Chemoinformatics%26pub%3DSpringer%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boido, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravazzolo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1124/mol.107.034702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1124%2Fmol.107.034702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=17452495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=197-207&author=N.+Pedemonteauthor=D.+Boidoauthor=O.+Moranauthor=M.+Giampieriauthor=M.+Mazzeiauthor=R.+Ravazzoloauthor=L.+J.+V.+Galietta&title=Structure-Activity+Relationship+of+1%2C4-Dihydropyridines+as+Potentiators+of+the+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Chloride+Channel&doi=10.1124%2Fmol.107.034702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel</span></div><div class="casAuthors">Pedemonte, Nicoletta; Boido, Davide; Moran, Oscar; Giampieri, Michele; Mazzei, Mauro; Ravazzolo, Roberto; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mutations occurring in the CFTR gene, encoding for the cystic fibrosis transmembrane conductance regulator chloride channel, cause cystic fibrosis (CF).  Mutations belonging to class II, such as ΔPhe508, give rise to a protein with both a defective maturation and altered channel gating.  Mutations belonging to class III, such as G551D and G1349D, cause only a gating defect.  We have previously identified antihypertensive 1,4-dihydropyridines (DHPs), a class of drugs that block voltage-dependent Ca2+ channels, as effective potentiators of CFTR gating, able to correct the defective activity of CFTR mutants.  However, optimization of potency for CFTR vs. Ca2+ channels is required to design selective compds. for CFTR pharmacotherapy.  In the present study, we have established DHP structure-activity relation for both CFTR potentiation and Ca2+ channel inhibition using cell-based assays for both types of channels.  A panel of 333 felodipine analogs was studied to understand the effect of various substitutions and modifications in the DHP scaffold.  Our results show that alkyl substitutions at the para position of the 4-Ph ring lead to compds. with very low activity on Ca2+ channels and strong effect as potentiators on the ΔPhe508, G551D, and G1349D CFTR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFwxDmiHiRObVg90H21EOLACvtfcHk0lgRAODXpBks0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyjsbs%253D&md5=b46d197776c619cc7929db781e4f803a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.034702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.034702%26sid%3Dliteratum%253Aachs%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DBoido%26aufirst%3DD.%26aulast%3DMoran%26aufirst%3DO.%26aulast%3DGiampieri%26aufirst%3DM.%26aulast%3DMazzei%26aufirst%3DM.%26aulast%3DRavazzolo%26aufirst%3DR.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DStructure-Activity%2520Relationship%2520of%25201%252C4-Dihydropyridines%2520as%2520Potentiators%2520of%2520the%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Chloride%2520Channel%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D197%26epage%3D207%26doi%3D10.1124%2Fmol.107.034702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fruscia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Gimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scudieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Picomolar Potency Pharmacological Corrector of the Mutant CFTR Chloride Channel</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">eaay9669</span>, <span class="refDoi"> DOI: 10.1126/sciadv.aay9669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1126%2Fsciadv.aay9669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=32128418" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=eaay9669&author=N.+Pedemonteauthor=F.+Bertozziauthor=E.+Caciauthor=F.+Soranaauthor=P.+Di+Frusciaauthor=V.+Tomatiauthor=L.+Ferreraauthor=A.+Rodr%C3%ADguez-Gimenoauthor=F.+Bertiauthor=E.+Pesceauthor=E.+Sondoauthor=A.+Gianottiauthor=P.+Scudieriauthor=T.+Bandieraauthor=L.+J.+V.+Galietta&title=Discovery+of+a+Picomolar+Potency+Pharmacological+Corrector+of+the+Mutant+CFTR+Chloride+Channel&doi=10.1126%2Fsciadv.aay9669"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay9669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay9669%26sid%3Dliteratum%253Aachs%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DSorana%26aufirst%3DF.%26aulast%3DDi%2BFruscia%26aufirst%3DP.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DFerrera%26aufirst%3DL.%26aulast%3DRodr%25C3%25ADguez-Gimeno%26aufirst%3DA.%26aulast%3DBerti%26aufirst%3DF.%26aulast%3DPesce%26aufirst%3DE.%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DGianotti%26aufirst%3DA.%26aulast%3DScudieri%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520Picomolar%2520Potency%2520Pharmacological%2520Corrector%2520of%2520the%2520Mutant%2520CFTR%2520Chloride%2520Channel%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26spage%3Deaay9669%26doi%3D10.1126%2Fsciadv.aay9669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mewshaw, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiffany, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbon, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borosky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferkany, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, M. E.</span></span> <span> </span><span class="NLM_article-title">Bridged Gamma-Carbolines and Derivatives Possessing Selective and Combined Affinity for 5-HT<sub>2</sub> and D<sub>2</sub> Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1021/jm00062a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00062a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3sXltFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1488-1495&author=R.+E.+Mewshawauthor=L.+S.+Silvermanauthor=R.+M.+Mathewauthor=C.+Kaiserauthor=R.+G.+Sherrillauthor=M.+Chengauthor=C.+W.+Tiffanyauthor=E.+W.+Karbonauthor=M.+A.+Baileyauthor=S.+A.+Boroskyauthor=J.+W.+Ferkanyauthor=M.+E.+Abreu&title=Bridged+Gamma-Carbolines+and+Derivatives+Possessing+Selective+and+Combined+Affinity+for+5-HT2+and+D2+Receptors&doi=10.1021%2Fjm00062a023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Bridged γ-carbolines and derivatives possessing selective and combined affinity for 5-HT2 and D2 receptors</span></div><div class="casAuthors">Mewshaw, Richard E.; Silverman, Lisa S.; Mathew, Rose M.; Kaiser, Carl; Sherrill, Ronald G.; Cheng, Menyan; Tiffany, Carol W.; Karbon, E. William; Bailey, Michael A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1488-95</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles and 6,7,8,9,10,11-hexahydro-7,11-imino-5H-cyclooct[b]indoles was prepd.  Structural modifications of the lead compd., 11-[4-(4-fluorobenzoyl)propyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclhept[b]indole (Ki = 0.82 nM vs [3H]ketanserin) enabled the identification of the functionality necessary for high affinity at serotonin 5-HT2 and dopamine D2 receptors in ligand binding studies.  The indole ring, as well as the benzoyl or isosteric benzisoxazole moiety, were essential for high affinity.  Variations of the length of the side chains resulted in ligands having either selective affinity for the 5-HT2 receptor or a combination of 5-HT2 and D2 affinity.  In vivo binding studies were performed on selected members in this series.  The most potent member, 2-fluoro-11-[4-(4-fluorobenzoyl)butyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (I) had an ED50 of <1 mg/kg at the 5-HT2 and D2 receptors following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7WNfXEenHlLVg90H21EOLACvtfcHk0lhmu98VUHdkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltFOhs78%253D&md5=c2660a6606dbd3b1865de8e036157adf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm00062a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00062a023%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DSilverman%26aufirst%3DL.%2BS.%26aulast%3DMathew%26aufirst%3DR.%2BM.%26aulast%3DKaiser%26aufirst%3DC.%26aulast%3DSherrill%26aufirst%3DR.%2BG.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DTiffany%26aufirst%3DC.%2BW.%26aulast%3DKarbon%26aufirst%3DE.%2BW.%26aulast%3DBailey%26aufirst%3DM.%2BA.%26aulast%3DBorosky%26aufirst%3DS.%2BA.%26aulast%3DFerkany%26aufirst%3DJ.%2BW.%26aulast%3DAbreu%26aufirst%3DM.%2BE.%26atitle%3DBridged%2520Gamma-Carbolines%2520and%2520Derivatives%2520Possessing%2520Selective%2520and%2520Combined%2520Affinity%2520for%25205-HT2%2520and%2520D2%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1488%26epage%3D1495%26doi%3D10.1021%2Fjm00062a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mewshaw, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbon, E. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro evaluation of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles: high-affinity ligands for the N,N′-di-o-tolylguanidine-labeled .sigma. binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1021/jm00055a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00055a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3sXitFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=343-352&author=R.+E.+Mewshawauthor=R.+G.+Sherrillauthor=R.+M.+Mathewauthor=C.+Kaiserauthor=M.+A.+Baileyauthor=E.+W.+Karbon&title=Synthesis+and+in+vitro+evaluation+of+5%2C6%2C7%2C8%2C9%2C10-hexahydro-7%2C10-iminocyclohept%5Bb%5Dindoles%3A+high-affinity+ligands+for+the+N%2CN%E2%80%B2-di-o-tolylguanidine-labeled+.sigma.+binding+site&doi=10.1021%2Fjm00055a005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro evaluation of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles:  high-affinity ligands for the N,N'-di-o-tolylguanidine-labeled σ binding site</span></div><div class="casAuthors">Mewshaw, Richard E.; Sherrill, Ronald G.; Mathew, Rose M.; Kaiser, Carl; Bailey, Michael A.; Karbon, E. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-52</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 5,6,7,8,9,10-hexahydro-7,10-iminocyclo[b]indole (I) derivs. substituted at the 5 and/or 11 positions was synthesized from tropinone.  Affinity for σ binding sites was detd. using [3H]-N,N'-di-o-tolylguanidine ([3H]DTG) and [3H]-(+)-3-(3-hydroxyphenyl)-N-1-propylpiperidine ([3H]-(+)-3-PPP) and for the dopamine D2 receptor labeled with [3H]sulpiride.  Nearly all compds. studied in this series possessed a higher affinity for [3H]DTG than [3H]-(+)-PPP-labeled σ sites, suggesting that [3H]DTG and [3H]-(+)-3-PPP radioligands label pharmacol. distinct σ binding sites, as reported previously.  Substitution at the 11 position with side chains contg. a four-carbon tether resulted in compds. having the highest affinity for the [3H]DTG-labeled σ site.  The most potent and selective member of this series was 11-[4-(2-furanyl)butyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (II).  Enantioselectivity was investigated by prepg. the (+)- and (-)-isomers of II.  (+)-II was more potent at the [3H]-DTG-labeled σ site, whereas (-)-II had a higher affinity at σ sites labeled with [3H]-(+)-PPP.  Racemic II was obsd. to possess a higher affinity than either of its resp. enantiomers at both the [3H]DTG- and [3H]-(+)-3-PPP labeled sites, suggesting an allosteric interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri_olGiHKBLbVg90H21EOLACvtfcHk0lhmu98VUHdkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitFaqsLg%253D&md5=5a54bae4c99d3e194087b43d9df6ce59</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm00055a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00055a005%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DSherrill%26aufirst%3DR.%2BG.%26aulast%3DMathew%26aufirst%3DR.%2BM.%26aulast%3DKaiser%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DM.%2BA.%26aulast%3DKarbon%26aufirst%3DE.%2BW.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520evaluation%2520of%25205%252C6%252C7%252C8%252C9%252C10-hexahydro-7%252C10-iminocyclohept%255Bb%255Dindoles%253A%2520high-affinity%2520ligands%2520for%2520the%2520N%252CN%25E2%2580%25B2-di-o-tolylguanidine-labeled%2520.sigma.%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D343%26epage%3D352%26doi%3D10.1021%2Fjm00055a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kametani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, M.</span></span> <span> </span><span class="NLM_article-title">Racemisation and Epimerisation in Isoquinoline and Indole Alkaloids</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.3987/s-1976-01-0649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3987%2FS-1976-01-0649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaE2sXnt12gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1976&pages=649-667&author=T.+Kametaniauthor=M.+Ihara&title=Racemisation+and+Epimerisation+in+Isoquinoline+and+Indole+Alkaloids&doi=10.3987%2Fs-1976-01-0649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Racemization and epimerization in isoquinoline and indole alkaloids</span></div><div class="casAuthors">Kametani, Tetsuji; Ihara, Masataka</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">649-68</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    </div><div class="casAbstract">A review with 22 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPewZkX4ws0rVg90H21EOLACvtfcHk0lhmu98VUHdkeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXnt12gsw%253D%253D&md5=68b7a1a8429966755dbfe07313daae57</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3987%2FS-1976-01-0649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FS-1976-01-0649%26sid%3Dliteratum%253Aachs%26aulast%3DKametani%26aufirst%3DT.%26aulast%3DIhara%26aufirst%3DM.%26atitle%3DRacemisation%2520and%2520Epimerisation%2520in%2520Isoquinoline%2520and%2520Indole%2520Alkaloids%26jtitle%3DHeterocycles%26date%3D1976%26volume%3D5%26spage%3D649%26epage%3D667%26doi%3D10.3987%2Fs-1976-01-0649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cholon, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinney, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulcher, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esther, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokholyan, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randell, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentzsch, M.</span></span> <span> </span><span class="NLM_article-title">Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">246ra96</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3008680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1126%2Fscitranslmed.3008680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25101886" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=246ra96&author=D.+M.+Cholonauthor=N.+L.+Quinneyauthor=M.+L.+Fulcherauthor=C.+R.+Estherauthor=J.+Dasauthor=N.+V.+Dokholyanauthor=S.+H.+Randellauthor=R.+C.+Boucherauthor=M.+Gentzsch&title=Potentiator+Ivacaftor+Abrogates+Pharmacological+Correction+of+DeltaF508+CFTR+in+Cystic+Fibrosis&doi=10.1126%2Fscitranslmed.3008680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008680%26sid%3Dliteratum%253Aachs%26aulast%3DCholon%26aufirst%3DD.%2BM.%26aulast%3DQuinney%26aufirst%3DN.%2BL.%26aulast%3DFulcher%26aufirst%3DM.%2BL.%26aulast%3DEsther%26aufirst%3DC.%2BR.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDokholyan%26aufirst%3DN.%2BV.%26aulast%3DRandell%26aufirst%3DS.%2BH.%26aulast%3DBoucher%26aufirst%3DR.%2BC.%26aulast%3DGentzsch%26aufirst%3DM.%26atitle%3DPotentiator%2520Ivacaftor%2520Abrogates%2520Pharmacological%2520Correction%2520of%2520DeltaF508%2520CFTR%2520in%2520Cystic%2520Fibrosis%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D246ra96%26doi%3D10.1126%2Fscitranslmed.3008680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramescu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdomo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phuan, P.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdany, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apaja, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szollosi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkbeiner, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span> <span> </span><span class="NLM_article-title">Some Gating Potentiators, Including VX-770, Diminish DeltaF508-CFTR Functional Expression</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">246ra97</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3008889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1126%2Fscitranslmed.3008889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25101887" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=246ra97&author=G.+Veitauthor=R.+G.+Avramescuauthor=D.+Perdomoauthor=P.-W.+Phuanauthor=M.+Bagdanyauthor=P.+M.+Apajaauthor=F.+Borotauthor=D.+Szollosiauthor=Y.-S.+Wuauthor=W.+E.+Finkbeinerauthor=T.+Hegedusauthor=A.+S.+Verkmanauthor=G.+L.+Lukacs&title=Some+Gating+Potentiators%2C+Including+VX-770%2C+Diminish+DeltaF508-CFTR+Functional+Expression&doi=10.1126%2Fscitranslmed.3008889"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008889%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DPerdomo%26aufirst%3DD.%26aulast%3DPhuan%26aufirst%3DP.-W.%26aulast%3DBagdany%26aufirst%3DM.%26aulast%3DApaja%26aufirst%3DP.%2BM.%26aulast%3DBorot%26aufirst%3DF.%26aulast%3DSzollosi%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.-S.%26aulast%3DFinkbeiner%26aufirst%3DW.%2BE.%26aulast%3DHegedus%26aufirst%3DT.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DSome%2520Gating%2520Potentiators%252C%2520Including%2520VX-770%252C%2520Diminish%2520DeltaF508-CFTR%2520Functional%2520Expression%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D246ra97%26doi%3D10.1126%2Fscitranslmed.3008889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scudieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musante, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baatallah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinzpeter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Bernardo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR through an Autophagy-Independent and USP13-Mediated Mechanism</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1464</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2018.01464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30618756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Olu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1464&author=E.+Pesceauthor=E.+Sondoauthor=L.+Ferreraauthor=V.+Tomatiauthor=E.+Caciauthor=P.+Scudieriauthor=I.+Musanteauthor=M.+Rendaauthor=N.+Baatallahauthor=N.+Servelauthor=A.+Hinzpeterauthor=D.+di+Bernardoauthor=N.+Pedemonteauthor=L.+J.+V.+Galietta&title=The+Autophagy+Inhibitor+Spautin-1+Antagonizes+Rescue+of+Mutant+CFTR+through+an+Autophagy-Independent+and+USP13-Mediated+Mechanism&doi=10.3389%2Ffphar.2018.01464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The autophagy inhibitor spautin-1 antagonizes rescue of mutant CFTR through an autophagy-independent and USP13-mediated mechanism</span></div><div class="casAuthors">Pesce, Emanuela; Sondo, Elvira; Ferrera, Loretta; Tomati, Valeria; Caci, Emanuela; Scudieri, Paolo; Musante, Ilaria; Renda, Mario; Baatallah, Nesrine; Servel, Nathalie; Hinzpeter, Alexandre; Di Bernardo, Diego; Pedemonte, Nicoletta; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1464</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The mutation F508del, responsible for a majority of cystic fibrosis cases, provokes the instability and misfolding of the CFTR chloride channel.  Pharmacol. recovery of F508del-CFTR may be obtained with small mols. called correctors.  However, treatment with a single corrector in vivo and in vitro only leads to a partial rescue, a consequence of cell quality control systems that still detect F508del-CFTR as a defective protein causing its degrdn.  We tested the effect of spautin-1 on F508delCFTR since it is an inhibitor of USP10 deubiquitinase and of autophagy, a target and a biol. process that have been assocd. with cystic fibrosis and mutant CFTR.  We found that short-term treatment of cells with spautin-1 downregulates the function and expression of F508del-CFTR despite the presence of corrector VX-809, a finding obtained in multiple cell models and assays.  In contrast, spautin-1 was ineffective on wild type CFTR.  Silencing and upregulation of USP13 (another target of spautin-1) but not of USP10, had opposite effects on F508del-CFTR expression/function.  In contrast, modulation of autophagy with known activators or inhibitors did not affect F508delCFTR.  Our results identify spautin-1 as a novel chem. probe to investigate the mol. mechanisms that prevent full rescue of mutant CFTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjGNm63Sb6WLVg90H21EOLACvtfcHk0livNZt72d2Pkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Olu7fF&md5=4c92c02a6f1338b611acd015b42a08fa</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01464%26sid%3Dliteratum%253Aachs%26aulast%3DPesce%26aufirst%3DE.%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DFerrera%26aufirst%3DL.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DScudieri%26aufirst%3DP.%26aulast%3DMusante%26aufirst%3DI.%26aulast%3DRenda%26aufirst%3DM.%26aulast%3DBaatallah%26aufirst%3DN.%26aulast%3DServel%26aufirst%3DN.%26aulast%3DHinzpeter%26aufirst%3DA.%26aulast%3Ddi%2BBernardo%26aufirst%3DD.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DThe%2520Autophagy%2520Inhibitor%2520Spautin-1%2520Antagonizes%2520Rescue%2520of%2520Mutant%2520CFTR%2520through%2520an%2520Autophagy-Independent%2520and%2520USP13-Mediated%2520Mechanism%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1464%26doi%3D10.3389%2Ffphar.2018.01464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Circumventing the Crabtree Effect: Replacing Media Glucose with Galactose Increases Susceptibility of HepG2 Cells to Mitochondrial Toxicants</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfm052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1093%2Ftoxsci%2Fkfm052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=17361016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=539-547&author=L.+D.+Marroquinauthor=J.+Hynesauthor=J.+A.+Dykensauthor=J.+D.+Jamiesonauthor=Y.+Will&title=Circumventing+the+Crabtree+Effect%3A+Replacing+Media+Glucose+with+Galactose+Increases+Susceptibility+of+HepG2+Cells+to+Mitochondrial+Toxicants&doi=10.1093%2Ftoxsci%2Fkfm052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants</span></div><div class="casAuthors">Marroquin, Lisa D.; Hynes, James; Dykens, James A.; Jamieson, Joseph D.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">539-547</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Many highly proliferative cells generate almost all ATP via glycolysis despite abundant O2 and a normal complement of fully functional mitochondria, a circumstance known as the Crabtree effect.  Such anaerobically poised cells are resistant to xenobiotics that impair mitochondrial function, such as the inhibitors rotenone, antimycin, oligomycin, and compds. like carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), that uncouple the respiratory electron transfer system from phosphorylation.  These cells are also resistant to the toxicity of many drugs whose deleterious side effect profiles are either caused, or exacerbated, by impairment of mitochondrial function.  Drug-induced mitochondrial toxicity is shown by members of important drug classes, including the thiazolidinediones, statins, fibrates, antivirals, antibiotics, and anticancer agents.  To increase detection of drug-induced mitochondrial effects in a preclin. cell-based assay, HepG2 cells were forced to rely on mitochondrial oxidative phosphorylation rather than glycolysis by substituting galactose for glucose in the growth media.  Oxygen consumption doubles in galactose-grown HepG2 cells and their susceptibility to canonical mitochondrial toxicants correspondingly increases.  Similarly, toxicity of several drugs with known mitochondrial liabilities is more readily apparent in aerobically poised HepG2 cells compared to glucose-grown cells.  Some drugs were equally toxic to both glucose- and galactose-grown cells, suggesting that mitochondrial impairment is likely secondary to other cytotoxic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Zb0elenmNbVg90H21EOLACvtfcHk0lgTA9DlVK8N2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D&md5=53d6a955ad0a942d1ced5043668bed19</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm052%26sid%3Dliteratum%253Aachs%26aulast%3DMarroquin%26aufirst%3DL.%2BD.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%2BD.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DCircumventing%2520the%2520Crabtree%2520Effect%253A%2520Replacing%2520Media%2520Glucose%2520with%2520Galactose%2520Increases%2520Susceptibility%2520of%2520HepG2%2520Cells%2520to%2520Mitochondrial%2520Toxicants%26jtitle%3DToxicol.%2520Sci.%26date%3D2007%26volume%3D97%26spage%3D539%26epage%3D547%26doi%3D10.1093%2Ftoxsci%2Fkfm052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuethe, J. T.</span></span> <span> </span><span class="NLM_article-title">Practical Methodologies for the Synthesis of Indoles</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2911</span>, <span class="refDoi"> DOI: 10.1021/cr0505270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0505270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlCitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=2875-2911&author=G.+R.+Humphreyauthor=J.+T.+Kuethe&title=Practical+Methodologies+for+the+Synthesis+of+Indoles&doi=10.1021%2Fcr0505270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Practical methodologies for the synthesis of Indoles</span></div><div class="casAuthors">Humphrey, Guy R.; Kuethe, Jeffrey T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2875-2911</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on prepn. of indole derivs.  A lot of procedures which have either been successfully demonstrated or are potentially useful for the large scale prepn. of indoles is presented with indication of reagents, reaction conditions, and yields.  The review focuses on the literature of the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGuTN17a6uM7Vg90H21EOLACvtfcHk0lgTA9DlVK8N2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlCitbg%253D&md5=ed3275cc7c57303254010e695c1a5a8e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fcr0505270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0505270%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DG.%2BR.%26aulast%3DKuethe%26aufirst%3DJ.%2BT.%26atitle%3DPractical%2520Methodologies%2520for%2520the%2520Synthesis%2520of%2520Indoles%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26spage%3D2875%26epage%3D2911%26doi%3D10.1021%2Fcr0505270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbert, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koe, B. K.</span></span> <span> </span><span class="NLM_article-title">Neuroleptic Activity in 5-Aryltetrahydro-Gamma-Carbolines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1021/jm00180a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00180a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaL3cXkt1Kgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=635-643&author=C.+A.+Harbertauthor=J.+J.+Plattnerauthor=W.+M.+Welchauthor=A.+Weissmanauthor=B.+K.+Koe&title=Neuroleptic+Activity+in+5-Aryltetrahydro-Gamma-Carbolines&doi=10.1021%2Fjm00180a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroleptic activity in 5-aryltetrahydro-γ-carbolines</span></div><div class="casAuthors">Harbert, Charles A.; Plattner, Jacob J.; Welch, Willard M.; Weissman, Albert; Koe, B. Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">635-43</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 5-aryltetrahydro-γ-carbolines I (R = Cl, Br, F, H, Me, MeO; R1 = Ph, substituted Ph; R2 = Me, (un)substituted 3-benzoylpropyl, (un)substituted 4-phenyl-4-hydroxybutyl) was prepd. by a novel N-arylation procedure and tested for neuroleptic activity in a rat antiamphetamine model.  Thus, p-FC6H4NH2.HCl was cyclized with 1-carbethoxy-4-piperidinone and the I (R = F, R1 = H, R2 = CO2Et) treated with p-BrC6H4F to give I (R = F, R1 = p-FC6H4, R2 = CO2Et) which was reduced with LiAlH4-AlCl3 to give I (R = F, R1 = p-FC6H4, R2 = Me).  The systematic exploration of structural parameters leading to I [R = F, R1 = p-FC6H4, R2 = p-FC6H4CH(OH)(CH2)3], a potent and long-acting neuroleptic compd., is described.  These semirigid compds. provide a new, structurally distinct series with which to probe the conformational requirements for potent activity at the dopamine receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRO_Er3zIjCbVg90H21EOLACvtfcHk0lgTA9DlVK8N2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXkt1Kgs7c%253D&md5=23b1fc549f96a5ee3e85f6b03e3a3194</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm00180a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00180a011%26sid%3Dliteratum%253Aachs%26aulast%3DHarbert%26aufirst%3DC.%2BA.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DWelch%26aufirst%3DW.%2BM.%26aulast%3DWeissman%26aufirst%3DA.%26aulast%3DKoe%26aufirst%3DB.%2BK.%26atitle%3DNeuroleptic%2520Activity%2520in%25205-Aryltetrahydro-Gamma-Carbolines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1980%26volume%3D23%26spage%3D635%26epage%3D643%26doi%3D10.1021%2Fjm00180a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridoux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houssin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Héanichart, J.-P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 8-Substituted Tetrahydro-γ-Carbolines</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570430308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1002%2Fjhet.5570430308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVaqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=571-578&author=A.+Bridouxauthor=L.+Goossensauthor=R.+Houssinauthor=J.-P.+H%C3%A9anichart&title=Synthesis+of+8-Substituted+Tetrahydro-%CE%B3-Carbolines&doi=10.1002%2Fjhet.5570430308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 8-substituted tetrahydro-γ-carbolines</span></div><div class="casAuthors">Bridoux, Alexandre; Goossens, Laurence; Houssin, Raymond; Henichart, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">571-578</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    
            (<span class="NLM_cas:orgname">HeteroCorporation</span>)
        </div><div class="casAbstract">The Fischer reaction is applied to the synthesis of 8-substituted tetrahydro-γ-carbolines with electron-donating or electron-withdrawing groups, using catalytic or thermal methods.  The reaction conditions must be varied according to the nature of the N(1) substituent of the piperidone.  The best results are obsd. when a releasing group is present on the arylhydrazine and a benzyl substituent on the nitrogen of piperidone.  Formation of carbolines with a withdrawing substituent is obsd. in soft acidic conditions.  In others, reaction ended at the hydrazone level or did not evolve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-1mUIzR_z7Vg90H21EOLACvtfcHk0lgTA9DlVK8N2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVaqtL8%253D&md5=687421bc3a3b38a02c86a3dbda6e4bbf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570430308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570430308%26sid%3Dliteratum%253Aachs%26aulast%3DBridoux%26aufirst%3DA.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DHoussin%26aufirst%3DR.%26aulast%3DH%25C3%25A9anichart%26aufirst%3DJ.-P.%26atitle%3DSynthesis%2520of%25208-Substituted%2520Tetrahydro-%25CE%25B3-Carbolines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2006%26volume%3D43%26spage%3D571%26epage%3D578%26doi%3D10.1002%2Fjhet.5570430308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penzis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaube, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appenroth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tränkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enzensperger, C.</span></span> <span> </span><span class="NLM_article-title">Beta and Gamma Carboline Derivatives as Potential Anti-Alzheimer Agents: A Comparison</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.ejmech.2014.09.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25240096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=63-70&author=R.+Ottoauthor=R.+Penzisauthor=F.+Gaubeauthor=T.+Wincklerauthor=D.+Appenrothauthor=C.+Fleckauthor=C.+Tr%C3%A4nkleauthor=J.+Lehmannauthor=C.+Enzensperger&title=Beta+and+Gamma+Carboline+Derivatives+as+Potential+Anti-Alzheimer+Agents%3A+A+Comparison&doi=10.1016%2Fj.ejmech.2014.09.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison</span></div><div class="casAuthors">Otto, Robert; Penzis, Robert; Gaube, Friedemann; Winckler, Thomas; Appenroth, Dorothea; Fleck, Christian; Traenkle, Christian; Lehmann, Jochen; Enzensperger, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Nine novel β- and γ-carboline derivs. bearing either methyl-, propargyl- or phenethyl-residues at the indole nitrogen were synthesized and tested as potential anti-Alzheimer drugs.  Antagonism of recombinantly expressed NMDA receptors, inhibition of cholinesterases, and radical scavenging properties were detd. for all compds.  Some were addnl. tested in vivo for their ability to reverse scopolamine-induced cognitive impairment in an 8-arm radial maze expt. with rats.  For the most promising candidates, the interaction with muscarinic M1 receptors was also investigated.  With this set of compds. assays the influence of the scaffold itself and the substituents can be investigated sep.  5-Methyl-γ-carboline (I) was the most potent (0.25 μmol/100 g b.w.) compd. in the in vivo test and might be a good starting point for the development of novel anti-Alzheimer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRwXrBRAcmgbVg90H21EOLACvtfcHk0lijKba4QMWr1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlsLzM&md5=d12fd4e4f527b4fe894e9aa80dd361cc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.048%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DR.%26aulast%3DPenzis%26aufirst%3DR.%26aulast%3DGaube%26aufirst%3DF.%26aulast%3DWinckler%26aufirst%3DT.%26aulast%3DAppenroth%26aufirst%3DD.%26aulast%3DFleck%26aufirst%3DC.%26aulast%3DTr%25C3%25A4nkle%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DJ.%26aulast%3DEnzensperger%26aufirst%3DC.%26atitle%3DBeta%2520and%2520Gamma%2520Carboline%2520Derivatives%2520as%2520Potential%2520Anti-Alzheimer%2520Agents%253A%2520A%2520Comparison%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D63%26epage%3D70%26doi%3D10.1016%2Fj.ejmech.2014.09.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.-F.</span></span> <span> </span><span class="NLM_article-title">“One-Pot” Synthesis of 4-Substituted 1,5-Diaryl-1H-Pyrazole-3-Carboxylates via Lithium Tert-Butoxide-Mediated Sterically Hindered Claisen Condensation and Knorr Reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2012.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.tet.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslejsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=627-635&author=J.-A.+Jiangauthor=W.-B.+Huangauthor=J.-J.+Zhaiauthor=H.-W.+Liuauthor=Q.+Caiauthor=L.-X.+Xuauthor=W.+Wangauthor=Y.-F.+Ji&title=%E2%80%9COne-Pot%E2%80%9D+Synthesis+of+4-Substituted+1%2C5-Diaryl-1H-Pyrazole-3-Carboxylates+via+Lithium+Tert-Butoxide-Mediated+Sterically+Hindered+Claisen+Condensation+and+Knorr+Reaction&doi=10.1016%2Fj.tet.2012.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">'One-pot' synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates via lithium tert-butoxide-mediated sterically hindered Claisen condensation and Knorr reaction</span></div><div class="casAuthors">Jiang, Jian-An; Huang, Wei-Bin; Zhai, Jiao-Jiao; Liu, Hong-Wei; Cai, Qi; Xu, Liu-Xin; Wang, Wei; Ji, Ya-Fei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-635</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A concise 'one-pot' synthesis of a variety of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates has been developed in moderate to good yields with excellent regioselectivity.  Less cost lithium tert-butoxide has been identified as a base for sterically hindered Claisen condensation to efficiently generate the labile 3-substituted 4-aryl-2,4-diketoesters.  Furthermore, extensive studies lead to a 'one-pot' process by combination of the Claisen condensation and the Knorr reaction for the synthesis of highly valuable 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_UiHKV4qkzLVg90H21EOLACvtfcHk0lijKba4QMWr1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslejsLzJ&md5=5af2084c22373bbcb2109ca955015141</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.-A.%26aulast%3DHuang%26aufirst%3DW.-B.%26aulast%3DZhai%26aufirst%3DJ.-J.%26aulast%3DLiu%26aufirst%3DH.-W.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DL.-X.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DY.-F.%26atitle%3D%25E2%2580%259COne-Pot%25E2%2580%259D%2520Synthesis%2520of%25204-Substituted%25201%252C5-Diaryl-1H-Pyrazole-3-Carboxylates%2520via%2520Lithium%2520Tert-Butoxide-Mediated%2520Sterically%2520Hindered%2520Claisen%2520Condensation%2520and%2520Knorr%2520Reaction%26jtitle%3DTetrahedron%26date%3D2013%26volume%3D69%26spage%3D627%26epage%3D635%26doi%3D10.1016%2Fj.tet.2012.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, G. W.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in Indole Ring Synthesis-Methodology and Applications</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1039/a909834h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1039%2Fa909834h" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=1045-1075&author=G.+W.+Gribble&title=Recent+Developments+in+Indole+Ring+Synthesis-Methodology+and+Applications&doi=10.1039%2Fa909834h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1039%2Fa909834h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa909834h%26sid%3Dliteratum%253Aachs%26aulast%3DGribble%26aufirst%3DG.%2BW.%26atitle%3DRecent%2520Developments%2520in%2520Indole%2520Ring%2520Synthesis-Methodology%2520and%2520Applications%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2000%26spage%3D1045%26epage%3D1075%26doi%3D10.1039%2Fa909834h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivashchenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mit’kin, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okun, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salimov, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedotov, A. I.</span></span> <span> </span><span class="NLM_article-title">Substituted 2,3,4,5-Tetrahydro-1H-Gamma-Carbolines: New Antagonists of Histamine H1 Receptors</span>. <i>Eksp. Klin. Farmakol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=21254595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVKisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2010&pages=25-29&author=A.+V.+Ivashchenkoauthor=O.+D.+Mit%E2%80%99kinauthor=I.+M.+Okunauthor=R.+M.+Salimovauthor=A.+I.+Fedotov&title=Substituted+2%2C3%2C4%2C5-Tetrahydro-1H-Gamma-Carbolines%3A+New+Antagonists+of+Histamine+H1+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted 2,3,4,5-tetrahydro-1H-γ-carbolines: New antagonists of histamine H1 receptors</span></div><div class="casAuthors">Ivashchenko, A. V.; Mit'kin, O. D.; Okun, I. M.; Salimov, R. M.; Fedotov, Yu. A.</div><div class="citationInfo"><span class="NLM_cas:title">Eksperimental'naya i Klinicheskaya Farmakologiya</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">25-29</span>CODEN:
                <span class="NLM_cas:coden">EKFAE9</span>;
        ISSN:<span class="NLM_cas:issn">0869-2092</span>.
    
            (<span class="NLM_cas:orgname">Izdatel'stvo Folium</span>)
        </div><div class="casAbstract">The properties of 2,3,4,5-tetrahydro-1H-γ-carbolines contg. acid, ether, and amido-substituents, were assessed as potential antagonists of histamine H1 receptors (H1R), capable of blocking histamine-induced calcium fluxes in SK-N-SH cells.  The structure - activity relationship for their antagonistic activity is discussed.  Among the γ-carbolines used in the study, the antihistamine activity considerably depends on the nature of substituents in positions 2, 5, and 8 of the heterocycle.  The most active antagonist, Et 3-(2-methyl-8-fluoro-2,3,4,5-tetrahydro-1H-γ-carboline-5-yl)propionate, with high affinity to the H1R (Ki = 6.5 nM), produces no adverse effects on motor activity of mice in doses 1 - 40 mg/kg, which shows the absence of a sedative effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTp92hkl5kd7Vg90H21EOLACvtfcHk0liEO9PcgnQ9GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVKisA%253D%253D&md5=164fd672569fb102a28106f5f6eb234f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIvashchenko%26aufirst%3DA.%2BV.%26aulast%3DMit%25E2%2580%2599kin%26aufirst%3DO.%2BD.%26aulast%3DOkun%26aufirst%3DI.%2BM.%26aulast%3DSalimov%26aufirst%3DR.%2BM.%26aulast%3DFedotov%26aufirst%3DA.%2BI.%26atitle%3DSubstituted%25202%252C3%252C4%252C5-Tetrahydro-1H-Gamma-Carbolines%253A%2520New%2520Antagonists%2520of%2520Histamine%2520H1%2520Receptors%26jtitle%3DEksp.%2520Klin.%2520Farmakol.%26date%3D2010%26volume%3D73%26spage%3D25%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span> <span> </span><span class="NLM_article-title">Priviliged Structures. An Update</span>. <i>Ann. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/s0065-7743(00)35027-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fs0065-7743%2800%2935027-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=289-298&author=A.+A.+Patchettauthor=R.+P.+Nargund&title=Priviliged+Structures.+An+Update&doi=10.1016%2Fs0065-7743%2800%2935027-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Chapter 26. Privileged structures - an update</span></div><div class="casAuthors">Patchett, Arthur A.; Nargund, Ravi P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-298</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 63 refs. on privileged structure-based ligands of G protein-coupled receptors in relation to the search for new agonists and antagonists in relation to drug design and discovery.  Although this review deals primarily with the use of privileged structures in the design of G-protein coupled receptor agonists and antagonists, their use extends beyond these receptors.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqy_U678fGfLVg90H21EOLACvtfcHk0liEO9PcgnQ9GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFGltb8%253D&md5=18fd0d98b8fb92fa51dbaf6034dee2e2</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fs0065-7743%2800%2935027-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0065-7743%252800%252935027-8%26sid%3Dliteratum%253Aachs%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26atitle%3DPriviliged%2520Structures.%2520An%2520Update%26jtitle%3DAnn.%2520Rep.%2520Med.%2520Chem.%26date%3D2000%26volume%3D35%26spage%3D289%26epage%3D298%26doi%3D10.1016%2Fs0065-7743%2800%2935027-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivachtchenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolov, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitkin, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kysil, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khvat, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okun, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachenko, S. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel Gamma-Carboline Analogues of Dimebon as Potent 5-HT<sub>6</sub> Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3183</span>– <span class="NLM_lpage">3187</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.bmcl.2009.04.128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=19443217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3183-3187&author=A.+V.+Ivachtchenkoauthor=E.+B.+Frolovauthor=O.+D.+Mitkinauthor=V.+M.+Kysilauthor=A.+V.+Khvatauthor=I.+M.+Okunauthor=S.+E.+Tkachenko&title=Synthesis+and+Biological+Evaluation+of+Novel+Gamma-Carboline+Analogues+of+Dimebon+as+Potent+5-HT6+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2009.04.128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel γ-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists</span></div><div class="casAuthors">Ivachtchenko, Alexandre V.; Frolov, Eugene B.; Mitkin, Oleg D.; Kysil, Volodymyr M.; Khvat, Alexander V.; Okun, Ilya M.; Tkachenko, Sergey E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3183-3187</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis, biol. evaluation and structure-activity relationships for a series of novel γ-carboline analogs of Dimebon, e.g., I and II, are described.  Among the studied compds., I and II have been identified as potent small mol. antagonists of histamine H1 (IC50 = 0.1 μM) and serotonin 5-HT6 (IC50 = 0.37 μM) receptors, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmSqs1g11Wn7Vg90H21EOLACvtfcHk0lg_kcMmJI9woA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eks7o%253D&md5=057a6c1ac2925dd9bad040130ff9dd36</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.128%26sid%3Dliteratum%253Aachs%26aulast%3DIvachtchenko%26aufirst%3DA.%2BV.%26aulast%3DFrolov%26aufirst%3DE.%2BB.%26aulast%3DMitkin%26aufirst%3DO.%2BD.%26aulast%3DKysil%26aufirst%3DV.%2BM.%26aulast%3DKhvat%26aufirst%3DA.%2BV.%26aulast%3DOkun%26aufirst%3DI.%2BM.%26aulast%3DTkachenko%26aufirst%3DS.%2BE.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Gamma-Carboline%2520Analogues%2520of%2520Dimebon%2520as%2520Potent%25205-HT6%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3183%26epage%3D3187%26doi%3D10.1016%2Fj.bmcl.2009.04.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Recent Developments on Synthesis and Biological Activities of Gamma-Carboline</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.ejmech.2018.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30103193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=447-461&author=J.+Daiauthor=W.+Danauthor=Y.+Zhangauthor=J.+Wang&title=Recent+Developments+on+Synthesis+and+Biological+Activities+of+Gamma-Carboline&doi=10.1016%2Fj.ejmech.2018.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments on synthesis and biological activities of γ-carboline</span></div><div class="casAuthors">Dai, Jiangkun; Dan, Wenjia; Zhang, Yunyun; Wang, Junru</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">447-461</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review on γ-carboline alkaloids are a family of natural and synthetic agents that have diverse bioactivities including antiviral, antibacterial, antifungal, antiparasitic, antitumor, anti-inflammatory, neuropharmacol. activities and so on.  They constitute an important class of pharmacol. active scaffolds that exhibit biol. activity via diverse mechanisms.  This review provides an update on the recent developments (2010-2017) in the synthesis and biol. activities of these compds.  In cases where sufficient information is available, the mechanism and the structure-activity relationship (SAR) of biol. activity are presented, and based on our expertise in the field and careful anal. of the recent literature, for the potential of γ-carboline alkaloids as medicinal drugs is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVZGnpLjWH7Vg90H21EOLACvtfcHk0lg_kcMmJI9woA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FJ&md5=a1d5ab2db417a27e581ce03e1f5ee480</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DDan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DRecent%2520Developments%2520on%2520Synthesis%2520and%2520Biological%2520Activities%2520of%2520Gamma-Carboline%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D447%26epage%3D461%26doi%3D10.1016%2Fj.ejmech.2018.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alekseyev, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurovskaya, M. A.</span></span> <span> </span><span class="NLM_article-title">γ-Carbolines and Their Hydrogenated Derivatives 3.* Hydrogenated Derivatives of γ-Carbolines: Chemical and Biological Properties (Review)</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1007/s10593-011-0652-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2Fs10593-011-0652-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVajtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=1169-1198&author=R.+S.+Alekseyevauthor=A.+V.+Kurkinauthor=M.+A.+Yurovskaya&title=%CE%B3-Carbolines+and+Their+Hydrogenated+Derivatives+3.*+Hydrogenated+Derivatives+of+%CE%B3-Carbolines%3A+Chemical+and+Biological+Properties+%28Review%29&doi=10.1007%2Fs10593-011-0652-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Carbolines and their hydrogenated derivatives. Part 3. Hydrogenated derivatives of γ-carbolines, chemical and biological properties</span></div><div class="casAuthors">Alekseyev, R. S.; Kurkin, A. V.; Yurovskaya, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1169-1198</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Published data on the chem. transformations and biol. properties of dihydro-, tetrahydro-, and hexahydro-γ-carbolines were reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLPq1p7flt_rVg90H21EOLACvtfcHk0lg_kcMmJI9woA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVajtrw%253D&md5=598733ff11417756d80a6c42cb8c7aae</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs10593-011-0652-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-011-0652-0%26sid%3Dliteratum%253Aachs%26aulast%3DAlekseyev%26aufirst%3DR.%2BS.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DYurovskaya%26aufirst%3DM.%2BA.%26atitle%3D%25CE%25B3-Carbolines%2520and%2520Their%2520Hydrogenated%2520Derivatives%25203.%252A%2520Hydrogenated%2520Derivatives%2520of%2520%25CE%25B3-Carbolines%253A%2520Chemical%2520and%2520Biological%2520Properties%2520%2528Review%2529%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2011%26volume%3D46%26spage%3D1169%26epage%3D1198%26doi%3D10.1007%2Fs10593-011-0652-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khorana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrick-Davis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Gamma-Carbolines: Binding at 5-HT<sub>5a</sub> Serotonin Receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/s0968-0896(02)00527-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2FS0968-0896%2802%2900527-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12538001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1Oqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=717-722&author=N.+Khoranaauthor=A.+Purohitauthor=K.+Herrick-Davisauthor=M.+Teitlerauthor=R.+A.+Glennon&title=Gamma-Carbolines%3A+Binding+at+5-HT5a+Serotonin+Receptors&doi=10.1016%2Fs0968-0896%2802%2900527-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Carbolines: binding at 5-HT5A serotonin receptors</span></div><div class="casAuthors">Khorana, Nantaka; Purohit, Anil; Herrick-Davis, Katherine; Teitler, Milt; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">717-722</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Screening of various agents resulted in the identification of 5-methyl-1,2,3,4-tetrahydro-γ-carboline (1; Ki=5,300 nM) as a compd. with modest affinity for mouse 5-HT5A receptors.  Structure-affinity studies were conducted resulting in 5-methyl-2-[3-(4-fluorophenoxy)propyl]-1,2,3,4-tetrahydro-γ-carboline (17; Ki=13 nM).  Although 17 also binds at 5-HT2 receptors, it serves as a novel lead for the further development of 5-HT5A ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRRuG1oyjp_7Vg90H21EOLACvtfcHk0lg_kcMmJI9woA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1Oqsg%253D%253D&md5=abc9cb09943ba0f90af15838a1e65525</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900527-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900527-8%26sid%3Dliteratum%253Aachs%26aulast%3DKhorana%26aufirst%3DN.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DHerrick-Davis%26aufirst%3DK.%26aulast%3DTeitler%26aufirst%3DM.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DGamma-Carbolines%253A%2520Binding%2520at%25205-HT5a%2520Serotonin%2520Receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D717%26epage%3D722%26doi%3D10.1016%2Fs0968-0896%2802%2900527-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khorana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrick-Davis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grella, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Binding of Tetrahydrocarboline Derivatives at Human 5-HT<sub>5a</sub> Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3930</span>– <span class="NLM_lpage">3937</span>, <span class="refDoi"> DOI: 10.1021/jm030080s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030080s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslKntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3930-3937&author=N.+Khoranaauthor=C.+Smithauthor=K.+Herrick-Davisauthor=A.+Purohitauthor=M.+Teitlerauthor=B.+Grellaauthor=M.+Dukatauthor=R.+A.+Glennon&title=Binding+of+Tetrahydrocarboline+Derivatives+at+Human+5-HT5a+Receptors&doi=10.1021%2Fjm030080s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of Tetrahydrocarboline Derivatives at Human 5-HT5A Receptors</span></div><div class="casAuthors">Khorana, Nantaka; Smith, Carol; Herrick-Davis, Kathy; Purohit, Anil; Teitler, Milt; Grella, Brian; Dukat, Ma-lgorzata; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3930-3937</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of an earlier finding that 5-methyl-5H-1,2,3,4-tetrahydropyrido[4,3-b]indole (5-methyl-1,2,3,4-tetrahydro-γ-carboline); (1) binds at murine 5-HT5A receptors, preliminary structure-affinity studies were conducted.  The present investigation extends these structure-affinity studies using human 5-HT5A receptors and examd. addnl. analogs of 1.  It was found (a) that there is little interspecies difference for the affinities of these compds., (b) that an intact 1,2,3,4-tetrahydro-γ-carboline ring system seems optimal and an N2-(3-(substituted-phenoxy)propyl) moiety results in high affinity, (c) that structurally related 1,2,3,4-tetrahydro-β-carbolines also bind at 5-HT5A receptors, and (d) that all examd. derivs. also possess affinity for 5-HT2A receptors.  Evidence is provided that 5-HT5A and 5-HT2A receptor affinities probably do not covary and that it might be possible, with continued investigation, to develop analogs with enhanced 5-HT5A selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAfW3H1It7T7Vg90H21EOLACvtfcHk0lhdLUZi-nUzDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslKntbw%253D&md5=b782a84c71eeb59741b785cb2d3f5589</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm030080s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030080s%26sid%3Dliteratum%253Aachs%26aulast%3DKhorana%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DHerrick-Davis%26aufirst%3DK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DTeitler%26aufirst%3DM.%26aulast%3DGrella%26aufirst%3DB.%26aulast%3DDukat%26aufirst%3DM.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DBinding%2520of%2520Tetrahydrocarboline%2520Derivatives%2520at%2520Human%25205-HT5a%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3930%26epage%3D3937%26doi%3D10.1021%2Fjm030080s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ustyugov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevtsova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachurin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, G.</span></span> <span> </span><span class="NLM_article-title">New Therapeutic Property of Dimebon as a Neuroprotective Agent</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5315</span>– <span class="NLM_lpage">5326</span>, <span class="refDoi"> DOI: 10.2174/0929867323666160804122746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.2174%2F0929867323666160804122746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27494393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVCkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=5315-5326&author=A.+Ustyugovauthor=E.+Shevtsovaauthor=G.+M.+Ashrafauthor=V.+V.+Tarasovauthor=S.+O.+Bachurinauthor=G.+Aliev&title=New+Therapeutic+Property+of+Dimebon+as+a+Neuroprotective+Agent&doi=10.2174%2F0929867323666160804122746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">New Therapeutic Property of Dimebon as a Neuroprotective Agent</span></div><div class="casAuthors">Ustyugov, Aleksey; Shevtsova, Elena; Ashraf, Ghulam Md.; Tarasov, Vadim V.; Bachurin, Sergey O.; Aliev, Gjumrakch</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5315-5326</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of "old" agents with prominent neuroprotective effects.  In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain's pathol. processes using in vivo proteinopathy models.  In the study, neurodegenerative pathol. has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which are involved in a no. of neurol. disorders.  We have also presented our in vitro model based on overexpression of an aberrant mutant form of transactive response DNA binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.  Dimebon treatment followed by the activation of autophagy markers resulted in reduced no. of inclusion contg. cells.  The most significant effects of Dimebon appeared to be on the improving cellular energy balance, mitochondria stability by increasing the threshold for nonselective mitochondrial pore opening as well as on increased calcium retention capacity while reducing lipid peroxidn.  The therapeutic potential of Dimebon and newly designed analogs show disease modifying properties and could be used to treat neurodegenerative disorders.  In addn., new data hint on a possible anti-aging effect and potential application of Dimebon for treatment of anxiety, ischemia and depression.  Overall, our findings suggest that the most pronounced effect of Dimebon was obsd. when treatment was started at the early stages of disease onset and this factor needs to be taken into account while planning future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg8NjWU4Z_4bVg90H21EOLACvtfcHk0lhdLUZi-nUzDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVCkt7o%253D&md5=0c88fc2ad3f61912e9dba52fe0e5f919</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160804122746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160804122746%26sid%3Dliteratum%253Aachs%26aulast%3DUstyugov%26aufirst%3DA.%26aulast%3DShevtsova%26aufirst%3DE.%26aulast%3DAshraf%26aufirst%3DG.%2BM.%26aulast%3DTarasov%26aufirst%3DV.%2BV.%26aulast%3DBachurin%26aufirst%3DS.%2BO.%26aulast%3DAliev%26aufirst%3DG.%26atitle%3DNew%2520Therapeutic%2520Property%2520of%2520Dimebon%2520as%2520a%2520Neuroprotective%2520Agent%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26spage%3D5315%26epage%3D5326%26doi%3D10.2174%2F0929867323666160804122746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Rescue of the Mutant CFTR Chloride Channel by Pharmacological Correctors and Low Temperature Analyzed by Gene Expression Profiling</span>. <i>Am. J. Physiol.: Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>301</i></span>,  <span class="NLM_fpage">C872</span>– <span class="NLM_lpage">C885</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.00507.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1152%2Fajpcell.00507.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=21753184" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2011&pages=C872-C885&author=E.+Sondoauthor=V.+Tomatiauthor=E.+Caciauthor=A.+I.+Espositoauthor=U.+Pfefferauthor=N.+Pedemonteauthor=L.+J.+V.+Galietta&title=Rescue+of+the+Mutant+CFTR+Chloride+Channel+by+Pharmacological+Correctors+and+Low+Temperature+Analyzed+by+Gene+Expression+Profiling&doi=10.1152%2Fajpcell.00507.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00507.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00507.2010%26sid%3Dliteratum%253Aachs%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DEsposito%26aufirst%3DA.%2BI.%26aulast%3DPfeffer%26aufirst%3DU.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DRescue%2520of%2520the%2520Mutant%2520CFTR%2520Chloride%2520Channel%2520by%2520Pharmacological%2520Correctors%2520and%2520Low%2520Temperature%2520Analyzed%2520by%2520Gene%2520Expression%2520Profiling%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Cell%2520Physiol.%26date%3D2011%26volume%3D301%26spage%3DC872%26epage%3DC885%26doi%3D10.1152%2Fajpcell.00507.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scudieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravazzolo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Association of TMEM16A Chloride Channel Overexpression with Airway Goblet Cell Metaplasia</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">6141</span>– <span class="NLM_lpage">6155</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2012.240838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1113%2Fjphysiol.2012.240838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=22988141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2012&pages=6141-6155&author=P.+Scudieriauthor=E.+Caciauthor=S.+Brunoauthor=L.+Ferreraauthor=M.+Schiavonauthor=E.+Sondoauthor=V.+Tomatiauthor=A.+Gianottiauthor=O.+Zegarra-Moranauthor=N.+Pedemonteauthor=F.+Reaauthor=R.+Ravazzoloauthor=L.+J.+V.+Galietta&title=Association+of+TMEM16A+Chloride+Channel+Overexpression+with+Airway+Goblet+Cell+Metaplasia&doi=10.1113%2Fjphysiol.2012.240838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia</span></div><div class="casAuthors">Scudieri, Paolo; Caci, Emanuela; Bruno, Silvia; Ferrera, Loretta; Schiavon, Marco; Sondo, Elvira; Tomati, Valeria; Gianotti, Ambra; Zegarra-Moran, Olga; Pedemonte, Nicoletta; Rea, Federico; Ravazzolo, Roberto; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6141-6155</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The TMEM16A protein has a potential role as a Ca2+-activated Cl- channel (CaCC) in airway epithelia where it may be important in the homeostasis of the airway surface fluid.  We investigated the function and expression of TMEM16A in primary human bronchial epithelial cells and in a bronchial cell line (CFBE41o-).  Under resting conditions, TMEM16A protein expression was relatively low.  However, TMEM16A silencing with short-interfering RNAs caused a marked inhibition of CaCC activity, thus demonstrating that a low TMEM16A expression is sufficient to support Ca2+-dependent Cl- transport.  Following treatment for 24-72 h with interleukin-4 (IL-4), a cytokine that induces mucous cell metaplasia, TMEM16A protein expression was strongly increased in approx. 50% of primary bronchial epithelial cells, with a specific localization in the apical membrane.  IL-4 treatment also increased the percentage of cells expressing MUC5AC, a marker of goblet cells.  Interestingly, MUC5AC was detected specifically in cells expressing TMEM16A.  In particular, MUC5AC was found in 15 and 60% of TMEM16A-pos. cells when epithelia were treated with IL-4 for 24 or 72 h, resp.  In contrast, ciliated cells showed expression of the cystic fibrosis transmembrane conductance regulator Cl- channel but not of TMEM16A.  Our results indicate that TMEM16A protein is responsible for CaCC activity in airway epithelial cells, particularly in cells treated with IL-4, and that TMEM16A upregulation by IL-4 appears as an early event of goblet cell differentiation.  These findings suggest that TMEM16A expression is particularly required under conditions of mucus hypersecretion to ensure adequate secretion of electrolytes and water.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxoXrLbFQ8grVg90H21EOLACvtfcHk0ljPVIzScvTeYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlaqtQ%253D%253D&md5=2d35524823abfa3e3f31ccac105e352f</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2012.240838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2012.240838%26sid%3Dliteratum%253Aachs%26aulast%3DScudieri%26aufirst%3DP.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DFerrera%26aufirst%3DL.%26aulast%3DSchiavon%26aufirst%3DM.%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DGianotti%26aufirst%3DA.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DRea%26aufirst%3DF.%26aulast%3DRavazzolo%26aufirst%3DR.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DAssociation%2520of%2520TMEM16A%2520Chloride%2520Channel%2520Overexpression%2520with%2520Airway%2520Goblet%2520Cell%2520Metaplasia%26jtitle%3DJ.%2520Physiol.%26date%3D2012%26volume%3D590%26spage%3D6141%26epage%3D6155%26doi%3D10.1113%2Fjphysiol.2012.240838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Sala</span>, <span class="hlFld-ContribAuthor ">Sophie Julie  Cnudde</span>, <span class="hlFld-ContribAuthor ">Alessandra  Murabito</span>, <span class="hlFld-ContribAuthor ">Alberto  Massarotti</span>, <span class="hlFld-ContribAuthor ">Emilio  Hirsch</span>, <span class="hlFld-ContribAuthor ">Alessandra  Ghigo</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113191. <a href="https://doi.org/10.1016/j.ejmech.2021.113191" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113191%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTherapeutic%252Bpeptides%252Bfor%252Bthe%252Btreatment%252Bof%252Bcystic%252Bfibrosis%25253A%252BChallenges%252Band%252Bperspectives%26aulast%3DSala%26aufirst%3DValentina%26date%3D2021%26volume%3D213%26spage%3D113191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madalena C  Pinto</span>, <span class="hlFld-ContribAuthor ">Iris AL  Silva</span>, <span class="hlFld-ContribAuthor ">Miriam F  Figueira</span>, <span class="hlFld-ContribAuthor ">Margarida D  Amaral</span>, <span class="hlFld-ContribAuthor ">Miquéias  Lopes-Pacheco</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental Pharmacology</span><span> <strong>2021,</strong> <em>Volume 13 </em>, 693-723. <a href="https://doi.org/10.2147/JEP.S255377" title="DOI URL">https://doi.org/10.2147/JEP.S255377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/JEP.S255377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FJEP.S255377%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520Pharmacology%26atitle%3DPharmacological%252BModulation%252Bof%252BIon%252BChannels%252Bfor%252Bthe%252BTreatment%252Bof%252BCystic%252BFibrosis%26aulast%3DPinto%26aufirst%3DMadalena%2BC%26date%3D2021%26date%3D2021%26volume%3DVolume%252013%26spage%3D693%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of known CFTR potentiators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Discovery of mutant CFTR potentiators by HTS. (A) Summary of results obtained by screening the entire chemical library on FRT cells expressing F508del-CFTR and HS-YFP, followed by 24 h of incubation at 32 °C to rescue the trafficking defect. The graphs report the normalized HS-YFP quenching rate (QR), reflecting CFTR-dependent iodide influx, for cells treated with forskolin (10 μM) plus test compounds (5 μM; gray dots), VX-770 (1 μM; red dots), or vehicle [dimethyl sulfoxide (DMSO), black dots]. (B) Ordered distribution of the QR scores measured, for each test compound, in the screening and displayed in (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Identification of novel potentiators of mutant CFTR. Dose–response relationships for selected compounds on (A) F508del-CFTR FRT cells rescued at 32 °C for 24 h and (B) on G551D-CFTR FRT cells, compared to VX-770 (1 μM for F508del and 5 μM for G551D). (C) Structures of potentiators <i>Hit-7</i> (<b>1</b>), <i>Hit-8</i> (<b>2</b>), and <i>Hit-9</i> (<b>3</b>), selected for further SAR evolution. The data are expressed as mean ± standard deviation (SD) (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric analysis of variance (ANOVA), followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance vs control (DMSO-treated): ***<i>p</i> < 0.001, **<i>p</i> < 0.01, and *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CFTR activation by tetrahydro-γ-carbolines on bronchial epithelial cells. (A) Dose–response relationships for selected compounds, compared to VX-770 (1 μM), on F508del-CFTR CFBE41o-cells rescued at 32 °C for 24 h. The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance vs control (DMSO-treated): ***<i>p</i> < 0.001 and **<i>p</i> < 0.01. (B) Representative traces show the response of CFTR to stimulation with the indicated concentrations of CPT-cAMP and compound <b>3</b>. The currents stimulated by compound <b>3</b> and CPT-cAMP were blocked by the selective CFTR inhibitor-172. Each experimental condition was tested in three independent experiments, each one performed with three biological replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Sites of chemical modifications on the structure of <b>3</b> to explore the SAR of the tetrahydro-γ-carboline class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Activity of selected tetrahydro-γ-carboline potentiators (<b>3</b>, <b>20</b>, <b>25</b>, <b>30</b>, and <b>39</b>) and, for comparison, VX-770 on (A) F508del-CFTR FRT and (B) on G551D-CFTR FRT cells. The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance vs control (DMSO-treated): ***<i>p</i> < 0.001, **<i>p</i> < 0.01, and *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Potentiator <b>39</b> does not influence mutant F508del rescue by correctors VX-809 and <b>ARN23765</b>. The graphs report the (A) values of normalized QR measured in the YFP-based functional assay on CFBE41o-expressing F508del-CFTR treated for 24 h with VX-809 (1 μM) or <b>ARN23765</b> (10 nM) in the absence or presence of compound <b>39</b> (5 μM) and (B) equivalent short-circuit current (calculated from TEER/PD measurements) in F508del/F508del bronchial epithelial cells treated for 24 h with VX-809 (1 μM) or <b>ARN23765</b> (10 nM) in the absence or presence of compound <b>39</b> (0.5 μM). The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Tukey test (for multiple comparisons). Symbols indicate statistical significance: ***<i>p</i> < 0.001, n.s. (not significant) indicates <i>p</i> > 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Efficacy of potentiator <b>39</b> on primary bronchial epithelial cells from non-CF individuals. (A) Representative traces of short-circuit current measurements showing the response of CFTR to stimulation with the indicated concentrations of CPT-cAMP in the absence or presence of potentiators <b>39</b> or VX-770 (1 μM for both compounds). (B) Bar graph showing the currents stimulated by submaximal concentration of CPT-cAMP measured in experiments performed as in (A). The data are expressed as mean ± SD (<i>n</i> = 9; from three independent experiments, each one having three biological replicates). Statistical significance was tested by parametric ANOVA, followed by the Dunnett multiple comparisons test (all groups against the control group). Symbols indicate statistical significance: **<i>p</i> < 0.01 and *<i>p</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tetrahydro-γ-carboline Amide Analogues <b>1–11</b> and <b>13–31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) HCl (36%), 0 °C, then NaNO<sub>2</sub>, H<sub>2</sub>O, SnCl<sub>2</sub> in HCl (6 M), 0 °C to r.t., 24 h; (ii) protocol A: <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate, HCl (36%), EtOH, 80 °C, and 16 h; protocol B: <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate, EtOH, r.t., then 2,4,6-trichloro-1,3,5-triazine, 90 °C, 8 h; protocol C: <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate, EtOH, 30 min, r.t., then removal of the solvent and addition of BF<sub>3</sub>·Et<sub>2</sub>O, AcOH, 90 °C, 16 h; (iii) protocol A: carboxylic acid, HATU, DIPEA, DMF, 0 °C, 10–30 min, then <b>45a,h,j,p–r</b> r.t., 16 h, 22–95%; protocol B: carboxylic acid, <b>45a–h,k-m,o–s</b>, Et<sub>3</sub>N, EDC·HCl, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 16 h, 6–77%.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i><sup>5</sup>-Methyl-tetrahydro-γ-carboline Analogue <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) (BOC)<sub>2</sub>O, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to r.t., 1 h; (ii) NaH (60% dispersion in mineral oil), CH<sub>3</sub>I, DMF, 0 °C to r.t., 16 h; (iii) HCl (4.0 M) in dioxane, DCM, r.t., and 20 h; and (iv) 5-trifluoromethyl-1<i>H</i>-pyrazole-3-carboxylic acid, HATU, DIPEA, DMF, 10 min, then <b>48</b>, r.t., 16 h, and 24%.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 6-Fluoro-9-methyl-Substituted γ-Carbolines <b>32–37</b> and <b>39–42</b> with Modified Tetrahydro-pyridine Ring<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) Protocol A: <i>tert</i>-butyl 2-methyl-4-oxo-piperidine-1-carboxylate [<i>rac</i>-<b>49</b>, (<i>R</i>)-<b>50</b>, and (<i>S</i>)-<b>51</b>] or <i>tert</i>-butyl 2,2-dimethyl-4-oxo-piperidine-1-carboxylate (<b>56</b>), toluene, 50 °C, then TsOH, 120 °C, and 24 h; protocol B: <i>tert</i>-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (<b>58</b>), HCl (36%), EtOH, 80 °C, and 16 h; (ii) 5-methyl-1<i>H</i>-pyrazole-3-carboxylic acid, HATU, DIPEA, DMF, 0 °C, 10–30 min, then <b>52–55</b>, <b>57</b>, <b>59</b>, r.t., 16 h, and 5–47%; (iii) semipreparative chiral separation: ChiralPak AD, <i>n</i>-heptane–EtOH (75:25) [for <b>36</b>, <b>37</b>, <b>41</b>, and <b>42</b>: absolute configuration not determined and arbitrary drawn].</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/medium/jm0c01050_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 7-Fluoro-10-methyl-2,4,5,6-tetrahydro-1<i>H</i>-azepino[4,5-<i>b</i>]indol-3-yl Amide <b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c01050/20210219/images/large/jm0c01050_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01050&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and reaction conditions: (i) <i>tert</i>-butyl 4-oxo-azepane-1-carboxylate (<b>60</b>), HCl (36%), EtOH, 80 °C, and 16 h; (ii) 5-methyl-1<i>H</i>-pyrazole-3-carboxylic acid, HATU, DIPEA, dry DMF, 0 °C to r.t., 16 h, and 7%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i125">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerholz, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, M. J.</span></span> <span> </span><span class="NLM_article-title">Origins of Cystic Fibrosis Lung Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1056/nejmra1300109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1056%2FNEJMra1300109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25607428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=351-362&author=D.+A.+Stoltzauthor=D.+K.+Meyerholzauthor=M.+J.+Welsh&title=Origins+of+Cystic+Fibrosis+Lung+Disease&doi=10.1056%2Fnejmra1300109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Origins of cystic fibrosis lung disease</span></div><div class="casAuthors">Stoltz, David A.; Meyerholz, David K.; Welsh, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-362/1-351-362/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discussing about the new animal models that mirror to cystic fibrosis in humans for discovering the origins of the lung disease.  Loss of CFTR gene function will leads to reduced chloride secretion, sodium hyperabsorption and reduced pH of airway-surface liq. that impairs bacteria killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovF2zZPdvgxrVg90H21EOLACvtfcHk0lg4c_qV4qTNwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGqtLs%253D&md5=2bca233cffb6701decfed5a340432b01</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1300109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1300109%26sid%3Dliteratum%253Aachs%26aulast%3DStoltz%26aufirst%3DD.%2BA.%26aulast%3DMeyerholz%26aufirst%3DD.%2BK.%26aulast%3DWelsh%26aufirst%3DM.%2BJ.%26atitle%3DOrigins%2520of%2520Cystic%2520Fibrosis%2520Lung%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D351%26epage%3D362%26doi%3D10.1056%2Fnejmra1300109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castellani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assael, B. M.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis: A Clinical View</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2393-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2Fs00018-016-2393-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27709245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1eiurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=129-140&author=C.+Castellaniauthor=B.+M.+Assael&title=Cystic+Fibrosis%3A+A+Clinical+View&doi=10.1007%2Fs00018-016-2393-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis: a clinical view</span></div><div class="casAuthors">Castellani, Carlo; Assael, Baroukh M.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-140</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF), a monogenic disease caused by mutations in the CFTR gene on chromosome 7, is complex and greatly variable in clin. expression.  Airways, pancreas, male genital system, intestine, liver, bone, and kidney are involved.  The lack of CFTR or its impaired function causes fat malabsorption and chronic pulmonary infections leading to bronchiectasis and progressive lung damage.  Previously considered lethal in infancy and childhood, CF has now attained median survivals of 50 years of age, mainly thanks to the early diagnosis through neonatal screening, recognition of mild forms, and an aggressive therapeutic attitude.  Classical treatment includes pancreatic enzyme replacement, respiratory physiotherapy, mucolitics, and aggressive antibiotic therapy.  A significant proportion of patients with severe symptoms still requires lung or, less frequently, liver transplantation.  The great no. of mutations and their diverse effects on the CFTR protein account only partially for CF clin. variability, and modifier genes have a role in modulating the clin. expression of the disease.  Despite the increasing understanding of CFTR functioning, several aspects of CF need still to be clarified, e.g., the worse outcome in females, the risk of malignancies, the pathophysiol., and best treatment of comorbidities, such as CF-related diabetes or CF-related bone disorder.  Research is focusing on new drugs restoring CFTR function, some already available and with good clin. impact, others showing promising preliminary results that need to be confirmed in phase III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpLpaQ4nR-M7Vg90H21EOLACvtfcHk0lg4c_qV4qTNwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1eiurfO&md5=9743e56d25aefba23d45b672df278f35</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2393-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2393-9%26sid%3Dliteratum%253Aachs%26aulast%3DCastellani%26aufirst%3DC.%26aulast%3DAssael%26aufirst%3DB.%2BM.%26atitle%3DCystic%2520Fibrosis%253A%2520A%2520Clinical%2520View%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D129%26epage%3D140%26doi%3D10.1007%2Fs00018-016-2393-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, J. W.</span></span> <span> </span><span class="NLM_article-title">Physiology of Epithelial Chloride and Fluid Secretion</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">a009563</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a009563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1101%2Fcshperspect.a009563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=22675668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a009563&author=R.+A.+Frizzellauthor=J.+W.+Hanrahan&title=Physiology+of+Epithelial+Chloride+and+Fluid+Secretion&doi=10.1101%2Fcshperspect.a009563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Physiology of epithelial chloride and fluid secretion</span></div><div class="casAuthors">Frizzell, Raymond A.; Hanrahan, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">a009563/1-a009563/19</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Epithelial salt and water secretion serves a variety of functions in different organ systems, such as the airways, intestines, pancreas, and salivary glands.  In cystic fibrosis (CF), the vol. and/or compn. of secreted luminal fluids are compromised owing to mutations in the gene encoding CFTR, the apical membrane anion channel that is responsible for salt secretion in response to cAMP/PKA stimulation.  This article examines CFTR and related cellular transport processes that underlie epithelial anion and fluid secretion, their regulation, and how these processes are altered in CF disease to account for organ-specific secretory phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvsW9XvchFd7Vg90H21EOLACvtfcHk0lhXHxZ02X1OkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemurw%253D&md5=812a3f3732ffa5e043a8cba77b364ee6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a009563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a009563%26sid%3Dliteratum%253Aachs%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DHanrahan%26aufirst%3DJ.%2BW.%26atitle%3DPhysiology%2520of%2520Epithelial%2520Chloride%2520and%2520Fluid%2520Secretion%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26spage%3Da009563%26doi%3D10.1101%2Fcshperspect.a009563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Criq, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of CFTR in Epithelial Physiology</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2391-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2Fs00018-016-2391-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27714410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ehsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=93-115&author=V.+Saint-Criqauthor=M.+A.+Gray&title=Role+of+CFTR+in+Epithelial+Physiology&doi=10.1007%2Fs00018-016-2391-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CFTR in epithelial physiology</span></div><div class="casAuthors">Saint-Criq, Vinciane; Gray, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-115</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Salt and fluid absorption and secretion are two processes that are fundamental to epithelial function and whole body fluid homeostasis, and as such are tightly regulated in epithelial tissues.  The CFTR anion channel plays a major role in regulating both secretion and absorption in a diverse range of epithelial tissues, including the airways, the GI and reproductive tracts, sweat and salivary glands.  It is not surprising then that defects in CFTR function are linked to disease, including life-threatening secretory diarrhoeas, such as cholera, as well as the inherited disease, cystic fibrosis (CF), one of the most common life-limiting genetic diseases in Caucasian populations.  More recently, CFTR dysfunction has also been implicated in the pathogenesis of acute pancreatitis, chronic obstructive pulmonary disease (COPD), and the hyper-responsiveness in asthma, underscoring its fundamental role in whole body health and disease.  CFTR regulates many mechanisms in epithelial physiol., such as maintaining epithelial surface hydration and regulating luminal pH.  Indeed, recent studies have identified luminal pH as an important arbiter of epithelial barrier function and innate defense, particularly in the airways and GI tract.  In this chapter, we will illustrate the different operational roles of CFTR in epithelial function by describing its characteristics in three different tissues: the airways, the pancreas, and the sweat gland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBfwGPqFkjnLVg90H21EOLACvtfcHk0lhXHxZ02X1OkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ehsrvM&md5=0d99eb0787bd06c3a87f4d2b469e16ff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2391-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2391-y%26sid%3Dliteratum%253Aachs%26aulast%3DSaint-Criq%26aufirst%3DV.%26aulast%3DGray%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520CFTR%2520in%2520Epithelial%2520Physiology%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D93%26epage%3D115%26doi%3D10.1007%2Fs00018-016-2391-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><a href="https://cftr2.org/mutations_history" class="extLink">https://cftr2.org/mutations_history</a> (accessed Mar 18, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fcftr2.org%2Fmutations_history+%28accessed+Mar+18%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pranke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinzpeter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edelman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sermet-Gaudelus, I.</span></span> <span> </span><span class="NLM_article-title">Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">121</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2019.00121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30873022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlaktb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=121&author=I.+Prankeauthor=A.+Golecauthor=A.+Hinzpeterauthor=A.+Edelmanauthor=I.+Sermet-Gaudelus&title=Emerging+Therapeutic+Approaches+for+Cystic+Fibrosis.+From+Gene+Editing+to+Personalized+Medicine&doi=10.3389%2Ffphar.2019.00121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine</span></div><div class="casAuthors">Pranke, Iwona; Golec, Anita; Hinzpeter, Alexandre; Edelman, Aleksander; Sermet-Gaudelus, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">An improved understanding of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein structure and the consequences of CFTR gene mutations have allowed the development of novel therapies targeting specific defects underlying CF.  Some strategies are mutation specific and have already reached clin. development; some strategies include a read-through of the specific premature termination codons (read-through therapies, nonsense mediated decay pathway inhibitors for Class I mutations); correction of CFTR folding and trafficking to the apical plasma membrane (correctors for Class II mutations); and an increase in the function of CFTR channel (potentiators therapy for Class III mutations and any mutant with a residual function located at the membrane).  Other therapies that are in preclin. development are not mutation specific and include gene therapy to edit the genome and stem cell therapy to repair the airway tissue.  These strategies that are directed at the basic CF defects are now revolutionizing the treatment for patients and should pos. impact their survival rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowHTuM1yYFRrVg90H21EOLACvtfcHk0lhXHxZ02X1OkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlaktb7M&md5=aa52affc198bae86359ced65c9716ca4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00121%26sid%3Dliteratum%253Aachs%26aulast%3DPranke%26aufirst%3DI.%26aulast%3DGolec%26aufirst%3DA.%26aulast%3DHinzpeter%26aufirst%3DA.%26aulast%3DEdelman%26aufirst%3DA.%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26atitle%3DEmerging%2520Therapeutic%2520Approaches%2520for%2520Cystic%2520Fibrosis.%2520From%2520Gene%2520Editing%2520to%2520Personalized%2520Medicine%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D121%26doi%3D10.3389%2Ffphar.2019.00121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Boeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, M. D.</span></span> <span> </span><span class="NLM_article-title">Progress in Therapies for Cystic Fibrosis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/s2213-2600(16)00023-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2FS2213-2600%2816%2900023-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27053340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2ht7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=662-674&author=K.+De%0ABoeckauthor=M.+D.+Amaral&title=Progress+in+Therapies+for+Cystic+Fibrosis&doi=10.1016%2Fs2213-2600%2816%2900023-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in therapies for cystic fibrosis</span></div><div class="casAuthors">De Boeck, Kris; Amaral, Margarida D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">662-674</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Std. follow-up and symptomatic treatment have allowed most patients with cystic fibrosis to live to young adulthood.  However, many patients still die prematurely from respiratory insufficiency.  Hence, further investigations to improve these therapies are important and might have relevance for other diseases-eg, exploring how to increase airway hydration, how to safely downscale the increased inflammatory response in the lung, and how to better combat lung infections assocd. with cystic fibrosis.  In parallel, development of modulators that target the underlying dysfunction in the cystic fibrosis transmembrane conductance regulator (CFTR) is fast moving forward.  Existing treatments are specific to certain mutations, or mutation class, in CFTR.  An effective, although not yet entirely corrective, treatment is available for patients with class III mutations, and a treatment with modest effectiveness is available for patients who are homozygous for Phe508del, albeit at a very high cost.  Corrective treatments that are non-specific to mutation class and thus applicable to all patients-eg, gene therapy, cell-based therapies, and activation of alternative ion channels that bypass CFTR-are being explored, but they are still in early stages of development.  In view of the large no. of patients with very rare mutations, a plan to advance personalised biomarkers to predict treatment effect is also being investigated and validated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooQ4wbeuHKo7Vg90H21EOLACvtfcHk0lhXHxZ02X1OkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2ht7w%253D&md5=e33405c2e6166a27b4df430706562670</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2900023-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252900023-0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBoeck%26aufirst%3DK.%26aulast%3DAmaral%26aufirst%3DM.%2BD.%26atitle%3DProgress%2520in%2520Therapies%2520for%2520Cystic%2520Fibrosis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D662%26epage%3D674%26doi%3D10.1016%2Fs2213-2600%2816%2900023-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramescu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houck, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guggino, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skach, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutting, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorscher, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span> <span> </span><span class="NLM_article-title">From CFTR Biology toward Combinatorial Pharmacotherapy: Expanded Classification of Cystic Fibrosis Mutations</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1091/mbc.e14-04-0935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1091%2Fmbc.e14-04-0935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=26823392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=424-433&author=G.+Veitauthor=R.+G.+Avramescuauthor=A.+N.+Chiangauthor=S.+A.+Houckauthor=Z.+Caiauthor=K.+W.+Petersauthor=J.+S.+Hongauthor=H.+B.+Pollardauthor=W.+B.+Gugginoauthor=W.+E.+Balchauthor=W.+R.+Skachauthor=G.+R.+Cuttingauthor=R.+A.+Frizzellauthor=D.+N.+Sheppardauthor=D.+M.+Cyrauthor=E.+J.+Sorscherauthor=J.+L.+Brodskyauthor=G.+L.+Lukacs&title=From+CFTR+Biology+toward+Combinatorial+Pharmacotherapy%3A+Expanded+Classification+of+Cystic+Fibrosis+Mutations&doi=10.1091%2Fmbc.e14-04-0935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</span></div><div class="casAuthors">Veit, Gudio; Avramescu, Radu G.; Chiang, Annette N.; Houck, Scott A.; Cai, Zhiwei; Peters, Kathryn W.; Hong, Jeong S.; Pollard, Harvey B.; Guggino, William B.; Balch, William E.; Skach, William R.; Cutting, Garry R.; Frizzell, Raymond A.; Sheppard, David N.; Cyr, Douglas M.; Sorscher, Eric J.; Brodsky, Jeffrey L.; Lukacs, Gergely L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">424-433</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of mol. cell biol. and functional phenotypes.  Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity.  Based on the mol. phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biol.  This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clin. benefit over available low-efficacy monotherapies.  Indeed, recent phase 3 clin. trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del).  This drug combination was recently approved by the U.S.  Food and Drug Administration for patients homozygous for ΔF508.  Emerging studies of the structural, cell biol., and functional defects caused by rare mutations provide a new framework that reveals a mixt. of deficiencies in different CFTR alleles.  Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq66J1miev7J7Vg90H21EOLACvtfcHk0lgcdYj6mluLdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N&md5=d8e30db897e38fc9e7f15f883d0050d6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e14-04-0935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e14-04-0935%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DChiang%26aufirst%3DA.%2BN.%26aulast%3DHouck%26aufirst%3DS.%2BA.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DPeters%26aufirst%3DK.%2BW.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26aulast%3DPollard%26aufirst%3DH.%2BB.%26aulast%3DGuggino%26aufirst%3DW.%2BB.%26aulast%3DBalch%26aufirst%3DW.%2BE.%26aulast%3DSkach%26aufirst%3DW.%2BR.%26aulast%3DCutting%26aufirst%3DG.%2BR.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DSheppard%26aufirst%3DD.%2BN.%26aulast%3DCyr%26aufirst%3DD.%2BM.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBrodsky%26aufirst%3DJ.%2BL.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DFrom%2520CFTR%2520Biology%2520toward%2520Combinatorial%2520Pharmacotherapy%253A%2520Expanded%2520Classification%2520of%2520Cystic%2520Fibrosis%2520Mutations%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2016%26volume%3D27%26spage%3D424%26epage%3D433%26doi%3D10.1091%2Fmbc.e14-04-0935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bobadilla, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macek, M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, P. M.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis: A Worldwide Analysis of CFTR Mutations-Correlation with Incidence Data and Application to Screening</span>. <i>Hum. Mutat.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1002/humu.10041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1002%2Fhumu.10041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12007216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVGktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=575-606&author=J.+L.+Bobadillaauthor=M.+Macekauthor=J.+P.+Fineauthor=P.+M.+Farrell&title=Cystic+Fibrosis%3A+A+Worldwide+Analysis+of+CFTR+Mutations-Correlation+with+Incidence+Data+and+Application+to+Screening&doi=10.1002%2Fhumu.10041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening</span></div><div class="casAuthors">Bobadilla, Joseph L.; Macek, Milan, Jr.; Fine, Jason P.; Farrell, Philip M.</div><div class="citationInfo"><span class="NLM_cas:title">Human Mutation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-606</span>CODEN:
                <span class="NLM_cas:coden">HUMUE3</span>;
        ISSN:<span class="NLM_cas:issn">1059-7794</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review with refs.  Although there have been numerous reports from around the world of mutations in the gene of chromosome 7 known as CFTR (cystic fibrosis transmembrane conductance regulator), little attention has been given to integrating these mutant alleles into a global understanding of the population mol. genetics assocd. with cystic fibrosis (CF).  We detd. the distribution of CFTR mutations in as many regions throughout the world as possible in an effort designed to: (1) increase our understanding of ancestry-genotype relationships, (2) compare mutational arrays with disease incidence, and (3) gain insight for decisions regarding screening program enhancement through CFTR multi-mutational analyses.  Information on all mutations that have been published since the identification and cloning of the CFTR gene's most common allele, ΔF508 (or F508del), was reviewed and integrated into a centralized database.  The data were then sorted and regional CFTR arrays were detd. using mutations that appeared in a given region with a frequency of 0.5% or greater.  Final analyses were based on 72,431 CF chromosomes, using data compiled from over 100 original papers, and over 80 regions from around the world, including all nations where CF has been studied using anal. mol. genetics.  Initial results confirmed wide mutational heterogeneity throughout the world; however, characterization of the most common mutations across most populations was possible.  We also examd. CF incidence, ΔF508 frequency, and regional mutational heterogeneity in a subset of populations.  Data for these analyses were filtered for reliability and methodol. strength before being incorporated into the final anal.  Statistical assessment of these variables revealed that there is a significant pos. correlation between ΔF508 frequency and the CF incidence levels of regional populations.  Regional analyses were also performed to search for trends in the distribution of CFTR mutations across migrant and related populations; this led to clarification of ancestry-genotype patterns that can be used to design CFTR multi-mutation panels for CF screening programs.  From comprehensive assessment of these data, we offer recommendations that multiple CFTR alleles should eventually be included to increase the sensitivity of newborn screening programs employing two-tier testing with trypsinogen and DNA anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewtcZ-Xuh27Vg90H21EOLACvtfcHk0lgcdYj6mluLdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVGktr0%253D&md5=56613b894dce26c9bb1840146464d95c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fhumu.10041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhumu.10041%26sid%3Dliteratum%253Aachs%26aulast%3DBobadilla%26aufirst%3DJ.%2BL.%26aulast%3DMacek%26aufirst%3DM.%26aulast%3DFine%26aufirst%3DJ.%2BP.%26aulast%3DFarrell%26aufirst%3DP.%2BM.%26atitle%3DCystic%2520Fibrosis%253A%2520A%2520Worldwide%2520Analysis%2520of%2520CFTR%2520Mutations-Correlation%2520with%2520Incidence%2520Data%2520and%2520Application%2520to%2520Screening%26jtitle%3DHum.%2520Mutat.%26date%3D2002%26volume%3D19%26spage%3D575%26epage%3D606%26doi%3D10.1002%2Fhumu.10041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. E.</span></span> <span> </span><span class="NLM_article-title">Defective Intracellular Transport and Processing of CFTR Is the Molecular Basis of Most Cystic Fibrosis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(90)90148-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2F0092-8674%2890%2990148-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1699669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3MXnvFKguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1990&pages=827-834&author=S.+H.+Chengauthor=R.+J.+Gregoryauthor=J.+Marshallauthor=S.+Paulauthor=D.+W.+Souzaauthor=G.+A.+Whiteauthor=C.+R.+O%E2%80%99Riordanauthor=A.+E.+Smith&title=Defective+Intracellular+Transport+and+Processing+of+CFTR+Is+the+Molecular+Basis+of+Most+Cystic+Fibrosis&doi=10.1016%2F0092-8674%2890%2990148-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis</span></div><div class="casAuthors">Cheng, Seng H.; Gregory, Richard J.; Marshall, John; Paul, Sucharita; Souza, David W.; White, Gary A.; O'Riordan, Catherine R.; Smith, Alan E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-34</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The gene assocd. with cystic fibrosis (VF) encodes a membrane-assocd., N-linked glycoprotein called CFTR.  Mutations were introduced into CFTR at residues known to be altered in CF chromosomes and in residues believed to play a role in its function.  Examn. of the various mutant proteins in COS-7 cells indicated that mature, fully glycosylated CFTR was absent from cells contg. ΔF508, ΔI507, K464M, F508R, and S549I cDNA plasmids.  Instead, an incompletely glycosylated version of the protein was detected.  The authors propose that the mutant versions of CFTR are recognized as abnormal and remain incompletely processed in the endoplasmic reticulum where they are subsequently degraded.  Since mutations with this phenotype represent at least 70% of known CF chromosomes, the authors argue that the mol. basis of most cystic fibrosis is the absence of mature CFTR at the correct cellular location.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDj-TBTgjbB7Vg90H21EOLACvtfcHk0lgcdYj6mluLdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXnvFKguw%253D%253D&md5=cb0ccaa858a164a7897715df83e9f040</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990148-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990148-8%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DS.%2BH.%26aulast%3DGregory%26aufirst%3DR.%2BJ.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DSouza%26aufirst%3DD.%2BW.%26aulast%3DWhite%26aufirst%3DG.%2BA.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DC.%2BR.%26aulast%3DSmith%26aufirst%3DA.%2BE.%26atitle%3DDefective%2520Intracellular%2520Transport%2520and%2520Processing%2520of%2520CFTR%2520Is%2520the%2520Molecular%2520Basis%2520of%2520Most%2520Cystic%2520Fibrosis%26jtitle%3DCell%26date%3D1990%26volume%3D63%26spage%3D827%26epage%3D834%26doi%3D10.1016%2F0092-8674%2890%2990148-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denning, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, M. J.</span></span> <span> </span><span class="NLM_article-title">Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator Is Temperature-Sensitive</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1038/358761a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1038%2F358761a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1380673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK38Xls1yrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=1992&pages=761-764&author=G.+M.+Denningauthor=M.+P.+Andersonauthor=J.+F.+Amaraauthor=J.+Marshallauthor=A.+E.+Smithauthor=M.+J.+Welsh&title=Processing+of+Mutant+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Is+Temperature-Sensitive&doi=10.1038%2F358761a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive</span></div><div class="casAuthors">Denning, Gerene M.; Anderson, Matthew P.; Amara, Jane F.; Marshall, John; Smith, Alan E.; Welsh, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6389</span>),
    <span class="NLM_cas:pages">761-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Cystic fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cAMP-dependent phosphorylation and by intracellular ATP.  Mutations in CFTR cause cystic fibrosis partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia.  The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTRΔF508). Studies on the biosynthesis and localization of CFTRΔF508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane.  These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTRΔF508. Chloride channel activity was detected, however, when CFTRΔF508 was expressed in Xenopus oocytes, Vero cells and Sf9 insect cells.  Because oocytes and Sf9 cells are typically maintained at lower temps. than mammalian cells, and because processing of nascent proteins can be sensitive to temp., the authors tested the effect of temp. on the processing of CFTRΔF508.  Here the authors show that the processing of CFTRΔF508 reverts towards that of wild-type as the incubation temp. is reduced.  When the processing defect is cor., cAMP-regulated Cl- channels appear in the plasma membrane.  These results reconcile previous contradictory observations and suggest that the mutant most commonly assocd. with cystic fibrosis is temp.-sensitive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMX1YIn_dUwbVg90H21EOLACvtfcHk0lgGALUFSB6RhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1yrur8%253D&md5=de4f38aa61b6e10173aad5223db47156</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F358761a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F358761a0%26sid%3Dliteratum%253Aachs%26aulast%3DDenning%26aufirst%3DG.%2BM.%26aulast%3DAnderson%26aufirst%3DM.%2BP.%26aulast%3DAmara%26aufirst%3DJ.%2BF.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DA.%2BE.%26aulast%3DWelsh%26aufirst%3DM.%2BJ.%26atitle%3DProcessing%2520of%2520Mutant%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Is%2520Temperature-Sensitive%26jtitle%3DNature%26date%3D1992%26volume%3D358%26spage%3D761%26epage%3D764%26doi%3D10.1038%2F358761a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okiyoneda, T.</span></span> <span> </span><span class="NLM_article-title">Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1100</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2018.01100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30319426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1100&author=R.+Fukudaauthor=T.+Okiyoneda&title=Peripheral+Protein+Quality+Control+as+a+Novel+Drug+Target+for+CFTR+Stabilizer&doi=10.3389%2Ffphar.2018.01100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral protein quality control as a novel drug target for CFTR stabilizer</span></div><div class="casAuthors">Fukuda, Ryosuke; Okiyoneda, Tsukasa</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1100</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Conformationally defective cystic fibrosis transmembrane conductance regulator (CFTR) including rescued ΔF508-CFTR is rapidly eliminated from the plasma membrane (PM) even in the presence of a CFTR corrector and potentiator, limiting the therapeutic effort of the combination therapy.  CFTR elimination from the PM is detd. by the conformation-dependent ubiquitination as a part of the peripheral quality control (PQC) mechanism.  Recently, the mol. machineries responsible for the CFTR PQC mechanism which includes mol. chaperones and ubiquitination enzymes have been revealed.  This review summarizes the mol. mechanism of the CFTR PQC and discusses the possibility that the peripheral ubiquitination mechanism becomes a novel drug target to develop the CFTR stabilizer as a novel class of CFTR modulator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7TVcV28xoO7Vg90H21EOLACvtfcHk0lgGALUFSB6RhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWjur4%253D&md5=f104f00a5e667ceafbda883a003b0069</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01100%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DR.%26aulast%3DOkiyoneda%26aufirst%3DT.%26atitle%3DPeripheral%2520Protein%2520Quality%2520Control%2520as%2520a%2520Novel%2520Drug%2520Target%2520for%2520CFTR%2520Stabilizer%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1100%26doi%3D10.3389%2Ffphar.2018.01100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riordan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinstein, S.</span></span> <span> </span><span class="NLM_article-title">The Delta F508 Mutation Decreases the Stability of Cystic Fibrosis Transmembrane Conductance Regulator in the Plasma Membrane. Determination of Functional Half-Lives on Transfected Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">21592</span>– <span class="NLM_lpage">21598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2FS0021-9258%2820%2980582-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=7691813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFOls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=21592-21598&author=G.+L.+Lukacsauthor=X.+B.+Changauthor=C.+Bearauthor=N.+Kartnerauthor=A.+Mohamedauthor=J.+R.+Riordanauthor=S.+Grinstein&title=The+Delta+F508+Mutation+Decreases+the+Stability+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+in+the+Plasma+Membrane.+Determination+of+Functional+Half-Lives+on+Transfected+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells</span></div><div class="casAuthors">Lukacs, Gergely L.; Chang, Xiu Bao; Bear, Christine; Kartner, Norbert; Mohamed, Abdalla; Riordan, John R.; Grinstein, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">21592-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Deletion of the phenylalanine at position 508 of the cystic fibrosis transmembrane conductance regulator (CFTR) is the most prevalent mutation in cystic fibrosis (CF).  This mutation (ΔF508CFTR) leads to a reduced cAMP-sensitive Cl- conductance in epithelial cells.  While the mutant protein can function as a Cl- channel, it seems to be misprocessed and unable to accumulate at normal levels in the plasma membrane.  Under conditions where the biosynthetic block of ΔF508CFTR is not complete, the residence time of ΔF508CFTR in the plasma membrane is a crit. determinant of the cAMP-sensitive Cl- conductance.  To assess the stability of the mutant and wild-type CFTR, the authors compared their functional half-lives at the plasma membrane of transfected Chinese hamster ovary cells.  The plasma membrane Cl- conductance was assessed by patch-clamp recordings and/or by fluorimetric detns. of the membrane potential.  Accumulation of ΔF508CFTR in the plasma membrane was promoted by growing the transfected cells at reduced temp. (24-28°), and was verified by immunoblotting and by detecting the appearance of a plasmalemmal cAMP-activated Cl- conductance.  Subsequently increasing the temp. to 37° inhibited further delivery of newly synthesized ΔF508CFTR to the surface membrane.  By studying the time dependence of the disappearance of the Cl- conductance, the functional half-life of the mutant protein at the plasma membrane was detd. to be <4 h, which is considerably shorter than the half-life of wild-type CFTR (>24 h).  The latter was estd. by terminating protein synthesis or secretion with cycloheximide or brefeldin A, resp.  Inhibition of protein synthesis did not alter the rate of disappearance of ΔF508CFTR at 37°, validating the difference in turnover between mutant and wild-type CFTR.  These results indicate that the structural abnormality of ΔF508CFTR affects not only the delivery of the protein to the plasma membrane, but also its stability therein.  Moreover, they suggest that overcoming the processing block at the endoplasmic reticulum may not suffice to restore normal Cl- conductance in CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6e6tsFZ_g7bVg90H21EOLACvtfcHk0lgGALUFSB6RhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFOls7o%253D&md5=4406d9ad4ecc91a49a684c2b484ff562</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2820%2980582-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252820%252980582-1%26sid%3Dliteratum%253Aachs%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26aulast%3DChang%26aufirst%3DX.%2BB.%26aulast%3DBear%26aufirst%3DC.%26aulast%3DKartner%26aufirst%3DN.%26aulast%3DMohamed%26aufirst%3DA.%26aulast%3DRiordan%26aufirst%3DJ.%2BR.%26aulast%3DGrinstein%26aufirst%3DS.%26atitle%3DThe%2520Delta%2520F508%2520Mutation%2520Decreases%2520the%2520Stability%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520in%2520the%2520Plasma%2520Membrane.%2520Determination%2520of%2520Functional%2520Half-Lives%2520on%2520Transfected%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D21592%26epage%3D21598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalemans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champigny, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavirani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecocq, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdunski, M.</span></span> <span> </span><span class="NLM_article-title">Altered Chloride Ion Channel Kinetics Associated with the Delta F508 Cystic Fibrosis Mutation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1038/354526a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1038%2F354526a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1722027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK38Xls1OnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=1991&pages=526-528&author=W.+Dalemansauthor=P.+Barbryauthor=G.+Champignyauthor=S.+Jallatauthor=S.+Jallatauthor=K.+Dottauthor=D.+Dreyerauthor=R.+G.+Crystalauthor=A.+Paviraniauthor=J.-P.+Lecocqauthor=M.+Lazdunski&title=Altered+Chloride+Ion+Channel+Kinetics+Associated+with+the+Delta+F508+Cystic+Fibrosis+Mutation&doi=10.1038%2F354526a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Altered chloride ion channel kinetics associated with ΔF508 cystic fibrosis mutation</span></div><div class="casAuthors">Dalemans, Wilfried; Barbry, Pascal; Champigny, Guy; Jallat, Sophie; Dott, Karin; Dreyer, Dominique; Crystal, Ronald G.; Pavirani, Andrea; Lecocq, Jean Pierre; Lazdunski, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6354</span>),
    <span class="NLM_cas:pages">526-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Cystic fibrosis is assocd. with a defect in epithelial chloride ion transport which is caused by mutations in a membrane protein called CFTR (cystic fibrosis transmembrane conductance regulator).  Heterologous expression of CFTR produces cAMP-sensitive Cl--channel activity.  Deletion of phenylalanine at amino acid position 508 in CFTR (ΔF508 CFTR) is the most common mutation in cystic fibrosis.  It has been proposed that this mutation prevents glycoprotein maturation and its transport to its normal cellular location.  The present study expressed both CFTR and ΔF508 CFTR in Vero cells using recombinant vaccinia virus.  Although far less ΔF508 CFTR reached the plasma membrane then normal CFTR, sufficient ΔF508 CFTR was expressed at the plasma membrane to permit functional anal.  ΔF508 CFTR expression induced a reduced activity of the cAMP-activated Cl- channel, with conductance, anion selectivity and open-time kinetics similar to those of CFTR, but with much greater closed times, resulting in a large decrease of open probability.  The ΔF508 mutation thus seems to have two major consequences, an abnormal translocation of the CFTR protein which limits membrane insertion, and an abnormal function in mediating Cl- transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyoig2cumxULVg90H21EOLACvtfcHk0lh07F8w6ix_Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1OnsQ%253D%253D&md5=620a06b7bf34b0e762064914dcca0b60</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F354526a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F354526a0%26sid%3Dliteratum%253Aachs%26aulast%3DDalemans%26aufirst%3DW.%26aulast%3DBarbry%26aufirst%3DP.%26aulast%3DChampigny%26aufirst%3DG.%26aulast%3DJallat%26aufirst%3DS.%26aulast%3DJallat%26aufirst%3DS.%26aulast%3DDott%26aufirst%3DK.%26aulast%3DDreyer%26aufirst%3DD.%26aulast%3DCrystal%26aufirst%3DR.%2BG.%26aulast%3DPavirani%26aufirst%3DA.%26aulast%3DLecocq%26aufirst%3DJ.-P.%26aulast%3DLazdunski%26aufirst%3DM.%26atitle%3DAltered%2520Chloride%2520Ion%2520Channel%2520Kinetics%2520Associated%2520with%2520the%2520Delta%2520F508%2520Cystic%2520Fibrosis%2520Mutation%26jtitle%3DNature%26date%3D1991%26volume%3D354%26spage%3D526%26epage%3D528%26doi%3D10.1038%2F354526a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bompadre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T.-C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of G551D-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Potentiation by a High Affinity ATP Analog</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">5364</span>– <span class="NLM_lpage">5369</span>, <span class="refDoi"> DOI: 10.1074/jbc.m709417200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1074%2Fjbc.M709417200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=18167357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1Omsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=5364-5369&author=S.+G.+Bompadreauthor=M.+Liauthor=T.-C.+Hwang&title=Mechanism+of+G551D-CFTR+%28Cystic+Fibrosis+Transmembrane+Conductance+Regulator%29+Potentiation+by+a+High+Affinity+ATP+Analog&doi=10.1074%2Fjbc.m709417200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of G551D-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Potentiation by a High Affinity ATP Analog</span></div><div class="casAuthors">Bompadre, Silvia G.; Li, Min; Hwang, Tzyh-Chang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5364-5369</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel gated by ATP binding and hydrolysis at its nucleotide binding domains (NBD).  The NBDs dimerize in a head-to-tail configuration, forming two ATP binding pockets (ABP) with the ATP mols. buried at the dimer interface.  Previous studies have indicated that ABP2, formed by the Walker A and B motifs of NBD2 and the signature sequence of NBD1, is the site crit. for the ATP-dependent opening of CFTR.  The G551D mutation in ABP2, the third most common cystic fibrosis-assocd. mutation, abolishes ATP-dependent gating, resulting in an open probability that is ∼100-fold lower than that of wild-type channels.  Interestingly, we found that the ATP analog N6-(2-phenylethyl)-ATP (P-ATP) increases G551D currents mainly by increasing the open time of the channel.  This effect is reduced when P-ATP is applied together with ATP, suggesting a competition between ATP and P-ATP for a common binding site.  Introducing mutations that lower the nucleotide binding affinity at ABP2 did not alter significantly the effects of P-ATP on G551D-CFTR, whereas an equiv. mutation at ABP1 (consisting of the Walker A and B motifs of NBD1 and the signature sequence of NBD2) dramatically decreased the potency of P-ATP, indicating that ABP1 is the site where P-ATP binds to increase the activity of G551D-CFTR.  These results substantiate the idea that nucleotide binding at ABP1 stabilizes the open channel conformation.  Our observation that P-ATP enhances the G551D activity by binding at ABP1 implicates that ABP1 can potentially be a target for drugs to bind and increase the channel activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlLz-J9RaKbLVg90H21EOLACvtfcHk0lh07F8w6ix_Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1Omsb0%253D&md5=51d93593ea61679db976c9040eb21748</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M709417200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M709417200%26sid%3Dliteratum%253Aachs%26aulast%3DBompadre%26aufirst%3DS.%2BG.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHwang%26aufirst%3DT.-C.%26atitle%3DMechanism%2520of%2520G551D-CFTR%2520%2528Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2529%2520Potentiation%2520by%2520a%2520High%2520Affinity%2520ATP%2520Analog%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D5364%26epage%3D5369%26doi%3D10.1074%2Fjbc.m709417200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Approaches to CFTR Dysfunction: From Discovery to Drug Development</span>. <i>J. Cystic Fibrosis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">S14</span>– <span class="NLM_lpage">S21</span>, <span class="refDoi"> DOI: 10.1016/j.jcf.2017.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.jcf.2017.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=28916430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=S14-S21&author=H.+Liauthor=E.+Pesceauthor=D.+N.+Sheppardauthor=A.+K.+Singhauthor=N.+Pedemonte&title=Therapeutic+Approaches+to+CFTR+Dysfunction%3A+From+Discovery+to+Drug+Development&doi=10.1016%2Fj.jcf.2017.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic approaches to CFTR dysfunction: From discovery to drug development</span></div><div class="casAuthors">Li, Hongyu; Pesce, Emanuela; Sheppard, David N.; Singh, Ashvani K.; Pedemonte, Nicoletta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2_Suppl.</span>),
    <span class="NLM_cas:pages">S14-S21</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) mutations have complex effects on the cystic fibrosis transmembrane conductance regulator (CFTR) protein.  They disrupt its processing to and stability at the plasma membrane and function as an ATP-gated Cl- channel.  Here, we review therapeutic strategies to overcome defective CFTR processing and stability.  Because CF mutations have multiple impacts on the assembly of CFTR protein, combination therapy with several pharmacol. chaperones is likely to be required to rescue mutant CFTR expression at the plasma membrane.  Alternatively, proteostasis regulators, proteins which regulate the synthesis, intracellular transport and membrane stability of CFTR might be targeted to enhance the plasma membrane expression of mutant CFTR.  Finally, we consider an innovative approach to bypass CFTR dysfunction in CF, the delivery of artificial anion transporters to CF epithelia to shuttle Cl- across the apical membrane.  The identification of therapies or combinations of therapies, which rescue all CF mutations, is now a priority.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2SZYcOKiVZ7Vg90H21EOLACvtfcHk0lh07F8w6ix_Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSmsb3M&md5=af3c0c02bd7a0ee583544672a15fae6c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2017.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2017.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DPesce%26aufirst%3DE.%26aulast%3DSheppard%26aufirst%3DD.%2BN.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DPedemonte%26aufirst%3DN.%26atitle%3DTherapeutic%2520Approaches%2520to%2520CFTR%2520Dysfunction%253A%2520From%2520Discovery%2520to%2520Drug%2520Development%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2018%26volume%3D17%26spage%3DS14%26epage%3DS21%26doi%3D10.1016%2Fj.jcf.2017.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Goor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCartney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wine, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashlock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negulescu, P. A.</span></span> <span> </span><span class="NLM_article-title">Correction of the F508del-CFTR Protein Processing Defect in Vitro by the Investigational Drug VX-809</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">18843</span>– <span class="NLM_lpage">18848</span>, <span class="refDoi"> DOI: 10.1073/pnas.1105787108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1073%2Fpnas.1105787108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=21976485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1WnsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18843-18848&author=F.+Van%0AGoorauthor=S.+Hadidaauthor=P.+D.+J.+Grootenhuisauthor=B.+Burtonauthor=J.+H.+Stackauthor=K.+S.+Straleyauthor=C.+J.+Deckerauthor=M.+Millerauthor=J.+McCartneyauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+A.+Negulescu&title=Correction+of+the+F508del-CFTR+Protein+Processing+Defect+in+Vitro+by+the+Investigational+Drug+VX-809&doi=10.1073%2Fpnas.1105787108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809</span></div><div class="casAuthors">Van Goor, Fredrick; Hadida, Sabine; Grootenhuis, Peter D. J.; Burton, Bill; Stack, Jeffrey H.; Straley, Kimberly S.; Decker, Caroline J.; Miller, Mark; McCartney, Jason; Olson, Eric R.; Wine, Jeffrey J.; Frizzell, Ray A.; Ashlock, Melissa; Negulescu, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">18843-18848, S18843/1-S18843/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs.  Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amts. of CFTR at the cell surface.  One strategy to treat these patients is to correct the processing of F508del-CFTR with small mols.  Here we describe the in vitro pharmacol. of VX-809, a CFTR corrector that was advanced into clin. development for the treatment of CF.  In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approx. 14% of non-CF human bronchial epithelial cells (EC50, 81 ± 19 nM), a level assocd. with mild CF in patients with less disruptive CFTR mutations.  F508del-CFTR cor. by VX-809 exhibited biochem. and functional characteristics similar to normal CFTR, including biochem. susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability.  VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors.  VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeOa93zl2aYLVg90H21EOLACvtfcHk0ljlWSUaqLwbuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1WnsL%252FO&md5=26ad0866327fd2f645bcc68e91c87354</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1105787108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1105787108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DStraley%26aufirst%3DK.%2BS.%26aulast%3DDecker%26aufirst%3DC.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%2BA.%26atitle%3DCorrection%2520of%2520the%2520F508del-CFTR%2520Protein%2520Processing%2520Defect%2520in%2520Vitro%2520by%2520the%2520Investigational%2520Drug%2520VX-809%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D18843%26epage%3D18848%26doi%3D10.1073%2Fpnas.1105787108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor for the Treatment of Cystic Fibrosis</span>. <i>Expert Rev. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1080/17476348.2018.1507741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1080%2F17476348.2018.1507741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30073878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2isbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=725-732&author=M.+A.+Salaauthor=M.+Jain&title=Tezacaftor+for+the+Treatment+of+Cystic+Fibrosis&doi=10.1080%2F17476348.2018.1507741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor for the treatment of cystic fibrosis</span></div><div class="casAuthors">Sala, Marc A.; Jain, Manu</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">725-732</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Cystic fibrosis (CF) is the most common, life-limiting autosomal recessive disease in Caucasians, and is caused by defects in prodn. of the CFTR ion channel.  Until recently, there were no available treatments targeting the disease-causing defects in CFTR but newly developed CFTR modulators are changing the course of disease in CF.  The newest modulator, tezacaftor, is a CFTR corrector that was recently approved by the FDA to be used in combination with the first approved CFTR potentiator, ivacaftor.  A detailed review of the clin. trials and published literature, focusing on safety and efficacy, leading to the approval of tezacaftor in CF.: Recent trials have demonstrated that the combination of tezacaftor-ivacaftor is a slightly superior combination to its predecessor, lumacaftor-ivacaftor, with respect to an increase in FEV1, adverse event profile, and drug-drug interactions.  It is also approved for a large no. of non-F508del, residual function mutations that are predicted to respond based on in vitro testing.  The horizon for continued improvements in CFTR-targeted treatments is promising, with three-drug combinations currently in Phase 3 clin. trials, and other drugs with novel mechanisms of action being studied.  Within the next 5 years, the vast majority of patients with CF are expected to have a modulator approved for their genotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotXmy8PebTLrVg90H21EOLACvtfcHk0ljlWSUaqLwbuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2isbvE&md5=d1f61fc51ab8fef966df314c78bf101f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F17476348.2018.1507741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17476348.2018.1507741%26sid%3Dliteratum%253Aachs%26aulast%3DSala%26aufirst%3DM.%2BA.%26aulast%3DJain%26aufirst%3DM.%26atitle%3DTezacaftor%2520for%2520the%2520Treatment%2520of%2520Cystic%2520Fibrosis%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2018%26volume%3D12%26spage%3D725%26epage%3D732%26doi%3D10.1080%2F17476348.2018.1507741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Goor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grootenhuis, P. D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlewood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCartney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wine, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frizzell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashlock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negulescu, P.</span></span> <span> </span><span class="NLM_article-title">Rescue of CF Airway Epithelial Cell Function in Vitro by a CFTR Potentiator, VX-770</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">18825</span>– <span class="NLM_lpage">18830</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904709106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1073%2Fpnas.0904709106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=19846789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18825-18830&author=F.+Van%0AGoorauthor=S.+Hadidaauthor=P.+D.+J.+Grootenhuisauthor=B.+Burtonauthor=D.+Caoauthor=T.+Neubergerauthor=A.+Turnbullauthor=A.+Singhauthor=J.+Joubranauthor=A.+Hazlewoodauthor=J.+Zhouauthor=J.+McCartneyauthor=V.+Arumugamauthor=C.+Deckerauthor=J.+Yangauthor=C.+Youngauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+Negulescu&title=Rescue+of+CF+Airway+Epithelial+Cell+Function+in+Vitro+by+a+CFTR+Potentiator%2C+VX-770&doi=10.1073%2Fpnas.0904709106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</span></div><div class="casAuthors">Van Goor, Fredrick; Hadida, Sabine; Grootenhuis, Peter D. J.; Burton, Bill; Cao, Dong; Neuberger, Tim; Turnbull, Amanda; Singh, Ashvani; Joubran, John; Hazlewood, Anna; Zhou, Jinglan; McCartney, Jason; Arumugam, Vijayalaksmi; Decker, Caroline; Yang, Jennifer; Young, Chris; Olson, Eric R.; Wine, Jeffrey J.; Frizzell, Raymond A.; Ashlock, Melissa; Negulescu, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">18825-18830, S18825/1-S18825/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung.  Most CF mutations either reduce the no. of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both.  There are currently no approved therapies that target CFTR.  Here we describe the in vitro pharmacol. of VX-770, an orally bioavailable CFTR potentiator in clin. development for the treatment of CF.  In recombinant cells VX-770 increased CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation.  VX-770 also increased Cl- secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈ 10-fold, to ≈ 50% of that obsd. in HBE isolated from individuals without CF.  Furthermore, VX-770 reduced excessive Na+ and fluid absorption to prevent dehydration of the apical surface and increased cilia, beating in these epithelial cultures.  These results support the hypothesis that pharmacol. agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo89BTNOARZ5bVg90H21EOLACvtfcHk0lgi9Qvkj85iVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI&md5=786c6c860d90115c29863a706f0e1248</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904709106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904709106%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%2BJ.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DNeuberger%26aufirst%3DT.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DJoubran%26aufirst%3DJ.%26aulast%3DHazlewood%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DArumugam%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%26atitle%3DRescue%2520of%2520CF%2520Airway%2520Epithelial%2520Cell%2520Function%2520in%2520Vitro%2520by%2520a%2520CFTR%2520Potentiator%252C%2520VX-770%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D18825%26epage%3D18830%26doi%3D10.1073%2Fpnas.0904709106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrivel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">High-Affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughput Screening</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">37235</span>– <span class="NLM_lpage">37241</span>, <span class="refDoi"> DOI: 10.1074/jbc.m205932200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1074%2Fjbc.M205932200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12161441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVaquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=37235-37241&author=T.+Maauthor=L.+Vetrivelauthor=H.+Yangauthor=N.+Pedemonteauthor=O.+Zegarra-Moranauthor=L.+J.+V.+Galiettaauthor=A.+S.+Verkman&title=High-Affinity+Activators+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+%28CFTR%29+Chloride+Conductance+Identified+by+High-Throughput+Screening&doi=10.1074%2Fjbc.m205932200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-Throughput Screening</span></div><div class="casAuthors">Ma, Tonghui; Vetrivel, L.; Yang, Hong; Pedemonte, Nicoletta; Zegarra-Moran, Olga; Galietta, Luis J. V.; Verkman, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">37235-37241</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein that reduce cAMP-stimulated Cl- conductance in airway and other epithelia.  The purpose of this investigation was to identify new classes of potent CFTR activators.  A collection of 60,000 diverse drug-like compds. was screened at 10 μm together with a low concn. of forskolin (0.5 μm) in Fisher rat thyroid epithelial cells co-expressing human CFTR and a green fluorescent protein-based Cl- sensor.  Primary screening yielded 57 strong activators (greater activity than ref. compd. apigenin), most of which were unrelated in chem. structure to known CFTR activators, and 284 weaker activators.  Secondary anal. of the strong activators included anal. of CFTR specificity, forskolin requirement, transepithelial short-circuit current, activation kinetics, dose response, toxicity, and activation mechanism.  Three compds., the most potent being a dihydroisoquinoline, activated CFTR by elevating cellular cAMP, probably by phosphodiesterase inhibition.  Fourteen compds. activated CFTR without cAMP elevation or phosphatase inhibition, suggesting direct CFTR interaction.  The most potent compds. had tetrahydrocarbazol, hydroxycoumarin, and thiazolidine core structures.  These compds. induced CFTR Cl- currents rapidly (<5 min) with Kd down to 200 nm and were CFTR-selective, reversible, and nontoxic.  Several compds., the most potent being a trifluoromethylphenylbenzamine, activated the CF-causing mutant G551D, but with much weaker affinity (Kd > 10 μm).  When added for 10 min, none of the compds. activated ΔPhe508-CFTR in transfected cells grown at 37° (with ΔPhe508-CFTR trapped in the endoplasmic reticulum).  However, after correction of trafficking by 48 h of growth at 27°, tetrahydrocarbazol and N-phenyltriazine derivs. strongly stimulated Cl- conductance with Kd < 1 μm.  The new activators identified here may be useful in defining mol. mechanisms of CFTR activation and as lead compds. in CF drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsfjCd611fW7Vg90H21EOLACvtfcHk0lgi9Qvkj85iVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVaquro%253D&md5=e792713776f4884685b8c974263efffd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M205932200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M205932200%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DT.%26aulast%3DVetrivel%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DHigh-Affinity%2520Activators%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520%2528CFTR%2529%2520Chloride%2520Conductance%2520Identified%2520by%2520High-Throughput%2520Screening%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D37235%26epage%3D37241%26doi%3D10.1074%2Fjbc.m205932200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopinath, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">35079</span>– <span class="NLM_lpage">35085</span>, <span class="refDoi"> DOI: 10.1074/jbc.m303098200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1074%2Fjbc.M303098200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12832418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntVWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=35079-35085&author=H.+Yangauthor=A.+A.+Shelatauthor=R.+K.+Guyauthor=V.+S.+Gopinathauthor=T.+Maauthor=K.+Duauthor=G.+L.+Lukacsauthor=A.+Taddeiauthor=C.+Folliauthor=N.+Pedemonteauthor=L.+J.+V.+Galiettaauthor=A.+S.+Verkman&title=Nanomolar+Affinity+Small+Molecule+Correctors+of+Defective+%CE%94F508-CFTR+Chloride+Channel+Gating&doi=10.1074%2Fjbc.m303098200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomolar Affinity Small Molecule Correctors of Defective ΔF508-CFTR Chloride Channel Gating</span></div><div class="casAuthors">Yang, Hong; Shelat, Anang A.; Guy, R. Kiplin; Gopinath, Vadiraj S.; Ma, Tonghui; Du, Kai; Lukacs, Gergely L.; Taddei, Alessandro; Folli, Chiara; Pedemonte, Nicoletta; Galietta, Luis J. V.; Verkman, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">35079-35085</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Deletion of Phe-508 (ΔF508) is the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) causing cystic fibrosis.  ΔF508-CFTR has defects in both channel gating and endoplasmic reticulum-to-plasma membrane processing.  We identified six novel classes of high affinity potentiators of defective ΔF508-CFTR Cl- channel gating by screening 100,000 diverse small mols.  Compds. were added 15 min prior to assay of iodide uptake in epithelial cells co-expressing ΔF508-CFTR and a high sensitivity halide indicator (YFP-H148Q/I152L) in which ΔF508-CFTR was targeted to the plasma membrane by culture at 27° for 24 h.  Thirty-two compds. with submicromolar activating potency were identified; most had tetrahydrobenzothiophene, benzofuran, pyramidinetrione, dihydropyridine, and anthraquinone core structures (360-480 Da).  Further screening of >1000 structural analogs revealed tetrahydrobenzothiophenes that activated ΔF508-CFTR Cl- conductance reversibly with Kd < 100 nM.  Single-cell voltage clamp anal. showed characteristic CFTR currents after ΔF508-CFTR activation.  Activation required low concns. of a cAMP agonist, thus mimicking the normal physiol. response.  A Bayesian computational model was developed using tetrahydrobenzothiophene structure-activity data, yielding insight into the phys. character and structural features of active and inactive potentiators and successfully predicting the activity of structural analogs.  Efficient potentiation of defective ΔF508-CFTR gating was also demonstrated in human bronchial epithelial cells from a ΔF508 cystic fibrosis subject after 27° temp. rescue.  In conjunction with correctors of defective ΔF508-CFTR processing, small mol. potentiators of defective ΔF508-CFTR gating may be useful for therapy of cystic fibrosis caused by the ΔF508 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKsIxV5mMoybVg90H21EOLACvtfcHk0lgi9Qvkj85iVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntVWqt7g%253D&md5=0ddaaaf14e4876baf40e6f1c41055966</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M303098200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M303098200%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26aulast%3DGopinath%26aufirst%3DV.%2BS.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DK.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26aulast%3DTaddei%26aufirst%3DA.%26aulast%3DFolli%26aufirst%3DC.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DNanomolar%2520Affinity%2520Small%2520Molecule%2520Correctors%2520of%2520Defective%2520%25CE%2594F508-CFTR%2520Chloride%2520Channel%2520Gating%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D35079%26epage%3D35085%26doi%3D10.1074%2Fjbc.m303098200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springsteel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sammelson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantz, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">CFTR Activation in Human Bronchial Epithelial Cells by Novel Benzoflavone and Benzimidazolone Compounds</span>. <i>Am. J. Physiol.: Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">L180</span>– <span class="NLM_lpage">L188</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00351.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1152%2Fajplung.00351.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12651632" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2003&pages=L180-L188&author=E.+Caciauthor=C.+Folliauthor=O.+Zegarra-Moranauthor=T.+Maauthor=M.+F.+Springsteelauthor=R.+E.+Sammelsonauthor=M.+H.+Nantzauthor=M.+J.+Kurthauthor=A.+S.+Verkmanauthor=L.+J.+V.+Galietta&title=CFTR+Activation+in+Human+Bronchial+Epithelial+Cells+by+Novel+Benzoflavone+and+Benzimidazolone+Compounds&doi=10.1152%2Fajplung.00351.2002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00351.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00351.2002%26sid%3Dliteratum%253Aachs%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DFolli%26aufirst%3DC.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DSpringsteel%26aufirst%3DM.%2BF.%26aulast%3DSammelson%26aufirst%3DR.%2BE.%26aulast%3DNantz%26aufirst%3DM.%2BH.%26aulast%3DKurth%26aufirst%3DM.%2BJ.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DCFTR%2520Activation%2520in%2520Human%2520Bronchial%2520Epithelial%2520Cells%2520by%2520Novel%2520Benzoflavone%2520and%2520Benzimidazolone%2520Compounds%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2003%26volume%3D285%26spage%3DL180%26epage%3DL188%26doi%3D10.1152%2Fajplung.00351.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diena, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieddu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravazzolo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Antihypertensive 1,4-Dihydropyridines as Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating Defect Caused by Cystic Fibrosis Mutations</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1124/mol.105.015149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1124%2Fmol.105.015149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=16150931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yksbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2005&pages=1736-1746&author=N.+Pedemonteauthor=T.+Dienaauthor=E.+Caciauthor=E.+Niedduauthor=M.+Mazzeiauthor=R.+Ravazzoloauthor=O.+Zegarra-Moranauthor=L.+J.+V.+Galietta&title=Antihypertensive+1%2C4-Dihydropyridines+as+Correctors+of+the+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Channel+Gating+Defect+Caused+by+Cystic+Fibrosis+Mutations&doi=10.1124%2Fmol.105.015149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations</span></div><div class="casAuthors">Pedemonte, Nicoletta; Diena, Tullia; Caci, Emanuela; Nieddu, Erika; Mazzei, Mauro; Ravazzolo, Roberto; Zegarra-Moran, Olga; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1736-1746</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel gene.  CF mutations like ΔF508 cause both a mistrafficking of the protein and a gating defect.  Other mutations, like G551D, cause only a gating defect.  Our aim was to find chem. compds. able to stimulate the activity of CFTR mutant proteins by screening a library contg. approved drugs.  Two thousand compds. were tested on Fischer rat thyroid cells coexpressing ΔF508-CFTR and a halide-sensitive yellow fluorescent protein (YFP) after correction of the trafficking defect by low-temp. incubation.  The YFP-based screening allowed the identification of the antihypertensive 1,4-dihydropyridines (DHPs) nifedipine, nicardipine, nimodipine, isradipine, nitrendipine, felodipine, and niguldipine as compds. able to activate ΔF508-CFTR.  This effect was not derived from the inhibition of voltage-dependent Ca2+ channels, the pharmacol. target of antihypertensive DHPs.  Indeed, methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-2(trifluoromethylphenyl)pyridine-5-carboxylate (BayK-8644), a DHP that is effective as an activator of such channels, also stimulated CFTR activity.  DHPs were also effective on the G551D-CFTR mutant by inducing a 16- to 45-fold increase of the CFTR Cl- currents.  DHP activity was confirmed in airway epithelial cells from patients with CF.  DHPs may represent a novel class of therapeutic agents able to correct the defect caused by a set of CF mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh_q5JcwdXJrVg90H21EOLACvtfcHk0lgTnHISygFVaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yksbfI&md5=b9a52dffd8f9d1108dbd4ae5c80d6d8a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.015149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.015149%26sid%3Dliteratum%253Aachs%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DDiena%26aufirst%3DT.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DNieddu%26aufirst%3DE.%26aulast%3DMazzei%26aufirst%3DM.%26aulast%3DRavazzolo%26aufirst%3DR.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DAntihypertensive%25201%252C4-Dihydropyridines%2520as%2520Correctors%2520of%2520the%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Channel%2520Gating%2520Defect%2520Caused%2520by%2520Cystic%2520Fibrosis%2520Mutations%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D68%26spage%3D1736%26epage%3D1746%26doi%3D10.1124%2Fmol.105.015149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbeson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilja, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttamsingh, V.</span></span> <span> </span><span class="NLM_article-title">Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.241497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1124%2Fjpet.117.241497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=28611092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=359-367&author=S.+L.+Harbesonauthor=A.+J.+Morganauthor=J.+F.+Liuauthor=A.+M.+Aslanianauthor=S.+Nguyenauthor=G.+W.+Bridsonauthor=C.+L.+Brummelauthor=L.+Wuauthor=R.+D.+Tungauthor=L.+Piljaauthor=V.+Bramanauthor=V.+Uttamsingh&title=Altering+Metabolic+Profiles+of+Drugs+by+Precision+Deuteration+2%3A+Discovery+of+a+Deuterated+Analog+of+Ivacaftor+with+Differentiated+Pharmacokinetics+for+Clinical+Development&doi=10.1124%2Fjpet.117.241497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development</span></div><div class="casAuthors">Harbeson, Scott L.; Morgan, Adam J.; Liu, Julie F.; Aslanian, Ara M.; Nguyen, Sophia; Bridson, Gary W.; Brummel, Christopher L.; Wu, Lijun; Tung, Roger D.; Pilja, Lana; Braman, Virginia; Uttamsingh, Vinita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">359-367</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ivacaftor is currently used for the treatment of cystic fibrosis as both monotherapy (Kalydeco; Vertex Pharmaceuticals, Boston, MA) and combination therapy with lumacaftor (Orkambi; Vertex Pharmaceuticals).  Each therapy targets specific patient populations: Kalydeco treats patients carrying one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, whereas Orkambi treats patients homozygous for the F508del CFTR mutation.  In this study, we explored the pharmacol. and metabolic effects of precision deuteration chem. on ivacaftor by synthesizing two novel deuterated ivacaftor analogs, CTP-656 (d9-ivacaftor) and d18-ivacaftor.  Ivacaftor is administered twice daily and is extensively converted in humans to major metabolites M1 and M6; therefore, the corresponding deuterated metabolites were also prepd.  Both CTP-656 and d18-ivacaftor showed in vitro pharmacol. potency similar to that in ivacaftor, and the deuterated M1 and M6 metabolites showed pharmacol. equiv. to that in the corresponding metabolites of ivacaftor, which is consistent with the findings of previous studies of deuterated compds.  However, CTP-656 exhibited markedly enhanced stability when tested in vitro.  The deuterium isotope effects for CTP-656 metab. (DV = 3.8, DV/K = 2.2) were notably large for a cytochrome P 450-mediated oxidn.  The pharmacokinetic (PK) profile of CTP-656 and d18-ivacaftor were assessed in six healthy volunteers in a single-dose crossover study, which provided the basis for advancing CTP-656 in development.  The overall PK profile, including the 15.9-h half-life for CTP-656, suggests that CTP-656 may be dosed once daily, thereby enhancing patient adherence.  Together, these data continue to validate deuterium substitution as a viable approach for creating novel therapeutic agents with properties potentially differentiated from existing drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopNUSS95AadbVg90H21EOLACvtfcHk0lgTnHISygFVaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbI&md5=bf7d11a94c047902d2c6e1a3cd3e8a62</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.241497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.241497%26sid%3Dliteratum%253Aachs%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DMorgan%26aufirst%3DA.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DAslanian%26aufirst%3DA.%2BM.%26aulast%3DNguyen%26aufirst%3DS.%26aulast%3DBridson%26aufirst%3DG.%2BW.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DPilja%26aufirst%3DL.%26aulast%3DBraman%26aufirst%3DV.%26aulast%3DUttamsingh%26aufirst%3DV.%26atitle%3DAltering%2520Metabolic%2520Profiles%2520of%2520Drugs%2520by%2520Precision%2520Deuteration%25202%253A%2520Discovery%2520of%2520a%2520Deuterated%2520Analog%2520of%2520Ivacaftor%2520with%2520Differentiated%2520Pharmacokinetics%2520for%2520Clinical%2520Development%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D359%26epage%3D367%26doi%3D10.1124%2Fjpet.117.241497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span> </span><span class="NLM_article-title">Study Designed to Assess the Safety, Tolerability
and PK of PTI-808
in Healthy Volunteers and in Adults with Cystic Fibrosis</span>. <span class="NLM_publisher-name">Proteostasis Therapeutics, Inc.</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03251092" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03251092</a>. , clinical trial: NCT03251092 (accessed Apr 27, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+Designed+to+Assess+the+Safety%2C+Tolerability%0Aand+PK+of+PTI-808%0Ain+Healthy+Volunteers+and+in+Adults+with+Cystic+Fibrosis.+Proteostasis+Therapeutics%2C+Inc.%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03251092.+%2C+clinical+trial%3A+NCT03251092+%28accessed+Apr+27%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520Designed%2520to%2520Assess%2520the%2520Safety%252C%2520Tolerability%250Aand%2520PK%2520of%2520PTI-808%250Ain%2520Healthy%2520Volunteers%2520and%2520in%2520Adults%2520with%2520Cystic%2520Fibrosis%26pub%3DProteostasis%2520Therapeutics%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
der Plas, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelgtermans, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Munck, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, S. L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dropsit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Blieck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joannesse, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaskovic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgonovi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Schueren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-Pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01288</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWqur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1425-1435&author=S.+E.+Van%0Ader+Plasauthor=H.+Kelgtermansauthor=T.+De+Munckauthor=S.+L.+X.+Martinaauthor=S.+Dropsitauthor=E.+Quintonauthor=A.+De+Blieckauthor=C.+Joannesseauthor=L.+Tomaskovicauthor=M.+Jansauthor=T.+Christopheauthor=E.+van+der+Aarauthor=M.+Borgonoviauthor=L.+Nellesauthor=M.+Geesauthor=P.+Stoutenauthor=J.+Van+Der+Schuerenauthor=O.+Mammolitiauthor=K.+Conrathauthor=M.+Andrews&title=Discovery+of+N-%283-carbamoyl-5%2C5%2C7%2C7-tetramethyl-5%2C7-dihydro-4H-thieno%5B2%2C3-c%5Dpyran-2-yl%29-1H-Pyrazole-5-carboxamide+%28GLPG1837%29%2C+a+Novel+Potentiator+Which+Can+Open+Class+III+Mutant+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+%28CFTR%29+Channels+to+a+High+Extent&doi=10.1021%2Facs.jmedchem.7b01288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent</span></div><div class="casAuthors">Van der Plas, Steven E.; Kelgtermans, Hans; De Munck, Tom; Martina, Sebastien L. X.; Dropsit, Sebastien; Quinton, Evelyne; De Blieck, Ann; Joannesse, Caroline; Tomaskovic, Linda; Jans, Mia; Christophe, Thierry; van der Aar, Ellen; Borgonovi, Monica; Nelles, Luc; Gees, Maarten; Stouten, Pieter; Van Der Schueren, Jan; Mammoliti, Oscar; Conrath, Katja; Andrews, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1425-1435</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR).  With the discovery of Ivacaftor and Orkambi, it has been shown that CFTR function can be partially restored by administering one or more small mols.  These mols. aim at either enhancing the amt. of CFTR on the cell surface (correctors) or at improving the gating function of the CFTR channel (potentiators).  Here the authors describe the discovery of a novel potentiator GLPG1837 which shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor, the first marketed potentiator.  The optimization of potency, efficacy and pharmacokinetic profile will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGRXdwDJ_CX7Vg90H21EOLACvtfcHk0ljIw_e49DRMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWqur%252FI&md5=74d8fdc364fad1d31a39cf47a87dcb37</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01288%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DS.%2BE.%26aulast%3DKelgtermans%26aufirst%3DH.%26aulast%3DDe%2BMunck%26aufirst%3DT.%26aulast%3DMartina%26aufirst%3DS.%2BL.%2BX.%26aulast%3DDropsit%26aufirst%3DS.%26aulast%3DQuinton%26aufirst%3DE.%26aulast%3DDe%2BBlieck%26aufirst%3DA.%26aulast%3DJoannesse%26aufirst%3DC.%26aulast%3DTomaskovic%26aufirst%3DL.%26aulast%3DJans%26aufirst%3DM.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%26aulast%3DBorgonovi%26aufirst%3DM.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DGees%26aufirst%3DM.%26aulast%3DStouten%26aufirst%3DP.%26aulast%3DVan%2BDer%2BSchueren%26aufirst%3DJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DAndrews%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520N-%25283-carbamoyl-5%252C5%252C7%252C7-tetramethyl-5%252C7-dihydro-4H-thieno%255B2%252C3-c%255Dpyran-2-yl%2529-1H-Pyrazole-5-carboxamide%2520%2528GLPG1837%2529%252C%2520a%2520Novel%2520Potentiator%2520Which%2520Can%2520Open%2520Class%2520III%2520Mutant%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520%2528CFTR%2529%2520Channels%2520to%2520a%2520High%2520Extent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1425%26epage%3D1435%26doi%3D10.1021%2Facs.jmedchem.7b01288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Plas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesse, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandevelde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stouten, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swensen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der
Schueren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of Novel CFTR Potentiators</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1221</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2018.01221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30416447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1221&author=M.+Geesauthor=S.+Muschauthor=S.+Van+der+Plasauthor=A.+S.+Wesseauthor=A.+Vandeveldeauthor=K.+Verdonckauthor=O.+Mammolitiauthor=T.+C.+Hwangauthor=K.+Sonckauthor=P.+Stoutenauthor=A.+M.+Swensenauthor=M.+Jansauthor=J.+Van+der%0ASchuerenauthor=L.+Nellesauthor=M.+Andrewsauthor=K.+Conrath&title=Identification+and+Characterization+of+Novel+CFTR+Potentiators&doi=10.3389%2Ffphar.2018.01221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of novel CFTR potentiators</span></div><div class="casAuthors">Gees, Maarten; Musch, Sara; Van Der Plas, Steven; Wesse, Anne-Sophie; Vandevelde, Ann; Verdonck, Katleen; Mammoliti, Oscar; Hwang, Tzyh-Chang; Sonck, Kathleen; Stouten, Pieter; Swensen, Andrew M.; Jans, Mia; Van Der Schueren, Jan; Nelles, Luc; Andrews, Martin; Conrath, Katja</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1221</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There is still a high unmet need for the treatment of most patients with cystic fibrosis (CF).  The identification and development of new Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators is necessary to achieve higher clin. benefit in patients.  In this report we describe the characterization of novel potentiators.  From a small screening campaign on F508del CFTR, hits were developed leading to the identification of preclin. candidates GLPG1837 and GLPG2451, each derived from a distinct chem. series.  Both drug candidates enhance WT CFTR activity as well as low temp. or corrector rescued F508del CFTR, and are able to improve channel activity on a series of Class III, IV CFTR mutants.  The obsd. activities in YFP halide assays translated well to primary cells derived from CF lungs when measured using Trans-epithelial clamp circuit (TECC).  Both potentiators improve F508del CFTR channel opening in a similar manner, increasing the open time and reducing the closed time of the channel.  When evaluating the potentiators in a chronic setting on cor. F508del CFTR, no redn. of channel activity in presence of potentiator was obsd.  The current work identifies and characterizes novel CFTR potentiators GLPG1837 and GLPG2451, which may offer new therapeutic options for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD98U-UNJ6gLVg90H21EOLACvtfcHk0ljIw_e49DRMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7P&md5=5a6ace814644342a62fb5e947651b055</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01221%26sid%3Dliteratum%253Aachs%26aulast%3DGees%26aufirst%3DM.%26aulast%3DMusch%26aufirst%3DS.%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DS.%26aulast%3DWesse%26aufirst%3DA.%2BS.%26aulast%3DVandevelde%26aufirst%3DA.%26aulast%3DVerdonck%26aufirst%3DK.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DHwang%26aufirst%3DT.%2BC.%26aulast%3DSonck%26aufirst%3DK.%26aulast%3DStouten%26aufirst%3DP.%26aulast%3DSwensen%26aufirst%3DA.%2BM.%26aulast%3DJans%26aufirst%3DM.%26aulast%3DVan%2Bder%2BSchueren%26aufirst%3DJ.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DConrath%26aufirst%3DK.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520Novel%2520CFTR%2520Potentiators%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1221%26doi%3D10.3389%2Ffphar.2018.01221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southern, K. W.</span></span> <span> </span><span class="NLM_article-title">Potentiators (Specific Therapies for Class III and IV Mutations) for Cystic Fibrosis</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">CD009841</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD009841.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1002%2F14651858.CD009841.pub3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30616300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2019&pages=CD009841&author=M.+Skiltonauthor=A.+Krishanauthor=S.+Patelauthor=I.+P.+Sinhaauthor=K.+W.+Southern&title=Potentiators+%28Specific+Therapies+for+Class+III+and+IV+Mutations%29+for+Cystic+Fibrosis&doi=10.1002%2F14651858.CD009841.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD009841.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD009841.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DSkilton%26aufirst%3DM.%26aulast%3DKrishan%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DI.%2BP.%26aulast%3DSouthern%26aufirst%3DK.%2BW.%26atitle%3DPotentiators%2520%2528Specific%2520Therapies%2520for%2520Class%2520III%2520and%2520IV%2520Mutations%2529%2520for%2520Cystic%2520Fibrosis%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2019%26volume%3D1%26spage%3DCD009841%26doi%3D10.1002%2F14651858.CD009841.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G.</span></span> <span> </span><span class="NLM_article-title">Failure and Success in Modern Drug Discovery: Guiding Principles in the Establishment of High Probability of Success Drug Discovery Organizations</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.2174/1573406054864106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.2174%2F1573406054864106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=16787336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXovFSjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=519-527&author=G.+Rishton&title=Failure+and+Success+in+Modern+Drug+Discovery%3A+Guiding+Principles+in+the+Establishment+of+High+Probability+of+Success+Drug+Discovery+Organizations&doi=10.2174%2F1573406054864106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Failure and success in modern drug discovery: Guiding principles in the establishment of high probability of success drug discovery organizations</span></div><div class="casAuthors">Rishton, Gilbert M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  The pharmaceutical industry currently suffers un-sustainably high program failure rates despite our best efforts to implement drug design methods and to develop high throughput biochem. screening technologies over the past 20 years.  While much of this failure is rationalized to be due to uncontrollable late stage drug development issues and clin. events, it has become increasingly clear that the choices we make in early drug discovery are vital to the ultimate failure or success outcomes of our drug discovery programs.  The judicious selection of high probability of success therapeutic modalities, the rigorous detn. of lead likeness and drug-likeness, and the all-important selection of high probability of success enzyme and receptor targets are the vital drivers of failure and success in small mol. drug discovery as it is performed in the age of biochem. screening.  Consideration of these guiding principles will improve our chances of success in drug discovery, and increase our ability to address unmet medical need in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQM24l-iJnLbVg90H21EOLACvtfcHk0lhg4Gnpapjefg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXovFSjtbw%253D&md5=c1184c063af82e457ed3db26cb15a66b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1573406054864106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406054864106%26sid%3Dliteratum%253Aachs%26aulast%3DRishton%26aufirst%3DG.%26atitle%3DFailure%2520and%2520Success%2520in%2520Modern%2520Drug%2520Discovery%253A%2520Guiding%2520Principles%2520in%2520the%2520Establishment%2520of%2520High%2520Probability%2520of%2520Success%2520Drug%2520Discovery%2520Organizations%26jtitle%3DMed.%2520Chem.%26date%3D2005%26volume%3D1%26spage%3D519%26epage%3D527%26doi%3D10.2174%2F1573406054864106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T.</span></span> <span> </span><span class="NLM_article-title">Strategies for Compound Selection</span>. <i>Curr. Drug Discovery Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.2174/1570163043334965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.2174%2F1570163043334965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=16472248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsFCnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=211-220&author=M.+Olahauthor=C.+Bologaauthor=T.+Oprea&title=Strategies+for+Compound+Selection&doi=10.2174%2F1570163043334965"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for compound selection</span></div><div class="casAuthors">Olah, Marius M.; Bologa, Cristian G.; Oprea, Tudor I.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-220</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhouse pharmaceutical collections are no longer sufficient for sampling chem. spaces.  As novel bioactive chemotypes are successfully identified by virtual and high -throughput screening, the ability to rapidly shift through large nos. of chems. prior to acquisition or expt. is required.  Strategies for compd. selection include some of the following steps:(1.) database assembly ('in silico' inventory);(2a.) structural integrity verification (keep unique structures only); (2b.) limited exploration of alternative chem. representations for the uniques (stereoisomers, tautomers, ionization states); (3.) property and structural filtering (remove unwanted structures); (4.) 3D-structure generation (for virtual screening or 3D-based similarity); (5a.) clustering or statistical design for selection; (5b.) similarity-based selection (if bioactives are known); (c.) receptor-based selection (if target binding site is known); (6.) add a random subset to the final list.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8LqW9273lrbVg90H21EOLACvtfcHk0lhg4Gnpapjefg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsFCnsr0%253D&md5=0df46725a91a4c4e9c04b83d33740f78</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F1570163043334965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570163043334965%26sid%3Dliteratum%253Aachs%26aulast%3DOlah%26aufirst%3DM.%26aulast%3DBologa%26aufirst%3DC.%26aulast%3DOprea%26aufirst%3DT.%26atitle%3DStrategies%2520for%2520Compound%2520Selection%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D211%26epage%3D220%26doi%3D10.2174%2F1570163043334965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuegge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alanine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleicher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutknecht, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neidhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stalder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjögren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotouhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodnow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Saal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Development of a Virtual Screening Method for Identification of “Frequent Hitters” in Compound Libraries</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1021/jm010934d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010934d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslais78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=137-142&author=O.+Rocheauthor=P.+Schneiderauthor=J.+Zueggeauthor=W.+Gubaauthor=M.+Kansyauthor=A.+Alanineauthor=K.+Bleicherauthor=F.+Danelauthor=E.-M.+Gutknechtauthor=M.+Rogers-Evansauthor=W.+Neidhartauthor=H.+Stalderauthor=M.+Dillonauthor=E.+Sj%C3%B6grenauthor=N.+Fotouhiauthor=P.+Gillespieauthor=R.+Goodnowauthor=W.+Harrisauthor=P.+Jonesauthor=M.+Taniguchiauthor=S.+Tsujiiauthor=W.+von+der+Saalauthor=G.+Zimmermannauthor=G.+Schneider&title=Development+of+a+Virtual+Screening+Method+for+Identification+of+%E2%80%9CFrequent+Hitters%E2%80%9D+in+Compound+Libraries&doi=10.1021%2Fjm010934d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries</span></div><div class="casAuthors">Roche, Olivier; Schneider, Petra; Zuegge, Jochen; Guba, Wolfgang; Kansy, Manfred; Alanine, Alexander; Bleicher, Konrad; Danel, Franck; Gutknecht, Eva-Maria; Rogers-Evans, Mark; Neidhart, Werner; Stalder, Henri; Dillon, Michael; Sjoegren, Eric; Fotouhi, Nader; Gillespie, Paul; Goodnow, Robert; Harris, William; Jones, Phil; Taniguchi, Mikio; Tsujii, Shinji; von Saal, Wolfgang; Zimmermann, Gerd; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A computer-based method was developed for rapid and automatic identification of potential "frequent hitters".  These compds. show up as hits in many different biol. assays covering a wide range of targets.  A scoring scheme was elaborated from substructure anal., multivariate linear and nonlinear statistical methods applied to several sets of one and two-dimensional mol. descriptors.  The final model is based on a three-layered neural network, yielding a predictive Matthews correlation coeff. of 0.81.  This system was able to correctly classify 90% of the test set mols. in a 10-times cross-validation study.  The method was applied to database filtering, yielding between 8% (compilation of trade drugs) and 35% (Available Chems. Directory) potential frequent hitters.  This filter will be a valuable tool for the prioritization of compds. from large databases, for compd. purchase and biol. testing, and for building new virtual libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXTt-wIDExe7Vg90H21EOLACvtfcHk0lhg4Gnpapjefg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslais78%253D&md5=8cdde2cd09735cbf0f6236b3aeb4452d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm010934d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010934d%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DO.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DZuegge%26aufirst%3DJ.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DAlanine%26aufirst%3DA.%26aulast%3DBleicher%26aufirst%3DK.%26aulast%3DDanel%26aufirst%3DF.%26aulast%3DGutknecht%26aufirst%3DE.-M.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DStalder%26aufirst%3DH.%26aulast%3DDillon%26aufirst%3DM.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DE.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DGillespie%26aufirst%3DP.%26aulast%3DGoodnow%26aufirst%3DR.%26aulast%3DHarris%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DTaniguchi%26aufirst%3DM.%26aulast%3DTsujii%26aufirst%3DS.%26aulast%3Dvon%2Bder%2BSaal%26aufirst%3DW.%26aulast%3DZimmermann%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DDevelopment%2520of%2520a%2520Virtual%2520Screening%2520Method%2520for%2520Identification%2520of%2520%25E2%2580%259CFrequent%2520Hitters%25E2%2580%259D%2520in%2520Compound%2520Libraries%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D137%26epage%3D142%26doi%3D10.1021%2Fjm010934d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, M. A.</span></span> <span> </span><span class="NLM_article-title">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed During a Sulfhydryl-Scavenging HTS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2091</span>– <span class="NLM_lpage">2113</span>, <span class="refDoi"> DOI: 10.1021/jm5019093</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2091-2113&author=J.+L.+Dahlinauthor=J.+W.+M.+Nissinkauthor=J.+M.+Strasserauthor=S.+Francisauthor=L.+Higginsauthor=H.+Zhouauthor=Z.+Zhangauthor=M.+A.+Walters&title=PAINS+in+the+Assay%3A+Chemical+Mechanisms+of+Assay+Interference+and+Promiscuous+Enzymatic+Inhibition+Observed+During+a+Sulfhydryl-Scavenging+HTS&doi=10.1021%2Fjm5019093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS</span></div><div class="casAuthors">Dahlin, Jayme L.; Nissink, J. Willem M.; Strasser, Jessica M.; Francis, Subhashree; Higgins, LeeAnn; Zhou, Hui; Zhang, Zhiguo; Walters, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2091-2113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant resources in early drug discovery are spent unknowingly pursuing artifacts and promiscuous bioactive compds., while understanding the chem. basis for these adverse behaviors often goes unexplored in pursuit of lead compds.  Nearly all the hits from our recent sulfhydryl-scavenging high-throughput screen (HTS) targeting the histone acetyltransferase Rtt109 were such compds.  Herein, we characterize the chem. basis for assay interference and promiscuous enzymic inhibition for several prominent chemotypes identified by this HTS, including some pan-assay interference compds. (PAINS).  Protein mass spectrometry and ALARM NMR confirmed these compds. react covalently with cysteines on multiple proteins.  Unfortunately, compds. contg. these chemotypes have been published as screening actives in reputable journals and even touted as chem. probes or preclin. candidates.  Our detailed characterization and identification of such thiol-reactive chemotypes should accelerate triage of nuisance compds., guide screening library design, and prevent follow-up on undesirable chem. matter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4XTJapoezkrVg90H21EOLACvtfcHk0lgNoyrrIUtUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeisbY%253D&md5=3f77702544cea2ec4c8184b60dd38b8a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm5019093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019093%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DJ.%2BL.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DStrasser%26aufirst%3DJ.%2BM.%26aulast%3DFrancis%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWalters%26aufirst%3DM.%2BA.%26atitle%3DPAINS%2520in%2520the%2520Assay%253A%2520Chemical%2520Mechanisms%2520of%2520Assay%2520Interference%2520and%2520Promiscuous%2520Enzymatic%2520Inhibition%2520Observed%2520During%2520a%2520Sulfhydryl-Scavenging%2520HTS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2091%26epage%3D2113%26doi%3D10.1021%2Fjm5019093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span> <i>An Introduction to Chemoinformatics</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2F978-1-4020-6291-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=A.+R.+Leach&title=An+Introduction+to+Chemoinformatics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-1-4020-6291-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4020-6291-9%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26btitle%3DAn%2520Introduction%2520to%2520Chemoinformatics%26pub%3DSpringer%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boido, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravazzolo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1124/mol.107.034702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1124%2Fmol.107.034702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=17452495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=197-207&author=N.+Pedemonteauthor=D.+Boidoauthor=O.+Moranauthor=M.+Giampieriauthor=M.+Mazzeiauthor=R.+Ravazzoloauthor=L.+J.+V.+Galietta&title=Structure-Activity+Relationship+of+1%2C4-Dihydropyridines+as+Potentiators+of+the+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Chloride+Channel&doi=10.1124%2Fmol.107.034702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel</span></div><div class="casAuthors">Pedemonte, Nicoletta; Boido, Davide; Moran, Oscar; Giampieri, Michele; Mazzei, Mauro; Ravazzolo, Roberto; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">197-207</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mutations occurring in the CFTR gene, encoding for the cystic fibrosis transmembrane conductance regulator chloride channel, cause cystic fibrosis (CF).  Mutations belonging to class II, such as ΔPhe508, give rise to a protein with both a defective maturation and altered channel gating.  Mutations belonging to class III, such as G551D and G1349D, cause only a gating defect.  We have previously identified antihypertensive 1,4-dihydropyridines (DHPs), a class of drugs that block voltage-dependent Ca2+ channels, as effective potentiators of CFTR gating, able to correct the defective activity of CFTR mutants.  However, optimization of potency for CFTR vs. Ca2+ channels is required to design selective compds. for CFTR pharmacotherapy.  In the present study, we have established DHP structure-activity relation for both CFTR potentiation and Ca2+ channel inhibition using cell-based assays for both types of channels.  A panel of 333 felodipine analogs was studied to understand the effect of various substitutions and modifications in the DHP scaffold.  Our results show that alkyl substitutions at the para position of the 4-Ph ring lead to compds. with very low activity on Ca2+ channels and strong effect as potentiators on the ΔPhe508, G551D, and G1349D CFTR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFwxDmiHiRObVg90H21EOLACvtfcHk0lgNoyrrIUtUAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyjsbs%253D&md5=b46d197776c619cc7929db781e4f803a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.034702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.034702%26sid%3Dliteratum%253Aachs%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DBoido%26aufirst%3DD.%26aulast%3DMoran%26aufirst%3DO.%26aulast%3DGiampieri%26aufirst%3DM.%26aulast%3DMazzei%26aufirst%3DM.%26aulast%3DRavazzolo%26aufirst%3DR.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DStructure-Activity%2520Relationship%2520of%25201%252C4-Dihydropyridines%2520as%2520Potentiators%2520of%2520the%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Chloride%2520Channel%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D197%26epage%3D207%26doi%3D10.1124%2Fmol.107.034702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fruscia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Gimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scudieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandiera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Picomolar Potency Pharmacological Corrector of the Mutant CFTR Chloride Channel</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">eaay9669</span>, <span class="refDoi"> DOI: 10.1126/sciadv.aay9669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1126%2Fsciadv.aay9669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=32128418" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=eaay9669&author=N.+Pedemonteauthor=F.+Bertozziauthor=E.+Caciauthor=F.+Soranaauthor=P.+Di+Frusciaauthor=V.+Tomatiauthor=L.+Ferreraauthor=A.+Rodr%C3%ADguez-Gimenoauthor=F.+Bertiauthor=E.+Pesceauthor=E.+Sondoauthor=A.+Gianottiauthor=P.+Scudieriauthor=T.+Bandieraauthor=L.+J.+V.+Galietta&title=Discovery+of+a+Picomolar+Potency+Pharmacological+Corrector+of+the+Mutant+CFTR+Chloride+Channel&doi=10.1126%2Fsciadv.aay9669"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aay9669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aay9669%26sid%3Dliteratum%253Aachs%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DBertozzi%26aufirst%3DF.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DSorana%26aufirst%3DF.%26aulast%3DDi%2BFruscia%26aufirst%3DP.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DFerrera%26aufirst%3DL.%26aulast%3DRodr%25C3%25ADguez-Gimeno%26aufirst%3DA.%26aulast%3DBerti%26aufirst%3DF.%26aulast%3DPesce%26aufirst%3DE.%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DGianotti%26aufirst%3DA.%26aulast%3DScudieri%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DDiscovery%2520of%2520a%2520Picomolar%2520Potency%2520Pharmacological%2520Corrector%2520of%2520the%2520Mutant%2520CFTR%2520Chloride%2520Channel%26jtitle%3DSci.%2520Adv.%26date%3D2020%26volume%3D6%26spage%3Deaay9669%26doi%3D10.1126%2Fsciadv.aay9669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mewshaw, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiffany, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbon, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borosky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferkany, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, M. E.</span></span> <span> </span><span class="NLM_article-title">Bridged Gamma-Carbolines and Derivatives Possessing Selective and Combined Affinity for 5-HT<sub>2</sub> and D<sub>2</sub> Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1021/jm00062a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00062a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3sXltFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1488-1495&author=R.+E.+Mewshawauthor=L.+S.+Silvermanauthor=R.+M.+Mathewauthor=C.+Kaiserauthor=R.+G.+Sherrillauthor=M.+Chengauthor=C.+W.+Tiffanyauthor=E.+W.+Karbonauthor=M.+A.+Baileyauthor=S.+A.+Boroskyauthor=J.+W.+Ferkanyauthor=M.+E.+Abreu&title=Bridged+Gamma-Carbolines+and+Derivatives+Possessing+Selective+and+Combined+Affinity+for+5-HT2+and+D2+Receptors&doi=10.1021%2Fjm00062a023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Bridged γ-carbolines and derivatives possessing selective and combined affinity for 5-HT2 and D2 receptors</span></div><div class="casAuthors">Mewshaw, Richard E.; Silverman, Lisa S.; Mathew, Rose M.; Kaiser, Carl; Sherrill, Ronald G.; Cheng, Menyan; Tiffany, Carol W.; Karbon, E. William; Bailey, Michael A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1488-95</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles and 6,7,8,9,10,11-hexahydro-7,11-imino-5H-cyclooct[b]indoles was prepd.  Structural modifications of the lead compd., 11-[4-(4-fluorobenzoyl)propyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclhept[b]indole (Ki = 0.82 nM vs [3H]ketanserin) enabled the identification of the functionality necessary for high affinity at serotonin 5-HT2 and dopamine D2 receptors in ligand binding studies.  The indole ring, as well as the benzoyl or isosteric benzisoxazole moiety, were essential for high affinity.  Variations of the length of the side chains resulted in ligands having either selective affinity for the 5-HT2 receptor or a combination of 5-HT2 and D2 affinity.  In vivo binding studies were performed on selected members in this series.  The most potent member, 2-fluoro-11-[4-(4-fluorobenzoyl)butyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (I) had an ED50 of <1 mg/kg at the 5-HT2 and D2 receptors following oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7WNfXEenHlLVg90H21EOLACvtfcHk0ljuefdKV8P96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltFOhs78%253D&md5=c2660a6606dbd3b1865de8e036157adf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm00062a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00062a023%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DSilverman%26aufirst%3DL.%2BS.%26aulast%3DMathew%26aufirst%3DR.%2BM.%26aulast%3DKaiser%26aufirst%3DC.%26aulast%3DSherrill%26aufirst%3DR.%2BG.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DTiffany%26aufirst%3DC.%2BW.%26aulast%3DKarbon%26aufirst%3DE.%2BW.%26aulast%3DBailey%26aufirst%3DM.%2BA.%26aulast%3DBorosky%26aufirst%3DS.%2BA.%26aulast%3DFerkany%26aufirst%3DJ.%2BW.%26aulast%3DAbreu%26aufirst%3DM.%2BE.%26atitle%3DBridged%2520Gamma-Carbolines%2520and%2520Derivatives%2520Possessing%2520Selective%2520and%2520Combined%2520Affinity%2520for%25205-HT2%2520and%2520D2%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1488%26epage%3D1495%26doi%3D10.1021%2Fjm00062a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mewshaw, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karbon, E. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro evaluation of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles: high-affinity ligands for the N,N′-di-o-tolylguanidine-labeled .sigma. binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1021/jm00055a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00055a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaK3sXitFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=343-352&author=R.+E.+Mewshawauthor=R.+G.+Sherrillauthor=R.+M.+Mathewauthor=C.+Kaiserauthor=M.+A.+Baileyauthor=E.+W.+Karbon&title=Synthesis+and+in+vitro+evaluation+of+5%2C6%2C7%2C8%2C9%2C10-hexahydro-7%2C10-iminocyclohept%5Bb%5Dindoles%3A+high-affinity+ligands+for+the+N%2CN%E2%80%B2-di-o-tolylguanidine-labeled+.sigma.+binding+site&doi=10.1021%2Fjm00055a005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro evaluation of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles:  high-affinity ligands for the N,N'-di-o-tolylguanidine-labeled σ binding site</span></div><div class="casAuthors">Mewshaw, Richard E.; Sherrill, Ronald G.; Mathew, Rose M.; Kaiser, Carl; Bailey, Michael A.; Karbon, E. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-52</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 5,6,7,8,9,10-hexahydro-7,10-iminocyclo[b]indole (I) derivs. substituted at the 5 and/or 11 positions was synthesized from tropinone.  Affinity for σ binding sites was detd. using [3H]-N,N'-di-o-tolylguanidine ([3H]DTG) and [3H]-(+)-3-(3-hydroxyphenyl)-N-1-propylpiperidine ([3H]-(+)-3-PPP) and for the dopamine D2 receptor labeled with [3H]sulpiride.  Nearly all compds. studied in this series possessed a higher affinity for [3H]DTG than [3H]-(+)-PPP-labeled σ sites, suggesting that [3H]DTG and [3H]-(+)-3-PPP radioligands label pharmacol. distinct σ binding sites, as reported previously.  Substitution at the 11 position with side chains contg. a four-carbon tether resulted in compds. having the highest affinity for the [3H]DTG-labeled σ site.  The most potent and selective member of this series was 11-[4-(2-furanyl)butyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (II).  Enantioselectivity was investigated by prepg. the (+)- and (-)-isomers of II.  (+)-II was more potent at the [3H]-DTG-labeled σ site, whereas (-)-II had a higher affinity at σ sites labeled with [3H]-(+)-PPP.  Racemic II was obsd. to possess a higher affinity than either of its resp. enantiomers at both the [3H]DTG- and [3H]-(+)-3-PPP labeled sites, suggesting an allosteric interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri_olGiHKBLbVg90H21EOLACvtfcHk0ljuefdKV8P96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitFaqsLg%253D&md5=5a54bae4c99d3e194087b43d9df6ce59</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm00055a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00055a005%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DSherrill%26aufirst%3DR.%2BG.%26aulast%3DMathew%26aufirst%3DR.%2BM.%26aulast%3DKaiser%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DM.%2BA.%26aulast%3DKarbon%26aufirst%3DE.%2BW.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520evaluation%2520of%25205%252C6%252C7%252C8%252C9%252C10-hexahydro-7%252C10-iminocyclohept%255Bb%255Dindoles%253A%2520high-affinity%2520ligands%2520for%2520the%2520N%252CN%25E2%2580%25B2-di-o-tolylguanidine-labeled%2520.sigma.%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D343%26epage%3D352%26doi%3D10.1021%2Fjm00055a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kametani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihara, M.</span></span> <span> </span><span class="NLM_article-title">Racemisation and Epimerisation in Isoquinoline and Indole Alkaloids</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.3987/s-1976-01-0649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3987%2FS-1976-01-0649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaE2sXnt12gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1976&pages=649-667&author=T.+Kametaniauthor=M.+Ihara&title=Racemisation+and+Epimerisation+in+Isoquinoline+and+Indole+Alkaloids&doi=10.3987%2Fs-1976-01-0649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Racemization and epimerization in isoquinoline and indole alkaloids</span></div><div class="casAuthors">Kametani, Tetsuji; Ihara, Masataka</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">649-68</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    </div><div class="casAbstract">A review with 22 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPewZkX4ws0rVg90H21EOLACvtfcHk0ljuefdKV8P96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXnt12gsw%253D%253D&md5=68b7a1a8429966755dbfe07313daae57</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3987%2FS-1976-01-0649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FS-1976-01-0649%26sid%3Dliteratum%253Aachs%26aulast%3DKametani%26aufirst%3DT.%26aulast%3DIhara%26aufirst%3DM.%26atitle%3DRacemisation%2520and%2520Epimerisation%2520in%2520Isoquinoline%2520and%2520Indole%2520Alkaloids%26jtitle%3DHeterocycles%26date%3D1976%26volume%3D5%26spage%3D649%26epage%3D667%26doi%3D10.3987%2Fs-1976-01-0649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cholon, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinney, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulcher, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esther, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokholyan, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randell, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentzsch, M.</span></span> <span> </span><span class="NLM_article-title">Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">246ra96</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3008680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1126%2Fscitranslmed.3008680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25101886" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=246ra96&author=D.+M.+Cholonauthor=N.+L.+Quinneyauthor=M.+L.+Fulcherauthor=C.+R.+Estherauthor=J.+Dasauthor=N.+V.+Dokholyanauthor=S.+H.+Randellauthor=R.+C.+Boucherauthor=M.+Gentzsch&title=Potentiator+Ivacaftor+Abrogates+Pharmacological+Correction+of+DeltaF508+CFTR+in+Cystic+Fibrosis&doi=10.1126%2Fscitranslmed.3008680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008680%26sid%3Dliteratum%253Aachs%26aulast%3DCholon%26aufirst%3DD.%2BM.%26aulast%3DQuinney%26aufirst%3DN.%2BL.%26aulast%3DFulcher%26aufirst%3DM.%2BL.%26aulast%3DEsther%26aufirst%3DC.%2BR.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDokholyan%26aufirst%3DN.%2BV.%26aulast%3DRandell%26aufirst%3DS.%2BH.%26aulast%3DBoucher%26aufirst%3DR.%2BC.%26aulast%3DGentzsch%26aufirst%3DM.%26atitle%3DPotentiator%2520Ivacaftor%2520Abrogates%2520Pharmacological%2520Correction%2520of%2520DeltaF508%2520CFTR%2520in%2520Cystic%2520Fibrosis%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D246ra96%26doi%3D10.1126%2Fscitranslmed.3008680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramescu, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdomo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phuan, P.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagdany, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apaja, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szollosi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkbeiner, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacs, G. L.</span></span> <span> </span><span class="NLM_article-title">Some Gating Potentiators, Including VX-770, Diminish DeltaF508-CFTR Functional Expression</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">246ra97</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3008889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1126%2Fscitranslmed.3008889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25101887" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=246ra97&author=G.+Veitauthor=R.+G.+Avramescuauthor=D.+Perdomoauthor=P.-W.+Phuanauthor=M.+Bagdanyauthor=P.+M.+Apajaauthor=F.+Borotauthor=D.+Szollosiauthor=Y.-S.+Wuauthor=W.+E.+Finkbeinerauthor=T.+Hegedusauthor=A.+S.+Verkmanauthor=G.+L.+Lukacs&title=Some+Gating+Potentiators%2C+Including+VX-770%2C+Diminish+DeltaF508-CFTR+Functional+Expression&doi=10.1126%2Fscitranslmed.3008889"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008889%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DPerdomo%26aufirst%3DD.%26aulast%3DPhuan%26aufirst%3DP.-W.%26aulast%3DBagdany%26aufirst%3DM.%26aulast%3DApaja%26aufirst%3DP.%2BM.%26aulast%3DBorot%26aufirst%3DF.%26aulast%3DSzollosi%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.-S.%26aulast%3DFinkbeiner%26aufirst%3DW.%2BE.%26aulast%3DHegedus%26aufirst%3DT.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DSome%2520Gating%2520Potentiators%252C%2520Including%2520VX-770%252C%2520Diminish%2520DeltaF508-CFTR%2520Functional%2520Expression%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D246ra97%26doi%3D10.1126%2Fscitranslmed.3008889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scudieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musante, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baatallah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinzpeter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Bernardo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR through an Autophagy-Independent and USP13-Mediated Mechanism</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1464</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.3389%2Ffphar.2018.01464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30618756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Olu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1464&author=E.+Pesceauthor=E.+Sondoauthor=L.+Ferreraauthor=V.+Tomatiauthor=E.+Caciauthor=P.+Scudieriauthor=I.+Musanteauthor=M.+Rendaauthor=N.+Baatallahauthor=N.+Servelauthor=A.+Hinzpeterauthor=D.+di+Bernardoauthor=N.+Pedemonteauthor=L.+J.+V.+Galietta&title=The+Autophagy+Inhibitor+Spautin-1+Antagonizes+Rescue+of+Mutant+CFTR+through+an+Autophagy-Independent+and+USP13-Mediated+Mechanism&doi=10.3389%2Ffphar.2018.01464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The autophagy inhibitor spautin-1 antagonizes rescue of mutant CFTR through an autophagy-independent and USP13-mediated mechanism</span></div><div class="casAuthors">Pesce, Emanuela; Sondo, Elvira; Ferrera, Loretta; Tomati, Valeria; Caci, Emanuela; Scudieri, Paolo; Musante, Ilaria; Renda, Mario; Baatallah, Nesrine; Servel, Nathalie; Hinzpeter, Alexandre; Di Bernardo, Diego; Pedemonte, Nicoletta; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1464</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The mutation F508del, responsible for a majority of cystic fibrosis cases, provokes the instability and misfolding of the CFTR chloride channel.  Pharmacol. recovery of F508del-CFTR may be obtained with small mols. called correctors.  However, treatment with a single corrector in vivo and in vitro only leads to a partial rescue, a consequence of cell quality control systems that still detect F508del-CFTR as a defective protein causing its degrdn.  We tested the effect of spautin-1 on F508delCFTR since it is an inhibitor of USP10 deubiquitinase and of autophagy, a target and a biol. process that have been assocd. with cystic fibrosis and mutant CFTR.  We found that short-term treatment of cells with spautin-1 downregulates the function and expression of F508del-CFTR despite the presence of corrector VX-809, a finding obtained in multiple cell models and assays.  In contrast, spautin-1 was ineffective on wild type CFTR.  Silencing and upregulation of USP13 (another target of spautin-1) but not of USP10, had opposite effects on F508del-CFTR expression/function.  In contrast, modulation of autophagy with known activators or inhibitors did not affect F508delCFTR.  Our results identify spautin-1 as a novel chem. probe to investigate the mol. mechanisms that prevent full rescue of mutant CFTR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjGNm63Sb6WLVg90H21EOLACvtfcHk0ljNILU4gOWAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Olu7fF&md5=4c92c02a6f1338b611acd015b42a08fa</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01464%26sid%3Dliteratum%253Aachs%26aulast%3DPesce%26aufirst%3DE.%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DFerrera%26aufirst%3DL.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DScudieri%26aufirst%3DP.%26aulast%3DMusante%26aufirst%3DI.%26aulast%3DRenda%26aufirst%3DM.%26aulast%3DBaatallah%26aufirst%3DN.%26aulast%3DServel%26aufirst%3DN.%26aulast%3DHinzpeter%26aufirst%3DA.%26aulast%3Ddi%2BBernardo%26aufirst%3DD.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DThe%2520Autophagy%2520Inhibitor%2520Spautin-1%2520Antagonizes%2520Rescue%2520of%2520Mutant%2520CFTR%2520through%2520an%2520Autophagy-Independent%2520and%2520USP13-Mediated%2520Mechanism%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1464%26doi%3D10.3389%2Ffphar.2018.01464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Circumventing the Crabtree Effect: Replacing Media Glucose with Galactose Increases Susceptibility of HepG2 Cells to Mitochondrial Toxicants</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfm052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1093%2Ftoxsci%2Fkfm052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=17361016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2007&pages=539-547&author=L.+D.+Marroquinauthor=J.+Hynesauthor=J.+A.+Dykensauthor=J.+D.+Jamiesonauthor=Y.+Will&title=Circumventing+the+Crabtree+Effect%3A+Replacing+Media+Glucose+with+Galactose+Increases+Susceptibility+of+HepG2+Cells+to+Mitochondrial+Toxicants&doi=10.1093%2Ftoxsci%2Fkfm052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants</span></div><div class="casAuthors">Marroquin, Lisa D.; Hynes, James; Dykens, James A.; Jamieson, Joseph D.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">539-547</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Many highly proliferative cells generate almost all ATP via glycolysis despite abundant O2 and a normal complement of fully functional mitochondria, a circumstance known as the Crabtree effect.  Such anaerobically poised cells are resistant to xenobiotics that impair mitochondrial function, such as the inhibitors rotenone, antimycin, oligomycin, and compds. like carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), that uncouple the respiratory electron transfer system from phosphorylation.  These cells are also resistant to the toxicity of many drugs whose deleterious side effect profiles are either caused, or exacerbated, by impairment of mitochondrial function.  Drug-induced mitochondrial toxicity is shown by members of important drug classes, including the thiazolidinediones, statins, fibrates, antivirals, antibiotics, and anticancer agents.  To increase detection of drug-induced mitochondrial effects in a preclin. cell-based assay, HepG2 cells were forced to rely on mitochondrial oxidative phosphorylation rather than glycolysis by substituting galactose for glucose in the growth media.  Oxygen consumption doubles in galactose-grown HepG2 cells and their susceptibility to canonical mitochondrial toxicants correspondingly increases.  Similarly, toxicity of several drugs with known mitochondrial liabilities is more readily apparent in aerobically poised HepG2 cells compared to glucose-grown cells.  Some drugs were equally toxic to both glucose- and galactose-grown cells, suggesting that mitochondrial impairment is likely secondary to other cytotoxic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Zb0elenmNbVg90H21EOLACvtfcHk0ljNILU4gOWAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsV2is7w%253D&md5=53d6a955ad0a942d1ced5043668bed19</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm052%26sid%3Dliteratum%253Aachs%26aulast%3DMarroquin%26aufirst%3DL.%2BD.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%2BD.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DCircumventing%2520the%2520Crabtree%2520Effect%253A%2520Replacing%2520Media%2520Glucose%2520with%2520Galactose%2520Increases%2520Susceptibility%2520of%2520HepG2%2520Cells%2520to%2520Mitochondrial%2520Toxicants%26jtitle%3DToxicol.%2520Sci.%26date%3D2007%26volume%3D97%26spage%3D539%26epage%3D547%26doi%3D10.1093%2Ftoxsci%2Fkfm052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuethe, J. T.</span></span> <span> </span><span class="NLM_article-title">Practical Methodologies for the Synthesis of Indoles</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2911</span>, <span class="refDoi"> DOI: 10.1021/cr0505270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0505270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlCitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2006&pages=2875-2911&author=G.+R.+Humphreyauthor=J.+T.+Kuethe&title=Practical+Methodologies+for+the+Synthesis+of+Indoles&doi=10.1021%2Fcr0505270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Practical methodologies for the synthesis of Indoles</span></div><div class="casAuthors">Humphrey, Guy R.; Kuethe, Jeffrey T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2875-2911</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on prepn. of indole derivs.  A lot of procedures which have either been successfully demonstrated or are potentially useful for the large scale prepn. of indoles is presented with indication of reagents, reaction conditions, and yields.  The review focuses on the literature of the last decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGuTN17a6uM7Vg90H21EOLACvtfcHk0lhODGgzjCoIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlCitbg%253D&md5=ed3275cc7c57303254010e695c1a5a8e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fcr0505270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0505270%26sid%3Dliteratum%253Aachs%26aulast%3DHumphrey%26aufirst%3DG.%2BR.%26aulast%3DKuethe%26aufirst%3DJ.%2BT.%26atitle%3DPractical%2520Methodologies%2520for%2520the%2520Synthesis%2520of%2520Indoles%26jtitle%3DChem.%2520Rev.%26date%3D2006%26volume%3D106%26spage%3D2875%26epage%3D2911%26doi%3D10.1021%2Fcr0505270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbert, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koe, B. K.</span></span> <span> </span><span class="NLM_article-title">Neuroleptic Activity in 5-Aryltetrahydro-Gamma-Carbolines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1021/jm00180a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00180a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADyaL3cXkt1Kgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=635-643&author=C.+A.+Harbertauthor=J.+J.+Plattnerauthor=W.+M.+Welchauthor=A.+Weissmanauthor=B.+K.+Koe&title=Neuroleptic+Activity+in+5-Aryltetrahydro-Gamma-Carbolines&doi=10.1021%2Fjm00180a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroleptic activity in 5-aryltetrahydro-γ-carbolines</span></div><div class="casAuthors">Harbert, Charles A.; Plattner, Jacob J.; Welch, Willard M.; Weissman, Albert; Koe, B. Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">635-43</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of 5-aryltetrahydro-γ-carbolines I (R = Cl, Br, F, H, Me, MeO; R1 = Ph, substituted Ph; R2 = Me, (un)substituted 3-benzoylpropyl, (un)substituted 4-phenyl-4-hydroxybutyl) was prepd. by a novel N-arylation procedure and tested for neuroleptic activity in a rat antiamphetamine model.  Thus, p-FC6H4NH2.HCl was cyclized with 1-carbethoxy-4-piperidinone and the I (R = F, R1 = H, R2 = CO2Et) treated with p-BrC6H4F to give I (R = F, R1 = p-FC6H4, R2 = CO2Et) which was reduced with LiAlH4-AlCl3 to give I (R = F, R1 = p-FC6H4, R2 = Me).  The systematic exploration of structural parameters leading to I [R = F, R1 = p-FC6H4, R2 = p-FC6H4CH(OH)(CH2)3], a potent and long-acting neuroleptic compd., is described.  These semirigid compds. provide a new, structurally distinct series with which to probe the conformational requirements for potent activity at the dopamine receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRO_Er3zIjCbVg90H21EOLACvtfcHk0lhODGgzjCoIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXkt1Kgs7c%253D&md5=23b1fc549f96a5ee3e85f6b03e3a3194</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm00180a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00180a011%26sid%3Dliteratum%253Aachs%26aulast%3DHarbert%26aufirst%3DC.%2BA.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26aulast%3DWelch%26aufirst%3DW.%2BM.%26aulast%3DWeissman%26aufirst%3DA.%26aulast%3DKoe%26aufirst%3DB.%2BK.%26atitle%3DNeuroleptic%2520Activity%2520in%25205-Aryltetrahydro-Gamma-Carbolines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1980%26volume%3D23%26spage%3D635%26epage%3D643%26doi%3D10.1021%2Fjm00180a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridoux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houssin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Héanichart, J.-P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 8-Substituted Tetrahydro-γ-Carbolines</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570430308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1002%2Fjhet.5570430308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVaqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2006&pages=571-578&author=A.+Bridouxauthor=L.+Goossensauthor=R.+Houssinauthor=J.-P.+H%C3%A9anichart&title=Synthesis+of+8-Substituted+Tetrahydro-%CE%B3-Carbolines&doi=10.1002%2Fjhet.5570430308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 8-substituted tetrahydro-γ-carbolines</span></div><div class="casAuthors">Bridoux, Alexandre; Goossens, Laurence; Houssin, Raymond; Henichart, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">571-578</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    
            (<span class="NLM_cas:orgname">HeteroCorporation</span>)
        </div><div class="casAbstract">The Fischer reaction is applied to the synthesis of 8-substituted tetrahydro-γ-carbolines with electron-donating or electron-withdrawing groups, using catalytic or thermal methods.  The reaction conditions must be varied according to the nature of the N(1) substituent of the piperidone.  The best results are obsd. when a releasing group is present on the arylhydrazine and a benzyl substituent on the nitrogen of piperidone.  Formation of carbolines with a withdrawing substituent is obsd. in soft acidic conditions.  In others, reaction ended at the hydrazone level or did not evolve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-1mUIzR_z7Vg90H21EOLACvtfcHk0lhODGgzjCoIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVaqtL8%253D&md5=687421bc3a3b38a02c86a3dbda6e4bbf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570430308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570430308%26sid%3Dliteratum%253Aachs%26aulast%3DBridoux%26aufirst%3DA.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DHoussin%26aufirst%3DR.%26aulast%3DH%25C3%25A9anichart%26aufirst%3DJ.-P.%26atitle%3DSynthesis%2520of%25208-Substituted%2520Tetrahydro-%25CE%25B3-Carbolines%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2006%26volume%3D43%26spage%3D571%26epage%3D578%26doi%3D10.1002%2Fjhet.5570430308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penzis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaube, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appenroth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tränkle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enzensperger, C.</span></span> <span> </span><span class="NLM_article-title">Beta and Gamma Carboline Derivatives as Potential Anti-Alzheimer Agents: A Comparison</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.ejmech.2014.09.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=25240096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOlsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=63-70&author=R.+Ottoauthor=R.+Penzisauthor=F.+Gaubeauthor=T.+Wincklerauthor=D.+Appenrothauthor=C.+Fleckauthor=C.+Tr%C3%A4nkleauthor=J.+Lehmannauthor=C.+Enzensperger&title=Beta+and+Gamma+Carboline+Derivatives+as+Potential+Anti-Alzheimer+Agents%3A+A+Comparison&doi=10.1016%2Fj.ejmech.2014.09.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison</span></div><div class="casAuthors">Otto, Robert; Penzis, Robert; Gaube, Friedemann; Winckler, Thomas; Appenroth, Dorothea; Fleck, Christian; Traenkle, Christian; Lehmann, Jochen; Enzensperger, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Nine novel β- and γ-carboline derivs. bearing either methyl-, propargyl- or phenethyl-residues at the indole nitrogen were synthesized and tested as potential anti-Alzheimer drugs.  Antagonism of recombinantly expressed NMDA receptors, inhibition of cholinesterases, and radical scavenging properties were detd. for all compds.  Some were addnl. tested in vivo for their ability to reverse scopolamine-induced cognitive impairment in an 8-arm radial maze expt. with rats.  For the most promising candidates, the interaction with muscarinic M1 receptors was also investigated.  With this set of compds. assays the influence of the scaffold itself and the substituents can be investigated sep.  5-Methyl-γ-carboline (I) was the most potent (0.25 μmol/100 g b.w.) compd. in the in vivo test and might be a good starting point for the development of novel anti-Alzheimer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRwXrBRAcmgbVg90H21EOLACvtfcHk0ljo3VKPD5zAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOlsLzM&md5=d12fd4e4f527b4fe894e9aa80dd361cc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.048%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DR.%26aulast%3DPenzis%26aufirst%3DR.%26aulast%3DGaube%26aufirst%3DF.%26aulast%3DWinckler%26aufirst%3DT.%26aulast%3DAppenroth%26aufirst%3DD.%26aulast%3DFleck%26aufirst%3DC.%26aulast%3DTr%25C3%25A4nkle%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DJ.%26aulast%3DEnzensperger%26aufirst%3DC.%26atitle%3DBeta%2520and%2520Gamma%2520Carboline%2520Derivatives%2520as%2520Potential%2520Anti-Alzheimer%2520Agents%253A%2520A%2520Comparison%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D63%26epage%3D70%26doi%3D10.1016%2Fj.ejmech.2014.09.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.-F.</span></span> <span> </span><span class="NLM_article-title">“One-Pot” Synthesis of 4-Substituted 1,5-Diaryl-1H-Pyrazole-3-Carboxylates via Lithium Tert-Butoxide-Mediated Sterically Hindered Claisen Condensation and Knorr Reaction</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2012.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.tet.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslejsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=627-635&author=J.-A.+Jiangauthor=W.-B.+Huangauthor=J.-J.+Zhaiauthor=H.-W.+Liuauthor=Q.+Caiauthor=L.-X.+Xuauthor=W.+Wangauthor=Y.-F.+Ji&title=%E2%80%9COne-Pot%E2%80%9D+Synthesis+of+4-Substituted+1%2C5-Diaryl-1H-Pyrazole-3-Carboxylates+via+Lithium+Tert-Butoxide-Mediated+Sterically+Hindered+Claisen+Condensation+and+Knorr+Reaction&doi=10.1016%2Fj.tet.2012.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">'One-pot' synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates via lithium tert-butoxide-mediated sterically hindered Claisen condensation and Knorr reaction</span></div><div class="casAuthors">Jiang, Jian-An; Huang, Wei-Bin; Zhai, Jiao-Jiao; Liu, Hong-Wei; Cai, Qi; Xu, Liu-Xin; Wang, Wei; Ji, Ya-Fei</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">627-635</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A concise 'one-pot' synthesis of a variety of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates has been developed in moderate to good yields with excellent regioselectivity.  Less cost lithium tert-butoxide has been identified as a base for sterically hindered Claisen condensation to efficiently generate the labile 3-substituted 4-aryl-2,4-diketoesters.  Furthermore, extensive studies lead to a 'one-pot' process by combination of the Claisen condensation and the Knorr reaction for the synthesis of highly valuable 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_UiHKV4qkzLVg90H21EOLACvtfcHk0ljo3VKPD5zAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslejsLzJ&md5=5af2084c22373bbcb2109ca955015141</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.-A.%26aulast%3DHuang%26aufirst%3DW.-B.%26aulast%3DZhai%26aufirst%3DJ.-J.%26aulast%3DLiu%26aufirst%3DH.-W.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DL.-X.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DY.-F.%26atitle%3D%25E2%2580%259COne-Pot%25E2%2580%259D%2520Synthesis%2520of%25204-Substituted%25201%252C5-Diaryl-1H-Pyrazole-3-Carboxylates%2520via%2520Lithium%2520Tert-Butoxide-Mediated%2520Sterically%2520Hindered%2520Claisen%2520Condensation%2520and%2520Knorr%2520Reaction%26jtitle%3DTetrahedron%26date%3D2013%26volume%3D69%26spage%3D627%26epage%3D635%26doi%3D10.1016%2Fj.tet.2012.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, G. W.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in Indole Ring Synthesis-Methodology and Applications</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1039/a909834h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1039%2Fa909834h" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=1045-1075&author=G.+W.+Gribble&title=Recent+Developments+in+Indole+Ring+Synthesis-Methodology+and+Applications&doi=10.1039%2Fa909834h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1039%2Fa909834h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa909834h%26sid%3Dliteratum%253Aachs%26aulast%3DGribble%26aufirst%3DG.%2BW.%26atitle%3DRecent%2520Developments%2520in%2520Indole%2520Ring%2520Synthesis-Methodology%2520and%2520Applications%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2000%26spage%3D1045%26epage%3D1075%26doi%3D10.1039%2Fa909834h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivashchenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mit’kin, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okun, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salimov, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedotov, A. I.</span></span> <span> </span><span class="NLM_article-title">Substituted 2,3,4,5-Tetrahydro-1H-Gamma-Carbolines: New Antagonists of Histamine H1 Receptors</span>. <i>Eksp. Klin. Farmakol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=21254595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVKisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2010&pages=25-29&author=A.+V.+Ivashchenkoauthor=O.+D.+Mit%E2%80%99kinauthor=I.+M.+Okunauthor=R.+M.+Salimovauthor=A.+I.+Fedotov&title=Substituted+2%2C3%2C4%2C5-Tetrahydro-1H-Gamma-Carbolines%3A+New+Antagonists+of+Histamine+H1+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted 2,3,4,5-tetrahydro-1H-γ-carbolines: New antagonists of histamine H1 receptors</span></div><div class="casAuthors">Ivashchenko, A. V.; Mit'kin, O. D.; Okun, I. M.; Salimov, R. M.; Fedotov, Yu. A.</div><div class="citationInfo"><span class="NLM_cas:title">Eksperimental'naya i Klinicheskaya Farmakologiya</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">25-29</span>CODEN:
                <span class="NLM_cas:coden">EKFAE9</span>;
        ISSN:<span class="NLM_cas:issn">0869-2092</span>.
    
            (<span class="NLM_cas:orgname">Izdatel'stvo Folium</span>)
        </div><div class="casAbstract">The properties of 2,3,4,5-tetrahydro-1H-γ-carbolines contg. acid, ether, and amido-substituents, were assessed as potential antagonists of histamine H1 receptors (H1R), capable of blocking histamine-induced calcium fluxes in SK-N-SH cells.  The structure - activity relationship for their antagonistic activity is discussed.  Among the γ-carbolines used in the study, the antihistamine activity considerably depends on the nature of substituents in positions 2, 5, and 8 of the heterocycle.  The most active antagonist, Et 3-(2-methyl-8-fluoro-2,3,4,5-tetrahydro-1H-γ-carboline-5-yl)propionate, with high affinity to the H1R (Ki = 6.5 nM), produces no adverse effects on motor activity of mice in doses 1 - 40 mg/kg, which shows the absence of a sedative effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTp92hkl5kd7Vg90H21EOLACvtfcHk0ljo3VKPD5zAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVKisA%253D%253D&md5=164fd672569fb102a28106f5f6eb234f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIvashchenko%26aufirst%3DA.%2BV.%26aulast%3DMit%25E2%2580%2599kin%26aufirst%3DO.%2BD.%26aulast%3DOkun%26aufirst%3DI.%2BM.%26aulast%3DSalimov%26aufirst%3DR.%2BM.%26aulast%3DFedotov%26aufirst%3DA.%2BI.%26atitle%3DSubstituted%25202%252C3%252C4%252C5-Tetrahydro-1H-Gamma-Carbolines%253A%2520New%2520Antagonists%2520of%2520Histamine%2520H1%2520Receptors%26jtitle%3DEksp.%2520Klin.%2520Farmakol.%26date%3D2010%26volume%3D73%26spage%3D25%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span> <span> </span><span class="NLM_article-title">Priviliged Structures. An Update</span>. <i>Ann. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/s0065-7743(00)35027-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fs0065-7743%2800%2935027-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2000&pages=289-298&author=A.+A.+Patchettauthor=R.+P.+Nargund&title=Priviliged+Structures.+An+Update&doi=10.1016%2Fs0065-7743%2800%2935027-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Chapter 26. Privileged structures - an update</span></div><div class="casAuthors">Patchett, Arthur A.; Nargund, Ravi P.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-298</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 63 refs. on privileged structure-based ligands of G protein-coupled receptors in relation to the search for new agonists and antagonists in relation to drug design and discovery.  Although this review deals primarily with the use of privileged structures in the design of G-protein coupled receptor agonists and antagonists, their use extends beyond these receptors.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqy_U678fGfLVg90H21EOLACvtfcHk0lh-x-NLOIGjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFGltb8%253D&md5=18fd0d98b8fb92fa51dbaf6034dee2e2</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fs0065-7743%2800%2935027-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0065-7743%252800%252935027-8%26sid%3Dliteratum%253Aachs%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26atitle%3DPriviliged%2520Structures.%2520An%2520Update%26jtitle%3DAnn.%2520Rep.%2520Med.%2520Chem.%26date%3D2000%26volume%3D35%26spage%3D289%26epage%3D298%26doi%3D10.1016%2Fs0065-7743%2800%2935027-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivachtchenko, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolov, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitkin, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kysil, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khvat, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okun, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkachenko, S. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Novel Gamma-Carboline Analogues of Dimebon as Potent 5-HT<sub>6</sub> Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3183</span>– <span class="NLM_lpage">3187</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.bmcl.2009.04.128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=19443217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1eks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3183-3187&author=A.+V.+Ivachtchenkoauthor=E.+B.+Frolovauthor=O.+D.+Mitkinauthor=V.+M.+Kysilauthor=A.+V.+Khvatauthor=I.+M.+Okunauthor=S.+E.+Tkachenko&title=Synthesis+and+Biological+Evaluation+of+Novel+Gamma-Carboline+Analogues+of+Dimebon+as+Potent+5-HT6+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2009.04.128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel γ-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists</span></div><div class="casAuthors">Ivachtchenko, Alexandre V.; Frolov, Eugene B.; Mitkin, Oleg D.; Kysil, Volodymyr M.; Khvat, Alexander V.; Okun, Ilya M.; Tkachenko, Sergey E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3183-3187</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis, biol. evaluation and structure-activity relationships for a series of novel γ-carboline analogs of Dimebon, e.g., I and II, are described.  Among the studied compds., I and II have been identified as potent small mol. antagonists of histamine H1 (IC50 = 0.1 μM) and serotonin 5-HT6 (IC50 = 0.37 μM) receptors, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmSqs1g11Wn7Vg90H21EOLACvtfcHk0lh-x-NLOIGjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1eks7o%253D&md5=057a6c1ac2925dd9bad040130ff9dd36</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.128%26sid%3Dliteratum%253Aachs%26aulast%3DIvachtchenko%26aufirst%3DA.%2BV.%26aulast%3DFrolov%26aufirst%3DE.%2BB.%26aulast%3DMitkin%26aufirst%3DO.%2BD.%26aulast%3DKysil%26aufirst%3DV.%2BM.%26aulast%3DKhvat%26aufirst%3DA.%2BV.%26aulast%3DOkun%26aufirst%3DI.%2BM.%26aulast%3DTkachenko%26aufirst%3DS.%2BE.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Gamma-Carboline%2520Analogues%2520of%2520Dimebon%2520as%2520Potent%25205-HT6%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3183%26epage%3D3187%26doi%3D10.1016%2Fj.bmcl.2009.04.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Recent Developments on Synthesis and Biological Activities of Gamma-Carboline</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2Fj.ejmech.2018.08.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=30103193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=447-461&author=J.+Daiauthor=W.+Danauthor=Y.+Zhangauthor=J.+Wang&title=Recent+Developments+on+Synthesis+and+Biological+Activities+of+Gamma-Carboline&doi=10.1016%2Fj.ejmech.2018.08.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments on synthesis and biological activities of γ-carboline</span></div><div class="casAuthors">Dai, Jiangkun; Dan, Wenjia; Zhang, Yunyun; Wang, Junru</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">447-461</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review on γ-carboline alkaloids are a family of natural and synthetic agents that have diverse bioactivities including antiviral, antibacterial, antifungal, antiparasitic, antitumor, anti-inflammatory, neuropharmacol. activities and so on.  They constitute an important class of pharmacol. active scaffolds that exhibit biol. activity via diverse mechanisms.  This review provides an update on the recent developments (2010-2017) in the synthesis and biol. activities of these compds.  In cases where sufficient information is available, the mechanism and the structure-activity relationship (SAR) of biol. activity are presented, and based on our expertise in the field and careful anal. of the recent literature, for the potential of γ-carboline alkaloids as medicinal drugs is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVZGnpLjWH7Vg90H21EOLACvtfcHk0lh-x-NLOIGjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FJ&md5=a1d5ab2db417a27e581ce03e1f5ee480</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DDan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DRecent%2520Developments%2520on%2520Synthesis%2520and%2520Biological%2520Activities%2520of%2520Gamma-Carboline%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D447%26epage%3D461%26doi%3D10.1016%2Fj.ejmech.2018.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alekseyev, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurkin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurovskaya, M. A.</span></span> <span> </span><span class="NLM_article-title">γ-Carbolines and Their Hydrogenated Derivatives 3.* Hydrogenated Derivatives of γ-Carbolines: Chemical and Biological Properties (Review)</span>. <i>Chem. Heterocycl. Compd.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1007/s10593-011-0652-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1007%2Fs10593-011-0652-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVajtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=1169-1198&author=R.+S.+Alekseyevauthor=A.+V.+Kurkinauthor=M.+A.+Yurovskaya&title=%CE%B3-Carbolines+and+Their+Hydrogenated+Derivatives+3.*+Hydrogenated+Derivatives+of+%CE%B3-Carbolines%3A+Chemical+and+Biological+Properties+%28Review%29&doi=10.1007%2Fs10593-011-0652-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Carbolines and their hydrogenated derivatives. Part 3. Hydrogenated derivatives of γ-carbolines, chemical and biological properties</span></div><div class="casAuthors">Alekseyev, R. S.; Kurkin, A. V.; Yurovskaya, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1169-1198</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Published data on the chem. transformations and biol. properties of dihydro-, tetrahydro-, and hexahydro-γ-carbolines were reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLPq1p7flt_rVg90H21EOLACvtfcHk0lh-x-NLOIGjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVajtrw%253D&md5=598733ff11417756d80a6c42cb8c7aae</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs10593-011-0652-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-011-0652-0%26sid%3Dliteratum%253Aachs%26aulast%3DAlekseyev%26aufirst%3DR.%2BS.%26aulast%3DKurkin%26aufirst%3DA.%2BV.%26aulast%3DYurovskaya%26aufirst%3DM.%2BA.%26atitle%3D%25CE%25B3-Carbolines%2520and%2520Their%2520Hydrogenated%2520Derivatives%25203.%252A%2520Hydrogenated%2520Derivatives%2520of%2520%25CE%25B3-Carbolines%253A%2520Chemical%2520and%2520Biological%2520Properties%2520%2528Review%2529%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2011%26volume%3D46%26spage%3D1169%26epage%3D1198%26doi%3D10.1007%2Fs10593-011-0652-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khorana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrick-Davis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Gamma-Carbolines: Binding at 5-HT<sub>5a</sub> Serotonin Receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1016/s0968-0896(02)00527-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1016%2FS0968-0896%2802%2900527-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=12538001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1Oqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=717-722&author=N.+Khoranaauthor=A.+Purohitauthor=K.+Herrick-Davisauthor=M.+Teitlerauthor=R.+A.+Glennon&title=Gamma-Carbolines%3A+Binding+at+5-HT5a+Serotonin+Receptors&doi=10.1016%2Fs0968-0896%2802%2900527-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">γ-Carbolines: binding at 5-HT5A serotonin receptors</span></div><div class="casAuthors">Khorana, Nantaka; Purohit, Anil; Herrick-Davis, Katherine; Teitler, Milt; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">717-722</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Screening of various agents resulted in the identification of 5-methyl-1,2,3,4-tetrahydro-γ-carboline (1; Ki=5,300 nM) as a compd. with modest affinity for mouse 5-HT5A receptors.  Structure-affinity studies were conducted resulting in 5-methyl-2-[3-(4-fluorophenoxy)propyl]-1,2,3,4-tetrahydro-γ-carboline (17; Ki=13 nM).  Although 17 also binds at 5-HT2 receptors, it serves as a novel lead for the further development of 5-HT5A ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRRuG1oyjp_7Vg90H21EOLACvtfcHk0ljlnsI0Uv1WEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1Oqsg%253D%253D&md5=abc9cb09943ba0f90af15838a1e65525</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900527-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900527-8%26sid%3Dliteratum%253Aachs%26aulast%3DKhorana%26aufirst%3DN.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DHerrick-Davis%26aufirst%3DK.%26aulast%3DTeitler%26aufirst%3DM.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DGamma-Carbolines%253A%2520Binding%2520at%25205-HT5a%2520Serotonin%2520Receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D717%26epage%3D722%26doi%3D10.1016%2Fs0968-0896%2802%2900527-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khorana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrick-Davis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grella, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dukat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Binding of Tetrahydrocarboline Derivatives at Human 5-HT<sub>5a</sub> Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3930</span>– <span class="NLM_lpage">3937</span>, <span class="refDoi"> DOI: 10.1021/jm030080s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030080s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslKntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3930-3937&author=N.+Khoranaauthor=C.+Smithauthor=K.+Herrick-Davisauthor=A.+Purohitauthor=M.+Teitlerauthor=B.+Grellaauthor=M.+Dukatauthor=R.+A.+Glennon&title=Binding+of+Tetrahydrocarboline+Derivatives+at+Human+5-HT5a+Receptors&doi=10.1021%2Fjm030080s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of Tetrahydrocarboline Derivatives at Human 5-HT5A Receptors</span></div><div class="casAuthors">Khorana, Nantaka; Smith, Carol; Herrick-Davis, Kathy; Purohit, Anil; Teitler, Milt; Grella, Brian; Dukat, Ma-lgorzata; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3930-3937</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of an earlier finding that 5-methyl-5H-1,2,3,4-tetrahydropyrido[4,3-b]indole (5-methyl-1,2,3,4-tetrahydro-γ-carboline); (1) binds at murine 5-HT5A receptors, preliminary structure-affinity studies were conducted.  The present investigation extends these structure-affinity studies using human 5-HT5A receptors and examd. addnl. analogs of 1.  It was found (a) that there is little interspecies difference for the affinities of these compds., (b) that an intact 1,2,3,4-tetrahydro-γ-carboline ring system seems optimal and an N2-(3-(substituted-phenoxy)propyl) moiety results in high affinity, (c) that structurally related 1,2,3,4-tetrahydro-β-carbolines also bind at 5-HT5A receptors, and (d) that all examd. derivs. also possess affinity for 5-HT2A receptors.  Evidence is provided that 5-HT5A and 5-HT2A receptor affinities probably do not covary and that it might be possible, with continued investigation, to develop analogs with enhanced 5-HT5A selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAfW3H1It7T7Vg90H21EOLACvtfcHk0ljlnsI0Uv1WEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslKntbw%253D&md5=b782a84c71eeb59741b785cb2d3f5589</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm030080s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030080s%26sid%3Dliteratum%253Aachs%26aulast%3DKhorana%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DHerrick-Davis%26aufirst%3DK.%26aulast%3DPurohit%26aufirst%3DA.%26aulast%3DTeitler%26aufirst%3DM.%26aulast%3DGrella%26aufirst%3DB.%26aulast%3DDukat%26aufirst%3DM.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DBinding%2520of%2520Tetrahydrocarboline%2520Derivatives%2520at%2520Human%25205-HT5a%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3930%26epage%3D3937%26doi%3D10.1021%2Fjm030080s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ustyugov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevtsova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachurin, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, G.</span></span> <span> </span><span class="NLM_article-title">New Therapeutic Property of Dimebon as a Neuroprotective Agent</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5315</span>– <span class="NLM_lpage">5326</span>, <span class="refDoi"> DOI: 10.2174/0929867323666160804122746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.2174%2F0929867323666160804122746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=27494393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVCkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=5315-5326&author=A.+Ustyugovauthor=E.+Shevtsovaauthor=G.+M.+Ashrafauthor=V.+V.+Tarasovauthor=S.+O.+Bachurinauthor=G.+Aliev&title=New+Therapeutic+Property+of+Dimebon+as+a+Neuroprotective+Agent&doi=10.2174%2F0929867323666160804122746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">New Therapeutic Property of Dimebon as a Neuroprotective Agent</span></div><div class="casAuthors">Ustyugov, Aleksey; Shevtsova, Elena; Ashraf, Ghulam Md.; Tarasov, Vadim V.; Bachurin, Sergey O.; Aliev, Gjumrakch</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5315-5326</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of "old" agents with prominent neuroprotective effects.  In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain's pathol. processes using in vivo proteinopathy models.  In the study, neurodegenerative pathol. has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which are involved in a no. of neurol. disorders.  We have also presented our in vitro model based on overexpression of an aberrant mutant form of transactive response DNA binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.  Dimebon treatment followed by the activation of autophagy markers resulted in reduced no. of inclusion contg. cells.  The most significant effects of Dimebon appeared to be on the improving cellular energy balance, mitochondria stability by increasing the threshold for nonselective mitochondrial pore opening as well as on increased calcium retention capacity while reducing lipid peroxidn.  The therapeutic potential of Dimebon and newly designed analogs show disease modifying properties and could be used to treat neurodegenerative disorders.  In addn., new data hint on a possible anti-aging effect and potential application of Dimebon for treatment of anxiety, ischemia and depression.  Overall, our findings suggest that the most pronounced effect of Dimebon was obsd. when treatment was started at the early stages of disease onset and this factor needs to be taken into account while planning future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg8NjWU4Z_4bVg90H21EOLACvtfcHk0ljlnsI0Uv1WEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVCkt7o%253D&md5=0c88fc2ad3f61912e9dba52fe0e5f919</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160804122746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160804122746%26sid%3Dliteratum%253Aachs%26aulast%3DUstyugov%26aufirst%3DA.%26aulast%3DShevtsova%26aufirst%3DE.%26aulast%3DAshraf%26aufirst%3DG.%2BM.%26aulast%3DTarasov%26aufirst%3DV.%2BV.%26aulast%3DBachurin%26aufirst%3DS.%2BO.%26aulast%3DAliev%26aufirst%3DG.%26atitle%3DNew%2520Therapeutic%2520Property%2520of%2520Dimebon%2520as%2520a%2520Neuroprotective%2520Agent%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2018%26volume%3D25%26spage%3D5315%26epage%3D5326%26doi%3D10.2174%2F0929867323666160804122746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Rescue of the Mutant CFTR Chloride Channel by Pharmacological Correctors and Low Temperature Analyzed by Gene Expression Profiling</span>. <i>Am. J. Physiol.: Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>301</i></span>,  <span class="NLM_fpage">C872</span>– <span class="NLM_lpage">C885</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.00507.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1152%2Fajpcell.00507.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=21753184" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2011&pages=C872-C885&author=E.+Sondoauthor=V.+Tomatiauthor=E.+Caciauthor=A.+I.+Espositoauthor=U.+Pfefferauthor=N.+Pedemonteauthor=L.+J.+V.+Galietta&title=Rescue+of+the+Mutant+CFTR+Chloride+Channel+by+Pharmacological+Correctors+and+Low+Temperature+Analyzed+by+Gene+Expression+Profiling&doi=10.1152%2Fajpcell.00507.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00507.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00507.2010%26sid%3Dliteratum%253Aachs%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DEsposito%26aufirst%3DA.%2BI.%26aulast%3DPfeffer%26aufirst%3DU.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DRescue%2520of%2520the%2520Mutant%2520CFTR%2520Chloride%2520Channel%2520by%2520Pharmacological%2520Correctors%2520and%2520Low%2520Temperature%2520Analyzed%2520by%2520Gene%2520Expression%2520Profiling%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Cell%2520Physiol.%26date%3D2011%26volume%3D301%26spage%3DC872%26epage%3DC885%26doi%3D10.1152%2Fajpcell.00507.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scudieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zegarra-Moran, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedemonte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravazzolo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, L. J. V.</span></span> <span> </span><span class="NLM_article-title">Association of TMEM16A Chloride Channel Overexpression with Airway Goblet Cell Metaplasia</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">6141</span>– <span class="NLM_lpage">6155</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2012.240838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=10.1113%2Fjphysiol.2012.240838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=22988141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2012&pages=6141-6155&author=P.+Scudieriauthor=E.+Caciauthor=S.+Brunoauthor=L.+Ferreraauthor=M.+Schiavonauthor=E.+Sondoauthor=V.+Tomatiauthor=A.+Gianottiauthor=O.+Zegarra-Moranauthor=N.+Pedemonteauthor=F.+Reaauthor=R.+Ravazzoloauthor=L.+J.+V.+Galietta&title=Association+of+TMEM16A+Chloride+Channel+Overexpression+with+Airway+Goblet+Cell+Metaplasia&doi=10.1113%2Fjphysiol.2012.240838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia</span></div><div class="casAuthors">Scudieri, Paolo; Caci, Emanuela; Bruno, Silvia; Ferrera, Loretta; Schiavon, Marco; Sondo, Elvira; Tomati, Valeria; Gianotti, Ambra; Zegarra-Moran, Olga; Pedemonte, Nicoletta; Rea, Federico; Ravazzolo, Roberto; Galietta, Luis J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6141-6155</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The TMEM16A protein has a potential role as a Ca2+-activated Cl- channel (CaCC) in airway epithelia where it may be important in the homeostasis of the airway surface fluid.  We investigated the function and expression of TMEM16A in primary human bronchial epithelial cells and in a bronchial cell line (CFBE41o-).  Under resting conditions, TMEM16A protein expression was relatively low.  However, TMEM16A silencing with short-interfering RNAs caused a marked inhibition of CaCC activity, thus demonstrating that a low TMEM16A expression is sufficient to support Ca2+-dependent Cl- transport.  Following treatment for 24-72 h with interleukin-4 (IL-4), a cytokine that induces mucous cell metaplasia, TMEM16A protein expression was strongly increased in approx. 50% of primary bronchial epithelial cells, with a specific localization in the apical membrane.  IL-4 treatment also increased the percentage of cells expressing MUC5AC, a marker of goblet cells.  Interestingly, MUC5AC was detected specifically in cells expressing TMEM16A.  In particular, MUC5AC was found in 15 and 60% of TMEM16A-pos. cells when epithelia were treated with IL-4 for 24 or 72 h, resp.  In contrast, ciliated cells showed expression of the cystic fibrosis transmembrane conductance regulator Cl- channel but not of TMEM16A.  Our results indicate that TMEM16A protein is responsible for CaCC activity in airway epithelial cells, particularly in cells treated with IL-4, and that TMEM16A upregulation by IL-4 appears as an early event of goblet cell differentiation.  These findings suggest that TMEM16A expression is particularly required under conditions of mucus hypersecretion to ensure adequate secretion of electrolytes and water.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxoXrLbFQ8grVg90H21EOLACvtfcHk0ljsZh1HCGfawQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlaqtQ%253D%253D&md5=2d35524823abfa3e3f31ccac105e352f</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2012.240838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2012.240838%26sid%3Dliteratum%253Aachs%26aulast%3DScudieri%26aufirst%3DP.%26aulast%3DCaci%26aufirst%3DE.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DFerrera%26aufirst%3DL.%26aulast%3DSchiavon%26aufirst%3DM.%26aulast%3DSondo%26aufirst%3DE.%26aulast%3DTomati%26aufirst%3DV.%26aulast%3DGianotti%26aufirst%3DA.%26aulast%3DZegarra-Moran%26aufirst%3DO.%26aulast%3DPedemonte%26aufirst%3DN.%26aulast%3DRea%26aufirst%3DF.%26aulast%3DRavazzolo%26aufirst%3DR.%26aulast%3DGalietta%26aufirst%3DL.%2BJ.%2BV.%26atitle%3DAssociation%2520of%2520TMEM16A%2520Chloride%2520Channel%2520Overexpression%2520with%2520Airway%2520Goblet%2520Cell%2520Metaplasia%26jtitle%3DJ.%2520Physiol.%26date%3D2012%26volume%3D590%26spage%3D6141%26epage%3D6155%26doi%3D10.1113%2Fjphysiol.2012.240838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i115"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01050">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83722"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01050?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01050</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">UPLC/MS traces and <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectral data for final compounds; chiral HPLC data for enantioenriched final compounds; UPLC/MS traces of primary hits from screening; and experimental procedures and results from additional <i>in vivo</i> assays (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_001.pdf">jm0c01050_si_001.pdf (12.43 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01050/suppl_file/jm0c01050_si_002.csv">jm0c01050_si_002.csv (3.47 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01050&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01050%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01050" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799dd28be511991","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
